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Human bone marrow-derived mesenchymal stem cells (hMSCs) can differentiate in vitro 
into various lineages including adipocytes, osteoblasts, and chondrocytes. Determining the 
earliest events of hMSC differentiation would provide a greater understanding of stem cell 
function, leading to novel therapeutic strategies. The molecular regulation of adipogenesis 
has  been  studied  extensively  using  preadipocyte  models  that  are  committed  to  the 
adipocyte  lineage.  However,  the  events  that  occur  in uncommitted  stem  cells  such  as 
hMSCs, and thus control the early stages of differentiation, have not been identified. In 
this  thesis,  hMSC  differentiation  to  adipocytes  was  induced  using  a  classic  induction 
cocktail, and transcriptional profiles were obtained at early timepoints using Affymetrix 
U133  Plus 2.0 microarrays.  Adipogenesis was  shown to  involve the regulation of over 
4200  genes,  which  were  clustered  into  distinct  temporal  patterns  of gene  expression. 
Recognised  adipogenic  regulators  were  expressed  at  the  later  stages  of adipogenesis 
alongside  genes  involved  in  lipid  metabolism,  thus  demonstrating  the  validity  of the 
system. Global annotation of genes showing early expression changes revealed temporal 
regulation of signaling pathways known to control adipogenesis, together with molecular 
processes  and pathway regulators  not previously implicated  in  adipogenesis.  A  further 
detailed analysis of gene function identified 83 potential candidates for novel adipogenic 
regulators.
Knock-down  of gene  expression  induced  by  virally-mediated  shRNA  is  an  effective 
method  to  assess  gene  function.  To  investigate whether the  candidate  genes  identified 
from the transcriptional profiling played a role in hMSC adipogenesis, retroviral shRNA 
library  screens  and  an  additional  lentiviral  shRNA  strategy  were  developed  and 
implemented.
Finally, the effect on hMSC differentiation of the introduction of oncogenic regulators was 
investigated. Oncogenic transformation of hMSCs may lead to aberrant differentiation and 
mesenchymal  tumour  formation.  It  was  found  that  the  progressive  addition  of 
transforming  genes  did  not  block  adipogenic  or osteogenic  differentiation,  but  caused 
significant impairment to the process.
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20CHAPTER 1. INTRODUCTION.1.1  Introduction to stem cells
Stem cells can broadly be described as possessing two major characteristics: an extensive 
self-renewal  capacity  and  the  ability  to  form  multiple  mature  cell  types  through 
differentiation  (Hall  and  Watt  1989,  Joseph  and  Morrison  2005).  Other  stem  cell 
characteristics  include  a  quiescent  nature  in  vivo,  the  ability  to  undergo  asymmetric 
division, and the ability to regenerate tissue after injury, but such properties may not be 
possessed by all stem cell populations, and may vary over time within a single population 
(Hall and Watt 1989, Potten and Loeffler 1990, Morrison 1997).
Stem  cells  offer  great  promise  in  advancing  the  field  of regenerative  medicine.  Their 
ability  to  proliferate  extensively  and  differentiate  into  several,  or  many,  cell  types 
(depending on the stem cell in question) may be exploited in the laboratory in order to 
derive healthy, replacement tissue in the instance of injury or disease. Further to this, and 
perhaps more fundamentally,  stem cells  also provide a unique opportunity to  study the 
processes of early development and cellular differentiation.
The  isolation  of stem  cells  from  embryos  as  well  as  adult  tissues  demonstrates  their 
existence throughout the development of an organism, and as such, stem cells have been 
classified in terms of their developmental potential. Totipotency defines the ability to form 
all extra-embryonic and embryonic tissues, and is a property possessed by the fertilised 
egg (Sell 2004). Pluripotent stem cells are able to form cells of the three embryonic germ 
layers, namely ectoderm (giving rise to skin and nervous system), endoderm (giving rise 
to  cells  of the  gastrointestinal  tract  and  internal  organs  such  as  liver),  and  mesoderm 
(giving rise to blood, blood vessels and connective tissue such as bone); this is the case for 
the inner cell mass of the blastocyst, embryonic stem cells, embryonic carcinoma cells and 
embryonic  germ  cells.  Stem  cell  populations  that  give  rise  to  several  cell  lineages, 
generally within one  germ  layer,  have been defined by terms  such  as multipotent  and 
oligopotent;  adult stem cells are classically described in this manner,  although this has 
been challenged in recent years (Section 1.3). Finally, multipotent stem cells can give rise 
to unipotent progenitors of multiple cell types, which ultimately form all mature tissues of 
the organism (Sell 2004).
22Several  methods  are  uniformly  used  to  define  stem  cell  populations,  including  the 
expression of certain cell surface markers, and the demonstration of specific functional 
properties. In vivo, the existence of a stem cell can be demonstrated via the reconstitution 
of a  specific  tissue  type  by  a  single  cell  after  transplantation  into  an  animal  model, 
including production of further stem cells that can be re-transplanted and exhibit the same 
properties.  In  vitro,  a  definitive  test  of stem  cell  nature  is  the  ability  of a  clonal  cell 
population to produce differentiated cells of multiple types.
1.2  Embryonic stem cells
Embryonic stem cells (ESCs) have been isolated through the culture of pre-implantation 
blastocysts from mice (Evans and Kaufman 1981, Martin 1981) and humans (Thomson et 
al 1998). ESCs have been defined in terms of the expression of specific markers, and also 
their  differentiation  potential.  Mouse  ES  cells  (mESCs)  express  cell  surface  markers 
including  SSEA-1;  in  striking  contrast,  human  ES  cells  (hESCs)  do  not  express  this 
antigen,  but  express  SSEA-3,  SSEA-4,  and  the  TRA-1-60  and  TRA-1-81  antigens 
(Thomson et al 1998). Both ESC populations express the transcription factor Oct4, which 
acts  to  maintain  their  undifferentiated  state  (Nichols  et  al  1998).  In  support  of this, 
siRNA-mediated  knockdown  (1.7.3)  of Oct4  in  hESCs  results  in  their  differentiation 
towards trophectoderm (Matin et al 2004).
ESCs are pluripotent: when mouse ESCs are injected into mouse embryos at the blastocyst 
stage, ESC contribution to all embryonic germ layers as well as the germ line is observed 
(Bradley  et  al  1984).  Further,  teratomas  formed  from  hESCs  transplanted  into 
immunodeficient mice contain cells of all germ layers (Thomson et al 1998). Both mouse 
and  hESCs  can  be  maintained  indefinitely  in  culture,  and  both  exhibit  in  vitro 
pluripotency:  they can spontaneously differentiate  into cells  of ectodermal,  endodermal 
and mesodermal origin (Reubinoff et al 2000, Evans and Kaufman  1981), a process that 
can  be  initiated  through  the  formation  of embryoid  bodies  (which  resemble  the  early 
embryo but lack polarity).  Enrichment of specific cell types from differentiating hESCs 
has  been  achieved,  including  haematopoietic  progenitors,  neurons  and  hepatocyte-like
23cells. However, hESC differentiation is not specific to a single cell lineage, but generally 
produces a mixture of cell types (Draper et al 2004a, Hoffman and Carpenter 2005).
Culturing primary embryo cells on replication-deficient cell feeder layers in the presence 
of FCS permitted the initial isolation of ESCs due to the presence of factors (either in the 
serum or secreted from the feeder cells) that supported ESC self-renewal and maintenance 
of pluripotency (Evans and Koufman 1981, Thomson et al 1998). Recently, some of these 
factors have been identified and can be used to culture ESCs in more defined conditions. 
In feeder-free conditions, the presence of the cytokine LIF is sufficient to maintain the 
self-renewal of mESCs (Williams et al 1988, Smith et al 1988). The same effect can also 
be achieved in serum-free conditions using LIF in combination with BMP proteins (Ying 
et  al  2003).  In  contrast  to  this,  LIF  is  not  capable  of  maintaining  hESCs  in  their 
undifferentiated state (Daheron et al 2004). The combination of the BMP inhibitor noggin 
and high levels of bFGF maintains hESC self-renewal and differentiation potential (Xu et 
al 2005). In that study, an incompletely defined serum replacement was used, but recent 
work has described the isolation of two hESC lines in entirely defined conditions; that is, 
using proteins  of purely human  origin  as  a  replacement  for animal  serum  and  matrix 
components (required for cell adherence) (Ludwig et al 2006). This is a crucial step for 
the use of hESCs in stem cell therapies.
Although ESCs offer great promise in deriving multiple cell types for use  in stem cell 
therapies,  several  complicating  issues  exist.  As  described  above,  hESC  cells  form 
teratomas  after  injection  into  immunodeficient  mice  in  their  undifferentiated  state, 
necessitating  their  terminal  differentiation  in  culture,  and  removal  of  any  remaining 
undifferentiated hESCs, prior to use in therapy. However, hESC in vitro differentiation is 
currently inefficient, and does not yield homogeneous populations of a specific cell type. 
Furthermore,  it  has  been  found  that  prolonged  culture  of hESCs  can  lead  to  culture 
adaptation - the selective outgrowth of cells with enhanced self-renewal capability due to 
karyotypic changes that occurred as a result of culturing methods employed (Draper et al 
2004a). This often involves the gain of chromosomes  17q and 12p, which are commonly 
seen  in  embryonal  carcinoma  cells  (the  tumourigenic  counterparts  of hESCs  that  are 
derived from teratocarcinomas), meaning that caution must be taken with the conditions
24used to culture hESCs (Draper et al 2004b). Lastly, the use of human embryos for research 
or therapeutic purposes is highly controversial, and has prompted many ethical debates, as 
the  embryos  are  ultimately  destroyed  by  the  process.  Therefore,  it  is  also  of  great 
importance to focus parallel research on adult stem cells, which are less surrounded by the 
ethical and scientific issues described here.
1.3  Adult stem cells
Stem cell populations have been identified within the adult organism that are capable of 
giving  rise  to  multiple  cell  types  within  a  specific  tissue.  Table  1.1  summarises  a 
representative selection of well characterised adult stem cell populations. Major goals in 
adult  stem  cell  research  are  the  isolation  of  pure  stem  cell  populations,  and  the 
identification of the molecular mechanisms underlying their stem cell properties. As well 
as producing tissue-specific cell types, some studies have raised the possibility that adult 
stem cells may be more plastic than originally thought, and may be able to differentiate to 
lineages from more than one germ layer (Table  1.1).  However, in  vivo (or in  vitro  co­
culture)  investigations  of  this  property  are  hampered  by  the  issue  of  whether  such 
observations are caused by cell fusion (stem cells fusing with mature cells of a specific 
type, thereby adopting their characteristics) or trans-differentiation (the true ability of stem 
cells  to  differentiate  to  a  lineage  outside  their  anticipated  range  without  cell  fusion). 
Haematopoietic and skin stem cells are leading examples of adult stem cell populations, 
and the subject of this thesis focuses on adult bone marrow-derived mesenchymal  stem 
cells.
25Adult stem cell population Lineages Reference
Haematopoietic 
Hair follicle 
Intestinal epithelial 
Neural
Skeletal muscle satellite 
Cardiac muscle 
Mesenchymal
Multipotent adult 
progenitor cells (MAPCs)
All blood lineages.
Hepatocytes? Muscle? Neural? 
Hair follicle lineages and 
surrounding epithelia 
All intestinal epithelial lineages
Neurons, astrocytes, 
oligodendrocytes, blood? Muscle?
Skeletal muscle cells, blood?
Smooth muscle cells
Adipocytes, osteoblasts, 
chondrocytes, tendon. Muscle? 
Neural? Hepatocytes?
Cells of all three germ layers 
including liver, brain and muscle
Morrison and 
Weissman 1994 
Levy et al 2005
Marshman et al 
2002
Morrison et al 
1999, Uchida et al 
2000
Jackson et al 
1999
Beltrami et al 
2003
Pittenger et al 
1999
Jiang et al 2002a
Table  1.1.  Adult stem cell populations (in humans as  well as  in animal models) and their 
differentiation potential.  Each stem cell population in this representative selection has been 
characterised  to  varying  degrees,  with  haematopoietic  stem  cells  being  the  most  well 
characterised stem cell population. Each adult stem cell population is responsible for forming 
distinct  cell  subsets,  but  there  may  be  some  degree  of plasticity  in  their  developmental 
potential (indicated by a ? next to the cell lineage, as stem cell plasticity is a debated, and not 
fully defined, phenomenon).
261.3.1  Haematopoietic stem cells
The presence of a cell within mouse bone marrow that could rescue the haematopoietic 
system of lethally irradiated mice provided the first evidence of the haematopoietic stem 
cell  (HSC).  Clonogenic  colonies  of donor origin  were  formed  in  the  spleen,  and were 
found to contain cells of the myeloerythroid lineage, as well as occasional cells that could 
reconstitute  secondary  hosts  after  serial  transplantation  (Till  and  McCulloch  1961, 
Siminovitch et al 1963). Identification of surface markers of bone marrow cells, followed 
by  purification  of  cell  populations  with  specific  marker  combinations,  allowed  the 
isolation  and  characterisation  of  mouse  HSC  and  multiple  progenitor  populations 
(Spangrude  et al  1988,  Morrison  and  Weissman  1994).  The  only population  with  the 
ability  to  self renew  and  form  cells  of all  blood  lineages  in  long-term  reconstitution 
experiments was termed long term HSC (LT-HSC, Fig 1.1 A), which has a specific marker 
expression  profile  (C-kit+Thy-1.1 ^Lin’Sca-1+)  (Spangrude  et  al  1988,  Morrison  and 
Weissman  1994).  Short  term  HSC  (ST-HSC)  and  multipotent  progenitors  (MPP)  are 
subsets of this population (with a Lin'/l0 phenotype); they are capable of giving rise to all 
blood  lineages but  ST-HSC  are  capable of short-term  self-renewal  whereas  MPP  have 
minimal  self-renewal  ability  (Morrison  and  Weissman  1994).  Several  oligopotent 
precursor  populations  also  exist,  such  as  common  myeloid  progenitors  (CMP)  and 
common lymphoid progenitors (CLP, Fig  1.1 A), which differentiate into distinct subsets 
of  blood  lineages  (Kondo  et  al  1997,  Akashi  et  al  2000).  Thus,  HSCs  exist  in  a 
developmental  hierarchy,  where  the  multipotent,  self-renewing  population  (LT-HSCs) 
gives  rise  to  various progenitor cells  with progressively more  restricted  differentiation 
and/or self-renewing potential, and eventually to precursors of a single mature cell type. 
As a result of the expression of specific sets of surface markers, populations at all levels of 
this hierarchy have been prospectively isolated and characterised in detail. The ability to 
obtain  highly  purified  populations  of mouse  HSC  has  allowed  for  their  in  vivo  self­
renewal  and  differentiation  capacity to  be  definitively  demonstrated  on  the  single-cell 
level (Spangrude et al 1988, Morrison and Weissman 1994, Osawa et al 1996). Whereas 
mouse  HSC  reside  mostly within  the  CD34'  population,  human  HSCs  have  also  been 
isolated, but are mostly CD34+;  they have been prospectively isolated  as  CD34+CD38' 
/k)Lin"(Baum et al 1992, Bhatia et al 1997), and are estimated to constitute 0.05-0.1%
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Figure  1.1. Adult stem cell populations. A, Haematopoietic stem cell lineage. LT-HSC have 
long term self-renewal capacity and can form all blood lineages. They give rise to ST-HSC 
with  short-term  self-renewal  capacity,  then  MPP,  with  no  or  little  self-renewal  capacity. 
Oligopotent  progenitors  include  CMP  and  CLPs.  CMPs  differentiate  into  MEPs  that  form 
erythrocytes  and  platelets,  and  also  GMPs  that  form  granulocytes  and  macrophages.  CLPs 
differentiate  into  T  lymphocytes,  B  lymphocytes  and  natural  killer  cells.  Both  CMPs  and 
CLPs give rise to dendritic cells. Figure adapted from Passegue et al 2003; B, Epidermal stem 
cells in the hair follicle. Stem cells reside in the bulge region (orange cells) from which they 
can migrate to the sebaceous gland, epidermis and basal region.  Here, they proliferate (blue 
cells)  and  form  cells  of  the  hair  follicles,  sebaceous  glands  and  possibly  interfollicular 
epidermis. Figure reprinted by permission from Macmillan Publishers Ltd:  Nature, Reya and 
Clevers © 2005.
28of human fetal bone marrow cells (Baum et al 1992). These cells could repopulate lethally 
irradiated SCID or NOD/SCID mice (Bhatia et al 1997). Rare CD34'CD38'Lin‘ cells with 
repopulation capacity in NOD/SCID mice have also been identified (Bhatia et al 1998).
As well as forming all cell types of the blood lineage, HSCs may be able to differentiate 
into cells of other germ layers.  For instance,  murine bone marrow-derived cells  (either 
partially or highly purified HSCs, or unfractionated bone marrow) have been reported to 
form cells of the liver (Lagasse et al 2000), muscle (Orlic et al 2001, LaBarge and Blau 
2002) and brain (Brazelton et al 2001, Mezey et al 2001). However, this plasticity remains 
controversial, as some researchers believe it to be due to cell fusion (reviewed in Wagers 
and  Weissman  2004).  In  contrast,  others  report  that  cell  fusion  does  not  contribute 
significantly  to  the  observations,  but  such  studies  used  un-fractionated  bone  morrow 
(Harris  et  al  2004),  or  a  partially  characterised  HSC  population  (Jang  et  al  2004). 
Definitive demonstration of transdifferentiation will  require  the use  of highly purified, 
phenotypically  characterised  cell  populations,  combined  with  functional  studies  of the 
“transdifferentiated”  cell  type,  and  importantly  evidence  (e.g.  using  FISH  to  detect  a 
diploid  chromosome  complement)  that  cell  fusion  has  not  occurred  (Wagers  and 
Weissman 2004).
1.3.2  Stem cells of the skin: hair follicle stem cells
The mammalian epidermis consists of multiple layers of epithelium punctuated by hair 
follicles, complex structures specialised in making the hair shaft, and sebaceous glands 
(Fig  1  .IB). Early studies identified cells within this niche with the ability to retain 3H- 
thymidine for long periods in mice (and thus were called label retaining cells or LRCs), 
indicating a slow cell cycle time; this is a characteristic of many stem cell populations 
(Cotsarelis et al 1990, Taylor et al 2000). The LRCs were found to be located in the bulge 
region of the hair follicle (Fig  1  .IB), and could give rise to cells of the hair follicle and 
upper epithelial cells (Taylor et al 2000). Furthermore, it has been shown that LRCs, also 
called bulge or hair follicle stem cells (HFSCs), can migrate into the basal region of the 
hair  follicle,  as  well  as  the  upper  follicle  and  epidermis,  and  give  rise  to  a  transit- 
amplifying  population,  capable  of  several  further  rounds  of  division  before  finally 
differentiating.  These  HFSCs  gave  rise  to  all  cell  lineages  of  the  hair  follicle  and
29sebaceous gland during homeostasis, as well as the interfollicular epidermis after trauma 
in mice, and were thus termed multipotential stem cells (Taylor et al 2000, Oshima et al 
2001).  Lineage-tracking  studies,  performed  by  labelling  the  bulge  cells  using  label 
retention or GFP expression driven by a promoter that is specifically activated in bulge 
cells  and  following their fate  in  vitro  or in  vivo,  allowed  enrichment of the bulge  cell 
population and again highlighted the ability of these cells to differentiate into all cell types 
in the  hair  follicle  and  surrounding  epithelia  (Tumbar et al 2004,  Morris  et al 2004). 
Recent work has succeeded in isolating clonal populations of murine bulge HFSCs using a 
combination of GFP-marking of the bulge cell population plus FACS sorting for CD34+ 
cells (a marker of HFSCs) (Blanplain et al 2004). This study demonstrated self renewal in 
vitro,  as  well  as  the  formation  of epidermis,  hair  follicles  and  sebaceous  glands  after 
grafting  of clonal  populations  (cultured  in  vitro)  into  recipient  mice,  providing  strong 
evidence  of their multipotentiality.  However,  other studies  suggest  that  HFSCs  do  not 
contribute to the epidermis during homeostasis, but only in response to tissue injury, and 
that other stem cell populations on the epidermal niche may perform this role (Claudinot 
et al 2005, Ito et al 2005, Levy et al 2005). This indicates that further definition of each 
cell  population  must  be  achieved;  progress  has  been  made  using  gene  expression 
microarray profiling (1.7.1) of either enriched (Tumbar et al 2004, Morris et al 2004) or 
clonal (Blanplain et al 2004) populations of bulge stem cells.  These were compared to 
profiles of non-stem cell populations from the epidermis, or other stem cell populations, 
and revealed numerous candidate genes that may contribute to their stem cell properties. 
These studies were performed using mouse models,  and recently human bulge cells,  of 
which  20%  represented  the  label-retaining  cell population,  were  obtained  from  human 
skin samples (Ohyama et al 2006). Their gene expression profile, obtained via microarray 
analysis,  was  compared  with  that  of  non-bulge  cells,  and  a  subset  of  genes  that 
characterised the bulge cell population was identified, including surface markers that may 
allow for enrichment of this cell population (Ohyama et al 2006). Thus, progress is being 
made towards defining the molecular basis of the stem cell properties of this adult stem 
cell population.
301.4  Mesenchymal stem cells
1.4.1  Identification of a multipotent mesenchymal stem cell within the bone marrow
Two  primary  elements  are  typically  thought  to  constitute  the  bone  marrow:  the 
haematopoietic tissue, and the associated stroma (Bonnet 2003).  The stromal portion of 
bone marrow contains many cell types,  including endothelial  cells,  mature cells  of the 
mesenchymal lineage, such as osteoblasts and adipocytes, and may also contain cells of 
the haematopoietic lineage, for example macrophages.  Bone marrow stromal cells were 
initially characterised as having the ability to support haematopoiesis, as well as maintain 
HSCs in an undifferentiated state (Pittenger and Marshak 2001). In recent years, a second 
bone  marrow  stem  cell  has  been  characterised  that  resides  within  the  stromal  cell 
compartment and can, like HSCs, give rise to multiple cell lineages.
The possibility of the existence within bone marrow of a cell with the  ability to  form 
various mesenchymal tissues first arose from experiments performed during the 1950s and 
60s.  The  osteogenic  potential  of bone  marrow  was  shown  when  whole  bone  marrow 
samples were transplanted at various sites into host animals. Histological analysis revealed 
extensive  formation  of  tissues  resembling  bone  and  marrow  stroma  at  the  site  of 
transplantation,  which  could  also  support  haematopoiesis  from  invading  host 
haematopoietic stem cells (Urist and McLean 1952, Tavassoli and Crosby 1968). Similar 
experiments  involved  the use  of diffusion chambers,  which  consist of semi-permeable 
membranes separated by a plastic ring that do not allow passage of donor or host cells. 
Transplantation  of chambers  containing  either  fragments  or  cell  suspensions  of bone 
marrow resulted in formation of osteogenic tissue (alkaline phosphatase-staining) within 
the chamber after around day 30 (Friedenstein et al 1966). This indicated that, rather than 
the donor material attracting osteogenic host cells, there existed within the transplanted 
marrow stroma a progenitor cell capable of differentiating into bone.
Friedenstein and co-workers showed that the osteogenic potential of bone marrow was a 
feature of a small population of cells, termed fibroblast colony forming cells (FCFC) or 
colony forming units-fibroblastic  (CFU-F).  When single-cell  suspensions of guinea pig 
bone marrow were cultured in vitro at low densities in serum-containing media, colonies
31of  fibroblasts,  derived  from  single  cells,  were  formed  (Friedenstein  et  al  1970, 
Friedenstein  1976). Rodent CFU-F were shown to have a high proliferative capacity in 
vitro,  but  to  be  in  a  resting  state  in  vivo  (Friedenstein  1976);  studies  of the  human 
counterpart of CFU-Fs were in strong agreement with this (Castro-Malaspina et al 1980). 
Intraperitoneal transplantation into host animals of diffusion chambers containing cultured 
guinea  pig  fibroblast  colonies  resulted  in  bone  formation,  which  did  not  occur  when 
fibroblasts cultured from the spleen were transplanted (Friedenstein et al 1970). This work 
was  confirmed  and  extended  by  others,  who  showed  extensive  formation  of  bone, 
cartilage and fibrous tissue within diffusion chambers inoculated with marrow fibroblast 
cultures  (Ashton  et  al  1980).  It  was  proposed  that  an  undifferentiated  stromal  cell 
precursor may exist, capable of forming both bone and cartilage; however the presence of 
committed progenitor cells, each giving rise to a different cell type, could not be ruled out. 
This  question was  addressed by  studies  of in  vivo  differentiation  of single  fibroblastic 
clones.  About  15%  of colonies  transplanted  under  the  renal  capsule  produced  bone 
marrow organ, consisting of osteogenic tissue, typical adipose cells and marrow stromal 
cells (Friedenstein 1980). Thus, colonies derived from a single cell were capable of giving 
rise to multiple cell lineages.
The concept of a multipotent stem cell of stromal  origin residing in bone marrow was 
formally presented by Owen in  1978.  It was suggested that the differentiated cell types 
residing in marrow stroma may derive from a single common progenitor, or stem cell, 
analogous to the haematopoietic system within the marrow (Owen 1978). A more detailed 
model was later proposed, in which stem cells, committed progenitors and mature cells 
were all present in marrow stroma, with reticular, fibroblastic, adipocytic and osteogenic 
being  the  possible  differentiated  phenotypes  due  to  experimental  evidence  showing 
differentiation  to  these  lineages  (Owen  1985,  1988).  Caplan  expanded  this  theory  to 
include all mesenchymal lineages, namely myocytes, chondrocytes, tenocytes, osteocytes, 
adipocytes and stromal and dermal fibroblasts (because these embryonic cell types were 
thought to derive from the mesodermal germ layer, rather than there being experimental 
evidence at the time to support this differentiation potential), and was the first to use the 
term mesenchymal stem cell (MSC) (Caplan 1991).
32The  studies  of differentiation  of isolated  clones  went  some  way to  demonstrating  the 
multipotentiality  of  MSCs.  Further  evidence  was  provided  from  differentiation  of 
conditionally immortalised mouse MSC clones, one of which had the ability to form four 
mesenchymal  phenotypes:  chondrocytes,  osteoblasts,  adipocytes  and  haematopoiesis- 
supportive cells (Dennis et al  1999).  A  key study in  1999  characterised human MSCs 
(hMSCs) and their differentiation potential. Human MSCs were estimated to constitute a 
fraction  (0.001-0.01%)  of nucleated  cells  within  the  bone  marrow.  It  was  shown  that 
hMSCs isolated from three different donors could all give rise to osteocytes, chondrocytes 
and adipocytes. Moreover, clonal populations were established, and 2 out of 6 populations 
could differentiate into all three lineages, consistent with the donor hMSCs from which 
they  were  derived  (Pittenger  et  al  1999).  Thus,  the  existence  of cells  with  in  vitro 
multipotentiality was demonstrated.
1.4.2  Differentiation potential of bone marrow-derived MSCs
1.4.2.1  MSC differentiation to mesodermal lineages
Adipocytes,  osteoblasts,  chondrocytes  and  haematopoiesis-supportive  stroma.  As
described  above,  MSCs  were  originally  identified via their  ability to  differentiate  into 
particular  mesodermal  lineages.  The  studies  by  Pittenger  and  Dennis  definitively 
demonstrated  their  ability,  at  the  clonal  level,  to  differentiate  in  vitro  into  adipocytes, 
osteoblasts, chondrocytes (Fig.  1.2), and also haematopoiesis-supporting stromal cells in 
the case of murine MSCs (Dennis et al  1999,  Pittenger et al  1999).  Defined hormonal 
regimens have been developed that induce robust and specific in vitro differentiation into 
adipocytes  (1.6.1),  osteocytes  and  chondrocytes  (Pittenger  et  al  1999,  Tustsumi  et  al 
2001), so the ability of MSCs (both human and rodent) to differentiate into these lineages 
is well established.
Tenocytes MSCs  from  rabbit bone marrow were  shown to  differentiate into tenocytes, 
capable of replacing severed tendon (a tissue of mesodermal origin) in an animal model 
(Young et al 1998), but this lineage is little studied, and in vitro differentiation of clonal 
hMSC populations to tenocytes has not been reported.
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Figure 1.2. Differentiation potential of MSCs. Clonal populations of MSCs can differentiate in 
vitro into adipocytes, osteocytes and chondrocytes. They have also been shown to give rise to 
haematopoiesis-supportive stromal cells and tenocytes capable of repairing damaged tendon. 
MSCs may also be able to form cells of the muscle and neural  lineages, but this capacity is 
under debate.
34Cardiac and skeletal muscle cells In vitro treatment of immortalised murine MSC clones 
with 5-azacytidine led to the generation of spontaneously beating cardiomyocyte-like cells 
in some clones, but as differentiation of these clones to other lineages was not assessed it 
could  not  be  ruled  out  that  these  cells  were  unipotential  progenitors  rather  than 
multipotential  MSCs  (Makino  et al  1999).  Similar results  were  obtained  when  human 
MSCs were treated with 5-azacytidine, but non-clonal hMSC populations were used (Xu 
et al 2004). When labelled hMSCs were injected into the heart of immunodeficient mice, 
cardiomyocyte-like labelled cells were detected  (see also  section  1.4.6),  but cell  fusion 
was not discounted as a causative factor (Toma et al 2002). A further study reported that 
unfractionated mouse bone marrow cells, when transplanted into immunodeficient mice, 
migrated  to  areas  of induced  skeletal  muscle  degeneration  and  underwent  myogenic 
differentiation  to  contribute  to  regeneration  (Ferrari  et  al  1998).  However,  this  result 
cannot be attributed directly to MSCs, as an unpurified cell population was used. Thus, 
there is some evidence of differentiation towards the myogenic lineage by cells that co- 
purify  with  MSCs,  but  further  work  using  clonal  populations  and  demonstrating 
multilineage potential is required to show that this is a property of MSCs rather than more 
restricted progenitor cells.
In vivo differentiation potential Several studies of systemic infusion of labelled murine 
MSCs  into  irradiated  mice  reported  engraftment  into  several  mesodermal  tissues, 
including marrow, bone and cartilage (as well as lung, an endodermal tissue), combined 
with  tissue-specific  gene  expression  (Pereira  et  al  1995)  and  signs  of  osteoblast 
differentiation in an osteogenesis imperfecta mouse model (Pereira et al 1998). In a more 
recent study, GFP-tagged, phenotypically characterised murine MSCs were intravenously 
infused into minimally irradiated mice, and were found after 1  month mainly in the lungs, 
liver and  kidney,  but  also  in the  muscle,  heart,  brain and  spleen  (Anjos-Alfonso  et al
2004).  Immunohistochemical  assessment  revealed  that  MSCs  differentiated  into  lung 
epithelial  cells, hepatocytes,  renal tubular-like  cells  and myofibroblasts,  albeit at  a low 
frequency.  Human  MSCs that had been transplanted  in  utero  into  sheep  engrafted and 
survived in multiple non-haematopoietic tissues for up to 13 months (Leichty et al 2000). 
Furthermore,  hMSCs  were  found  to  differentiate  into  cells  with  morphological  and 
phenotypic  properties  of chondrocytes,  adipocytes,  bone  marrow  stromal  cells,  thymic
35epithelial  cells,  cardiomyocytes  and  skeletal  myocytes.  Thus,  these  studies  provide 
knowledge  of  MSC  behaviour  in  vivo,  but  it  must  again  be  emphasised  that  these 
populations were not clonal, and cell  fusion was not investigated.  However,  as well  as 
mesodermal  differentiation,  the  cell  populations  used  were  found  to  differentiate  into 
lineages  of  non-mesodermal  origin,  providing  evidence  that  heterogeneous  MSC 
populations may have additional differentiation properties.
1.4.2.2  MSC differentiation to non-mesodermal lineages
Hepatocytes A small study described the treatment of non-clonal hMSCs with hepatocyte 
growth  factor (Wang  et  al  2004).  After 20  days,  slight  expression  at  the  mRNA  and 
protein level of some hepatocytes markers was seen, indicating a possible hepatocyte-like 
phenotype, but functional studies were not performed.
Neural cells Several studies that have claimed to induce in vitro neural differentiation of 
rodent or human MSCs used /3-ME or DMSO/BHA to initiate the process. This protocol 
was pioneered by Woodbury and co-workers: after treatment, human or rat MSCs showed 
expression of neurological markers and outgrowth of neuronal processes (Woodbury et al 
2000).  Similar  studies  reported  the  generation  of  neurons  with  electrophysiological 
properties (Hung et al 2002), or with characteristics similar to neurons produced after co­
culture with Schwann cells (Zurita et al 2005). However, it has recently been reported that 
/3-ME  or  DMSO/BHA  treatment  causes  stress-induced  depolymerisation  of the  actin 
cytoskeleton and  retraction of the  cytoplasm  in numerous  cell  types,  meaning  that the 
“neural” morphology observed was a result of stress rather than differentiation (Lu et al 
2004, Neuhuber et al 2004). Moreover, no increase in neural marker expression was seen 
using Western blotting, and it was concluded that the increase in immunohistochemical 
staining for neural markers was due to higher antigen density associated with smaller cell 
size.
Other in vitro studies have utilised growth factors known to promote neural differentiation 
of ESCs and neural stem cells. Incubation of human or mouse bone marrow stromal cells 
with  differentiation  medium  containing  such  factors,  or  co-culture  of labelled  murine 
MSCs  with rat midbrain cell  suspensions,  resulted  in  a small  percentage  of cells  with
36morphologies  similar to  immature  neurons  or  glial  cells  and  occasional  expression  of 
neural  markers  (Sanchez-Ramos  et  al  2000).  Again  however,  cell  fusion  was  not 
discounted  from  the  co-culture  experiments.  Also,  no  tests  of neuronal  function  were 
performed.  Hermann  and  co-workers  used  suspension  culture  of  non-clonal  hMSCs 
followed by incubation with different neural growth factors (Hermann et al 2004). Cells 
with  various  phenotypic  and  functional  properties  reminiscent  of  neural  cells  were 
obtained, including: dopamine-releasing cells expressing some neural markers; cells with 
phenotypic characteristics of astrocytes, oligodendrocytes and rare immature neuron-like 
cells. A proportion of cells treated with a specific growth factor had voltage-dependent 
electrophysiological outputs in patch-clamp experiments typical of glial cells.
With regards to the  in  vivo  ability of MSCs to  form neural cells,  Kopen  et al injected 
BrdUrd-labelled  murine  MSCs  into  neonatal  mouse  brains  (Kopen  et  al  1999).  Cells 
double-labelled for BrdUrd and GFAP, an astrocyte marker, or neurofilament, a neuronal 
marker,  were  identified,  indicating  that  the  MSCs  differentiated  into  these  cell  types, 
although the question of whether MSCs may have fused with recipient brain cells was not 
addressed.
In summary, although these studies have raised the possibility of MSC differentiation to 
neural and hepatic lineages, definitive evidence of this ability has not yet been provided. 
This will require in vitro studies of clonal MSC populations incorporating phenotypic and 
functional assays, combined with in vivo investigations that also address the issue of cell 
fusion.
1.4.2.3  Multipotent adult progenitor cells (MAPCs)
A  subpopulation  of bone  marrow  cells  that  co-purify with  hMSCs,  and  that  could  be 
isolated from human or rodent marrow, has been described (Reyes et al 2001, Jiang et al 
2002a, 2002b). They were termed multipotent adult progenitor cells, or MAPCs. Colonies 
derived from single cells were shown to be able to differentiate in  vitro into cells with 
phenotypic  and  functional  characteristics  of  endothelial  cells  (visceral  mesoderm), 
neurons, astrocytes and oligodendrocytes (neuroectoderm), and hepatocytes (endoderm), 
as  well  as cells  of mesenchymal  lineages  (Reyes  et al 2001,  2002,  Jiang  et al 2002a,
372002b, Schwartz et al 2002). In fact when injected into an early mouse blastocyst, single 
mouse  MAPCs  contributed  to  most  somatic  tissues  (Jiang  et  al  2002a).  A  possibility 
suggested to explain these findings was that MAPCs could represent a pluripotential stem 
cell that persists into adulthood and is capable of differentiating into cells of all three germ 
layers. However, it could not be ruled out that cell fusion may be responsible for the in 
vivo  observations  (Jiang et al 2002a).  The relationship  of MAPCs to  hMSCs  is  also  a 
matter for debate. The in vitro culture conditions of the two populations are very different; 
MAPCs are cultured at low densities and 2% FCS, whereas hMSCs are cultured at higher 
densities  and  10%  FCS.  It  is  possible  that  this  could  contribute  to  the  differences  in 
potentiality observed, and that hMAPCs are the result of de-differentiation of hMSCs due 
to culture conditions (Bonnet 2003). Thus, whether MAPCs truly exist as a pluripotential 
stem cell population in vivo is as yet unknown, and whether they may be related to hMSCs 
is a matter for future research.
1.4.3  Characterisation of the human bone marrow MSC population
As previously stated, bone marrow hMSCs reside within a tissue consisting of numerous 
cell types, and it has been the aim of many investigations to characterise hMSCs in order 
to isolate a pure hMSC population. The classical method of hMSC isolation is via density 
gradient centrifugation to separate the mononuclear cell fraction, followed by adherence to 
plastic, thus giving some degree of purification as non-adherent haematopoietic cells are 
removed (Pittenger et al 1999). However, a lack of knowledge regarding surface markers 
has  precluded  the  use  of more  sensitive  antibody-aided  selection.  Studies  of  surface 
markers of cultured hMSCs have shown that they are distinct from haematopoietic cells, 
as they do not express CD45, CD34  and CD 14,  markers of the haematopoietic  lineage 
(Pittenger et al 1999, Conget and Minguell 1999). Numerous other surface molecules have 
been  identified  (Table  1.2),  and  indicate  that  hMSCs  do  not  have  a  unique  antigenic 
profile,  but  express  markers  of  mesenchymal  (SH2,  SH3  and  SH4,  markers  of 
mesenchymal  progenitors;  ACTA1,  vascular  smooth  muscle  marker),  endothelial 
(VCAM-1) and epithelial cells (cytokeratins  18 and  19) (Conget and Minguell  1999). It 
must be noted however that varied culture conditions used by different laboratories and 
continued time in culture mean that contradictory results regarding MSC marker profiles 
are frequent (Bonnet 2003).
38Marker Type Marker Name
Expressed Not expressed
Specific antigens 
Haematopoietic markers 
Cytokines and growth factors
Cytokine and growth factor 
receptors
Adhesion molecules
Extracellular matrix 
molecules and receptors
Other
SH2, SH3, SH4, Stro-1, 
ACTA1
IL- la,6, 7, 8, 11, 12, 14, 
and 15
LIF, SCF, GM-CSF, G- 
CSF, M-CSF 
IL1R, IL3R, IL4R, IL6R, 
IL7R, LIFR, SCFR, G- 
CSFR, IFNyR, TNFR1, 
TNFR2, TGF/3R1, 
TGF/5R2, bFGFR, 
PDGFR, EGFR 
Integrins ol (CD49a), 02 
(CD49b), o3 (CD49c), ao 
(CD49e), /31 (CD29), < 5 3  
(CD61), /S4 (CD 104) 
ICAM-1 (CD54), ICAM-2 
(CD 102), VCAM-1 
(CD 106), ALCAM-1 
(CD 166), LFA3 (CD58), 
L-selectin (CD62L), 
endoglin (CD 105), 
hyaluronate receptor 
(CD44)
CK18, CK19 
CD9, CD13, Thy-1 
(CD90), HLA-ABC 
(MHC I) (low)
CD 133
CD4, CD 14, CD34, CD45 
(PTPRC), c-kit/SCFR (CD117)
IL-2R (CD25)
o4 (CD49d), oL (CD1 la), C/52 
(CD 18)
ICAM-3 (CD50), E-selectin 
(CD62E), P-selectin (CD62P), 
PEC  AM-1  (CD31), vWF, 
Cadherin 5
HLA-DR (MHC II)
Table  1.2.  Surface marker expression profile of MSCs.  Data obtained from Pittenger et al 
1999, Minguel et al 2001, Majumdar et al 2003 and Wagner et al 2005.
39Unique markers are needed to definitively identify and purify non-expanded MSCs. To 
date,  the  most  promising  candidate  has  been  the  monoclonal  antibody  STRO-1.  It’s 
antigen (as yet unidentified) is expressed by a population of bone marrow stromal cells 
(termed CFU-Fs in these studies) that possesses the ability to proliferate extensively and 
differentiate  in  vitro  into  osteoblasts,  adipocytes,  chondrocytes  and  haematopoiesis- 
supportive stroma (Simmons and Torok-Storb  1991, Dennis et al 2002). However, around 
95% of this STRO-1+ population constituted glycophorin A-positive nucleated erythroid 
precursors,  so  a  further  glycophorin  A'  selection  was  required  to  enrich  for  CFU-Fs 
(Simmons  and Torok-Storb  1991).  Double  selection for cells  from  whole  human bone 
marrow  expressing  high  levels  of  STRO-1  (STR01br1ght)  and  also  VCAM1/CD106 
resulted  in  5000-fold  enrichment  of the  CFU-F  population  (Gronthos  et  al 2003a).  A 
subset of STR01brightVCAM+ cells exhibited extensive in vitro proliferation and clonal 
multipotentiality;  as other clones  exhibited  low proliferation and differentiation,  it was 
concluded that multipotential  stem cells constituted a subset of the  isolated population, 
which  also  contained  more restricted progenitor cells  (Gronthos  et  al 2003a).  CFU-Fs 
have also been enriched via selection of CD45‘,CD14’,CD73+/CD49a+ (Boiret et al 2005) 
or  CD45low ,D7-FIB+  (a  fibroblast  marker  of  unknown  function,  Jones  et  al  2002) 
populations from non-expanded bone marrow samples, but a pure CFU-F population was 
not obtained from either of these methods. Other attempts to define the hMSC population 
have  included  comparison  of the  gene  expression  profiles  of  hMSCs  from  different 
locations  (1.4.5)  and fibroblasts  (which  are  morphologically similar to  hMSCs),  where 
certain genes were enriched or depleted in hMSCs (Ishii et al 2005). Combined with the 
cell surface marker studies it is clear that progress  is being made towards  defining the 
hMSC population, but there is as yet no marker that is unique to hMSCs.
1.4.4  The stem cell nature of MSCs
Although  the  term  mesenchymal  stem  cell  is  widely  used,  no  unequivocal  evidence 
demonstrating stem cell properties for hMSC in vivo has yet been provided (Dennis and 
Caplan 2004, Baksh et al 2004). Although hMSC can be expanded for 15-25 passages in 
vitro  depending  on  culture  conditions  and  donor  age  without  losing  differentiation 
potential, this in vitro proliferative capacity is not indefinite (Bruder et al  1997, Conget 
and  Minguell  1999,).  Furthermore,  it  is  possible  that  hMSC  in  vitro  represent  a
40heterogeneous population of multipotential stem cells and lineage-restricted progenitors; 
evidence  from  this  comes  from  the  studies  of Gronthos  and  Pittenger  where  only  a 
proportion of hMSC clones could differentiate into three lineages (Pittenger et al  1999, 
Gronthos et al 2003a,). This could be a reflection of a stem cell hierarchy similar to HSC 
(Owen 1985, Minguel et al 2001). Furthermore, sub-optimal culturing conditions in vitro 
may also  cause loss of potentiality of a proportion of multipotential  cells,  leading to  a 
heterogeneous population.  Definitive proof of hMSC  self-renewal  and multipotentiality 
would  come  from  the  isolation  of  a  highly  purified  cell  population  followed  by 
demonstration that, at the single cell level, un-manipulated hMSCs could give rise in vivo 
to diverse progeny and repopulate host  animals after serial  transplantation  (Joseph and 
Morrison 2005).  Currently the only adult stem cell population for which these rigorous 
criteria  have  been  demonstrated  is  the  HSC  (1.3.1),  and  the  lack  of a  hMSC-specific 
marker  precludes  such  work  in  this  population.  However,  various  observations  from 
cultured or freshly isolated hMSCs point towards a stem cell function.
Clonal populations of hMSC  are capable of giving rise robustly to multiple lineages  in 
vitro, arguing strongly for the presence of a multipotential stem cell (Pittenger et al 1999, 
Gronthos  et  al  2003a).  In  addition,  studies  of freshly  isolated,  non-expanded  hMSCs 
revealed that they lacked detectable expression of the Ki-67 antigen, a marker of cycling 
cells,  and  were mostly in G0/G1  phase  of the  cell  cycle,  entering  the  cell  cycle  after 
exposure to serum in culture (Castro-Malaspina et al  1980, Conget and Minguell  1999, 
Gronthos et al 2003a). This indicates that hMSC in vivo are a resting cell population, a 
characteristic of other stem cell populations (Taylor et al 2000).  Freshly isolated hMSC 
were also found to exhibit telomerase activity (Gronthos et al 2003a) which persisted in 
culture for at least 12 passages (Pittenger et al 1999); this is again a characteristic of stem 
cells with self-renewal capacity.
In  summary,  bone  marrow-derived  hMSCs  exhibit  multiple  stem  cell  properties,  but 
further work will be needed to definitively demonstrate their in vivo stem cell nature. In 
vitro studies of their stem cell characteristics, such as the ability to robustly differentiate 
into specific lineages, may further our understanding of stem cell  function and provide 
mechanisms to study this population in vivo.
411.4.5  Tissue-specific MSCs
In  addition to  their presence  in bone  marrow,  cells  with  the  characteristics  of hMSCs 
reside in other human tissues, including trabecular bone (Noth et al 2002), deciduous teeth 
(Miura et al 2003),  skin and muscle (Young  et al 2001).  MSC-like cells  from adipose 
tissue  and umbilical cord blood have received the most  attention.  Fibroblastic,  plastic- 
adherent cell populations were isolated from lipoaspirates (ADSC, Zuk et al 2001, 2002) 
and placental blood (UBSC, Erices et al 2000, Lee et al 2004a) which could be maintained 
in vitro for many population doublings. Clonal populations of both ADSCs and UBSCs 
showed  trilineage  differentiation  potential  to  adipocytes,  osteocytes  and  chondrocytes 
(Zuk et al 2002, Lee et al 2004a), although these multipotential clones were reported to be 
rare in ADSC and bi- and uni-potential clones were also observed. ADSC were shown to 
differentiate into adipocytes that functionally resembled white adipose tissue, as well as 
adipocytes from differentiated bone marrow hMSC (Rodriguez et al 2004, Dicker et al
2005). Clonally-derived UBSC populations underwent differentiation into hepatocyte-like 
and neural cells (Lee et al 2004a). Heterogeneous populations of ADSC and UBSC have 
been shown to differentiate into myogenic cells (Zuk et al 2001, 2002, Gang et al 2004), 
and ADSC  may also be able to  form hepatocyte-like  (Seo  et al 2005)  and neural  cell 
lineages (Zuk et al 2002,  Safford  et al 2002).  However,  some of the methods used to 
induce  neurogenesis  in  these  studies  have  come  under  question  (1.4.2.2),  and  clonal 
studies will be needed to confirm findings from mixed cell populations because of a high 
potential for the presence of contaminating cells causing the observations.
The  relationship  between  bone  marrow  hMSCs,  ADSCs  and  UBSCs  has  been 
investigated.  Surface  marker  profiles  were  found  to  be  comparable  between  all 
populations  (Zuk  et  al  2002,  Lee  et  al  2004a,  Wagner  et  al  2005).  A  microarray 
comparison found ADSCs and bone marrow-hMSCs to be highly similar, with only 25 
genes from an array representing over 10,000 genes showing differential expression (Lee 
et  al  2004b).  However,  a  second  study  showed  numerous  genetic  differences  through 
pairwise comparisons of the three populations, but Gene Ontology analysis (1.7.1.2) of the 
differentially expressed genes did not reveal gene expression trends characteristic of the 
tissue of origin (Wagner et al 2005).
42Interestingly, there have also been reports of the isolation of cells with a similar antigenic 
profile to MSCs and the ability to differentiate into adipocytes and osteocytes from normal 
whole  blood  (Zvaifler  et  al  2000,  Kuznetsov  et  al  2001).  An  elegant  study  captured 
circulating precursor cells in rats that demonstrated adipogenic, osteogenic, chondrogenic 
and  myogenic  differentiation  in  culture,  and  when  immortalised  showed  clonal 
differentiation to these lineages (Wu et al 2003). Furthermore, labelled clonal cells were 
shown to home to the bone marrow and also areas of injured cardiac tissue (Wu et al
2003).  These studies indicate that a multipotential precursor cell,  reminiscent of MSC, 
may circulate in the blood and have the ability to home to sites of injury or disease. This 
may  also  provide  a  link  between  the  bone  marrow  and  tissue-specific  MSC-like 
populations, but as some studies were not able to isolate such cells from peripheral blood 
the  ability of MSC  to  circulate  is  still  controversial,  and  such theories  require  further 
investigation.
1.4.6  Physiological and therapeutic roles for MSCs
HSCs and HFSCs reside in tissues that constantly turnover and play an essential role in 
normal  tissue  replacement  and  response  to  injury  (Joseph  and  Morrison  2005).  It  is 
possible  that  a  physiological  role  for hMSC  would  also  be  tissue  repair  and  renewal 
(Dennis  and  Caplan  2004).  The  presence  of multipotential  hMSC-like  cells  in  tissues 
which they are capable of giving rise to, combined with a possible ability to circulate in 
the blood and home to a specific location, may support this theory, but this will remain as 
speculation  until  there  is  definitive  evidence  that  MSCs  exhibit  self-renewal  and 
multilineage differentiation at the clonal level in vivo (Roufosse et al 2004).
Although  a physiological  role  for  in  vivo  hMSCs  remains  hypothetical,  there  is  clear 
evidence of the efficacy of hMSCs use in therapeutic repair strategies for human diseases 
of mesenchymal  tissues.  Human  MSCs  are  easily  isolated,  expanded  and manipulated, 
have  the  potential  for  allogenic  transplantation,  and  as  adult  stem  cells  they  are  not 
surrounded by the  ethical  issues  created  by using  embryonic  stem  cells  for  stem  cell 
therapy.  By way  of example,  MSCs  from  animal  models  have  shown  promise  in  the 
treatment of tendon (Young et al 1998) and cartilage defects (Wakitani et al 1994). LacZ- 
tagged hMSCs, when injected into the hearts of healthy mice, were shown to differentiate
43into cardiomyocytes, as assessed by morphological changes and expression of myogenic 
markers, but cell fusion was not ruled out (Toma et al 2002). Such experiments involved 
the injection of MSCs either systemically,  or into the site of injury/disease, where they 
engrafted and showed signs of differentiating into the desired tissue, leading to repair of 
damage  and/or improved tissue function.  In a group of clinical  studies,  allogenic bone 
marrow transplantation was used to treat osteogenesis imperfecta in children,  a genetic 
disorder that causes severe bone fracturing and growth abnormalities.  Six months  after 
transplantation dramatic improvements in bone mineral content, body growth and fracture 
incidence were seen, but growth rate gradually slowed over time (Horwitz et al 1999). In 
further  work,  retrovirally-tagged  allogenic  hMSCs  were  infused  systemically  into 
osteogenesis imperfecta patients that had undergone this marrow transplantation, and were 
found  to  engraft,  to  varying  degrees,  in bone,  skin  and  marrow  stroma,  and produced 
measurable growth improvements (Horwitz et al 2002).
An  understanding  of the  molecular events  occurring  during  hMSC  differentiation  into 
specific lineages could provide novel therapeutic interventions for certain conditions. It is 
now known that osteoblasts play a crucial role in maintaining the HSC niche within the 
bone marrow (reviewed in Moore and Lemischka 2006). It has also been suggested that 
there may be a reciprocal relationship between osteogenesis and adipogenesis within the 
bone marrow, and that the decrease in bone mass associated with osteoporosis and age- 
related osteopenia may be a consequence of the increasing marrow adipose differentiation 
that  is  also  observed  with  age  (Gimble  et  al  1996,  Nuttall  and  Gimble  2000).  Thus, 
controlling the balance of differentiation into these two lineages may provide a means to 
stabilise  bone  formation,  and  maintain  a  constant  microenvironment  within  the  bone 
marrow.
441.5  Adipose tissue
1.5.1  Structure and development of adipose tissue
Adipocytes are the main constituent of adipose tissue,  and make up around one to two 
thirds of the total cell number (Ailhaud et al 1992). They are held in a network of collagen 
fibres,  and  contribute  the  major role  of adipose  tissue by  storing  lipid  in the  form  of 
triacylglycerol (Albright and Stem 1998). Two types of adipose tissue exist: white adipose 
tissue (WAT) and brown adipose tissue (BAT), which have opposing physiological roles 
(1.5.2). Mature white adipocytes vary greatly in size, reflecting their ability to accumulate 
different amount of lipids, and are unilocular; they contain a single, centrally located lipid 
droplet  that  pushes  the  nucleus  towards  the  plasma  membrane  (Fig.  1.3).  Brown 
adipocytes are smaller than white adipocytes and have multiple, smaller fat droplets and a 
high number of mitochondria (the cytochromes  of which result  in the typical  “brown” 
colour,  Cinti  2001).  Adipose  tissue  contains  numerous  other  cell  types.  It  is  highly 
vascularised  and  innervated,  and  also  contains  fibroblastic  connective  tissue  cells, 
macrophages and adipocyte precursor cells (or preadipocytes). These preadipocytes do not 
yet contain lipid, but are committed to the adipocyte lineage (Albright and Stem 1998).
The development of white adipose tissue begins prenatally in humans, probably during 
late  gestation,  but takes place  to  a  large  extent postnatally (Ailhaud 2001).  The  initial 
signs of adipogenesis (or the process of fat cell formation) are the organisation of vascular 
structures associated with accumulation of mesenchymal cells. It is thought that primitive 
mesenchymal  stem cells,  the  embryonal  equivalent of adult bone marrow  MSCs,  exist 
within the embryo and give rise to the preadipocytes and adipocytes within adipose tissue 
(Ailhaud et al 1992). Unipotential adipoblasts are the progeny of embryonic multipotential 
stem cells and presumably give rise to preadipocytes committed to the adipocyte lineage, 
but as specific markers to distinguish these populations in vivo do not exist, the processes 
of  early  adipose  tissue  development,  and  the  events  controlling  each  step,  remain 
somewhat unclear (Ailhaud 2001).  Preadipocyte  formation is  followed by formation of 
primitive  adipocyte  clusters,  containing  dense  masses  of  fat  cells  grouped  around 
capillaries (Ailhaud et al 1992). Initially, adipocytes contain few, small lipid droplets. The 
later  phases  of prenatal  adipose  development  involve  an  increase  in  the  number  of
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Figure  1.3.  Structure of white and brown adipocytes.  White adipocytes are unilocular and 
contain few mitochondria and an eccentric nucleus. Brown adipocytes contain multiple lipid 
droplets and mitochondria, and the nucleus may be centrally located. The structure of brown 
and white adipocytes  corresponds  closely to  their roles  in energy storage and dissipation, 
respectively. Figure adapted from Albright and Stem 1998.
46preadipocytes,  as  well  as  adipocytes,  but the lipid droplets  do not expand.  After birth, 
adipose tissue mass increases quickly, mainly due to an increase in adipocyte size from 
increasing volume and number of lipid droplets; the differentiation of preadipocytes also 
contributes to growth of adipose tissue at this time (Ailhaud et al  1992).  3H-thymidine 
labelling experiments have shown that preadipocytes are highly proliferative postnatally, 
whereas mature adipocytes cannot proliferate or divide,  so the development of adipose 
tissue is dependent upon de novo differentiation of preadipocytes (Rosen and Spiegelman
2000).  Adipose  tissue  development  occurs  throughout  the  lifetime  of  an  organism; 
preadipocytes  exist  in  adult  mammals  that  can  differentiate  in  response  to  diet  and 
environmental  conditions  (Ailhaud  et al  1992).  Mild  obesity  in  humans  is  caused  by 
increasing size of adipocytes (hypertrophy), but cells have a limit to how much lipid they 
can  store,  and  when  this  limit  is  reached  preadipocytes  differentiate,  increasing  the 
number of fat cells (hyperplasty); this occurs in severe obesity (Grimaldi 2001).
1.5.2  Role of adipose tissue in the body
The traditional role attributed to mammalian adipose tissue was the storage and release of 
excess energy as lipid. Modem studies have dramatically altered this view, and it is now 
apparent that adipose tissue is a highly active metabolic and endocrine organ.
As discussed above, two forms of adipose tissue exist in mammals: WAT and BAT. As 
opposed to the energy storage role carried out by WAT, BAT serves primarily to dissipate 
energy in the form of heat. The BAT-specific protein UCP1 is central to this function, and 
uncouples energy production from fuel metabolism by dissipating the proton gradient over 
the inner mitochondrial membrane created by the electron transport chain.  In this way, 
fuel metabolism can continue regardless of the cell’s energy status, allowing significant 
heat generation (Ricquier and Bouillaud 2000). This function of BAT is cmcial for non­
shivering  thermogenesis  in  hibernating  mammals;  accordingly  they  have  large  BAT 
deposits throughout life. In humans, BAT exists mainly in the neonatal period, and only in 
negligible  amounts  in  adults  (UCP1  mRNA  can  be  detected  in  adult  human  WAT, 
indicating that small numbers of BAT cells may remain) (Champigny and Ricquier 1996). 
Its physiological significance in humans is unknown, although it has been suggested that 
BAT may protect against obesity in all species where it is present (Rosen and Spiegelman
472000). Thus, the predominant adipose species in humans is WAT, so most studies on the 
role and development of human adipose tissue have focused on WAT.
Adipose  tissue  in  humans  is  found  mainly  either  under  the  skin  (subcutaneous)  or 
surrounding major organs (visceral). Lipid storage at these sites serves multiple functions; 
subcutaneous adipose tissue is important for heat insulation, as it conducts energy poorly, 
and visceral  adipose tissue provides  a mechanical  cushion and protects  internal  organs 
from jarring (Albright and  Stem  1998).  However, the main role of adipose tissue is to 
provide a buffering system when energy intake  and output are imbalanced.  In times of 
excess  energy  intake,  adipocytes  remove  lipid  from  the  bloodstream  (found  in 
chylomicrons or lipoproteins) as fatty acids through the action of lipoprotein lipase that is 
secreted by adipocytes and attached to the capillary endothelium (Albright and Stem 1998, 
Boschmann  2001).  Fatty  acids  are  then  converted  back  to  triacylglycerol  through  the 
action of numerous enzymes,  and are stored in the cytoplasm as non-membrane-bound 
droplets. Triacylglycerol constitutes an ideal energy store because of it’s high density and 
low water content relative to other energy-rich molecules such as glycogen (Klaus 2001). 
When energy output is greater than intake, triacylglycerol can be broken down into fatty 
acids and released into the bloodstream for use in energy-requiring tissues such as muscle 
and  liver.  This  process  is  mediated  mainly  by  the  enzyme  hormone-sensitive  lipase 
(Boschmann 2001). Adipose tissue receives many signals to control this dynamic balance 
of  fat  metabolism,  such  as  nutrient  status  (excess  blood-bome  lipid),  neural  signals 
(catecholamines  from  the  sympathetic  nervous  system:  increased  triacylglycerol 
mobilisation)  and  hormone  action  (insulin:  increased  fatty  acid  uptake  and  decreased 
triacylglycerol mobilisation).  It is a highly plastic organ, and can adapt swiftly to  large 
changes in energy status, acting as a long-term energy reservoir or an immediate energy 
source (Spiegelman and Flier 1996, Boschmann 2001, Bays et al 2004).
Adipose tissue is now described as  an endocrine organ;  as well  as being controlled by 
many signals,  adipose tissue  is known to  express and  secrete  a range  of molecules,  or 
adipokines, that exert their effects locally (autocrine/paracrine) or through release into the 
bloodstream (endocrine) (Kershaw and Flier 2004). The discovery of the hormone leptin 
in  1994 led to this description (Zhang et al  1994).  It is produced in adipose tissue and
48secreted into the bloodstream. The major target of leptin is the hypothalamus, although its 
receptor can be found in other tissues of the body,  indicating that is has wide-ranging 
effects (Trayhum and Beattie 2001). The most well documented role of leptin is  as an 
indicator of energy sufficiency. Leptin signals to decrease food intake and increase energy 
expenditure, and its levels correlate closely with extent of obesity (Spiegelman and Flier 
1996). Furthermore, mutations in the genes encoding leptin and its receptor are known to 
cause obesity and diabetes in mice (Zhang et al 1994, Chen et al 1996a) and further work 
has revealed that congenital  leptin deficiency can cause  early onset obesity in humans 
(Montague et al  1997).  Other important endocrine roles of leptin include regulation of 
immune  function,  angiogenesis  and  haematopoiesis  (Kershaw  and  Flier  2004).  Recent 
years have seen the discovery of many other adipocyte-secreted factors. Adiponectin is 
involved in insulin sensitisation of tissues including muscle, liver and adipose; low levels 
are  detected  in  obese  individuals  and  are  also  associated  with  insulin  resistance  and 
atherosclerosis  (Fu  et  al  2005).  Adiponectin  is  therefore  considered  an  interesting 
candidate  for  a  link  between  obesity  and  the  high  levels  of obesity-induced  insulin 
resistance and ensuing type II diabetes (Hutley and Prins 2005). The levels of visfatin, a 
newly identified adipokine, increase during the development of visceral obesity. Visfatin 
was  found  to  mimic  the  effects  of insulin  (i.e.  glucose  uptake)  on  insulin-responsive 
tissues,  and it’s expression may be controlled by insulin resistance-inducing hormones, 
making it another potential factor involved in the link between adipose tissue, obesity and 
insulin resistance (Fukuhara et al 2005, Krailsch et al 2005). Adipose tissue also produces 
immune-related factors such as the pro-inflammatory cytokine TNFa which may also be 
associated with obesity-induced insulin resistance (Kershaw and Flier 2004), and factors 
associated  with  the  cardiovascular  system  including  angiotensinogen,  which  plays  a 
central role in blood pressure regulation (Trayhum and Beattie 2001).
The characterisation of these adipokines demonstrates that adipose tissue plays a major 
role  in  controlling  multiple  processes  including  glucose  homeostasis,  immunological 
functions  and  the  cardiovascular  system.  Obesity,  or  the  excess  of adipose  tissue,  is 
associated  with  major  health  risks,  such  as  insulin  resistance,  type  II  diabetes,  heart 
disease and hypertension (collectively known as the metabolic syndrome or syndrome X), 
conditions that may be potentiated by the misexpression of adipose-derived  adipokines
49(Hutley and Prins 2005).  Ongoing studies of the endocrine nature of adipose tissue are 
therefore required to combat the predominance of obesity in western society today.
1.6  Molecular control of adipogenesis
1.6.1  Cellular models of adipogenesis
The  molecular  events  and  external  stimuli  controlling  commitment  of  embryonal 
precursors  into  the  adipocyte  lineage,  and  the  differentiation  of  preadipocytes  to 
adipocytes in vivo, are as yet unknown.  Studying preadipocyte differentiation in vivo is 
extremely difficult as they are hard to distinguish from other fibroblastic cells or from 
other preadipocytes at different stages of differentiation (Ntambi and Young-Cheul 2000). 
Studying primary preadipocytes in culture is also problematic, largely because they have a 
limited lifespan (Ntambi and Young-Cheul 2000). Because of this, in vitro models have 
primarily been used to study adipogenesis. The establishment of preadipocyte cell lines in 
the 1970s greatly aided studies of the molecular processes involved in adipogenesis. The 
most commonly used models are the 3T3-L1  and 3T3-F442A cell lines, which represent 
preadipocytes committed to the adipocyte lineage, but are aneuploid (Green and Kehinde 
1974,  1975,  1976).  These  were  derived  from  disaggregated  mouse  Swiss  embryos, 
through  selection  for  cells  with  susceptibility to  form  lipid-filled  adipocyte-like  cells. 
When  injected  into  mice  3T3-F442A  cells  were  shown  to  produce  fat  pads 
indistinguishable from normal adipose tissue;  such preadipocyte cell  lines are therefore 
thought to be reliable models of in vivo adipogenesis (Green and Kehinde  1979). Murine 
multipotent  cells  lines  also  exist,  such  as  C3H10T1/2,  which  can  be  induced  to 
differentiate into several lineages including adipocytes, but these are less frequently used 
than  preadipocytes  (Reznikoff et  al  1973,  Taylor  and  Jones  1979).  Differentiation  of 
preadipocytes  to  adipocytes  in  culture  will  occur  spontaneously  over  a  period  of 2-4 
weeks. However, the addition of a specific combination of hormones and drugs enhances 
their rate of differentiation (Rubin et al 1977). Thus, after hormonal stimulation of post­
confluent, growth arrested cells, a morphological change from elongated to rounded shape 
is observed. Markers of mature adipocytes can be seen by day 3, and by day 7 lipid-laden, 
rounded adipocytes are abundant (Ntambi and Young-Cheul 2000).
50The  classic  combination  of  reagents  used  to  induce  adipogenesis  includes  insulin, 
dexamethasone  and  isobutylmethylxanthine  (IBMX).  Their  use  arose  from  studies 
investigating  substances  with  the  ability  to  increase  the  rate  and/or  extent  of 
triacylglycerol accumulation in the 3T3-L1 and 3T3-F442A lines, which was at that stage 
the only marker known for adipogenic differentiation (Green and Kehinde  1975, Russell 
and Ho 1976, Rubin et al 1978). For the most part, the methods by which these substances 
stimulate  adipogenesis  are  still relatively unknown,  but  several  mechanisms  have been 
described and are summarised in Figure 1.4. Insulin is a hormone secreted by the pancreas 
which  has  well  known  effects  on  metabolism,  including  enhancing  fat  accumulation 
(Green and Kehinde 1975). It is now thought that as well as enhancing fat accumulation in 
vivo, insulin may promote differentiation by activating signalling through kinases such as 
PKB/AKT and PDK1  (Magun et al  1996, Yin et al 2005). Dexamethasone, a synthetic 
glucocorticoid,  activates  the  glucocorticoid  receptor  pathway  (Rubin  et  al  1978).  It 
stimulates expression of C/EBPS which activates adipogenesis, and downregulates DLK1 
and TGF/3 which inhibit the process. In addition, Cushing’s syndrome, a disorder giving 
rise  to  enhanced  glucocorticoid  levels  in  the  bloodstream,  is  associated  with  visceral 
obesity,  providing  evidence  for  a  physiological  role  for  glucocorticoids  in  inducing 
adipocyte differentiation (Rosen and Spiegelman 2000). IBMX is a synthetic inhibitor of 
cAMP phosphodiesterases, and raises intracellular cAMP concentrations (Russell and Ho 
1976).  IBMX  activates  C/EBP/3  and  CREB,  and  may  inhibit  Wnt  signalling.  A 
modification  of  this  cocktail  was  made  for  differentiating  hMSCs  into  adipocytes: 
indomethacin, a prostaglandin synthesis inhibitor was added (Williams and Polakis 1977). It 
is thought that  indomethacin may be a  ligand  for PPARy,  which  could  account  for its 
adipogenic effects (Lehmann et al 1997).
1.6.2  Transcriptional control of adipogenesis
1.6.2.1  The core transcriptional cascade
Figure  1.4  summarises  the  major  events  in  the  control  of adipogenesis.  The  first  key 
regulators of adipogenesis to be expressed are two members of the C/EBP family of basic 
leucine zipper transcription factors,  C/EBP/3 and -5;  this  occurs within a few hours of 
hormonal stimulation (Tang and Lane 1999). Mice lacking both the C/EBP/3 and -6 genes 
showed abnormally small fat pads, indicating the importance of these proteins for
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Figure  1.4.  Major  events  of the  transcriptional  regulation  of adipogenesis.  Adipogenesis  is 
stimulated  by  a  specific  induction  cocktail  which  initiates  a  complex  regulatory  network 
leading to the upregulation of adipocyte specific genes such as adipsin, aP2, FASN and LPL. 
The main controller of this network is PPARy, which  is induced by C/EBPp and -6, and it’s 
expression is maintained by C/EBPct Numerous factors upstream and downstream of this core 
network are involved. The majority of these events are likely to represent later regulation of 
adipogenesis  as  they  were  shown  to  control  differentiation  of  preadipocytes  that  are 
committed to the adipocyte lineage.
52adipocyte differentiation in  vivo (Tanaka et al  1997). C/EBP/3 and — 5 expression can be 
stimulated by the action of IBMX and dexamethasone, respectively (Cao et al 1991, Yeh 
et al 1995). C/EBP/3/6 are then responsible for upregulating the expression of PPARy and 
C/EBPa through binding to elements in their promoters (Yeh et al 1995, Wu et al 1995, 
1996). PPARy is a member of the nuclear hormone receptor family and upon activation by 
ligand binding, heterodimerizes with RXRa and regulates transcription of target genes by 
binding to  a consensus element within their promoters  (Tontonoz et al  1994a).  PPARy 
exists  in  two  isoforms,  PPARy 1   and  -y2,  generated  through  the  use  of  alternative 
promoters. PPARy2 contains an additional 30 N-terminal amino acids, which are thought 
to contribute to ligand-independent transcriptional activation domain, rendering PPARy2 
more potent  than  PPARy 1   (Mueller  et  al 2002).  PPARy2  expression  is  limited  to  the 
adipocyte, whereas PPARy 1   is expressed in multiple tissues. The activity of PPARy2 is 
crucial for adipogenesis; its expression is necessary and sufficient to induce adipogenesis 
in  normally  non-adipogenic  cell  lines  e.g.  NIH-3T3  (Tontonoz  et  al  1994b).  Mice 
chimeric for wild type and PPARy null cells show little or no contribution of null cells to 
adipose tissue (Rosen et al 1999, Barak et al 1999). Additionally, RNAi-mediated (1.7.2) 
suppression of PPARy expression in 3T3L1 cells blocked their differentiation (Hosono et 
al 2005). C/EBPa is expressed concomitantly with PPARy during adipogenesis, and these 
proteins act in a positive feedback loop to maintain each other’s expression throughout 
differentiation  (Wu  et  al  1999).  PPARy  is  responsible  for  directly  activating  the 
transcription  of  genes  characteristic  of mature  adipocytes,  or  additional  transcription 
factors  that  give  rise  to  adipocyte-specific  gene  expression.  Mature  adipocyte  markers 
include  aP2,  adipsin,  LPL,  FASN  and  perilipin.  Although  capable  of  activating 
transcription of a subset of adipocyte-specific  genes, it is thought that the main role of 
C/EBPa is to sustain PPARy expression (Rosen et al 2002).
A  key  event  that  is  absolutely  required  for  terminal  differentiation  into  adipocytes  is 
growth arrest. It is thought that preadipocyte cell lines in vitro undergo one or two rounds 
of mitotic clonal expansion. This begins after an initial growth arrest induced by contact 
inhibition, and ceases concomitant with expression  of C/EBPa and  PPARy (Rosen and 
Spiegelman 2000). This  second growth arrest is permanent,  and is likely to be brought 
about directly by the action of these proteins. PPARy can induce expression of the cyclin-
53dependent kinase inhibitors pi8  and p21  (Morrison and Farmerl999),  and also inhibits 
E2F/DP-DNA  binding  activity  through  downregulation  of PP2A  (Altiok  et  al  1997). 
C/EBPa may also play a role in inducing p21 (Rosen and Spiegelman 2000). Additionally, 
the retinoblastoma protein Rb regulates adipogenesis; it interacts with C/EBP/3 during the 
early stages and enhances DNA binding activity (Chen et al 1996b, Cole et al 2004), but 
is later inhibitory to PPARy’s transactivation function (Fajas et al 2002).
1.6.2.2  Activators of adipogenesis
A vast array of factors are known to play a role in promoting adipogenesis; these act at 
different  stages  of the  process,  mostly  feeding  into  or  out  of the  core  transcriptional 
network;  here,  a  summary  of  regulatory  mechanisms  is  provided.  Autocrine  and/or 
paracrine signalling mediated by LIFR and IPR positively regulates adipogenesis (Aubert 
et  al  1999,  2000).  Stimulation of these receptors  activates  the  ERK/MAPK  signalling 
cascade,  leading  to  phosphorylation  and  activation  of the  transcription  factor  CREB, 
which then activates transcription of C/EBP/3 and -5 (Belmonte et al 2001).  Additionally, 
IPR stimulates PKA activity by increasing cAMP concentrations, and this again leads to 
C/EBP  expression  through  phosphorylation  and  activation  of CREB  (Belmonte  et  al
2001).  CREB  can  also  directly  activate  the  transcription  of several  adipocyte  specific 
genes, including aP2 and FASN (Reusch et al 2000). KROX20 and KLF6 have recently 
been identified  as regulating early events of adipogenesis;  KROX20  promotes  3T3-L1 
adipogenesis through C/EBP/3 dependent and independent mechanisms (Chen et al 2005), 
and KLF6 represses the inhibitory protein DLK1  that is expressed in preadipocytes (Li et 
al 2005). Many positive adipogenic regulators act by increasing PPARy activity. Members 
of the  STAT  family  of transcription  factors,  specifically  STAT5A  and  STAT5B,  are 
expressed just prior to  PPARy during 3T3L1  adipogenesis and  may be  involved  in  the 
production  of PPARy  ligands (Floyd  and  Stephens 2003).  Additionally,  the helix-loop- 
helix transcription factor SREBPlc  is  induced  during adipogenesis  at around the  same 
time as PPARy, and can activate its transcription as well as the transcription of adipocyte- 
specific  genes through promoter E-box  motifs  (Fajas  et al  1999).  It  is  also  likely that 
SREBPlc  can  further  activate  PPARy  by  production  of an  endogenous  ligand,  thus 
enhancing  adipogenesis  (Kim  et  al  1998).  KLF15  acts  synergistically with  C/EBPa to 
activate PPARy expression during preadipocyte differentiation  (Mori  et al 2005a).  Late
54adipogenic  activators  include  RORy  and  Rev-Erba,  which  are  targets  of PPARy  and 
mediate its effects by activating the transcription of subsets of adipocyte-specific genes 
(Austin et al 1998, Fontaine et al 2003).
Several  signalling  pathways  have  been  shown  to  positively  regulate  adipogenesis, 
including the  BMP  signalling pathway.  BMP  ligands bind a  subset of receptors  which 
transduce  signals  through  SMAD  proteins  1,  5  and  8  to  control  transcription  in  the 
nucleus. The effects of BMPs 2, 4 and 7 on adipogenesis have been studied in mice, where 
addition of these ligands  in low doses to the multipotent C3H10T1/2  cell  line  induced 
adipogenesis; this effect was however dose-dependent, as higher doses led to osteogenic 
and chondrogenic differentiation (Ahrens et al 1993, Wang et al 1993, Gimble et al 1995, 
Asahina  et  al  1996,  Tang et al 2004).  The  effect of BMP2  may be  mediated  through 
BMPR-1A rather than BMPR-1B, as a constitutively active BMPR-1A led to an increase 
in PPARy levels (Chen et al 1998).
1.6.2.3  Inhibitors of  adipogenesis
Many  inhibitors  of  adipogenesis  are  expressed  in  preadipocytes  and  must  be 
downregulated  for differentiation to proceed.  These  include the transmembrane protein 
DLK1  and  transcription  factors  GATA2  and  -3,  which  have  been  shown  by 
overexpression studies to block adipogenesis (Tong et al 2000, Lee et al 2003); GATA2 
and -3 may perform this function by suppressing transcription from the PPARy promoter, 
as well as forming repressive protein complexes with C/EBPa and -(3 (Tong et al 2005). 
GILZ was recently identified as an inhibitor of adipogenesis in C3H10T1/2 cells, and also 
acts  through  binding  and  repression  of the  PPARy  promoter  (Shi  et  al  2003).  KLF2 
inhibits preadipocyte differentiation via repression of PPARy expression, and also partly 
through upregulation of DLK1, but has no effect on the formation of preadipocytes from 
murine  precursor cells  (Baneijee  et  al  2003,  Wu  et  al 2005).  The  transcription  factor 
FOXC2 blocks adipogenesis, likely through inhibiting PPARy transactivation of selected 
promoters (Davis et al 2004).  Protein-protein interactions are a common mechanism of 
adipogenic inhibition.  CHOP 10  is  an  inhibitory member of the  C/EBP  family that can 
form dominant negative dimers with other C/EBP proteins and inhibit their transcriptional 
activity (Tang and Lane 2000, Pereira et al 2004). Interestingly, the translocation typically
55found  in myxoid and round cell  liposarcomas  involves  the  fusion of the basic  leucine 
zipper domain of CHOP 10 to FUS or EWS transcription factors (Crozat et al 1993). The 
inhibitor of DNA binding (ID) family of nuclear proteins also have the helix-loop-helix 
structure of some transcription factors, but lack the basic DNA binding domain, and form 
non-functional  heterodimers  with  other  helix-loop-helix  proteins,  for  ID2  and  -3  this 
includes SREBPlc (Moldes etal 1997, 1999).
The Wnt and TGF/3 signalling pathways have long been known as crucial regulators of the 
development  of  mesenchymal  tissues  (Roelen  and  Dijke  2003),  and  their  roles  in 
development  of adipose  tissue  has  been  investigated.  Wnt  signalling  is  inhibitory  to 
adipogenesis in 3T3-L1 preadipocytes; this is due to suppression of PPARy and C/EBPa, 
rather than C/EBP/3 and -5, but the exact mechanism by which this occurs is unknown 
(Ross  et  al 2000,  Bennett  et  al 2002).  Transgenic  mice  expressing  Wnt 10b  under the 
control of an adipose-specific promoter showed a significant reduction in adipose tissue 
mass (Longo et al 2004), and when /3-catenin was deleted in the mouse uterus, a switch 
from  smooth  muscle  to  adipose  tissue  was  seen  (Arango  et  al  2005).  Human  MSCs 
express various Wnt signalling components (Etheridge et al 2004), and an inhibitory effect 
of Wnt signalling on hMSC adipogenesis has also been shown (De Boer et al 2004). The 
TGF/3 pathway inhibits adipogenesis of human and rodent MSCs as well as preadipocytes 
(Ignotz and Massague 1985, Locklin et al 1999), and TGF/3 overexpression in transgenic 
mice  prevents  adipose  differentiation  (Clouthier  et  al  1997).  Inhibition  of  3T3L1 
adipogenesis may be mediated by activin A,  a TGF/3-family ligand  (Hirai  et  al 2005), 
amongst others. The TGF/3 pathway inhibits adipogenesis in a similar manner to CHOP 10, 
in that SMAD3 binds to and sequesters the function of the C/EBP proteins (Choy et al 
2000, 2003).
1.6.2.4  The earliest events of adipogenesis
The vast majority of this research was carried out using the preadipocyte models discussed 
in section  1.6.1.  As implied by their name,  these cells  are  committed to  the  adipocyte 
lineage,  so  the  transcriptional  networks  described  control  the  later,  post-commitment 
stages  of  adipogenesis.  Thus,  there  is  little  information  on  the  earliest  mechanisms 
involved in stem cell differentiation into adipocytes prior to commitment to this lineage,
56and how this relates to the later regulatory networks described. The earliest events in the 
transcriptional cascade are of crucial importance, as they set in motion the multitude of 
events that lead to a specific change in phenotype. A detailed knowledge of the earliest 
mechanisms  by  which  adipogenesis  is  brought  about  may  be  extremely  valuable  in 
manipulating  the  differentiation  of  hMSCs,  as  well  as  providing  a  more  detailed 
knowledge of the events involved in stem cell differentiation.
The  knowledge that hMSCs  differentiate  into  adipocytes,  and the  ability to  do  this  in 
culture,  is  fairly  new  relative  to  the  preadipocyte  models.  However,  some  detail  is 
emerging  about  events  and  factors  that  may  regulate  early  differentiation  events,  in 
particular those that control the decision to differentiate along a specific lineage. TAZ, a 
transcriptional  coactivator,  was  recently  found  to  enhance  osteogenesis  but  inhibit 
adipogenesis through modulation of transcription by the main osteogenic (CBFA1)  and 
adipogenic factors (PPARy) (Hong et al 2005). Interestingly, cell shape and cytoskeletal 
tension was found to be crucial  for hMSC  lineage commitment choice (McBeath et al 
2004).  A  less  spread  shape  with  lower  cytoskeletal  tension  favoured  adipogenesis, 
whereas  cells that were more  spread out  so had higher cytoskeletal tension underwent 
osteogenesis. These events were mediated by the Rho GTPase RhoA and it’s effector Rho 
kinase;  Rho  activity  induced  osteogenesis  and  a  dominant  negative  RhoA  induced 
adipogenesis (McBeath et al 2004).  In a study using MEFs, Rho activity was shown to 
control the decision between adipogenesis and myogenesis by mediating lineage-specific 
responses to IGF-1 signalling rather than in response to cytoskeletal tension. Similar to the 
McBeath  study,  a  constitutively  active  form  of  Rho  blocked  adipogenesis  whereas 
dominant-negative Rho blocked myogenesis (Sordella et al 2003). Finally, Jakkaraju et al 
identified three isoforms of a novel gene which were regulated by mechanical stretch; a 
condition that induces myogenic differentiation in embryonic mesenchymal cells (Jakkaru 
et  al  2005).  TIP-1,  induced  by  stretch,  has  pro-myogenic  activity,  whereas  stretch 
inhibited  TIP-3,  a  factor  that  promotes  adipogenesis.  These  proteins  had  chromatin 
remodelling  activity,  and  it  was  shown  that  remodelling  at  the  promoters  of lineage- 
specific genes contributed to the observations of lineage choice (Jakkaru et al 2005).
571.7  Techniques for functional genomics
Functional genomics has been described as the  study of gene function through parallel 
expression measurements of a genome  (Butte et al 2002).  Although sequencing of the 
human genome has provided a wealth of information regarding the sequence and structure 
of human genes,  knowledge of the  function of these genes remains  far from  complete 
(Lander et al 2001, Venter et al 2001). Techniques have been developed that can assess 
the  expression  and/or  function  of many  genes  in  a  single  assay;  these  include  gene 
expression microarrays and RNA interference.
1.7.1 Microarray analysis of gene expression
The concept of microarray technology was developed when it was noted that the use of 
fluorescent labels allowed sensitive detection of a specific target analyte. This meant that 
“microspots” of “capture agent” (now known as probe), only a few /mi in diameter were 
sufficient so multiple microspots detecting different analytes could be grouped together on 
a  microarray  and  analysed  simultaneously  (Ekins  and  Chu  1999).  Although  this 
technology  was  originally  developed  for  antibody  analysis  in  immunodiagnostics,  the 
authors speculated that it could be used for many other ligand binding assays (Ekins and 
Chu 1991). Indeed, in the mid-1990s the production of DNA microarrays, and their use to 
monitor gene expression in Arabidopsis thaliana, was described (Schena et al 1995). This 
microarray  contained  45  cDNAs;  the  continuing  development  of  this  technology, 
combined with the sequencing of entire genomes, now allows the simultaneous analysis of 
the expression of every known gene in an organism.
1.7.1.1 Microarray design
The fundamental basis of microarray technology is the hybridisation of labelled RNA or 
DNA targets derived from biological samples to a collection of DNA molecules that are 
immobilised  on  a  solid  surface.  These  immobilised  DNA  molecules,  or  probes,  each 
represent a specific gene or transcript and the fluorescence signal created by hybridisation 
of the complementary target molecule  gives an expression readout for each gene. Two 
types of DNA microarray exist: cDNA arrays and oligonucleotide arrays. cDNA arrays are 
produced by the automated spotting onto glass slides of cDNA molecules, produced from
58PCR amplification of specific targets or from library clones, which are typically hundreds 
of base pairs in length. They have the advantage that they can be custom-designed, but 
tend to contain fewer probes than oligonucleotide arrays so permit analysis of expression 
of fewer genes; nevertheless, this number can still be in the thousands (Choudhuri 2004). 
Oligonucleotide  array  technology  is  used  for  Affymetrix  Genechips 
(www.affymetrix.com). These arrays are synthesised via the controlled sequential addition 
of nucleotides to the surface of glass slides. This process builds up 25mer oligonucleotide 
probes designed to be complementary to a region of a specific gene transcript (Affymetrix
2004). Where possible, probe design is biased toward the 3' region of each transcript, as 
the  method  used  to  synthesise  target  molecules  occurs  from  this  end,  so  uneven 
amplification from transcripts of different lengths would give misrepresentative results if 
many 5' probes were included. Eleven probe sequences are designed for each transcript. 
Each probe sequence is represented by a perfect match (PM) and mismatch (MM) probe, 
where the PM probe is exactly complementary to the target transcript but the MM probe 
contains one mismatched base at position 13. The  11 pairs of PM and MM probes for a 
single transcript are collectively called a probeset (Fig.  1.5).  Inclusion of PM and MM 
probes allows for calculation of background and non-specific hybridisation. Each probe is 
present in multiple copies located in a specific cell on the array,  thus allowing for the 
sensitive analysis of expression of each gene (Knudsen 2004).
Target RNA molecules can be synthesised and labelled in either one or two colour format. 
In two-colour format labelling, RNA is extracted from two biological samples and used as 
a template for cDNA synthesis.  Each cDNA  sample is  labelled with different coloured 
dyes, normally Cy3 and Cy5 as with two-colour arrays produced by Agilent Technologies 
(www.agilent.com),  and a comparison is made by hybridising the  samples to the  same 
array  and  measuring  colour  change  to  detect  over-  or  under-expressed  genes  in  each 
sample.  This  format  is  mostly  applicable  to  spotted cDNA  arrays  (Stears  et al  2003). 
Oligonucleotide arrays, more specifically Affymetrix Genechips, generally use one-colour 
target labelling. RNA is extracted from each biological sample, reverse transcribed, then 
cRNA synthesis is performed using biotin-labelled ribonucleotides. Biotin-labelled cRNA 
probes are hybridised to the arrays, which are then washed and stained with a streptavidin- 
phycoerythrin conjugate and scanned. The level of fluorescence emitted by a particular
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Figure  1.5.  Design  of an  Affymetrix  probeset  on  the  U133  Plus  2.0  GeneChip  Array.  A 
probeset consists of 11  probe pairs. Each probe pair contains a perfect match (PM) probe (25 
bases in length) that exactly matches the target sequence, and a mismatch (MM) probe, which 
contains one mutation at base 13. Each probe is present in multiple copies within a probe cell. 
This design results in sensitive quantification of target abundance, represented by the different 
levels of shading in each probe cell (dark shading represents high levels of target hybridisation 
to its probe -  note that some level of hybridisation can also occur on the MM probes).
60probe is a measure of the abundance of it’s target in the biological sample, and between- 
chip comparisons allow for analysis of gene expression change (Affymetrix 2004).
1.7.1.2  Microarray data processing and analysis
The raw product of array scanning is a fluorescent signal for each probe on the array. 
Statistical methods are required to rationally process this signal and produce an expression 
value for each transcript that truly reflects it’s abundance in the original sample. Further 
techniques are employed to identify trends in the data through comparison of expression 
values across arrays.
Pre-processing of the raw signal image to produce expression values is performed in three 
steps: background correction (or image processing), normalisation and summarisation of 
the expression values  for each probe in a probeset to  give a single value.  Background 
correction is designed to minimise the effects of variation caused by technical  artefacts 
such  as uneven hybridisation  across  an array. Normalisation  is performed to  take  into 
account variation across multiple arrays caused by experimental variation (i.e. variation 
that was not present in the biological sample), and is often performed by fitting the data 
from each array to a single statistical model. This allows comparison of expression values 
between arrays. Finally, expression values for each probeset on each array are estimated, 
often using log2 scale values (Allison et al 2006). Several methods have been developed to 
perform  these  functions  on  Affymetrix  microarray  data,  including  MAS5  (Affymetrix
2001), MBEI (Li and Wong 2001) RMA (Irizarry et al 2003a), and GC-RMA (Wu and 
Irizarry 2004).
Once data pre-processing is  complete,  analytical  methods  can be  employed  to  identify 
differential expression of genes between biological samples. Typically, modified t-tests or 
ANOVA are used to calculate significant changes in expression of a gene between two 
conditions, given that replicates of each condition have been performed (Knudsen 2004). 
This will produce  a fold-change  value  with  an  associated  p-value  for  a  gene  between 
conditions, and allows a cut-off to be set in order to define significantly changed genes. 
Significance at the 0.05  level, and/or a fold change greater than 2, are frequently used. 
Importantly,  when  analysing  microarray  data  thousands  of  hypothesis  tests  will  be
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methods  have  been  developed  that  decrease  the  likelihood  of  false  positive  results, 
including the highly stringent Bonferroni correction, and False Discovery Rate correction, 
which is less severe and more biologically relevant (Benjamini and Hochberg 1995).
Classification  of  genes  or  arrays  in  terms  of  similarity  in  expression  profiles  is  a 
commonly  used  method  for  identifying  biological  trends  and  relationships  within  a 
microarray dataset. Supervised classification entails designing algorithms that best assign 
objects  (i.e.  genes)  to  pre-defined  categories,  and  assumes  prior  knowledge  of these 
categories.  Unsupervised  classification  methods  assume  no  prior  knowledge  and 
categories are developed during the analysis (Allison et al 2006). Unsupervised methods 
include hierarchical cluster analysis, which forms groups of genes based on similarity of 
expression profiles and represents these relationships in a dendrogram (Eisen et al 1998). 
The  Euclidean  distance  is  often  used  to  measure  distance  (or degree  of dissimilarity) 
between genes. Other cluster analysis methods include self-organising maps and k-means 
clustering (Knudsen 2004).
Gene  annotation and pathway analysis are  increasingly popular methods  used to  relate 
gene  expression  change  to  biological  responses.  This  form  of  analysis  is  becoming 
possible due to the development of microarrays that assay whole transcriptomes, allowing 
a  comprehensive  view  of entire  pathways  or  functional  classes.  Gene  Ontology  is  a 
structured vocabulary which attempts to unify gene product descriptions across  species 
and databases (Ashbumer et al 2000). It can be used to extract information regarding the 
function of a group of co-expressed genes in a microarray experiment.  Similarly, up- or 
downregulation  of genes  in  a  specific  pathway  can  be  investigated  using  searchable 
pathway maps, and statistical analysis of these annotations can attach a significance value 
to the findings (Curtis et al 2005).
1.7.2  The use of microarrays to study adipogenesis
As  well  as  a  gene-by-gene  approach  to  investigating  adipogenic  regulation  (1.6.2), 
microarrays  have  been  used  to  simultaneously  analyse  the  expression  of thousands  of 
genes at specific stages of differentiation. These analyses identified many potential novel
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processes involved in adipogenesis.
The first such study used cDNA microarrays representing around 5000 cDNA clones to 
compare  the  expression  profiles  of  primary  human  preadipocytes  before  and  after 
differentiation in vitro (Zhou et al  1999).  A similar study was performed but in greater 
detail,  as it utilised a larger sample size and arrays containing  17000 cDNAs,  and also 
used  mature  primary  adipocytes  for  comparison  rather  than  in  v/Yro-differentiated 
preadipocytes  (Urs  et  al  2004).  Both  groups  identified  a  list  of  genes  that  were 
differentially  expressed  between  conditions,  including  some  novel  genes  which  were 
concluded to be potentially important for preadipocyte differentiation. In 2001  Soukas et 
al published a comprehensive study in which Affymetrix murine microarrays representing 
11,000  transcripts  were  used  to  investigate  the  expression  profiles  of  primary 
preadipocytes  and  adipocytes  and  compare  them  to  undifferentiated  and  differentiated 
3T3-L1  cells.  It was found that while many of the gene expression changes associated 
with in vivo and in vitro differentiation overlapped, distinct subsets of genes were only 
expressed in one or the other condition, revealing that 3T3-L1  cells do not completely 
mimic the fully differentiated adipocyte phenotype (Soukas et al 2001).
Microarray studies, mainly using 3T3-L1 cells, have been used obtain temporal expression 
profiles of adipogenesis in order to elucidate molecular regulation over the differentiation 
time-course. The study by Soukas et al also followed a differentiation time-course, and 
included  10 timepoints ranging from pre-confluent to 28 day differentiated cells (Soukas 
et al 2001). Other studies utilised the same murine microarrays and focused on the first 
day of 3T3-L1  differentiation (Burton et al 2002, 2004). The earliest timepoint studied 
was 2h; in one experiment an inhibitor of adipogenesis was used to identify and eliminate 
gene expression responses to the differentiation induction cocktail that were not specific to 
differentiation  (Burton  et  al  2004).  In  each  of  these  studies,  different  arrays,  data 
normalisation, clustering methods and significance cut-offs were used. Although in every 
study the  main  adipogenic  regulators  were  identified,  the  overall  lists  of significantly 
changed  genes  differed.  However,  each  investigation  contributed  towards  the 
understanding of preadipocyte differentiation, and achieved their aim of identifying targets
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such  as  Wnt  and  PPARy  ligands,  have  also  been  investigated  in  3T3-Lls  in  order to 
identify downstream targets of these  factors  (Ross  et al 2002,  Gerhold  et al 2002).  A 
comprehensive investigation of 3T3L1  differentiation has recently been published, which 
used large arrays and advanced analysis techniques to provide a global overview of the 
molecular processes  of adipogenesis,  as  well  as  identifying  interesting  candidates  for 
further work (Hackl et al 2005). This study highlighted the ability of microarray analysis 
combined  with  the  latest  annotation  methods  to  provide  a  detailed  insight  into 
differentiation.
In addition to the  3T3L1  work,  microarray analyses of hMSC  adipogenesis have been 
performed. The earliest study, performed in 2003, used cDNA arrays representing 3400 
clones to study adipogenesis over a 14-day time-course, with the earliest timepoint during 
differentiation at day 1   (Nakamura et al 2003). Sekiya et al used Affymetrix Genechips 
containing around  12,000 genes, and similarly chose the day  1   timepoint as the earliest 
point of study, but carried differentiation through until day 21  (Sekiya et al 2004). Both 
studies identified genes upregulated at day 1  that had been shown to be repressed during 
3T3-L1  differentiation, leading to the conclusion that they may be involved in stages of 
differentiation occurring prior to the committed stage that preadipocytes represent (Burton 
and McGehee 2004). A more detailed analysis  of the data  from  Sekiya et al has been 
performed  (Ylostalo  et  al  2006).  Hierarchical  clustering  was  used  to  group  genes 
according to their expression pattern during differentiation, and novel downstream targets 
of PPARy and C/EBPa were identified via selection of genes that were co-expressed in 
clusters with known targets. Their target status was then confirmed via identification of 
PPARy or C/EBPa binding sites in their promoter (Ylostalo et al 2006). Work published 
by  Hung  et  al  used  cDNA  arrays  comprising  7,500  cDNAs/ESTs  to  compare 
undifferentiated hMSCs with day 3-differentiated cells (Hung et al 2004a), and identified 
numerous genes which had not before been associated with adipogenesis. A recent study 
of bovine  MSC  adipogenesis  also  identified  numerous  differentially  expressed  genes 
across a time-course; gene expression was analysed after 6h of differentiation, but some 
discrepancies such as the lack of upregulation of PPARy were noted  (Tan  et al 2006). 
These studies highlighted the importance of studying adipogenesis from the uncommitted
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controlling early adipogenesis.  However, no  study of human adipogenesis has analysed 
gene expression during the first day of differentiation. Furthermore, the use of small arrays 
and few functional annotation methods means that much detail of the earliest events of 
hMSC adipogenesis has yet to be described.
1.7.3  RNAi and it’s application to study gene function
1.7.3.1 Mechanism of  RNAi
The term RNA interference (RNAi) was first used by Fire and co-workers, who noted that 
the introduction of dsRNA into Caenorhabditis elegans elicited a potent sequence-specific 
inhibition of gene expression (Fire et al 1998).  In fact, this phenomenon had previously 
been noted in plants when introduction of exogenous pigmentation genes resulted in their 
silencing as well as occasional silencing of the endogenous gene (van der Krol et al 1990, 
Napoli et al 1990). It is now known that RNAi is an evolutionarily conserved mechanism 
that  operates  in  eukaryotes,  possibly  as  a  defence  mechanism  against  transposons  or 
replicating viruses (Shi 2003). A similar pathway controls RNAi in all organisms. Entry of 
dsRNA into a cell, experimentally or as a consequence of natural phenomena such as viral 
infection, results in cleavage by an RNase Ill-like enzyme termed Dicer (Figure 1.6). The 
products  are  21-23nt  small  interfering  dsRNAs  (siRNA)  that  have  a  2-nucleotide  3' 
overhang.  These  are  incorporated  into  the  RNA-induced  silencing  complex  (RISC), 
composed of multiple protein subunits. The helicase activity of RISC results in unwinding 
of the RNA duplex, after which the antisense strand is retained within RISC and guides 
the protein complex to the target mRNA. Through RISC endonuclease activity, the target 
mRNA  is  cleaved  and  degraded,  resulting  in  silencing  of the  gene  with  homologous 
sequence to the siRNA (Zou and Yoder 2005, Sledz and Williams 2005).
1.7.3.2 Application of  RNAi in mammalian cells
Although long dsRNA can be used effectively to  silence gene expression in organisms 
such  as  C.  elegans  and  Drosophila,  dsRNAs  longer  than  30nt  trigger  an  antiviral 
interferon  response  mechanism  in  mammalian  cells  that  results  in  non-specific 
degradation of transcripts  and  shutdown of protein  synthesis  in the  cell  (Williams  and 
Haque 1997). This was overcome by the production of synthesised versions of the Dicer
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Figure  1.6.  Mechanism of RNA interference.  Long dsRNA are processed by Dicer into  21- 
23nt siRNAs. Synthetic siRNAs and shRNAs, which are probably nicked by Dicer in the loop 
structure  to  produce  double  stranded  RNA,  mimic  these  siRNAs  and  can  substitute  as 
substrates for RISC. RISC binds the siRNAs and after removal of one RNA strand, converts 
into it’s active form. The ssRNA guides active RISC to the target mRNA, to which it binds in 
a  sequence-specific  manner  and  induces  target  mRNA  cleavage  by  RISC  endonuclease 
activity. Figure adapted from www.cenix-bioscience.com.
66siRNA  products,  similar  in  length  and  with  3'  overhangs,  which  could  be  processed 
directly by the RISC complex. Their size (21nt) was sufficient to induce gene silencing, 
but small enough that the interferon response was not initiated (Elbashir et al 2001).
Synthetic siRNA can be introduced into mammalian cells using a variety of transfection 
methods.  The  strength  of  silencing  depends  on  the  overall  siRNA  dose,  but  more 
importantly siRNA potency can vary greatly depending on the target sequence (Hannon 
and Rossi 2004).  Indeed, siRNA (and also shRNA,  see below) design is still not  100% 
efficient, and in some cases no knock-down effect is observed. A comprehensive study 
determined 8 criteria that should be considered when selecting a siRNA (or shRNA) target 
sequence, which have been incorporated into many siRNA design programs (Reynolds et 
al 2004). In an attempt to combat this problem, several siRNAs are often designed against 
a single transcript in order to maximise the knock-down effect (Zou and Yoder 2005).
A major drawback of siRNA is that it’s effects are transient so gene silencing is gradually 
lost, depending on the half-life of the siRNA molecule. As a consequence, vector-based 
delivery  systems  have  been  developed  that  increase  the  length  of siRNA  expression 
(Brummelkamp et al 2002a, 2002b). An RNA polymerase III promoter, such as HI or U6, 
drives  expression  of  a  small  hairpin  RNA  molecule  (shRNA)  that  mediates  RNAi. 
shRNAs are created by cloning a  19-29nt sense strand,  followed by a spacer sequence, 
followed by the 19-29nt antisense strand, downstream of the polymerase III promoter. The 
spacer  allows  base-pairing  within  the  transcribed  shRNA  molecule  and  consequently 
forms a hairpin loop which is probably nicked by Dicer to form a siRNA-like structure. 
Polymerase III promoters are suitable for driving shRNA expression as they generate short 
messages that terminate precisely and leave a 3' overhang, a feature required for shRNA 
function (Brummelkamp et al 2002a). Viral-mediated shRNA delivery results in longer- 
term expression due to viral integration and stable expression of shRNA from the host 
genome. Retroviral, adenoviral and lentiviral vector systems are now available containing 
shRNA expression cassettes combined with selectable markers that allow for long-term 
shRNA expression and selection of cells containing the viral construct (Brummelkamp et 
al 2002b, Abbas-Terki et al 2002, Shen et al 2003, Clements et al 2006).
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Genome sequencing in various organisms followed by identification of the encoded genes 
has allowed RNAi to be used on a large scale to investigate gene function. Simultaneous 
knock down of the expression of multiple genes  followed by assay for loss of function 
provides a high throughput method to identify genes involved in a specific process. The 
creation of RNAi libraries has augmented this approach to functional genomics.
An early high throughput screen in C. elegans involved feeding the nematode worms with 
different bacterial  strains,  each  engineered to  express  a  single  dsRNA  oligonucleotide, 
which constitute a library targeting  86%  of all  C.  elegans  genes  (Ashrafi  et al 2003). 
Visualisation  of changes  in  fat  storage  by  staining  with  the  lipophilic  dye  Nile  Red 
identified genes which either stimulate (0.7% of all genes) or inhibit (1.8%) the process, 
some of which had mammalian homologues (Ashrafi et al 2003).
Mammalian  oligonucleotide  siRNA  libraries  have  been  developed,  and  one  study 
demonstrated their utility to identify genes involved in TRAIL-induced apoptosis (Aza- 
Blanc et al 2003) using a high-throughput screening strategy. A siRNA library directed 
against 510 genes, focusing on kinases, was designed and arrayed in microplate format so 
that each well contained a single siRNA oligonucleotide species. Reverse transfection of 
HeLa cells was performed and transfected cells were incubated with or without TRAIL to 
assay for increased or decreased cell death induced by knock-down of a TRAIL-associated 
gene.  Both TRAIL-sensitisers  (less  apoptosis)  and  TRAIL  inhibitors  (more  apoptosis) 
were identified (Aza-Blanc et al 2003).
As mentioned previously, siRNA-mediated gene knockdown has the drawback that it only 
produces  a  transient  effect  on  gene  expression.  In  the  context  of  high-throughput 
screening, it is also an extremely expensive approach, as many siRNAs are synthesised 
and  experiments  must  be  replicated.  Accordingly,  in  2004  two  groups  described  the 
creation of retrovirally delivered  shRNA  libraries  containing  shRNAs  designed  against 
human, or both human and mouse genes (Bems et al 2004, Paddison et al 2004). Paddison 
et al developed a shRNA library covering around  10000 human and 5000 mouse genes, 
with 2-9 shRNAs for each gene (Paddison et al 2004). Each 29nt shRNA was linked with
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in mixed populations using microarrays containing each barcode sequence as a probe. The 
efficacy of this library has been demonstrated in several studies; it was used to recover 
shRNAs involved in proteasome function by assaying for loss of function after shRNA 
introduction using a fluorescent reporter coupled to a degradation signal (Paddison et al 
2004).  In a mammalian screen for genes preventing epithelial cell transformation, a cell 
line  susceptible  to  transformation by a  single  genetic  event  (through prior addition  of 
transgenes,  section  1.8.3)  were  transduced with  the  library and  assayed  for anchorage 
independent growth (Westbrook et al 2005). Anchorage-independent clones were pooled 
and enriched barcodes linked to shRNAs causing this colony outgrowth were identified. 
These  shRNAs targeted  several  genes  implicated  in  cancer pathogenesis,  as  well  as  a 
novel  tumour  suppressor,  REST  (Westbrook  et  al  2005).  Recently,  a  shRNA  library 
constructed using a doxycycline-inducible vector was used in a similar screening strategy, 
and identified a novel gene involved in the survival of a specific cancer subtype (Ngo et al 
2006).
The shRNA library developed by Bernards and co-workers consists of three 19nt shRNAs 
targeted against each of 7914 human genes, cloned individually into a retroviral vector 
(Bems et al 2004). An early version of this library targeting 50 deubiquitination enzymes 
was shown to be efficient in a simple screening strategy; each shRNA was individually 
transfected into HEK-293 cells along with a NF-kB luciferase reporter construct. Knock­
down of CYLD  expression  led  to  higher NF-kB  transcription  and  therefore  luciferase 
activity, identifying this gene as a novel NF-kB regulator (Brummelkamp et al 2003). The 
full  retroviral  library has been used  in the  more  complicated  selection  strategy,  where 
shRNA  pools  are  used  to  transduce  a  cell  population,  and  after  exposure  to  a  certain 
condition,  shRNAs  conferring  a  survival  advantage  in  that  condition  permit  cell 
outgrowth, allowing subsequent shRNA isolation by PCR, sub-cloning and re-screening, 
or by the use of the shRNA sequence as a molecular barcode (Bems et al 2004). This 
strategy led to the identification of novel regulators of p53-mediated proliferation arrest 
(Bems et al 2004), and has recently demonstrated that PITX1 is a novel suppressor of Ras 
activity and therefore tumourigenicity (Kolfschoten et al 2005). It is therefore clear that 
shRNA  library  screens  can  be  used  in  a  variety  of experimental  strategies,  and  are
69extremely effective at identifying novel genes with a particular function or involved in a 
specific process.
1.8  Stem cells and cancer
1.8.1  Cancer stem cells
Cancer stem cells are currently defined in terms of functional  attributes; thus,  a cancer 
stem cell is a tumour cell that has the ability, after transplantation into immunodeficient 
mice, to form tumours containing all cell types of the tumour of origin, including further 
cancer stem cells (Polyak and Hahn 2005, Bjerkvig et al 2005).
It has been observed that only a small number of cancer cells are capable of extensive 
proliferation in vitro or in vivo, and large numbers of cancer cells must be transplanted 
into an animal model in order to initiate new tumours (Al-Hajj and Clarke 2004). These 
findings could be explained by every cancer cell having the ability to proliferate and form 
new  tumour  cells,  with  the  probability  of them  doing  so  being  small.  An  alternative 
explanation  was  the  existence  of a  small  subset  of cancer  cells  with  stem  cell-like 
properties  including an  extensive  self-renewal  capacity,  which  is  exclusive to  this  cell 
population  (Reya  et  al  2001).  The  existence  of  cancer  stem  cells  was  definitively 
demonstrated in acute myeloid leukaemia (AML, Bonnet and Dick 1997). A rare subset of 
human  AML  cells,  termed  SCID  leukaemia-initiating  cells  (SL-IC),  was  capable  of 
proliferating  and  sustaining  human  AML  after  transplantation  into  NOD/SCID  mice. 
Furthermore,  SL-IC  were capable of self-renewal  in  serial  transplantation  experiments. 
Crucially, these cells could be prospectively identified and purified as CD34+CD38'; only 
this population had self-renewal capability during serial transplantation so exhibited the 
defining characteristics of a cancer stem cell (Bonnet and Dick 1997).
Cancer stem cells have also been identified in tumours of breast and brain cancer. Al-Hajj 
et al found that a small population of human breast cancer cells were capable of forming 
tumours in NOD/SCID mice (Al-Hajj et al 2003), which were purified as CD44+CD24' 
/Iow .  These  cells  formed  tumours  6  months  after injection,  whereas  CD44+CD24+ cells
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capable of tumour formation, but larger numbers of other cells were not.  Lastly, it was 
shown that these cells could give rise to further CD44+CD24’/low  cells that formed tumours 
after serial transplantation, as well as non-tumourigenic cells with diverse phenotypes that 
recapitulated the complexity of the tumour from which they were derived (Al-Hajj et al 
2003). When dissociated paediatric brain tumours were cultured in vitro using conditions 
that favoured neural stem cell growth, a small fraction of cells demonstrated growth into 
clonally derived neurospheres termed tumour spheres, whereas other tumour cells failed to 
proliferate (Singh et al 2003).  All neurosphere-like cells stained positive for CD 133,  a 
neural stem cell marker, but did not express markers of differentiated cell types. Tumour 
spheres were capable of in  vitro  self-renewal,  with cells from more  aggressive tumour 
types showing higher self-renewal capacity, and differentiated preferentially into the cell 
type predominant on the tumour of origin (Singh et al 2003). Self-renewal capacity was 
limited to the CD133+ (and not the CD 133 ) population. It was unlikely that these findings 
were due to contamination by normal neural stem cells as the population studied exhibited 
an  abnormal  karyotype  (Singh  et  al  2003).  A  further  study  by  the  group  of  Dirks 
demonstrated that injection of as few as 100 CD133+ cells into NOD/SCID mice initiated 
tumour  formation,  whereas  injection  of  100000  CD 133’  cells  resulted  in  no  tumour 
formation (Singh et al 2004).  Serial transplantation of tumours from CD133+ cells was 
possible and resulted in tumours phenotypically resembling the human tumour of origin, 
thus demonstrating in vivo cancer stem cell properties of this subset of brain cancer cells 
(Singh  et  al  2004).  Thus,  defined  cellular hierarchies  have  been  described  in  several 
human cancers, where a small cell population with stem cell-like properties gives rise to 
the heterogeneous phenotypes present in the tumour.
1.8.2  The relationship between normal stem cells and cancer
The cellular origin of cancer, or cancer stem cells, remains to be determined. However, the 
biology of cancer often closely resembles the biology of normal stem cells, leading to the 
suggestion that normal stem cells may be the source of cancer stem cells. Normal stem 
cells have the ability to self renew, as do cancer stem cells, but it is poorly controlled in 
this instance. Normal stem cells have the ability to differentiate; so do cancer stem cells, 
but it is aberrant and does not produce mature cells with normal  function (Pardal et al
712003).  Crucially,  and perhaps  understandably from these observations,  many pathways 
involved in stem cell function are deregulated during cancer progression, further posing 
the  possibility that  normal  stem  cells  are  the  source  of cancer stem  cells.  By way of 
example, the Wnt signalling cascade promotes self-renewal ability (but can also control 
lineage-specific differentiation in some contexts, section 1.6.2.3) in several adult stem cell 
populations including HSC, skin stem cells and intestinal epithelial stem cells (reviewed 
in Reya and Clevers 2005). Significantly, alterations that cause constitutive activation of 
this pathway are associated with cancers of these lineages, classically intestinal tumours 
such as adenocarcinomas (Reya and Clevers 2005, Radtke and Clevers 2005). In addition, 
Rb family members are known to play roles in differentiation of mesenchymal tissues (see 
1.6.2.3,  for  example);  perhaps  related  to  this,  a  500-fold  greater  occurrence  of 
osteosarcoma is exhibited by individuals with inherited heterozygous loss of the RB gene 
than the general population (Thomas and Kansara 2006). Further, as previously mentioned 
(1.2), it has been reported that prolonged culture of hESC lines can lead to chromosomal 
abnormalities that strongly resemble those observed in their cancer-derived counterparts, 
embryonic carcinoma cells (Draper et al 2004b).
Given  the  close  relationship  between  normal  stem  cells  and  cancer  cells,  it  could  be 
hypothesised  that  cancer-causing  mutations  would  take  place  in  the  normal  stem  cell 
population, leading to their transformation into cancer stem cells (Marx 2003, Passague et 
al 2003). The self-renewal ability of normal stem cells, combined with their long life span, 
could  render  stem  cells  more  likely  to  accumulate  mutations  than  progenitor  cells  or 
mature cell types; progenitor cells would have to regain this self-renewal ability (Pardal et 
al 2003, Marx 2003). In addition, it has recently been found that both embryonic and adult 
stem  cells  lack a specific  cell  cycle  checkpoint  that renders  them  more  likely to  gain 
chromosomal  aberrations,  and  the  efficiency  of  this  checkpoint  increases  as  cells 
differentiate  (Damelin  et  al  2005).  In  most  AML  subtypes,  the  only  cells  capable  of 
initiating AML in NOD/SCID mice (as described above) have a CD34+CD38' phenotype, 
similar to normal HSCs (Bonnet and Dick 1997). Furthermore, one of the most common 
translocations in AML results in AML1-ETO fusion transcripts in leukaemic cells.  One 
study found this translocation in a subset of normal HSCs that did not exhibit leukaemic 
properties (Miyamoto et al 2000). This indicated that this translocation occurred originally
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HSC subset or in their downstream progeny. Alternatively, cancer stem cells may arise 
from  mutations  in  progenitor or mature  cells  that  allow  re-acquisition  of self-renewal 
ability, and subsequent accumulation of further mutations. Myeloid leukaemias have been 
shown  to  arise  when  transgenes  are  expressed  in  a  haematopoietic  progenitor  cell 
population (Krivtsov et al 2006). Thus, it appears that mutations leading to cancer may 
appear in both stem and progenitor cells, depending on the cancer type. It will be of great 
interest  to  investigate  further  the  molecular  transformation  of stem  cell  populations, 
including the effects on self-renewal and differentiation.
1.8.3  Molecular pathways of cancer progression
Cancers are believed to arise from a series of stepwise mutations that accumulate as a 
result of environmental challenges or genetic instability; early mutations give rise to cells 
with increased propensity to  accumulate  further tumourigenic  mutations  (Hanahan and 
Weinberg 2000, Bjerkvig et al 2005). The progression of a normal cell to a cancer cell 
capable of forming tumours is termed neoplastic transformation. Much work has focused 
on the molecular pathways that underlie transformation in all cancers. Although over 100 
distinct types of cancer exist that contain mutations in a wide variety and combination of 
genes,  disruption of a  defined  set  of regulatory pathways  may be  sufficient to  induce 
transformation of many, or all, types of human cell (Hahn and Weinberg 2002). Broadly, 
it has been proposed that normal cells undergoing transformation acquire the capabilities 
to:  generate  their own  growth  signals,  become  refractory to  growth-inhibition  signals, 
evade apoptosis, proliferate without limit (become immortalised), induce angiogenesis in 
their  local  environment  and  lastly  to  metastasise  and  invade  other  tissues.  Genome 
instability of cancer cells may contribute to the attainment of these attributes (Hanahan 
and Weinberg 2000, Hahn and Weinberg 2002).
These  conclusions  were  drawn  largely  from  studies  aimed  at  elucidating  the  type  and 
number of mutations required to transform a specific cell type in vitro, focusing mainly on 
human  and  murine  cells.  Properties  of in  vftro-transformed  cells  include  density-  and 
anchorage-independent  growth,  a  lack  of requirement  for  growth  factors  and  tumour 
formation after transplantation into animal models. It has been shown that whilst murine
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require 4-6 hits depending on the cell type (Hahn et al  1999, Rangaranjan et al 2004). 
Stepwise  introduction  of  distinct  viral  oncogenes  or  mutated  proto-oncogenes,  or 
inhibition of tumour suppressor gene activity, leads to in vitro cellular transformation (Fig. 
1.7). These steps can include the introduction of hTERT, the rate-limiting subunit of the 
telomerase  enzyme  required  for  immortalisation  (bypass  of  senescence  and  crisis), 
followed by introduction of the human papillomavirus E6 and E7 proteins.  E6 binds to 
and inhibits the function of p53, which normally senses DNA damage and can inhibit the 
cell cycle and induce apoptosis. E7 sequesters the function of pRb, an important regulator 
of the  Gl/S  phase  of the  cell  cycle  which  normally responds  to  (anti)growth  signals. 
Alternatively, the SV40 large T antigen (LT) can be employed which sequesters both pRb 
and  p53.  Further,  introduction  of  the  SV40  small  T  antigen  (ST)  inhibits 
dephosphorylation of Myc, resulting in increased Myc activity thus leading to increased 
cell  proliferation  and  impaired  differentiation.  Finally,  introduction  of  an  oncogenic 
version  of the  signalling  protein  Ras  results  in  uncontrolled  pro-growth  signals.  Ras 
normally  transmits  pro-growth  signals  from  growth  factor  signalling  through  three 
pathways, mediated by PI3K, Raf, and RAL-GEFs. It has been shown that at least two of 
these pathways must be perturbed  for transformation  of human  cells,  but the pathway 
combinations and numbers required differ between cell types. Thus, combinations of these 
introduced genes can transform a wide variety of normal human somatic cell types (Hahn 
et al 1999, 2002, Hahn and Weinberg 2002, Rangaranjan et al 2004, Zhao et al 2004).
As  mentioned  above,  human  somatic  cells  require  4-6  hits  to  become  transformed.  In 
contrast to  this,  when  embryonic  stem  cells  are  implanted  into  immunodeficient mice, 
teratomas are formed, showing that these cells have tumourigenic capability without the 
need  for transforming  mutations  (Thomson  et  al  1998).  Transplantation  of minimally 
cultured  normal  adult  stem  cells  into  recipient  animals  does  not  result  in  tumour 
formation, but their stem cell properties such as self-renewal may imply that some, but not 
all, tumourigenic properties are already possessed by adult stem cells (Polyak and Hahn 
2006). Elucidating the number of hits required to transform adult human stem cells may be 
performed  by  determining  the  effects  of  increasing  hits  on  their  self-renewal  and
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Figure  1.7.  Pathways  sufficient  for  transformation  of  human  somatic  cells.  hTERT  (or 
alternative  lengthening of telomeres,  ALT)  lead  to  telomere  stabilisation.  pRB  and  p53  are 
inactivated by viral oncoproteins such as El A, human papilloma virus subtype  16 E7 and E6; 
the SV40  LT  antigen encoded by the  SV40  early region (ER)  can inactivate both pRB  and 
p53. The SV40 ST antigen inactivates PP2A, leading to stabilisation of MYC and upregulated 
PI3K-AKT  and  RAC/RHO  small  GTPase  function.  Oncogenic  RAS  transmits  constitutive 
signals through several pathways. The concerted action of these disruptive changes results in 
deregulation of processes such as the cell cycle, growth and migration.  Figure adapted from 
Zhao et al 2004.
75differentiation  capabilities,  and  could  advance  the  understanding  of  step-wise  cancer 
development.
1.8.4  hMSC transformation and mesenchymal tumours
Sarcomas are  a diverse group  of tumours  that  arise  in mesenchymal  tissues.  They are 
generally sporadic and constitute around  1% of all cancers. Around 50 sarcoma subtypes 
have  been  identified,  some  of  which  resemble  their  tissue  of  origin;  for  example 
osteosarcomas resemble bone tissue, whereas liposarcomas have characteristics of adipose 
tissue (Helman and Meltzer 2003, Mocellin et al 2006). A recent study has suggested the 
presence of a stem cell-like population in osteosarcomas (Gibbs et al 2005). This study 
showed the formation of “sarcospheres”,  similar to neurospheres,  from a proportion of 
cells from dissociated osteosarcomas. These cells showed in vitro self-renewal ability for 
several passages, expressed hMSC markers such as STRO-1, and could differentiate into 
cells with characteristics of osteoblasts and adipocytes (Gibbs et al 2005). This study was 
far less comprehensive than those characterising leukaemia, breast and brain tumour stem 
cells (1.8.1), and hence extensive further work is required in order to fully define this cell 
population. However, it may indicate the possibility that cancer stem cells are also present 
in  sarcomas,  extending  further the  question of the  cell  of origin  of such tumours.  An 
interesting candidate  has  to  be  hMSCs;  hMSCs  are  capable  of differentiating  into  the 
tissue types from which such tumours originate, and previous evidence has suggested that 
cancer stem cells may arise from tumourigenic mutations in the stem cell population that 
lead to aberrant self-renewal and differentiation properties (1.8.2).
Various studies have investigated the potential of MSCs to become transformed. Human 
adipose  tissue  derived-MSCs  cultured  for  4-5  months  gave  rise  to  tumours  in 
immunodeficient  mice  so  were  considered  to  have  been  spontaneously  transformed, 
whereas hMSCs grown for ~2 months did not, and hence had only reached the stage of 
spontaneous  immortalisation  (Rubio  et  al  2005).  This  spontaneous  transformation  of 
hMSCs  highlighted  the  fact  that  mutated  stem  cells  may  be  able  to  initiate  tumour 
formation (Rubio et al 2005). In a further study, murine MSCs cultured for 29 passages or 
more  showed  spontaneous  transformation  associated  with  chromosomal  abnormalities 
including  elevated  c-Myc  and  telomerase  expression  (Miura  et  al  2006).  These  cells
76formed tumours resembling fibrosarcomas in immunodeficient mice. The authors were not 
able, however, to transform human MSCs under the same conditions, perhaps reflecting 
experimental  differences  between  the  two  studies  (Miura  et  al  2006).  Human  MSCs 
artificially immortalised by retroviral introduction of the hTERT gene have also showed 
spontaneous transformation and tumour formation in immunodeficient mice (Serakinci et 
al 2004). Transformation was associated with acquired genetic changes, including deletion 
of the INK4A/ARF locus and an activating mutation in the K-Ras gene (Serakinci et al
2004). When single-cell clones from a cell line of these transformed hMSCs was analysed 
for their tumourigenicity, all clones were found to form tumours, but to a widely varying 
extent; it was therefore concluded that the cell line represented a cancer stem cell model 
that was hierarchical in nature (Bums et al 2005).
Some researchers have also applied the stepwise transformation model described in the 
previous section to investigate the effects on hMSCs. Two studies introduced the hTERT 
gene into hMSCs, and showed that the cells became immortalised, as demonstrated by a 
greatly extended lifespan in culture (Shi et al 2002, Simonsen et al 2002). Furthermore, it 
was shown that their differentiation potential was not diminished at high passage numbers 
(Shi et al 2002, Simonsen et al 2002). Hung and co-workers transduced hMSCs with a 
retrovirus  expressing  the  E6  and  E7  proteins,  and  found  that  the  cells  became 
immortalised, as assessed by unlimited passaging, but were not transformed as growth in 
soft agarose  or tumour formation in mice were not observed (Hung et al 2004b).  The 
hMSCs  also  retained  multilineage  differentiation  potential.  In  other  work,  retroviral 
introduction of hTERT did not immortalise hMSCs; addition of E6 and E7 was required 
for immortalisation but this did not affect differentiation ability (Okamoto et al 2002). 
Thus, several studies have investigated the potential of MSCs to spontaneously transform, 
and  have  raised  the  intriguing  possibility  that  MSCs  may  be  the  target  of mutations 
leading to tumour formation. It has also been shown that the introduction of up to three 
hits does not induce full transformation of hMSCs or affect differentiation capabilities. 
Therefore, a comprehensive analysis of hMSC transformation using the full range of hits 
required  to  transform  human  somatic  cells,  and  the  corresponding  effects  on 
differentiation, has yet to be undertaken.
771.9  Thesis hypothesis and aims
The  overall  hypothesis  of  this  thesis  is  that  crucial  molecular  events  regulate  the 
commitment  and  differentiation  of  hMSCs  towards  adipocytes,  but  are  as  yet 
uncharacterised. The application of functional genomics during the early stages of hMSC 
adipogenesis will enable the identification of such events.
In order to investigate this hypothesis, this thesis aims to achieve the following:
Establish optimal hMSC differentiation to adipocytes. Human MSCs can be isolated 
from human bone marrow samples, and protocols for their growth and differentiation to 
adipocytes  are  well  established.  However,  hMSC  isolation,  growth  and  adipogenic 
differentiation  will  be  optimised  in  order  to  achieve  the  robust  and  reproducible 
differentiation required for functional genomics.
Define the time-course of molecular events during adipogenesis in order to identify 
the earliest stages of differentiation. Much detail is known regarding the later molecular 
regulation of adipogenesis. This knowledge will be related to hMSC adipogenesis in order 
to define the point during differentiation at which crucial  early events  are  likely to  be 
occurring.
Identify  and  validate  the  gene  expression  patterns  that  characterise  early 
differentiation using microarray analysis. Microarrays covering all known human genes 
will  be  used  to  obtain  transcriptional  profiles  during  a  time-course  study  of the  early 
stages of hMSC adipogenesis. Data processing and analytical techniques will be employed 
to  define  gene  expression  patterns  during  early  differentiation,  and  the  accuracy  and 
reproducibility of the data will be assessed.
Characterise the  nature  of early  transcriptional  events  through  global  annotation 
techniques,  and  identify  potential  candidates  for  novel  regulators  of adipogenesis.
The  use  of  genome-wide  arrays  in  this  study,  combined  with  automated  annotation
78methods, will allow comprehensive annotation of the molecular processes and pathways 
involved  in  early  differentiation.  Furthermore,  manual  investigation  of  gene  function 
coupled  with  stringent  selection  criteria  will  be  used  to  identify  genes  showing  early 
regulation that may play an essential role during early stem cell differentiation.
Develop  and  apply techniques  allowing  the  use  of RNAi  screening  to  functionally 
investigate the role of candidate genes during hMSC  adipogenesis.  Several methods 
for using retroviral RNAi libraries to screen for genes with a particular function have been 
described, but have not been applied to hMSCs. Therefore, a technique for using an RNAi 
library,  plus  an  additional  screening  method,  will  be  developed  and  applied  to  hMSC 
adipogenesis to investigate the role of candidate genes during the process.
Investigate the effects  of specific mutations involved  in  cellular transformation  on 
hMSC  differentiation.  It  has  been  proposed  that  cancer  stem  cells  may  arise  from 
tumourigenic mutations in the normal stem cell population, which would be expected to 
affect intrinsic stem cell properties such as differentiation. Human MSCs will therefore be 
investigated  for  their  differentiation  capabilities  after  the  introduction  of progressive 
numbers of transforming mutations.
79CHAPTER 2. MATERIALS AND METHODS.2.1 Materials
All  reagents,  histochemical  stains  and  general  chemicals  were  from  Sigma-Aldrich 
(Dorset, UK), unless otherwise stated. All  tissue culture media and other tissue culture 
reagents  (trypsin/EDTA,  PBS)  were  from  Gibco  (Invitrogen,  Paisley,  UK),  unless 
otherwise  stated.  Viral  vectors  and  antibody  sources  are  listed  in  Tables  2.1  and  2.2, 
respectively. The source of all other materials is specified in the relevant section.
LiSa2 cells (Wabitsch et al 2000) were a gift from Dr. D. Guiliano (UCL, UK). The 293gp 
cells were from Clontech (Saint-Germain-en-Laye,  France),  and 293T  cells  were a gift 
from Dr. D. Trono (Geneva University, Switzerland)
2.2 Cells
2.2.1  MSC isolation and culture
Bone marrow aspirates were taken from the iliac crest of healthy transplantation donors 
after informed consent and with prior approval from University College London Hospital 
ethics  of human  research  committee,  in  association  with  the  Molecular  Haematology 
Department, UCL. The average bone marrow aspirate volume was  10ml. Aspirates were 
passed through a cell strainer (pore size 40/zm) to remove tissue fragments, and washed 
with an equal volume of PBS. Aspirates were carefully loaded onto 20ml Ficoll-Paque 
(1.077g/ml, Amersham Biosciences, Bucks, UK) in a 50ml Falcon tube and centrifuged 
(1800rpm, 30min, PK120 centrifuge, DJB Labcare, Bucks, UK) at room temperature (20- 
25°C). The cell layer containing mononuclear cells was isolated, washed with PBS  and 
resuspended in Mesencult medium containing  10% human serum (both from Stem Cell 
Technologies,  Vancouver,  Canada)  with  or  without  lng/ml  bFGF  supplement  (R&D 
Systems,  Oxon,  UK).  Cells were plated  onto  6-well plates  at  a density of 2xl05   bone 
marrow  mononuclear  cells/cm2,  and  incubated  at  37°C  and  5%  CO2  in  a  humidified 
atmosphere. Two days after plating, non-adherent cells were removed with a PBS wash 
and fresh media was added. Human MSC colonies formed were designated as passage 0, 
and  were  maintained  in  the  appropriate  medium,  with  the  first  passage  occurring 
approximately 7 days after initial isolation. Cells were kept at sub-confluent levels during 
culture, and were passaged at a ratio of 1:4 on reaching 70% confluence, which occurred
81Vector construct Map (Figure) Source
pMSCV-Hyg 2.1
Purchased fromClontech (Saint-Germain-en-Laye, France)
pMSCV-Hyg-PPARyl 2.1 Constructed as described
p M SCV-Hy g-PP  A Ry  2 2.1 Constructed as described
pMSCV-Puro 2.1 Purchased fromClontech
pMSCV-Puro-WPRE-eGFP 2.1 Gift from E. Crick (UCL,UK)
pRetro Super-Puro(-s h RN  A) 2.1 and 5.1 NKiRNAi  libraiy
pRS-Neo-GFP(-shRNA) 2.1 and 5.5 Purchased from OligoEngine (Seattle, WA, USA) (and 
shRNA constructs cloned as described)
p SilR-H 1-Scrambed 2.1 and 5.6 Purchased from A mb ion (Cambs, UK)
pSilR-Hl(-shRNA) 2.1 and 5.6 Purchased from Ambion (and shRNA constructs cloned 
as described)
pCSGW (-shRNA) 5.11 and 2.2 Gift from A. Godfrey (UCL, UK) (and shRNA constructs 
cloned as described)
pCSGW-v-cyclin 5.11 and 2.2 Gift from A. Godfrey (UCL, UK)
pVSVG 2.2 Purchased fromlnvitrogen (Paisley, UK)
pLPl 2.2 Purchased fromlnvitrogen
pLP2 2.2 Purchased fromlnvitrogen
Table 2.1 Plasmids used in this thesis and their source.
82Antibody Conjugation Dilution
Incubation 
time (min) Details
1° Antibody 2° Antibody 1° 2° 1° T 1° 2°
CD13 PE 1:10 30 BD Biosciences
CD  34 FITC 1:10 30 BD Biosciences
CD44 PE 1:10 30 BD Biosciences
CD45 PECy7 1:30 20 BD Biosciences
CD49b FITC 1:10 30 BD Biosciences
CD49d PE 1:10 30 BD Biosciences
CD117/C-kit - FITC 1:10 1:400 20 30 Chemicon DakoCytomation
CD133* PE 1:40 20 BD Biosciences
HLA-ABC FITC 1:10 30 BD Biosciences
HLA-DR APC 1:10 30 BD Biosciences
SH2 FITC 1:50 20 Stem Cell Technologies
SH4 FITC 1:50 20 Stem Cell Technologies
Stro-1 - PE 1:5 1:8 40 30 R&D Systems DakoCytomation
Table 2.2 Antibodies used to define the cell surface marker profile of hMSCs. The dilution at 
which each antibody was used and the incubation time are indicated.  *co-incubate with Fc 
Receptor block whilst staining. All primary antibodies were monoclonal and raised in mouse; 
all secondary antibodies were polyclonal goat anti-mouse immunoglobulins. BD Biosciences 
(Oxon,  UK);  Chemicon  (Hampshire,  UK);  DakoCytomation  (Glostrup,  Denmark);  R&D 
Systems (Oxon, UK); Stem Cell Technologies (Vancouver, Canada).
83generally  every  3  days  and  corresponded  to  re-plating  the  cells  at  a  density  of 
approximately 4xl03cells/cm2. For all hMSC experiments, cells were used at passage 4-6, 
and were from a healthy 31 year old male donor, unless otherwise indicated.
2.2.2  hMSC differentiation
2.2.2.1 Adipogenic differentiation
For adipogenic differentiation, cells were grown to confluence in media containing bFGF 
(unless otherwise indicated). One day post-confluence, medium was changed to Mesencult 
+10%  serum  without  bFGF  (unless  otherwise  indicated),  supplemented  with  lpM 
dexamethasone, 500/zM IBMX, 200/iM indomethacin and 10/zg/ml human insulin (Roche, 
Sussex, UK). Medium was changed every 3 days (unless otherwise indicated) and the day 
of addition of differentiation media to cells was designated as day 0.
2.2.2.2 Osteogenic differentiation
For  osteogenic  differentiation,  cells  were  grown  to  confluence  as  for  adipogenic 
differentiation. One day post-confluence, medium was changed to Mesencult +10% serum 
without bFGF (unless otherwise  indicated),  supplemented with  lOOnM  dexamethasone, 
50/iM  ascorbic  acid  phosphate  and  lOmM  /3-glycerophosphate.  Medium  was  changed 
every 3 days (unless otherwise indicated) and the day of addition of differentiation media 
to cells was designated as day 0.
2.2.2.3 Chondrogenic differentiation (performed by S.  Vujovic)
Chondrocyte  differentiation  media  was  composed  of  high  glucose  DMEM  with  1% 
penicillin/streptomycin  (Invitrogen),  1/iM  dexamethasone,  50/xg/ml  ascorbate-2- 
phosphate,  40/zg/ml  1-proline,  100/ig/ml  sodium  pyruvate,  50  mg/ml  insulin/ 
transferrin/selenium  +  Premix  (6.25/xg/ml  insulin,  6.25/ig/ml  transferrin,  6.25ng/ml 
selenious  acid,  1.25mg/ml  BSA,  5.35mg/ml  linoleic  acid,  BD  Biosciences,  Franklin 
Lakes, NJ, USA), 500ng/ml BMP6 (R&D Systems), lOng/ml TGF/33 (R&D Systems). To 
initiate  chondrogenesis,  2.5x105   hMSCs  were  suspended  in  500/d  chondrocyte 
differentiation media, placed in  a  15  ml  Falcon tube and centrifuged (600g,  30min) to 
form a loose cell pellet. Pellets were then incubated at 37°C and 5% CO2 in a humidified
84atmosphere. The first media change occurred 4 days later, after which the differentiation 
media was changed every 3 days (protocol adapted from Sekiya et al 2002).
2.2.3 Staining protocols for assessment of differentiation
2.2.3.1 Oil Red O: adipogenesis
Lipid accumulation was  assessed by Oil  Red  O  staining (Koopman et al 2001)  at the 
timepoint indicated. Cells were fixed in 4% formaldehyde and  1.5% methanol (in sodium 
phosphate  buffer,  final  concentration  75mM)  for  30min,  washed  twice  with  PBS  and 
stained for 2h with 0.04% Oil Red O dissolved in 40% triethyl phosphate. Excess dye was 
removed with two PBS washes and cells were visualised by phase contrast microscopy 
using an Axiovert 100 inverted microscope with Axiocam (Zeiss, Herts, UK).
2.2.3.2 Alkaline phosphatase activity: osteogenesis
Alkaline  phosphatase  activity  was  assayed  as  a  marker  of osteogenesis  using  Sigma 
Aldrich Kit 85L-2, following manufacturer’s instructions. Fast Blue RR salts were used 
(Sigma-Aldrich),  resulting  in  a  blue  colour  where  alkaline  phosphatase  activity  was 
present.
2.2.3.3 Alizarin Red: osteogenesis
Calcium  deposition  during  osteogenic  differentiation  was  assessed  with  Alizarin  Red 
staining at the timepoint indicated. Cells were fixed with ice-cold 100% methanol for 15 
min, and then washed 3 times with dH20 and stained for 10 min with 1.5% w/v Alizarin 
red (pH 4.2 with ammonium hydroxide).  Excess  stain was removed with  further dH20 
washes and cells were left to air-dry before being visualised.
2.2.3.4 Toluidine Blue: chondrogenesis (in collaboration with S.  Vujovic)
Wax embedding and sectioning of chondrogenic pellets Chondrocyte pellets were fixed 
in 4% paraformaldehyde in 2x PBS overnight at 4°C. Pellets were then placed in cellsafe 
biopsy capsules and subjected to the following dehydration steps:  30%  ethanol,  lOmin; 
80% ethanol,  lOmin; 95% ethanol,  lOmin;  100% ethanol, 30min; xylene, 20min. Pellets 
were then embedded in paraffin and left overnight to set at 4°C. Wax sections were cut
855fim thick and floated in a water bath at 40°C before being applied to polysine coated 
slides, and allowed to dry on a hotplate overnight.
Staining of wax sections with toluidine blue Slides were dewaxed in xylene for lOmin, 
rehydrated in 90% ethanol 5min,  70% ethanol 5min and washed in distilled water.  The 
toluidine blue stain (0.1% w/v toluidine blue dissolved in 0.1 M sodium phosphate buffer -  
94% 0.1M NahhPCU, 6% 0.1M Na2HPC>4) was applied for 45sec and washed with distilled 
water.  The  slides  were  then  dehydrated  by  consecutive  ethanol  washes  (70%,  90%, 
100%), and dipped in xylene for 5min. Slides were air dried and mounted with DPX.
2.2.4 Other cell lines
LiSa-2
LiSa2 cells were grown in DMEM/Ham’s F12 (1:1) media with  10% FCS (Gibco), and 
were incubated at 37°C and 5% CO2 in a humidified atmosphere. On reaching confluence, 
cells were passaged at a ratio of 1:3.
293gp and 293T
293gp (retroviral packaging cell line containing Moloney murine leukaemia virus gag and 
pol genes integrated in the genome) and 293T (human renal epithelial cell line transduced 
with SV40 LT antigen) cells were grown in DMEM + Glutamax media supplemented with 
10% FCS  (Perbio  Science, Northumberland, UK),  and were incubated at 37°C  and  5% 
CO2 in a humidified atmosphere. At confluence, cells were passaged at a ratio of 1:5-1:10.
2.2.5 Splitting cells
All cell lines were passaged using the same protocol. Cell monolayers were washed with 
lx PBS then incubated for 2-5min at 37°C with trypsin/EDTA (0.25%/1% v/v). Detached 
cells  were  harvested  and  trypsin  was  inactivated  via  a  wash  with  serum-containing 
medium.  Cells  were  collected  via  centrifugation  (1200rpm,  5min,  PK120  centrifuge). 
Media was then removed and the cell pellet was resuspended at the required dilution in 
fresh media.
862.2.6  Counting cells
At the passage number specified, hMSCs were harvested as above (2.2.5). After collecting 
cells via centrifugation (1200rpm, 5min, PK120 centrifuge), the pellet was resuspended in 
a  known  volume  of  media,  and  the  cell  number  in  10/d  was  quantified  using  a 
haemocytometer (counting at least 100 cells).
For growth curves, the total number of cells was then calculated and cells were re-seeded 
at the specified density. This process was repeated after the interval indicated;  the total 
cell number before passaging was again quantified and cells were reseeded at the same 
density at every passage. Total cell numbers were used to calculate population doublings 
using the formula:
Population doublings = log2(total cell number obtained/total cell number seeded)
Cumulative population doublings were calculated via addition of population doublings at 
each passage.
2.3  FACS analysis
2.3.1  Antibody staining for surface marker expression
Subconfluent hMSCs at passage 4 were harvested (2.2.5) and washed in MACS buffer 
(PBS containing 2 mM EDTA and 0.5% w/v BSA, pH7.2) via centrifugation (1200rpm, 
5min, PK120 centrifuge) to remove traces of media. Aliquots of 5x10s cells per sample 
were incubated with the appropriate primary antibody (all monoclonal and raised in mice) 
for the  specific time (see  Table  2.2  for antibody  information,  dilutions  and incubation 
time) in MACS buffer (final volume  100/d) on ice and in the dark. Cells incubated with 
the anti-CD 133 antibody were simultaneously incubated with human Fc receptor blocking 
reagent (Miltenyi Biotech, Surrey, UK) to avoid cross-reaction of the antibody with this 
receptor. After removal of excess antibody via 3x MACS buffer washes (3 min, 2500rpm, 
Heraeus Biofuge Pico, DJB Labcare), secondary antibody (all polyclonal goat anti-mouse 
immunoglobulins) incubations were carried out as before if required, followed by further 
washes.  Control  hMSCs  were  stained  with  FITC-secondary  antibody  only  for  FITC-
87conjugated  antibodies,  PE-secondary  antibody  only  for  PE-conjugated  antibodies,  and 
control cells were unstained for PE-Cy7 or APC-conjugated antibodies.  Surface marker 
expression was then determined by counting  10000 events per sample on a FACScalibur 
flow cytometer (BD Biosciences, Oxon, UK).
Cell  size  and  shape were analysed  and gates were  set to  exclude  debris.  Control  cells 
(either unstained, or stained with the appropriate control antibody) were analysed on the 
wavelength corresponding to the fluorescent signal being detected, and a gate was set to 
contain >99% of this population. Positive events in specific antibody-stained cells were 
then scored as those that were outside of this gate (i.e. above the background level).
2.3.2  GFP expression
To  analyse GFP  expression after transduction with  GFP-containing  viral  vectors,  cells 
were harvested (2.2.5) and washed once with lx PBS to remove excess media. Cells were 
resuspended  in  PBS  +  1%  v/v  FCS  and  then  fixed  with  CellFix  (lOx  stock,  BD 
Biosciences).  GFP  expression  was  determined  by  counting  10000  events  per  sample. 
FACS gating was set up as described above, with untransduced cells as a control.
2.4  Cloning
2.4.1 Vectors used
Table 2.1 lists all vectors used in this thesis and their source, and vector maps are shown 
in Figures 2.1 and 2.2.
2.4.2 General cloning protocols
The  following  protocols  were  used  for  all  cloning  work;  any  modifications  to  these 
protocols are indicated in the specific section.
2.4.2.1  Restriction digestion
Restriction digestions  of plasmid  DNA or PCR  fragments were  set up  in the volumes 
indicated. Final concentrations in a 20/d reaction were: 5 units each enzyme (specified, all 
from Promega, Southampton, UK);  lx Promega buffer (specified); DNA:  I fig DNA was
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Figure 2.1. Schematic illustration of the retroviral vectors used in this thesis and their purpose. 
Blue shaded sections indicate cloning procedures that were used to create vectors containing 
the  indicated  genes;  during  experimentation,  the  empty  vectors  (name  indicated,  not 
containing blue shaded sections) were used as controls.
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Figure 2.2. Production of lentivirus particles through transfection of 293T cells with lentiviral 
vector plus packaging plasmids. pHR-SIN CSGW (Clements et al 2006): derived from HIV-1. 
It  is  a  self-inactivating  virus  (SIN):  a  ~400bp  fragment  of the  3'  LTR  has  been  deleted, 
including the TATA box, thus abolishing the promoter activity of the LTR. This is transferred 
to the 5' LTR during reverse transcription. Thus, after viral integration into the host genome, 
viruses are replication-deficient (Zufferey et al  1998).  CSGW also  lacks  the viral proteins 
required for assembly of viral particles within the 293T cells (gag, pol, env, rev).  With the 
Invitrogen  ViraPower™  Packaging  Mix,  these  genes  are  provided  by  three  packaging 
plasmids, pLPl, pLP2 and pLP/VSVG. pLPl: contains gag and pol ORFs; gag encodes core 
viral proteins for the structure of the viral particle and pol encodes enzymes required for viral
90replication and integration.  Their expression is dependent on rev binding to the RRE  (rev 
response element)  in pLPl. pLP2  contains the rev ORF which, in addition to  it’s gag/pol 
expression role, binds another RRE in CSGW and promotes nuclear export of unspliced viral 
RNA  for packaging  into  viral particles.  pLP/VSVG  encodes  the vesicular stomatitis  virus 
glycoprotein, a viral envelope glycoprotein that enables a broad host range. The presence of 
these genes on three separate plasmids reduces the chance of recombination events producing 
active virus.  \|/: viral packaging signal; cPPT: central copy of the polypurine tract enhances 
nuclear import and transduction efficiency of the viral genome; SFFV: spleen focus forming 
virus promoter; eGFP: enhanced green fluorescent protein; WPRE: woodchuck hepatitis virus 
response element: enhances transgene expression in the target cells. Transfection of 293T cells 
with these 4 plasmids leads to production of lentiviral particles within 48h.
91used in 20/d diagnostic restriction digests, and 3/ig was used in initial cloning restriction 
digests  (50/d).  Subsequent  cloning  steps  used  all  products  from  the  first  restriction 
digestion. Reactions were carried out for  lh (unless otherwise specified) at 37°C. DNA 
fragments were either purified using a Gel Extraction Kit (Qiagen, Sussex, UK), according 
to  manufacturer’s  protocols,  and  eluted  in  30/d  (IH2O,  or  separated  on  agarose  gels
(2.4.2.3).
2.4.2.2 Shrimp alkaline phosphatase (SAP) treatment
This was performed to remove free 5* phosphate groups from linearised vector to prevent 
re-ligation. Reactions were set up as follows in a 50/d volume:  lunit SAP (Promega) per 
1/ig DNA;  lx  SAP buffer (lOx stock, Promega).  Reactions were incubated at 37°C for 
15min, then 65°C for 15min to inactivate the reaction.
2.4.2.3 Gel separation of  DNA for cloning
To  isolate PCR or restriction digestion products,  DNA  was  separated on  agarose gels, 
density as  specified,  composed  of x%  w/v  agarose  in  TAE  buffer  (tris-acetate  0.4M, 
EDTA  0.01M)  plus  0.00002%  v/v  ethidium  bromide  for  DNA  visualisation,  using 
autoclaved  DNA  loading  buffer  (6x  stock  concentration:  15%  ficoll,  0.125%  xylene- 
cyanol in dtfjO). DNA was excised from gels via visualisation on a UV block. DNA was 
then  isolated  and  purified  using  a  Gel  Extraction  kit,  according  to  manufacturer’s 
protocols, and eluted in 30/d dt^O.
2.4.2.4 Ligation
Insert and vector were ligated using two different protocols:
Protocol 1: Ligation reactions (10/d final volume) were set up as follows: 3 units T4 DNA 
ligase (Promega),  lx ligase buffer, 50ng insert DNA, 750ng vector DNA. Ligations were 
carried out overnight at 16°C.
Protocol 2: Ligation reactions (10/d final volume) were set up as follows: 400 units T4 
DNA ligase (New England Biolabs, Herts, UK); lx ligase buffer, 50ng insert DNA, 700ng 
vector DNA. Ligations were carried out for lhr at room temperature (20-25°C).
For both ligation protocols and in all cloning procedures, control ligations were set up by 
replacing insert DNA with an equal volume of dH20.
922.4.2.5 Transformation and isolation of bacterial clones
One fi\ of each ligation reaction was transformed into 50/d CaCl2-competent TOP 10 E. 
coli (prepared in the laboratory), always including the control ligation so that the level of 
re-ligation of the empty vector backbone could be assessed. This was accomplished by 
incubating DNA and bacteria on ice for 30min, followed by a 90sec incubation at 42°C. 
Following a further 2min incubation on ice, 950/d LB (Lennox L Broth® base, Invitrogen) 
was added and cells were expanded at 37°C in a shaking incubator for 30-45min. Next, 
50-100/d of culture was plated using sterile glass beads onto LB-Agar (Lennox L Agar®, 
Invitrogen) plates  containing  50/ig/ml  ampicillin (unless  otherwise  stated),  which were 
incubated overnight at 37°C. Bacterial colonies formed overnight were picked individually 
into 2-4ml LB + 50/xg/ml ampicillin. These were cultured overnight at 37° C in a shaking 
incubator.  The  following  morning,  a  Spin  Miniprep  Kit  (Qiagen)  was  used  to  isolate 
plasmid DNA.
2.4.2.6 Plasmid DNA isolation
Plasmid DNA was isolated using Spin Miniprep Kit, Midiprep Kit or Maxiprep Kits from 
Qiagen,  according  to  manufacturer’s  protocols.  Plasmid  preparations  were  quantified 
using  a  Nanodrop  ND-1000  spectrophotometer  (Nanodrop  Technologies,  Montchanin, 
DE, USA).
2.4.2.7 DNA sequencing (performed by DNA sequencing service,  WIBR)
All DNA sequencing was performed using a Beckman Coulter CEQ 8000 genetic analysis 
system  (Beckman  Coulter,  Bucks,  UK).  Normal  sequencing  was  performed  using  a 
Quickstart Kit DTCS, CEQ™ (Beckman Coulter), and shRNA hairpins were sequenced 
using a Methods Development Kit, GenomeLab™ (Beckman Coulter).
2.4.3  PPARy isoforms: specific protocols
RT-PCR primers were designed that would amplify the human PPARy 1   and -2 iso forms 
separately (Table 2.3). Restriction sites for Xhol and Smal were included on the 5* and 3' 
primers, respectively (plus additional bases to allow optimal efficiency of the restriction 
enzymes),  in order to  clone the PCR fragments  into pMSCV-Hygro  (Table  2.1).  Total 
RNA was extracted (2.6.1) from 1.5 xlO6 hMSCs at day 4 of adipogenesis (2.2.2.1), and
93Gene GenBankID Fwd Rev TaqMan Probe Product 
size (bp)
Goning Primers
PPARY 1 NM  138712 CCGCTCGAGCGGATGGTTGACAC TCCCCCGGGGGAT GCT  AGT AC  A ~1.4kb
AGAGATGCC AGTCCTTGTAG
PPARY2 NM  015869 CCGCTCGAGCGGATGGGTGAAA TCCCCCGGGGGATGCTAGTACA ~1.5kb
CTCTGGAGA AGTCCTTGTAG
pRS - CCCTTGAACCTCCTCGTTCGACC GAGACGTGCTACTTCCATTTGTC N/A
Sequencing primers
pRS Seq _ GCTGACGTCATCAACCCGCT N/A N/A
pSilR-Hl Seq _ TTGTACACCCTAAGCCTC N/A N/A
OPCR Primers
GAPDH Primers designed GGAGTCAACGGATTTGGTCGTA GGCAACAATATCCACTTTACCA CGCCTGGTCACCAGGGCTGC 78
against a region GAGT
common to all
GAPDH sequences
CSGW
_ GCACGGCAAGAGGCGA CGCACCCATCT CT CT CCTT CT A CGGCGACTGGTGAGTACGCCAA 84
packaging AAAT
signal (\j/)
Table 2.3. Primers used for gene expression studies, cloning techniques or sequencing (continued overleaf).
V OGene GenBankID Fwd Rev Product 
size (bp)
RT-PCR primers
ACTA2 NM_001613 ACTGGGACGACATGGAAAAG GAAGGAATAGCCACGCTCAG 368
Adipsin NM  001928 GGTCACCCAAGCAACAAAGT CCACCTCAGCCTCCTGAGTA 248
ALP NM_000478 GGACATGCAGTACGAGCTGA AGACTGCGCCTGGTAGTTGT 457
aP2 NM  001442 TGCAGCTTCCTTCTCACCTT CAT CCCCATT  CACACTGATG 192
/5-actin NM001101 CCAAGGCCAACCGCGAGAAGATGAC AGGGTACATGGTGGTGCCGCCAGAC 587
CBFA1 NM_004348 CGCATTCCTCAT CCCAGT  AT TATGGAGTGCTGCTGGTCTG 581
C/EBP a NM_004364 GAGGAGGGGAGAATTCTTGG CCCT  A T GTTT CCA CCCCTTT 302
CLP1 NM_001884 TGCTCAGATTGCAAAAGTGG TATCTGGGAAACCCACGAAG 170
COL1A1 NM_000088 TCGTGGAAATGATGGTGCTA ACCAGGTTCACCGCTGTTAC 349
DACT1 NM_016651 A A GA A GT  GTCGCTTCCCA GA GGGCCTCTTCGTAGGAAATC 244
DLX2 NM_004405 AGCAGCTATGACCTGGGCTA GAAGCACAAGGTGGAGAAGC 380
DNCH1 NM_001376 GGAAAGTGGCTGGrGTTGTT GGAAGTGCTTCAGAGCAACC 610
FAT NM_005245 GCA CA GT  CCT GCTTT  CCTT C GT  GA TT  A CGCCGGA C  A GTTT 504
GAPDH NM  002046 GATCATCAGCAATGCCTCCT TGTGGTCATGAGTCCTTCCA 97
HES1 NM_005524 CTACCCCAGCCAGTGTCAAC CATTGATCTGGGTCATGCAG 408
HOXA7 NM  006896 TCA A CA GCCCCCTTT  ATCA G C  A GTCGGA CCTT CGTCCTT  A 417
HOXB2 NM_002145 AGCTGCTGGAACTGGAGAAG CTCCGGATAGCTGGAGACAG 501
INSIG1 NM_ 198336 ACCGATTCTGAGAGCAAGGA ACCTACCTCCTTTGGGCACT 375
LHFPL2 NM_005779 CCTTGCCCTGAGTGAATCAT CCTT  GT  GACICTTCCCAGGT 620
LIFR NM_002310 GAACAGGCCGTGGTACTGAT TTCCAAGGGCATATCTGAGG 422
MEOX2 NM  005924 AGAAGTGCACCGCTATTGCT TTCCTGGGAGTCTGAGCTGT 657
NEDD9 NM  006403 TGTATGACATCCCGCCTACA GACATGTTACTCCGGGTGCT 506Gene GenBank ID Fwd Rev Product 
size (bp)
RT-PCR primers continued
Osteocalcin NM_199173 GGCAGCGAGGT  AGTGA  AGAG CTGGAGAGGAGCAGAACTGG 230
PLZF NM_006006 CAAGGCTGACGCTGTATTGA TTTGrGGCTCTTGAGrGTGC 676
PPARy NM_138712 TTCAGAAATGCCTTGCAGTG CACCTCTTTGCTCrGCTCCT 332
NM  015869
SIX2 NM_016932 CTGGAGAGCCACCAGTTCTC CGGGTTGTGGCTGTTAGAAT 393
SNAI1 NM_005985 ACCGCACATCCTTCTCACTG (XGACA  AGTGA CAGCCATT  A 552
SNAI2 NM_003068 GAGCAT ACAGCCCCATCA CT CTCCCCCGTGTGAGTTCTAA 479
SOCS3 NM_003955 CCACCrGAGTCTCCAGCTTC GAGGAGCATGTCACCAGGAT 332
TBX2 NM_005994 TATCAGATCCGGGTCACCAT CCAGITTTATCACGCGGTCT 684
TCF8 NM_030751 GCACCTGA A GAGGA CCA GAG TGGTGATGCTGAAAGAGACG 537
TGFBR3 NM_003243 CAATGGCTCCTGTGGCTAAT CCATCTGGCCAACCACTACT 589
TGIF NM  003244 GAAAGGATGGCAAAGATCCA TTT  AGCA  ATCCCATGTGCA A 639was quantified using  a Nanodrop ND-1000  spectrophotometer.  cDNA  was  synthesised 
from I fig total RNA (2.6.2) and used as a template (0.25 fig) in 100/d PCR reactions with 
isoform-specific  primers  (Table  2.3)  to  amplify  the  cDNAs  of interest  (2.6.3.1).  PCR 
fragments were separated on  1% agarose gels then isolated and purified (2.4.2.3).  PCR 
fragments  were  digested  with  Smal  in  50/d  reaction  volumes  using  Multicore  buffer 
(Promega) to produce blunt ends (2.4.2.1). Simultaneously, 5fig pMSCV-Hygro (Fig. 2.1 
and Table 2.1) was digested with Hpal in Multicore buffer to produce a blunt end in the 
multiple cloning site.  DNA was isolated and purified  from both reactions as described
(2.4.2.3). The products of these reactions were next digested with Xhol in Promega buffer 
D in 50/d reactions; the pMSCV-Hygro restriction digest was carried out for 3hrs due to 
the close proximity of the Xhol site to the already cut Hpal site rendering the reaction less 
efficient. The digested fragments and vector were separated on 1% agarose gels then DNA 
was isolated and purified as before. The PCR fragments and linearised vector were ligated 
overnight  (2.4.2.4,  protocol  1).  Ligation  products  were  transformed  into  bacteria  and 
plated onto  LB-agar containing 50/ig/ml ampicillin (2.4.2.5).  Bacterial colonies  formed 
overnight were picked (10 for each isoform), suspended in 25/d dH20, and 2.5/d of each 
was used as a template in a PCR screen (20pl reaction volume, using the PPARy isoform- 
specific primers, 2.6.3.1) to identify positive clones. Positive clones were grown in LB + 
ampicillin (50/ig/ml) overnight, and then DNA was isolated using a Spin Miniprep Kit. 
Plasmids were sequenced (2.4.2.7) using the cloning primers to  ensure that the  coding 
sequences did not contain nonsense or missense mutations.
2.4.4  Retroviral shRNA constructs: specific protocols
2.4.4.1  PCR-based shRNA insert isolation from RNAi library
Bacterial  cultures  (in  LB  +  100/ig/ml  ampicillin,  containing  a  mix  of the  3  shRNA 
constructs for each gene) were inoculated directly from the RNAi library glycerol stocks 
and grown overnight. If bacteria did not grow, glycerol stocks were picked and bacteria 
was suspended directly in 25/d dH20. To amplify the shRNA inserts, 2/d bacterial culture 
(or suspension) was used in 50/d PCR reactions  (2.6.3.1) with the pRS primers (Table 
2.3).  PCR products  were  separated  on  1.5%  agarose  gels  and  DNA  was  isolated  and 
purified  as  described.  Both  PCR products  and pRetroSuper-Puro  vector were  digested 
simultaneously with Xhol  and EcoRA in Promega buffer H in  50/d  reactions,  and then
97DNA was separated on 2% agarose gels.  Linearised vector and digested PCR products 
were  isolated  and  purified  from  the  gel,  and  ligated  overnight  (2.4.2.4,  protocol  1). 
Ligations were transformed into bacteria and plated onto LB-agar containing  100/ig/ml 
ampicillin.  Bacterial  colonies  formed  overnight  were  picked  (10  for  each  shRNA), 
suspended in 25/d dH20, and  1/d of this was used as a template in a PCR screen (20/d 
reaction volume,  using the pRS  primers)  to  identify positive  clones  (2.6.3.1).  Positive 
clones  were  grown  in  LB  +  100/ig/ml  ampicillin  overnight,  and  then  plasmids  were 
isolated using a Spin Miniprep Kit. Plasmids were sequenced (2.4.2.7) using the pRS Seq 
primer to ensure that the shRNA inserts did not contain mutations.
2.4.4.2  Sub-cloning of  shRNA inserts into different retroviral vectors 
When  it  was  found  that  the  pRetroSuper-Puro  plasmid  used  above  had  recombined, 
shRNA inserts were sub-cloned into pRS-Neo/GFP and then pSilR-Hl. pSuperRetro-Puro 
shRNA constructs were digested simultaneously with Xhol and ZscoRI in Promega buffer 
H in 50/d reactions. Additionally, pRS-Neo/GFP or pSilR-Hl  was digested in the same 
manner. Restriction digest products were separated on a 1.5% agarose gel, and the shRNA 
insert  and  linearised  vector  were  isolated,  purified  and  ligated  (2.4.2.4,  protocol  2). 
Plasmid DNA was isolated from a selection of bacterial colonies (5 for each shRNA) as 
described (2.4.2.5). A diagnostic XhoVEcoRl restriction digestion in 20/d reactions was 
used to confirm the presence of shRNA inserts. The shRNA insert was sequenced (2.4.2.7) 
using  the  pSilR-Hl  Seq  primer  (Table  2.3)  to  ensure  that  no  further  mutations  had 
occurred.
2.4.5  Lentiviral shRNA constructs: specific protocols
2.4.5.1  shRNA oligonucleotide design
For two genes, 19nt shRNA sequences were obtained from the literature. For two further 
genes,  19nt  sequences  were  designed using  OligoEngine  design  software  (available  at 
www.oligoengine.com).  Oligonucleotides  were then ordered which contained the  sense 
and  antisense  19nt  sequence  separated  by  a  hairpin  sequences  (Table  2.4  illustrates 
shRNA  and  hairpin  sequences  and  an  example  of the  full  oligonucleotide  sequence). 
Additionally,  BglII  and  Hindlll  overhangs  at  the  5'  and  3*  ends,  respectively,  plus  an 
additional EcoiRl site downstream of the shRNA were included.
98Gene (insert name)  shRNA sequence  Hairpin
Nki RNAi library
HOXA7X CTCA CA GA GA A GCGGCT  A C TTCAAGAGA
HOXA7Y GCGTCTTTAAGAGACTCAC unless
TCF8X GCT  GTT  GTTCTGCCA ACAG otherwise
TCF8Y CAAGGTGGCCATTCTGTTA stated
TCF8Z GGTCAACrATCACrAGTGr
HOXB2X GGAGrTCGACATTAATTCCT
HOXB2Y TTTGAGAGGGAGATTGGGT
TBX2X CTGCTGAGCATCCAGAGAC
MEOX2X CCA GA GCC  A GTTT  CTT  GT  C
TCHFX GGGGCAACCTACCCAAGGA
TGIF Y CATGAGGAATCTGGCTGCT
FAT X CTACGACAGTCACTTCGAT
FAT Y CrCTGCAGCTAAGACTTAT
LHFPL2 X TTCTGGCA GGCC'A CA GCT  A
LHFPL2Y GCAGAAATTGCAACCTCTA
LHFPL2Z GGA A TTGCA GGT  CT  A TTCC
SIX2 X CGAGAACTCCAATTCTAAC
SIX2 Y CATGrCAGCCAACCTCGTG
SNA 12 X GATGCATATTCGGACCCAC
PPARy X GAGCCTTCCAACTCCCTCA
Control hairpins
Scrambled ACTACCGTTGTTATAGGrG
KSHV viral cyclin GTTCCTGCCA A CGTCA TTCCGCA G TTCG
Published sequences
DACT1 GA A TTCGA A A CAGGCGTGT
SNAI1 G jCGA GCIGCA GGA CTCTAA GAAGCTTG
Custom designed (using OligoEngine software)
SIX2 a CAAGGCACACTACATCGA
SIX2b AACGAGAACTCCAATTCTA
TCF8 a AAGCAGGATGTACAGTAA
TCF8b CTAGrCAGCCACCTTTAAA
Bglll 
GATCCCC-f 
GGG
19nt
hairpin 19nt EcoRI  Hindi 1 1  
H I ITTGAATTC 
AAAAACTTAAGTCGA
Table 2.4.  shRNAs sequences and hairpins used in this thesis, and design of oligonucleotide 
used for cloning shRNAs into lentiviral vectors.
992.4.5.2 Annealing oligonucleotides
To anneal each complementary pair of oligonucleotides, each individual oligo was diluted 
to 3mg/ml using nuclease-free dthO, then 1/d of each oligo was added to 48/d annealing 
buffer (100 mM NaCl, 50 mM HEPES, pH 7.4). The reaction was incubated at 94°C for 
4min, then cooled using a thermal cycler in 2-3  degrees steps until  75°C,  incubating at 
each temperature for 4min.  The reaction was then cooled in 5  degree steps until 50°C, 
incubating at each temperature for 4min. The reaction was then cooled in 10 degree steps 
until  20°C,  incubating at  each temperature  for  lOmin.  Annealed oligos  were  stored  at 
-20°C for a short time before ligation.
2.4.5.3 Ligation into retroviral shuttle vector
The retroviral  shuttle vector used was pSilR-Hl,  which contains the HI  promoter plus 
BamHl  and  Hindlll  restriction  sites  in  the  desired  locations  (Fig.  2.1,  this  vector  is 
purchased linearised with Hindlll  and BamHl,  which produces  sticky ends compatible 
with Bglll ends). Oligonucleotides and linearised vector were ligated (2.4.2.4, protocol 2), 
and then transformed into bacteria (2.4.2.5). Plasmid DNA was isolated from a selection 
of bacterial colonies (for each shRNA, 2.4.2.5) and was then digested with EcoRI (20/il 
reaction, buffer H) to confirm the presence of shRNA inserts.
As  the  DACT1  shRNA  sequence  contained  an  EcoRI  site,  this  oligonucleotide  was 
directly ligated (as described for other shRNA oligonucleotides) into pSilR-Hl. Positive 
clones  were  identified  as  described  above,  and  this  vector  was  then  used  for 
experimentation.  This construct was sequenced (2.4.2.7) with the pSilR-Hl  Seq primer 
(Table 2.3).
2.4.5.4 Transferring the HI promoter and shRNA into CSGW
pSilR-Hl-shRNA constructs were  digested with EcoRI  to  excise  the  HI  promoter and 
shRNA insert, which was then separated on a  1.5% agarose gel and purified as before. 
Next,  3/ig  CSGW  was  digested  with  3  units  EcoRI  (Multicore  buffer,  10/d  reaction 
volume),  for 30min at 37°C (due to two EcoRI star sites elsewhere in the vector). The 
DNA was purified as before and SAP-treated (2.4.2.2). Next, the restriction digest mixture 
was  separated  overnight  at  low  voltage  on  a  1%  agarose  gel  to  ensure  removal  of
100undigested  vector.  The  band  corresponding  to  linearised  vector  (as  compared  to 
undigested  vector  control  run  simultaneously  on  the  gel)  was  excised  and  DNA  was 
purified  as  before.  Ligations  were  performed  as  described  (2.4.2.4,  protocol  2),  and 
transformed into bacteria.  The EcoRI diagnostic restriction digest described above was 
used to identify shRNA-positive vectors. Constructs were sequenced using the pSilR-Hl 
Seq primer (2.4.2.7).
2.5  Cell manipulation: transfection and infection
2.5.1 Transfection: all retroviral vectors
A common protocol was used to transfect 293gp cells with all retroviral vectors.  Cells 
were at 75% confluence at the time of transfection.  Equal ratios of vector and pVSVG 
helper plasmid were combined in serum-free DMEM. The amount of DNA used varied 
according  to  the  scale  of  the  transfection,  and  was  determined  according  to  the 
manufacturer’s protocols for the Lipofectamine reagent (Invitrogen), but typically for one 
well  of  a  6-well  plate,  2  fig  of  each  plasmid  were  combined  in  250/d  media. 
Simultaneously, the corresponding  amount of Lipofectamine was diluted  in serum-free 
media; 6/d was used for each well of a 6-well plate and added to 250/d media (this was 
scaled up if necessary). Diluted DNA and Lipofectamine were then mixed and incubated 
at room temperature (20-25°C) for 20min. Following this, DNA-Lipofectamine complexes 
were added drop-wise to cells. After 16h, media was changed to Mesencult +10% human 
serum supplement if hMSCs were to be infected, or to fresh DMEM +10% FCS if LiSa2 
cells were to be infected.  Sixty hours after the media change, target cells were infected 
with the fresh viral supernatant produced.
2.5.2 Transfection: all lentiviral vectors
Figure  2.2  illustrates  how  viral  particles  are  produced  from  CGSW  and  the  helper 
plasmids. For this transfection, 293T cells (at around 75% confluence) were used as they 
do not have stably integrated gag or pol genes (like 293gps) which would compete with 
the  helper  plasmids.  DNA  was  mixed  in  serum-free  DMEM  at  a  ratio  of 
CSGW:pLPl:pLP2:pVSVG 3:2:2:2. For a 10cm dish, a total of 4.5/ig DNA was used in 
50/d media.  Simultaneously, Fugene transfection reagent (Roche) was diluted in serum-
101free DMEM;  for a  10cm dish,  13.5/d Fugene (3x amount of DNA w/v) was diluted in 
200/d media. The two solutions were then mixed and incubated at room temperature (20- 
25°C) for 15min. Following this, DNA-Fugene complexes were added drop-wise to cells. 
After  16h, media was changed to Mesencult +10% human serum supplement for hMSC 
infection.  Sixty hours  after the  media  change,  viral  supernatant was  collected,  filtered 
through a 0.45/zm filter, and frozen in 1ml aliquots at -80°C.
2.5.3 Infection: all retroviral vectors
Fresh retroviral supernatant was used to infect hMSCs or LiSa2 cells, which were at 30- 
50% confluence at the time of infection. Viral supernatant was collected, filtered through a 
0.45/mi filter, diluted 1:2 in fresh media (corresponding to the target cell’s normal growth 
media), and supplemented with polybrene (final concentration 4/jg/ml). Target cell media 
was removed and diluted viral supernatant was added. Fresh media (corresponding to the 
target  cell’s  normal  growth  media)  was  added  to  the  transfected  293gps.  This  was 
performed in the evening; the following morning, media on target cells was changed, and 
in the evening the infection process was repeated, as this was found to increase infection 
rates. The next morning, media was again changed, and if cells were reaching confluence 
they were split 1:2 to prepare them for drug selection.
2.5.4 Infection: all lentiviral vectors
Frozen  viral  supernatant  was  thawed  slowly  at  4°C,  according  to  requirements. 
Simultaneously,  target  hMSCs  were  harvested  and  counted  (2.2.6),  and  divided  into 
aliquots  containing  5xl04  cells.  For  neat  infections,  these  cells  were  collected  via 
centrifugation  (1200rpm,  5min,  PK120  centrifuge),  resuspended  in  undiluted  viral 
supernatant, and seeded at 2.5x104 cells/cm2. For all other infections, hMSC growth media 
was  added  to  achieve the  dilution  indicated.  Cells  were  then  resuspended  in  this  and 
seeded at 2.5x104 cells/cm2. After 16hr, cells had adhered and media was changed. Cells 
were either harvested ~48h after infection for GFP expression studies, or allowed to reach 
confluence before experimentation.
2.5.5 Drug selection (retroviral vectors only)
Drug selection was commenced 2 days after the final infection (or when cells were around 
70-80%  confluent).  Each  drug  was  added at the  final  concentrations  indicated to  cells
102containing vectors expressing the corresponding resistance cassette.  Drug selection was 
continued for the duration indicated, or until  100% cell death was observed in uninfected 
cells incubated with the specific drug.  When selection was complete, media was changed 
and if cells were sparse, they were passaged and reseeded at higher densities. Hygromycin 
(Calbiochem, Nottingham, UK): 50/zg/ml for hMSCs, 200/tg/ml for LiSa2s, added for 4-6 
days.  Puromycin:  750ng/ml  for hMSCs,  added  for 3-4  days.  Neomycin:  500/ig/ml  for 
hMSCs, added for 4-6 days.
2.5.6  Titering lentivirus (in collaboration with R. Vart)
Genomic DNA was extracted from lxlO5  hMSCs 48h after infection with a 1:2 dilution of 
viral supernatant for each lentiviral shRNA construct (plus empty CSGW lentivirus). This 
was performed in duplicate for each construct, using the QIAamp DNA Mini Kit (Qiagen) 
and following the protocol for cultured cells. DNA was eluted in 70/d AE buffer (10 mM 
Tris-Cl;  0.5  mM  EDTA;  pH  9.0,  Qiagen)  and  quantified  using  a Nanodrop  ND-1000 
spectrophotometer.  TaqMan QPCR was used to determine the average number of viral 
copies per cell for each construct, using an ABI Prism 7700 Sequence Detection System® 
(Applied  Biosystems,  Warrington,  UK).  Gene-specific  primers  and  TaqMan  probes 
(conjugated  with  the  6-FAM™  fluorescent  dye  and  TAMRA™  fluorescent  quencher) 
were designed using Primer Express Software (Applied Biosystems) against the CSGW 
packaging signal (v|/),  and an  endogenous reference  gene,  GAPDH  (Table 2.3).  Q-PCR 
reactions  were  carried  out  in  50/d  volumes,  using  PCR  mastermix  from  Applied 
Biosystems, and 10/d template from each sample. PCR cycle conditions used were: 50°C 
for 2min, 95°C for 15min, then 40 cycles of 95°C for 15sec then 60°C for lmin. In 96-well 
plate format, standard curves for \|/ and GAPDH were constructed via determination of the 
threshold cycle number obtained from duplicate serial dilutions of DNA in which the copy 
number of GAPDH and \p  is known. The threshold cycle number, Ct, is the number of 
PCR cycles required to reach a threshold fluorescence value (that is constant across the 
entire experiment),  where  fluorescence is  emitted  from TaqMan probes bound to their 
target gene undergoing amplification, and hence is proportional to target abundance. On 
the  same  reaction plate,  the  Ct  for  GAPDH  and  \|/  in  1:1  and  1:10  dilutions  of each 
duplicate unknown sample (genomic DNA from hMSCs transduced with each lentiviral 
construct) was determined.  The standard curves  were used to determine the number of
103cells  (from  GAPDH  standard  curve)  or  viral  copies  (from  \|/  standard  curve)  that 
corresponded to the average  Ct value  from each unknown sample.  Average viral  copy 
number per cell was then calculated by dividing the number of cells in each sample by the 
number of viral copies.
2.6  Gene expression analysis
2.6.1 RNA extraction (including microarrays)
Total RNA was extracted using RNeasy Mini Kit (Qiagen, day 0 -   1   of differentiation), 
following the protocol for cultured cells, or RNeasy Lipid Mini Kit (Qiagen, day 2 -  7 of 
differentiation)  following  manufacturers  protocols,  and  eluted  in  nuclease-free  dH2 0 . 
RNA was quantified using a Nanodrop ND-1000  spectrophotometer and was  stored  at 
-80°C.
2.6.2 cDNA synthesis (excluding microarrays)
cDNA was synthesised from 0.1 /ig total RNA (unless otherwise stated) using Superscript 
II reverse transcriptase (Invitrogen), following manufacturer’s protocols. RNA was diluted 
to a volume of 10/d in nuclease-free dH20, and 1/d each of dNTP mix and oligo(dT)i5_i8 
primer were added (stock concentrations lOmM and 500/ig/ml, respectively). The mixture 
was incubated at 65°C for 5min, then 4/d first strand buffer (Invitrogen,  5x stock), 2/d 
DTT (stock concentration 0.1M), and 1/d dH20 were added. This was incubated at 42°C 
for 2min, and then 200 units of Superscript II were added.  First strand cDNA synthesis 
was carried out at 42°C for 50min, and the reaction was inactivated at 70°C for 15min.
2.6.3 PCR
Two  PCR  protocols  were  used  during  this  study;  the  protocol  was  changed  for  gene 
expression  studies  in  Chapter  5  in  an  attempt  to  increase  sensitivity  and  maximise 
detection of small  changes  in  gene  expression.  The primers  used  in  each  of the  PCR 
studies  are  listed  in  Table  2.3.  Both  PCR protocols  were  executed  using  either  DNA 
Engine  DYAD®  (BioRad,  Herts,  UK)  or  Primus  96PL U S  (MWG-Biotech,  Ebersberg, 
Germany) thermal cyclers.
1042.6.3.1 Protocol 1: used  for PPARy cloning and gene expression studies, and for shRNA 
cloning in Chapter 5
Gene expression studies and PCR screens were carried out in 20/d reactions,  and PCR 
amplification of cloning fragments was carried out in 50/d or 100/d reactions. A typical 
20/d PCR reaction was set up with the final concentration of reagents as follows: 250/zM 
dNTP mix (Promega),  lx DyNAzyme™ EXT Buffer containing  1.5mM MgCh  (unless 
otherwise  stated,  Finnzymes,  Herts,  UK),  IpM  each  primer,  5%  DMSO,  0.2  units 
DyNAzyme EXT DNA polymerase (Finnzymes),  50ng template.  Larger reactions were 
scaled up following these proportions. PCR conditions used were:
PPARy cloning and PCR screens: (3mM MgCh) 94°C for 5min, 30 cycles of (94°C for 
30sec, 55°C for lmin, 72°C for 1.5min), then 72°C for lOmin.
shRNA cloning and PCR screens:  (1.5mM MgCk) 94°C for lOmin, 30 cycles of (94°C 
for 20sec, 62°C for 30sec, 68°C for 1.5min), then 68°C for lOmin.
Gene expression studies in Chapters 3, 4 and 6: (1.5mM MgCh) 94°C for 2min, X cycles 
(indicated in experimental section) of (94°C for 30sec, 55°C for  lmin, 72°C for 45sec), 
then 72°C for lOmin.
2.6.3.2 Protocol 2: used  for gene expression studies in Chapter 5
Gene expression studies in Chapter 5 were carried out in 20/d reactions, with reagent final 
concentrations as follows: 200/zM dNTP mix,  lx green GoTaq® Flexi Buffer (Promega), 
1.5mM MgC^,  1/iM each primer, 5% DMSO, 0.2 units GoTaq® Flexi DNA polymerase 
(Promega), 50ng template. PCR conditions used were: (1.5mM MgCl2) 94°C for 2min, X 
cycles (indicated in experimental section) of (94°C  for 30sec,  55°C  for  lmin,  72°C  for 
45sec), then 72°C for lOmin.
2.6.3.3 Gel separation for gene expression
For both PCR protocols, reactions were separated on agarose gels (density as specified, 
composed of x% w/v agarose (typically 1.5% for gene expression studies) in TAE buffer 
plus 0.00002% v/v ethidium bromide for DNA visualisation), with protocol 1  using DNA 
loading  buffer  (6x  stock  concentration:  15%  ficoll,  0.125%  xylene-cyanol),  and  then 
visualised on a VersaDoc 3000 Imaging System (BioRad, Herts, UK).
1052.7  Microarray gene expression studies
2.7.1 Synthesis of cRNA probes
Total RNA was extracted and quantified as described (2.6.1) from differentiating hMSCs 
at the timepoints indicated.  First and second strand cDNA synthesis and preparation of 
biotin-labelled cRNA probes were performed using the One Cycle Target Labelling Kit 
(Affymetrix,  Bucks,  UK),  following  manufacturers  instructions  (Affymetrix  (2004), 
section II, chapter I). The following details or modifications were employed. For the first 
strand synthesis reaction: the standard protocol was employed, and  10/xg total RNA and 
400units  Superscript II reverse transcriptase were used.  PolyA RNA  controls  were not 
added. The 2nd strand cDNA synthesis reaction was performed immediately after the  1st 
strand reaction,  and EDTA was not added after the reaction was complete.  cDNA was 
next cleaned up and eluted in 14/d cDNA elution buffer. The in vitro transcription reaction 
to produce biotin-labelled cDNA was performed immediately after the 2nd strand reaction, 
using the entire volume of eluted cDNA. The reaction was performed overnight at 37°C, 
then  cleaned up  and  eluted  as per  manufacturer’s  protocols.  Probe  quantity was  then 
determined  using  a  Nanodrop  ND-1000  spectrophotometer,  and  probe  quality  was 
assessed  using  the  Agilent  2100  Bioanalyzer  (Agilent  Technologies,  Cheshire,  UK). 
Probes  were  stored  at  -80°C  prior to  fragmentation,  when  20/ig  of cRNA  probe  was 
fragmented as per manufacturer’s protocols.
2.7.2 Array hybridisation, washing, staining and scanning (performed by Affymetrix 
microarray service, WIBR)
Hybridisation of fragmented cDNA probes to U133 Plus 2.0 Affymetrix GeneChips was 
performed  according  to  manufacturer’s  protocols  for  the  49  array  format  (standard) 
(Affymetrix (2004) section II, chapter II). Array staining with streptavidin-phycoerythrin 
conjugate,  washes  and  array  scanning  were  performed  according  to  manufacturer’s 
protocols for the 49 format using the Fluidics Station 450, GeneChip Scanner 3000 with 
autoloader,  and GeneChip Operating Software,  all  from Affymetrix (Affymetrix  (2004) 
section II, chapter III).
1062.7.3  Data processing and analysis (in collaboration with Dr M Trotter for Chapter 
3, and Dr S Henderson for Chapter 4)
Array scanning produces .cel files (Appendix Folder 1) which contain fluorescent signal 
intensity readings for each probe on the array. To obtain expression values for each gene, 
the  robust  multi-array  analysis  method  of Irizzary  et  al  (2003a,  2003b)  was  used  to 
process  these  files.  The  R  statistical  environment  and  software packages  therein  were 
employed to accomplish this.  Specifically, the “affy” package and the “rma” algorithm 
from Bioconductor were used (Bolstad et al 2003, Gentleman et al 2004). RMA performs 
three steps: probe-level background correction, quantile normalisation and summarisation 
of all the signal values in a probeset to give a single expression value. Firstly, background 
correction algorithms remove “obscuring variation” from the data caused by factors such 
as uneven washing of the microarrays causing patches of uneven signal intensity within 
the array, with the aim that “interesting variation”,  namely changes in gene expression 
across arrays, is more accurately represented. Only the PM probes (1.7.1.1) are included in 
RMA processing;  MM probes  are considered ineffectual  in this  method  (Irizarry et al 
2003a).  Probe-level  log2-transformed expression signals are obtained,  allowing up-  and 
downregulation to be evenly distributed over a numerical scale and to reduce skew caused 
by outliers. Normalisation attempts to equalise expression profiles of the arrays present, 
and is thus essential if values across arrays are to be compared. The quantile normalisation 
method  is  used,  which  normalises  data  quantile  by quantile,  starting  with  the  highest 
expression intensities (Bolstad et al 2003). Finally, an additive linear model is fit to the 
normalized data to obtain an expression measure for each probe on each array. Expression 
measures are reported in RMA expression units (log2), which range from 4-16.
To calculate statistically significant gene expression changes, expression values for each 
gene were compared between consecutive timepoints (i.e. 0-lh,  l-3h, 3-9h, 9h-7d, named 
“phases” of differentiation) using the LIMMA package in R (Smyth 2004). This method 
uses robust estimation of variance combined with a standard t-test to increase the accuracy 
of the statistical result, which could be affected by the low number of replicates used in 
this study (n=3). Robust estimation of variance entails using an estimated variance based 
not only on the probeset in question but on the variance of other probesets with similar 
expression intensities on the same array.
107To correct for false positives (probesets classified as significant by chance) caused as a 
result of multiple testing, the false discovery method (FDR) of Benjamini and Hochberg 
was employed (Benjamini and Hochberg 1995). Q values, the result of FDR, are obtained 
by multiplying the p value for a particular probeset by the number of probesets that have 
already been tested,  if genes  are  ranked  according to  their p-value  and those  with the 
smallest p-value are tested first. This results in q values for each probeset that are higher 
than their p values; thus, if a particular significance cut-off is chosen, less genes will be 
classified  as  significant but  there  is  less  likelihood  of identifying  false  positives.  The 
significance  cut-off of q<0.05  was  chosen  to  select  genes  with  significant  expression 
changes in at least one phase of differentiation.
Boxplots were created using the “affy” package in R to demonstrate the expression value 
data for each array before normalisation. Pearson correlation coefficients (PCC) were also 
calculated in R. The PCC is a measure the strength of a linear relationship between two 
variables. Thus, PCCs close to  1   indicate a strong positive correlation. Each permutation 
of two replicates at each timepoint (i.e. OhA-OhB, OhA-OhC, OhB-OhC) was compared in 
this manner and an average PCC for each timepoint was calculated from the mean average 
of the three PCCs obtained.
Average  linkage clustering using Euclidean distances  was performed using entire  gene 
expression  profiles  from  each  array  using  the  “affy”  package  in  R  to  examine  the 
relationships between the expression profiles of each array.  Euclidian distances allow a 
method  of  measuring  the  dissimilarity  between  arrays,  or  probesets.  Agglomerative 
hierarchical clustering using Euclidean distances was performed using the 6319 probesets 
(selected  as  having  at  least  one  significant  expression  change  during  adipogenesis 
according  to  the  significance  cut-off  used)  to  group  probesets  according  to  their 
expression pattern during differentiation,  and results  were  graphically represented on a 
heatmap using the Cluster and Treeview software of Eisen (Eisen et al 1998).
1082.7.4  Global annotation of adipogenesis
2.7.4.1 Automated annotation
Automated annotation of global  molecular processes during adipogenesis was  achieved 
using the  Gene  Ontology  (GO)  classification  system  (1.7.1.2)  and  WebGestalt  (WEB- 
based GEne SeT AnaLysis Toolkit, Zhang et al 2005). Briefly, this analysis tool retrieves 
annotations for each input ID (here, Affymetrix probeset IDs were used) in a given list, 
including  GO  categories  or  KEGG  metabolic  pathways.  To  calculate  statistically 
significant enrichment, the number of genes in a specific GO category or KEGG pathway 
is compared in two conditions: the sample (here, the gene list for each expression cluster, 
uploaded to  WebGestalt)  and a reference (here,  the  gene list  for the  entire Affymetrix 
U133 Plus 2.0 GeneChip, available in WebGestalt). As these lists are not independent of 
each  other,  the  hypergeometric  test  (Zhang  et  al  2005)  was  used  to  identify  GO 
categories/KEGG pathways that were significantly enriched in the sample list, with the 
significance cut-off or p<0.05 used (unless otherwise stated). WebGestalt does not provide 
the facility to correct for multiple testing.
Analysis of the temporal expression of signalling  intermediates  in the Wnt, TGF/3 and 
BMP pathways  during  adipogenesis  was performed  using  a free trial  of the  Ingenuity 
Pathway Analysis software (Ingenuity® Systems, www.ingenuity.com). Briefly, data files 
containing the log2-fold change values, plus their corresponding significance (q) value, for 
each gene in each “phase” of differentiation (Appendix Table  1), were uploaded to the 
website. The software represented these changes on interactive pathway “maps”, with red 
shades indicating degrees of upregulation during a differentiation phase (defined by the 
fold-change value), and green shades indicating downregulation.
2.7.4.2 Manual annotation
Manual  annotation of gene  function was performed  systematically  for each  expression 
cluster  indicated.  Manual  searches  of the  GeneCards  (www.genecards.org),  Net  Affix 
(www.affymetrix.com/analysis/index.affx)  OMIM,  EntrezGene  and  PubMed  (all  at 
www.ncbi.nlm.nih.gov) databases were performed for each gene. Data was compiled in a 
single file for each expression cluster and  summarised to provide an overview of gene 
function.
109CHAPTER 3. OPTIMISATION OF hMSC ISOLATION AND 
ADIPOGENESIS, AND DEFINITION OF THE 
DIFFERENTIATION TIME-COURSE.
1103.1  Introduction and aims
Human MSCs possess multiple stem cell properties (1.4.4), including the in vitro capacity 
to  differentiate  clonally  into  adipocytes,  osteocytes  and  chondrocytes  (Pittenger  et  al 
1999). The ability to achieve robust adipogenesis in culture provides the opportunity to 
study the  molecular events  underlying  differentiation.  However,  many different  hMSC 
isolation, growth and differentiation protocols have been used by other laboratories, and it 
is  therefore  necessary to  determine  the  optimal  conditions  for  experimentation  in  this 
system. Additionally, the fact that different protocols exist makes defining the particular 
conditions used crucial, so that comparisons between this thesis and other work can be 
made.
Human  MSC-like  cells  can  be  isolated  from  numerous  locations  in  the  body  (1.4.5), 
including umbilical cord blood (Erices et al 2000,  Lee et al 2004a) and adipose tissue 
(Zuk et al 2001,  2002),  but the  most well  characterised population  are  bone  marrow- 
derived. The classic method of hMSC isolation from this location is via plastic adherence 
(Pittenger et al 1999), but other methods including antibody-aided selection are also being 
pioneered (Gronthos et al 2003a,  1.4.3). Cell surface marker profiles and differentiation 
assays are frequently used to define these cell populations as hMSCs. The expression of a 
range of antigens (Table 1.2), the most specific being STRO-1 (Simmons and Torok-Storb 
1991,  Dennis  et  al 2002,  Gronthos  et  al  2003a),  is  currently  used  to  define  hMSCs. 
Various methods  of hMSC  culture have been described,  involving the use  of different 
growth media, serum concentrations and supplementation of cytokines or growth factors 
(for example, Pittenger et al 1999, Conget and Minguell 1999, Wagner et al 2005). These 
differences between research groups will inevitably lead to alterations, however slight, in 
the  biology  of the  cells.  It  is  therefore  necessary  to  define  the  properties  of the  cell 
population  under  investigation,  as  well  as  the  effects  of any  supplements  used.  The 
addition bFGF to hMSC growth media during expansion has been employed in several 
studies, and has been reported to increase the growth rate and life-span of hMSCs without 
diminishing their multilineage potential (Tsutsumi et al 2001). In other work, bFGF has 
been reported to enhance osteogenic (Hanada et al  1997), chondrogenic (Solchaga et al 
2005) and adipogenic (Neubauer et al 2004) potential of hMSCs from a variety of sources.
IllThus, the use of bFGF may have advantages, but its effects should be fully described in 
order to relate the current work to other research.
A cocktail of chemical reagents  including  insulin,  IBMX and dexamethasone has been 
developed  that  maximises  the  efficiency  of  preadipocyte  differentiation  (1.6.1). 
Modifications of this cocktail, such as the addition of indomethacin (Williams and Polakis 
1977, Lehmann et al 1997) have been made for inducing adipogenesis in other cell types 
including hMSCs.  However, the direct targets of these inducers have on the whole not 
been  identified  (1.6.1  and  Fig  1.4),  and  therefore  the  relative  contribution  of  each 
individual substance to hMSC adipogenesis is unknown. Through studies of adipogenesis 
in murine preadipocyte cell  lines  such as  3T3L1  and  3T3-F442A,  extensive  detail  has 
been revealed regarding the molecular control of adipogenesis (1.6.2). PPARy lies at the 
heart  of the process,  and  regulation both up-  and  downstream  of this  factor  acts  in  a 
cascade manner to bring about the eventual expression of adipocyte marker genes. The 
adipogenic  role  of PPARy was definitively demonstrated  by it’s  ectopic  expression  in 
NIH-3T3 fibroblasts, which do not normally differentiate into adipocytes (Tontonoz et al 
1994b).  PPARy over-expression led to adipocyte formation, but required the additional 
presence of dexamethasone and a PPAR ligand. The effect of PPARy over-expression in 
hMSCs has not before been tested, and it would be interesting to reveal whether PPARy 
alone  is  sufficient to  induce adipogenesis,  or whether additional  inducers  are  required. 
Ectopic expression of other genes in hMSCs has been achieved (for example,  Shi et al 
2002, McBeath et al 2004), with the aim of investigating the role of such genes in these 
cells. It would be advantageous to establish such a technique in this system, which could 
subsequently be used to assess the role of interesting genes identified in later work.
As preadipocytes are committed to the adipocyte lineage, the regulatory factors involved 
in their differentiation are likely to control post-commitment events, which could therefore 
be  considered to  occur relatively “late”  during  differentiation.  In  contrast,  hMSCs  are 
uncommitted progenitors of this lineage, so their differentiation would involve additional 
regulation that occurs prior to, or during, commitment. A major step towards investigating 
these “early” differentiation events is to define the point during the hMSC differentiation 
time-course at which they occur. However, this is difficult as few factors that control early
112hMSC differentiation are known. One technique to achieve this could be to identify the 
time at which “late” regulators, such as PPARy, are expressed during adipogenesis in the 
system used in this study. Furthermore, several time-course studies of hMSC adipogenesis 
have been performed, and have described genes that are expressed at specific timepoints 
during differentiation, the earliest of those being day 1  (Nakamura et al 2003, Sekiya et al 
2004). Studying the relationship of this work to the hMSC differentiation system used in 
this  thesis  would  be  instrumental  in  defining  the  time-frame  of  the  cascade  of 
transcriptional regulation involved in hMSC  adipogenesis.  Importantly,  this would  also 
allow identification of the specific phase of differentiation that may represent the early 
stages of interest, so should be the focus of further work in this thesis.
Aims
The major goal of these experiments is to isolate hMSCs and define their time-course of 
differentiation to adipocytes; adipogenic differentiation of hMSCs had not previously been 
established in this laboratory. This would provide a background on which future work will 
be based. Specific aims required to achieve this are:
•  To isolate hMSCs from bone marrow aspirates and characterise the cell population that 
will be used for subsequent studies
•  To optimise the growth and differentiation protocols to be used
•  To establish adipogenic differentiation of hMSCs and investigate the contribution of 
specific factors to this process
•  Finally,  to  investigate  the  time-course  of hMSC  differentiation  and  determine  the 
timepoints which represent the earliest regulatory stages of adipogenesis.
1133.2  Isolation of hMSCs and optimisation of growth protocols
Human  MSCs  are  most  often  isolated  from  bone  marrow  aspirates.  Some  variability 
between research groups has been reported in terms of cell surface antigens and growth 
properties of the isolated cell populations. It was therefore the aim of these experiments to 
isolate hMSCs from bone marrow and characterise their properties in detail,  in order to 
fully define the cell population that would be used in future experiments.
3.2.1  Human MSC isolation
Fresh  bone  marrow  samples  from  healthy  transplant  donors  who  had  given  research 
consent were used for the isolation of hMSCs.  It was chosen to isolate hMSCs via the 
plastic adherent method as it is efficient and does not require the specialised equipment 
used in some antibody-mediated cell sorting techniques. Additionally, there is currently no 
agreement regarding the particular antibodies that definitely define hMSCs (1.4.3). Bone 
marrow aspirates were processed as described in section 2.2.1 to isolate the bone marrow 
mononuclear cell  fraction. These cells were plated onto plastic dishes in hMSC growth 
media  supplemented  with  lng/ml  bFGF  (see  section  3.2.3)  and  10%  human  serum 
supplement.  After  two  days  the  growth  media  was  changed,  and  contaminating  non­
adherent cells, which may include populations such as HSCs (Pittenger et al 1999), were 
mostly removed by this process. By this stage individual (or small clusters of) adherent, 
spindle-shaped fibroblastic cells were visible (Fig. 3.1 A). At day 7 after isolation, clusters 
of spindle-shaped cells had formed (Fig. 3. IB). When the cell density of these clusters was 
nearing confluence (this occurred on average at day 7), cells were detached using trypsin 
and passaged at a ratio of 1:4. Cells were then re-plated at approximately 4xl03  cells/cm2 
in growth media containing bFGF; this passage was designated passage 1. For expansion, 
cells  were  maintained  at  sub-confluent  levels  and  passaged  at  70%  confluence.  Sub­
confluent  cells  exhibited  an  elongated,  spindle-like  morphology  (Fig.  3.1C),  and  on 
reaching  confluence  retained  this  morphology  and  exhibited  a  distinct  swirling 
arrangement (Fig. 3. ID). The morphology and growth characteristics of the isolated cells 
were  consistent  with  previous  reports  for  hMSCs  (Pittenger  et  al  1999,  Conget  and 
Minguell 1999).
114Figure 3.1  Representative illustration of the stages during isolation and expansion of hMSCs 
from bone marrow aspirates. Bone marrow mononuclear cells were isolated from fresh bone 
marrow via density gradient centrifugation, washed and plated at a density of approximately 
2xl05   cells/cm2   in  medium  containing  lng/ml  -bFGF  (2.2.1);  A,  Day  2  after  isolation: 
adherent cells are visible. Non-adherent cells were removed and fresh media added; B, Day 7 
after  isolation:  clusters  of hMSCs  have  formed  and  cells  were  passaged;  C,  cells  were 
maintained at subconfluent levels  during expansion;  D, For differentiation, cell monolayers 
were grown to confluence. Scale bars represent  150/mi. Panels A and B are the work of S. 
Elliman.
1153.2.2  Properties of the hMSC population
MSCs are reported to express a defined selection of cell surface markers (Pittenger et al 
1999, Conget and Minguell  1999, Majumdar et al 2003, Wagner et al 2005). Therefore, 
adherent  cells  at  passage  4  was  harvested  at  sub-confluent  levels  and  stained  with 
antibodies (2.3.1) to detect a range of markers that define hMSCs (Fig. 3.2 and Table 1.2). 
The population was positive for the STRO-1   antigen, which has previously been used to 
isolate mesenchymal cells with multilineage potential (Simmons and Torok-Storb  1991, 
Dennis et al 2002). The expression level of this marker was variable, with a minority of 
cell  expressing it  to  a high  level.  Cells  were  also positive  for  SH2  and  SH4,  and  the 
adhesion molecules CD49b, CD49d (integrins o2 and o4), CD44 (hyaluronate receptor), 
and  CD 13.  All  of these  markers  have  previously  been  used  to  positively  distinguish 
hMSCs (Pittenger et al 1999, Minguel et al 2001). Human MSCs have been reported to be 
both positive (Conget and Minguell 1999) and negative (Pittenger et al 1999) for CD49d; 
this  could  reflect  some  variability between  isolation/culture  methods  or  length  of cell 
culture time before marker expression was assessed. Cells were negative for markers of 
the haematopoietic lineage including c-Kit (CD117), CD45, and CD34, indicating that this 
cell population was not haematopoietic in origin, and also that there was no contamination 
from haematopoietic cells. CD 133, a stem cell-specific marker, was also not expressed, 
but this has been previously reported for hMSCs (Wagner et al 2005). Finally, expression 
of HLA-ABC (MHC class I) but not HLA-DR (MHC class II) was detected, which is in 
line with other work characterising hMSCs (Majumdar et al 2003, Wagner et al 2005). 
Thus, the expression marker profile detected in this  study was comparable to previous 
reports  for hMSCs,  so  from hereon it is  considered that the  adherent,  fibroblastic  cell 
population represents hMSCs.
To investigate their differentiation ability,  hMSCs  isolated  from  a  single bone marrow 
were induced to differentiate into adipocytes, osteocytes and chondrocytes using specific 
induction  protocols  (2.2.2).  Many  reports  of  multilineage  differentiation  use 
heterogeneous hMSC populations (Tsutsumi et al 2001), although it has also been shown 
that  clonal  hMSC  populations  possess  this  ability  (Pittenger et al  1999).  Here,  it  was 
shown that the heterogeneous hMSC population could differentiate robustly to cells of the 
adipogenic (Fig. 3.3 A, as assessed by Oil Red O staining of lipid deposition), osteogenic
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Figure 3.2. Flow cytometry analysis of cell surface markers of hMSCs. Subconfluent, passage 
4 hMSCs were harvested, washed and stained with the appropriate antibody (5xl05  cells per 
sample),  and  then  secondary  antibody  if required  (2.3.1).  Expression  was  determined  by 
counting  104  events  per  sample.  Shaded  histograms  (blue)  indicate  secondary  antibody 
controls, and green lines indicate cells stained with the marker-specific antibodies.
117Figure 3.3. Multilineage differentiation of hMSCs. Human MSCs from a single bone marrow 
(24yr old  male)  at  passage  5  were  induced  to  differentiate  into  adipocytes,  osteocytes  and 
chondrocytes  using  different  combinations  of  induction  reagents  (2.2.2);  A,  at  day  14, 
adipogenic differentiation (2.2.2.1) was terminated and cells were stained with Oil Red O to 
visualise lipid accumulation (2.2.3.1);  B,  at day 21,  osteogenic  cells  (22.2.2) were assessed 
for  alkaline  phosphatase  activity  (2.2.3.2,  blue  staining);  C,  at  day  21  cells  that  had  been 
induced to undergo chondrogenesis in pellet culture (2.2.2.3) were stained with toluidine blue, 
which  stains  nuclear material  blue,  and  extracellular  matrix  proteoglycans  purple  (2.2.3.4). 
Chondrogenic differentiation and toluidine blue staining were performed in collaboration with 
S. Vujovic. Scale bars in A and B represent 200/mi, scale bar in C represents 400/zm.
118(Fig. 3.3B, as assessed by alkaline phosphatase activity) and chondrogenic (Fig. 3.3C, as 
assessed by toluidine blue staining of extracellular matrix proteoglycans) lineages (2.2.3). 
Human MSC populations isolated from four different bone marrows that were assessed in 
this manner had similar differentiation capabilities.  Thus,  the hMSCs described  in this 
thesis exhibited multilineage differentiation properties.
Finally, the in vitro growth potential of five hMSC populations was determined. Human 
MSCs isolated from different bone marrow donors were seeded at passage 4 (p4) - p6 at 
6250 cells/cm2 in media containing bFGF. Total cell number was quantified (2.2.6) every 
three days when cells were passaged (before contact inhibition), and cells were reseeded at 
6250 cells/cm  every passage. This was continued for 9 passages, and it was found that the 
majority of bone marrows exhibited comparable growth kinetics and achieved an average 
of 15.8 population doublings in this time (Fig. 3.4). One bone marrow (55yr old female) 
exhibited substantially slower growth, ceased to proliferate after around 5 passages and 
achieved a total of only 6.7 population doublings. This could possibly be due to the age of 
the donor, and suggests that hMSCs from different bone marrows are heterogeneous in 
their expansion potential. Further, these data reveal that the majority of hMSC populations 
can  be  expanded  for  at  least  15  population  doublings  with  no  significant  loss  of 
proliferation, although population doubling time increased slightly every passage.  When 
the  ability of hMSCs  from  a  single bone marrow to undergo  adipogenesis  at different 
passages was assessed, it was found that adipogenic differentiation potential at passage 9 
was  less  than  that  at  passage  5,  and  by  passage  15  hMSCs  had  virtually  lost  their 
adipogenic  differentiation  potential  (Fig.  3.5).  As  with  the  surface  marker profile  and 
multilineage differentiation capability, these data are  in line with most other studies of 
hMSC growth and differentiation. Taken together, these results demonstrate that the cells 
used in subsequent experiments in this thesis are analogous to hMSCs described in the 
literature (Bruder et al 1997, Pittenger et al 1999, Conget and Minguell 1999).
3.2.3  The effect of bFGF on hMSC growth and differentiation
Several  methods  have  been  employed  to  maximise  hMSC  outgrowth  and  expansion 
potential in culture. These include selection of serum batches with the highest ability to 
promote outgrowth of hMSCs with differentiation potential (Pittenger et al 1999), or
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Figure  3.4.  Growth rates  of hMSCs  isolated  from  different donors.  Frozen  hMSCs  isolated 
from several bone marrows (age and gender indicated) were expanded in bFGF-supplemented 
media. At the passage indicated for each bone marrow, cells were seeded at 6250 cells/cm2  in 
triplicate  for  each  growth  curve.  Three  days  later  cells  were  counted  and  reseeded  at  this 
density; this process was repeated for a total of 9 passages (2.2.6). Data represent cumulative 
population doublings (PD) and are mean ± standard deviation (SD).  Experiments performed 
by S. Vujovic, data analysis performed by C. Westwood.
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Figure 3.5. Adipogenic ability of hMSCs after continued passaging. MSCs from a single bone 
marrow (age/gender unknown) were expanded for the indicated number of passages, and then 
grown  to  confluence  in  media  supplemented  with  bFGF.  Adipogenic  differentiation  was 
induced  as  described  (2.2.3.1).  At  day  9,  differentiation  was  terminated  and  quantified  by 
counting the number of adipocytes  in two  fields of view  for each condition.  Data represent 
number of adipocytes per field of view and are mean ± SD.
120addition of bFGF to the growth media (Tsutsumi et al 2001). The addition of bFGF has 
been  shown  to  extend  the  proliferative  capacity  of hMSCs  without  diminishing  their 
differentiation  potential,  but  may  enhance  differentiation  to  all  lineages  (3.1).  It  was 
therefore  decided  that  the  effects  of bFGF  on  hMSCs  in  this  system  would  be  fully 
described.  For consistency in this thesis a commercial hMSC  growth media and serum 
supplement  (Stem  Cell  Technologies,  Vancouver,  Canada)  were  used  throughout 
experimentation;  the  serum  supplement  is  optimised  by  the  company  for  hMSC 
expansion.
Firstly, the growth rates of hMSCs expanded from isolation in media with/without lng/ml 
bFGF supplement were investigated. At passage 4, cells from both conditions were seeded 
at 5200 cells/cm2. Three days later, +bFGF hMSCs were at -70% confluence and needed 
passaging, whereas by day 6 after seeding, -bFGF cells were near to, but had not reached, 
this level of confluence. Therefore, +bFGF cells were passaged every 3 days for a total of 
10 times, whereas -bFGF cells were passaged every 6 days, for a total of 5 times. At each 
round of expansion, the total number of cells was counted. By day 30, -bFGF cells had 
undergone  a  total  of 5.0  population  doublings  on  average,  whereas  +bFGF  cells  had 
undergone  on  average  15.7  population  doublings  (Fig.  3.6).  The  slow  growth  rate  of 
-bFGF cells obtained in this system could present problems with obtaining enough early 
passage  cells  for  subsequent  experiments.  However,  growth  of  hMSCs  in  bFGF- 
supplemented media reduced the population doubling time and led to an abundant supply 
of low passage cells.
In order to investigate the effects of bFGF on hMSC  differentiation,  cells  expanded  in 
+bFGF  or -bFGF  media  were  induced  to  undergo  osteogenesis  or  adipogenesis  with 
lineage-specific  induction  cocktails.  In  addition,  the  direct  effect  of  bFGF  on 
differentiation was assessed by including it in the differentiation media. After 14 days of 
differentiation in the absence of bFGF, the extent of adipogenesis was assessed by Oil Red 
O  staining  and  it  was  found  that  hMSCs  expanded  both  with  and  without  bFGF 
differentiated to a similar extent (Fig. 3.7A). The rate of differentiation was also similar 
with and without bFGF,  as assessed by the timepoint that lipid accumulation was  first 
observed (data not shown). Interestingly, it seemed that the presence of bFGF in the
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Figure  3.6.  The  effect of bFGF  on hMSC  growth  rate.  hMSCs  were  isolated  from  a  single 
bone marrow (29yr old male),  and  immediately suspended in media with or without  lng/ml 
bFGF.  Cells  were maintained  in these conditions  throughout the  experiment.  At passage 4, 
cells were seeded at 5200 cells/cm2  in triplicate for each growth curve. Three (+bFGF) or 6 (- 
bFGF) days later cells were counted and reseeded at this density; this process was repeated for 
a total  of 10  (+bFGF)  or 5  (-bFGF)  rounds  of expansion.  Cumulative population  doublings 
(PD) were calculated from cell counts (2.2.6). Data represent cumulative PD and are mean ± 
SD.
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Figure 3.7. Continued overleaf.
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Figure 3.7. The effect of bFGF on hMSC  adipogenesis and osteogenesis.  Passage  5  hMSCs 
grown  with/without  bFGF  were  induced  to  differentiate  into  adipocytes  (A,  2.2.2.1)  or 
osteoblasts  (B,  2.2.2.2)  in  the  presence/absence  bFGF;  A,  At  day  14  of  adipogenesis, 
differentiated and control cells were fixed and stained with Oil Red O (2.2.3.1); B, At day 21 
of osteogenesis,  cells  were  fixed  and  stained  with  Alizarin  Red  (2.2.3.3),  or  assayed  for 
alkaline phosphatase activity. Scale bars represent 200/un.
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124differentiation media decreased the number of differentiated cells. When osteogenesis was 
assessed at day 21, a similar effect was observed; there was little difference in the extent 
of osteogenesis  between  cells  grown  with  or  without  bFGF  as  assessed  by  staining 
calcium  deposition  (using  alizarin  red)  or  alkaline  phosphatase  activity  (Fig.  3.7B). 
However, there seemed to be a higher background level of alizarin red staining when cells 
were  expanded  in  bFGF  but  were  not  differentiated.  The  highest  level  of  calcium 
deposition was seen in cells that were expanded and differentiated without bFGF, but a 
similar pattern with alkaline phosphatase activity was not observed.
These results demonstrate that the use of bFGF supplementation in hMSC growth media 
allowed a higher number of cells to be obtained than in the absence of bFGF, but without 
affecting their ability to  differentiate to  either adipocytes  or osteoblasts.  Hence,  bFGF 
supplementation was used to expand hMSCs for all future experiments.
3.3  Factors affecting hMSC adipogenesis
3.3.1  Contribution of  induction cocktail constituents to hMSC adipogenesis 
Various induction protocols  for initiating adipogenesis  in  vitro have been reported (for 
example,  Gimble  et  al  1995,  Pittenger  et  al  1999,  Neubauer  et  al  2004).  MSC 
differentiation is  commonly initiated using  a modified cocktail  originally designed  for 
preadipocyte differentiation, but how each reagent contributes to adipogenic induction is 
not fully understood. The aim of this experiment was therefore to investigate the effect of 
individual  reagents  on  adipogenesis,  and  to  identify the  optimal  induction cocktail  for 
initiating differentiation in this system.
Confluent  monolayers  of hMSCs  were  incubated  with  individual  components  of the 
induction  cocktail,  or  combinations  thereof.  Assessment  of  lipid  accumulation  was 
performed at day 14 (Fig. 3.8). The only substance capable of inducing differentiation on 
its own, albeit to a low level, was dexamethasone. Differentiation was frequently higher 
with reagent combinations where dexamethasone was present. Indomethacin also played a 
significant role in the induction cocktail, and the combination of these two substances led
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Figure 3.8. Contribution of individual components to the differentiation cocktail. MSCs were 
grown to confluence then induced to undergo adipogenesis using combinations of components 
of the differentiation cocktail as shown. Cells were fixed and stained with Oil Red O at day 14 
of differentiation  (2.2.3.1).  Each  condition  was  assessed  in  triplicate,  and  a  representative 
image  is  shown;  D,  1/zM  dexamethasone;  X,  500/zM  isobutylmethylxanthine;  IN,  10/rg/ml 
insulin;  IM,  200/tM  indomethacin;  Ctrl,  no  differentiation  induced.  Scale  bars  represent 
200/zm.
126to extensive differentiation. The addition of IBMX to this combination did not seem to 
significantly increase adipogenesis; rather, there appeared to be a higher level of apoptosis 
in undifferentiated cells. When insulin, dexamethasone and indomethacin were employed, 
less  differentiation  was  observed  than  in hMSCs  in  equivalent  conditions  but  without 
insulin; however the size of the lipid droplets in each cell was larger. The combination of 
insulin,  dexamethasone  and  IBMX  is  classically  used  to  induce  differentiation  in 
preadipocyte cell lines; in hMSCs however this combination did not induce a high level of 
adipocyte formation. The addition of indomethacin to this combination led to the highest 
proportion of differentiated cells, and thus was employed as the differentiation protocol in 
subsequent experiments.
3.3.2  Manipulation of  hMSC differentiation to adipocytes via overexpression of  PPARy 
The possibility of using  genetic  manipulation  to  study hMSC  differentiation  was  next 
assessed, as this may be an efficient means to characterise interesting genes identified in 
future work.  It has previously been  shown that  overexpression  of PPARy  in NIH-3T3 
fibroblasts  can  induce  adipogenesis  (Tontonoz  et  al  1994b),  and  hence  the  effect  of 
PPARy overexpression on hMSC differentiation was investigated to test the efficacy of 
this technique in hMSCs.
To this end, RNA was extracted from hMSCs induced to undergo adipogenesis for four 
days (2.6.1), and then cDNA was synthesised from the RNA (2.6.2). Two sets of primers 
were designed in order to amplify each isoform of PPARy separately using the cDNA as a 
template for PCR (2.6.3.1). PPARyl and -y2 cDNAs were then cloned separately into the 
retroviral vector pMSCV-Hygro (Fig. 2.1 and Table 2.1, 2.4.3). Virus was produced from 
these constructs via transfection of the retroviral packaging cell line 293gp (2.5.1). Next, 
hMSCs were transduced with this virus (2.5.3), and hMSC populations stably expressing 
each isoform of PPARy, or the empty vector, were established via hygromycin selection 
(50/ig/ml for 4-6 days) of transduced cells (2.5.5). A human liposarcoma cell line LiSa2 
(2.2.4) was also transduced and drug-selected (200/zg/ml hygromycin for 4-6 days) in the 
same manner (Wabitsch et al 2000). The LiSa2 cell line has been shown to have a high 
capacity for chemically-induced adipogenesis, and could thus be considered analogous to 
3T3L1. The 3T3L1 cell line was not employed as it is murine in origin and thus the human
127PPARy  cDNAs  used  in  this  study  may  not  function  fully  in  these  cells.  RNA  was 
extracted  from  sub-confluent  hMSCs  and  LiSa2s  (2.6.1)  and  cDNA  was  synthesised 
(2.6.2)  for use  in  RT-PCR  analysis  using primers  that  identify  both  PPARy  isoforms 
(2.6.3.1). LiSa2s and MSCs transduced with either PPARy 1  or -2 expressed high levels of 
PPARy (Fig.  3.9A).  PPARy was  expressed at  a  level  below the detection  threshold  in 
empty vector-transduced or untransduced  control  hMSCs,  and  was  expressed to  a  low 
level  in  the  equivalent  LiSa2  cells.  It  was  noted  that  cells  expressing  either  PPARy 
isoforms exhibited slower growth than those containing the empty vector, possibly due to 
the pro-growth  arrest  properties  of PPARy  (1.6.2.1).  Transduced  cells  were  grown  to 
confluence,  then  incubated  in  hMSC  growth  media  lacking  both bFGF  and  induction 
reagents.  After incubation in this  media  for  14  days,  Oil  Red  O  staining  was  used  to 
determine whether lipid accumulation (and thus adipogenic differentiation) had occurred. 
No differentiation occurred in empty vector-transduced cells, but in both LiSa2 and hMSC 
over-expressing PPARy 1, cells containing several lipid droplets, and therefore resembling 
adipocytes, were visible (Fig. 3.9B). Over-expression of PPARy2 induced differentiation 
more  strongly than PPARy 1; the number of cells containing cytoplasmic lipid droplets 
increased, as did the number of lipid droplets per cell. Over-expression of either PPARy 
isoform  induced  more  LiSa2  cells  to  differentiate  than  hMSCs.  Thus,  PPARy 
overexpression in hMSCs and LiSa2 cells led to adipogenic differentiation without the 
need  for  chemical  inducers,  although  the  differentiation  rate  was  lower  than  in 
untransduced cells differentiated using chemical reagents.
3.4  Determination of the adipogenic differentiation time-course
The major goal of this thesis is to investigate the earliest transcriptional events of hMSC 
adipogenesis, and identify novel genes that act at this stage. The aim of this experimental 
section  was  therefore  to  use  both  morphological  and  molecular  analyses  of  hMSC 
adipogenesis to establish the exact stage during differentiation of hMSCs in this system at 
which the earliest regulatory events are occurring.
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Figure 3.9. Continued overleaf.
129Figure 3.9. Overexpression of PPARy isoforms induces differentiation of hMSCs and LiSa2 
cells.  Populations of hMSC and LiSa2  stably transduced with retroviral vectors expressing 
each of the PPARy isoforms (2.4.3), or the empty vector control, were produced (2.5.1, 2.5.3 
and 2.5.5); A, RNA was extracted from subconfluent cells (2.6.1) and PPARy expression was 
determined by RT-PCR (2.6.2 and 2.6.3.1).  EV:  empty vector, hMSC/LiSa2: parental cells 
(untransduced).  GAPDH:  housekeeping gene used  as  an internal  control.  -RT:  no  reverse 
transcription control (using adipsin primers). PCR cycle numbers: GAPDH, 25; other genes, 
28;  B,  Cells  were  allowed  to  reach  confluence,  and  then  bFGF  was  removed.  No 
differentiation cocktail was added, and cells were left for 14 days with media changes every 3 
days. Differentiation was induced in parental cells as a positive control. Lipid accumulation 
was assessed on day 14 via Oil Red O staining (2.2.3.1). Scale bars represent 150/im.
1303.4.1 Morphological changes during hMSC differentiation to adipocytes
The time-course of adipogenesis was initially studied by assessing lipid accumulation and 
cell morphology at different times after adipogenic induction. The adipogenic induction 
cocktail was added to post-confluent MSCs isolated from the bone marrow of a 31  yr old 
male donor (Sid'), and morphological changes were monitored via Oil Red O staining and 
phase contrast microscopy.  By day  1   of differentiation,  the majority of cells  lost their 
elongated,  fibroblastic  morphology  and  appeared  rounded,  similar  to  adipocytes  (Fig. 
3.10).  Small lipid droplets were observed in some cells at the 2nd day of differentiation, 
and  by  day  7,  cells  containing  multiple  lipid  droplets,  and  thus  resembling  mature 
adipocytes, were visible. As the time-course progressed, the number of lipid droplets per 
cell increased (14d, Fig. 3.10), but the number of cells containing lipid did not increase 
dramatically.  After  prolonged  incubation  in  differentiation  media  lipid  droplet  size 
increased, perhaps due to coagulation of smaller droplets (28d, Fig. 3.10). These changes 
were not observed in hMSCs cultured for the same period in medium lacking inducers.
It was found in earlier experiments that hMSCs isolated from different bone marrows can 
have different growth rates (Fig. 3.4). The question of whether the rate of differentiation is 
conserved between hMSCs isolated from different bone marrows was therefore addressed 
by performing time-course experiments on two additional hMSC populations (from 24$ 
and 30c?). As seen in Figure 3.11A and 3.1 IB (and additionally Figure 3.10), the number 
of lipid-filled adipocytes visible at day 7 remained fairly constant, and represented 58% 
(on average) of total cells at this stage, so the extent of differentiation (i.e. the proportion 
of total cells that differentiated) was similar between hMSCs isolated from different bone 
marrows. On average, 80% of hMSCs adopted a rounded morphology by day 1, and at day 
two  30%  of cells  on  average  contained  lipid  droplets,  although  this  varied  somewhat 
between hMSCs  from bone marrows (15-40%). Notably,  cells containing  several  small 
intracellular lipid droplets at day  1   of differentiation were visible in the 30c?  cells (Fig.
3.1 IB,  Id, inset), whereas in the 31c? or 24c? populations lipid was not visible until day 2. 
Taken  together,  these  observations  show  that  morphological  markers  of  terminal 
differentiation i.e. rounded cell morphology and intracellular lipid droplets, are visible at 
day  1-2  of the  differentiation  time-course,  so  the  process  of differentiation  is  rapid.
131Figure 3.10. Time course of hMSC differentiation to adipocytes. Human MSCs from a single 
bone marrow (31yr old male donor, passage 6) were grown to confluence and differentiated to 
adipocytes  (2.2.2.1).  At  the  timepoints  indicated,  cells  were  fixed,  stained  with  Oil  Red  O 
(2.2.3.1) and visualised via phase contrast microscopy.  Arrows  indicate lipid droplets.  Scale 
bars represent 150/mi.
132Figure 3.11. Adipogenic differentiation rates of hMSCs isolated from different donors. Human 
MSCs  from  different  bone  marrows  (age  and  gender  indicated,  passage  6)  were  grown  to 
confluence and differentiated to adipocytes (2.2.2.1).  At the timepoints indicated, cells were 
fixed, stained with Oil Red O (2.2.3.1) and visualised via phase contrast microscopy. Arrows 
indicate lipid droplets. Scale bars represent 100/zm.
133Furthermore,  the  rate  at  which  the  differentiation  process  occurs  may  vary  between 
hMSCs isolated from different bone marrows.
3.4.2  Molecular time-course of hMSC differentiation to adipocytes
To  study the  differentiation  time-course  at the  mRNA  level,  RNA  was  collected  from 
hMSCs  at  various  times  after  adipogenic  induction,  and  the  expression  of  known 
adipogenic regulators and markers of the mature adipocyte phenotype was examined using 
RT-PCR  (see  Table  2.3  for  primer  sequences).  Slight  upregulation  of  the  main 
transcriptional  regulator of adipogenesis,  PPARy,  was  observed  at  5h  (Fig.  3.12).  The 
expression of this gene increased substantially at  Id, and reached its highest levels at 7d. 
In concert with this, expression of C/EBPa also began to increase at Id. Furthermore, two 
PPARy transcriptional  targets  and  mature  adipocyte  markers,  adipsin  and  aP2,  showed 
enhanced expression  Id and 2d, respectively, which increased further at later timepoints. 
As these factors are involved in the differentiation of preadipocytes or are expressed in 
mature adipocytes, they can be considered to represent the later phases of adipogenesis. 
Their upregulation during the first day of differentiation, combined with the observation of 
cellular  lipid  accumulation  at  day  2,  indicate  that  a  phenotype  reminiscent  of mature 
adipocytes  has  been  attained  by this  time.  LIFR  is  known to  be  expressed  by hMSCs 
(Table 1.2), but is also involved in the early stages of preadipocyte differentiation, prior to 
C/EBPa  or  PPARy  (Aubert  et al  1999).  The  expression  of this  gene  increased  at  5h, 
reaching a peak at  12h-ld, and then decreased to basal levels by day 7 of differentiation. 
This  indicated  that  within the  first  24h  of hMSC  adipogenesis,  specific  transcriptional 
events occur that are known to characterise early preadipocyte differentiation.
To further define the phase of differentiation in which uncharacterised, early events were 
occurring,  a study focusing on the  first day of differentiation was performed.  This was 
accomplished using a small-scale microarray analysis of gene expression, which allowed 
more  rapid determination of the expression of multiple genes than RT-PCR.  RNA was 
extracted from confluent hMSCs prior to differentiation,  from 7 day-differentiated cells, 
and  from  cells  induced  to  differentiate  for  9h.  This  timepoint  was  chosen  because 
substantial upregulation of late adipogenic markers (such as PPARy or aP2, for example) 
had not yet occurred, but a marker of early preadipocyte differentiation, LIFR, was
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Figure 3.12. Analysis of mRNA levels of adipogenic markers during the differentiation time- 
course. RNA was extracted from differentiating hMSCs (2.6.1) at the timepoints indicated and 
RT-PCR (2.6.2 and 2.6.3.1) was used to follow gene expression across the full differentiation 
time-course. The expression of: major adipogenic transcription factors (PPARy and C/EBPa), 
and late (aP2 and adipsin) and early (LIFR) differentiation markers was assessed.  PCR cycle 
numbers:  GAPDH,  25;  all  other  genes  28.  -RT:  no  reverse  transcription  control  (adipsin 
primers).
135upregulated. It was therefore hypothesised that if further genes known to be expressed in 
preadipocytes (or during their early differentiation) were upregulated at 9h compared with 
Oh or 7d, then studies focusing earlier than this timepoint should identify uncharacterised 
events. Furthermore, a previous cDNA microarray study of gene expression during hMSC 
adipogenesis identified several phases of gene expression during the process, and day  1  
was  the  earliest  timepoint  studied  (Nakamura  et  al  2003).  Consequently,  genes  were 
selected that showed regulation during the early phases in that study and their expression 
was analysed in this system in order to relate the two time-courses and thus further define 
the unexplored areas of hMSC adipogenesis.
RNA  from each timepoint was used to  synthesise biotin-labelled cRNA probes  (2.7.1), 
which  were  hybridised  to  Affymetrix  U133A  GeneChip  Arrays  (2.7.2).  One  array per 
timepoint was used as this was an exploratory experiment,  so  statistical  significance of 
expression change between timepoints  could not be calculated.  Because of this,  results 
were interpreted with caution, but the approach was deemed acceptable as this analysis 
was performed only in order to design the full experiment described in Chapter 4.  The 
RMA method of Irizzary et al (2003a) was used to background correct and normalise the 
data,  and produce  expression  values  for each  gene  at  Oh,  9h  and  7d  (2.7.3  and  4.2.2). 
“Significant”  expression changes between  successive timepoints  (i.e.  between  0h-9h  or 
9h-7d)  for all  selected genes were then determined by comparing expression values (in 
RMA units) at each timepoint. A difference of one expression unit (which represents an 
expression  fold  change  of 2,  as  RMA  units  are  on  a  log2  scale,  2.7.3)  between  two 
timepoints  was  set  as  the  arbitrary  significance  cut-off,  and  genes  with  at  least  one 
“significant” change were represented in a heatmap (Fig. 3.13). A blue colour represents 
expression below the mean average for a particular gene over the timepoints studied, a red 
colour  represents  expression  above  the  average,  and  change  is  measured  in  standard 
deviations from the mean.
On the whole, every gene analysed that was known to be expressed in preadipocytes or 
during  their  early  differentiation,  such  as  C/EBP5,  and/or  had  been  identified  as 
upregulated  at  day  1   (the  earliest  phase)  in  the  Nakamura  study  (red  boxes)  were 
expressed at the highest level at 9h (Fig. 3.12). The only exception was SOD2, which was
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Figure  3.13.  Exploratory  microarray  analysis  of  early  hMSC  adipogenesis.  RNA  from 
undifferentiated,  9h-  and  7  day-differentiated  cells  was  used  to  synthesise  biotin-labelled 
cRNA probes (2.7.1). These were hybridised to U133A Affymetrix microarrays (2.7.2), with 
one array per timepoint.  Data was  processed as described (2.7.3).  The expression of known 
adipogenic markers, or genes expressed at specific timepoints in a recent hMSC adipogenesis
f  i
microarray  study  (Nakamura  et  al  2003)  was  investigated  in  order  to  determine  the  time- 
course of differentiation in this system.  On the heatmap, a blue colour represents expression 
below  the  mean  average  for  a  particular  gene  over  the  timepoints  studied,  a  red  colour 
represents expression above the average, and change is measured in standard deviations from
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the  mean  (scale  bar  below  heatmap).  Microarray  data  processing  and  production  of  the 
heatmap was performed in collaboration with Dr. M. Trotter.
137upregulated at 9h compared to Oh, but expression was highest at 7d. A further pattern that 
was identified in the Nakamura study was genes upregulated at  l-3d and also 7d (orange 
boxes); these genes showed above average expression at 9h in this system. Additionally, 
genes that had shown transient downregulation at l-3d in the work by Nakamura et al here 
were  downregulated  at  9h,  and  Disabled  homolog-2,  which  showed  a  further phase of 
downregulation at  7d  in that work,  was  also  identified  as  further downregulated  at  7d. 
Genes known to characterise the later stages of adipogenesis, and that were upregulated at 
the last two timepoints in the Nakamura study, were upregulated only at 7d in this work.
To  summarise,  this  analysis  shows  that  the  series  of transcriptional  events  known  to 
characterise  adipogenesis,  and  also  identified  previously  during  hMSC  differentiation, 
occurred in the same sequence in this study (Rosen and Spiegelman 2000, Nakamura et al 
2003). Furthermore, the 9h timepoint was found to closely resemble the earliest timepoint 
in the Nakamura study, and also represented a possible “preadipocyte stage”, as several 
preadipocyte genes were expressed at this point. Therefore, future studies focusing prior to 
the 9h timepoint would be most likely to uncover the transcriptional events of early hMSC 
adipogenesis.
1383.5  Discussion
This work has documented the isolation of a fibroblastic, adherent cell population from 
human bone marrow that displays the cell surface marker profile, differentiation potential 
and expansion capability characteristic of hMSCs.  Further,  adipogenic differentiation of 
these  hMSCs  was  established,  and  was  found  to  be  stimulated  to  different  extents  by 
combinations  of  chemical  inducers,  or  by  PPARy  overexpression.  Finally,  hMSC 
differentiation was shown to occur rapidly under optimal conditions, and investigation of 
the expression of known adipogenic regulators revealed that the early events of interest 
were likely to occur within the first day, and more specifically within the initial 9 hours, of 
differentiation.
Some variability in the phenotype of hMSCs has been reported that is likely to be due to 
different isolation or growth protocols, so the hMSC population that was used in this study 
was  characterised  in  order  for  comparisons  to  other  work  to  be  made.  Both  the 
morphology  and  surface  marker  profile  (Figs.  3.1  and  3.2)  of this  hMSC  population 
strongly  resembled  those  documented  elsewhere  (Pittenger  et  al  1999,  Conget  and 
Minguell  1999,  Majumdar et  al 2003,  Wagner  et  al  2005).  When  the  surface  marker 
profile of hMSCs was assessed, many markers defining hMSCs, such as SH2,  SH4 and 
CD 13  were uniformly expressed,  suggesting that a uniform hMSC population had been 
isolated,  and  no  contamination  from  other cell  populations  was  detectable.  A  point  of 
variability in this work compared  with some published  analyses was  the  expression  of 
CD49d by hMSCs.  However, this variation is not unique to this study,  as hMSCs have 
been shown to be both positive and negative for CD49d (Pittenger et al 1999, Conget and 
Minguell  1999). Thus, as no unexpected variation in surface marker profile was detected, 
and most markers were expressed uniformly within the population, the cells used in this 
thesis are analogous to other reports of hMSCs.
In contrast to most markers, the expression of the STRO-1  antigen was variable within the 
population, with a subset of cell expressing it to a high level; this is similar to previous 
findings with freshly isolated (uncultured) hMSCs (Gronthos et al 2003a), meaning that it 
could be an inherent characteristic of the hMSC population. A further explanation for this
139variability could be that the cells were analysed at passage 4 (representing around 19 days 
in culture), and it has been shown that hMSCs begin to lose STRO-1 expression after two 
weeks in culture (Simmons and Torok-Storb  1991). As the hMSC population resides in 
the  STRO-1B R IG H T  bright  fraction,  variable  STRO-1  expression  could  reflect  a 
heterogeneous population, possibly analogous to the cellular hierarchies proposed for stem 
cell populations (Owens  1988, Weismann et al 2001). It is currently difficult to overcome 
this  issue  without  employing  technically  advanced  methods  of cell  sorting  that  were 
beyond the remit of this study, and even these techniques do not completely remove the 
heterogeneity. However, the cell population could differentiate with high efficiency into 
three  mesenchymal  lineages,  and  close  to  60%  of cells  were  capable  of undergoing 
adipogenesis, so I consider it unlikely that committed progenitors constitute the majority 
of the population.
The robust multilineage differentiation ability of heterogeneous hMSC  populations was 
also a factor in deciding not to use clonal populations to investigate hMSC adipogenesis. 
Further to this, isolating clonal populations is problematic, as the low culturing densities 
required to generate hMSC clones is deleterious to their growth. Clonal populations could 
have been derived via plating the mononuclear cell fraction directly after isolation from 
bone marrow into 96-well plates  at a density that would be  likely to result in a single 
hMSC colony per well. However, it would have been difficult to obtain large enough cell 
numbers  at  a  low  passage  for use  in  subsequent  microarray  studies,  so  heterogeneous 
populations were used in future experiments in this thesis.
Investigation of the hMSC growth rate revealed variations between hMSCs from different 
donors  (Fig.  3.4).  This  has previously been reported  (Bruder et al  1997,  Phinney et al 
1999), so is not unusual, but is an important factor that must be taken into account when 
designing future experiments. Furthermore, work described here showed that hMSCs from 
most  donors  have  an  extensive  proliferation  capacity  in  vitro,  but  that  adipogenic 
differentiation  was  lost  as  the  passage  number  increased  (Fig.  3.5),  an  effect  that  has 
previously been noted (Conget and Minguell  1999) and reveals that low passage hMSCs 
should  be  used  for  differentiation  studies.  Taken  together,  these  observations  again
140highlight  the  similarity  between  the  hMSCs  used  in  this  thesis  and  the  published 
properties of this cell type.
Supplementation of bFGF to the growth media had a mitogenic effect on hMSCs similar 
to previous reports (Fig  3.6, Tsutsumi et al 2001),  thus allowing sufficient numbers of 
hMSCs  to  be  obtained  after  few  passages  for  use  in  subsequent  experiments.  This 
supplement  has  not  previously  been  used  to  expand  hMSCs  for  microarray  gene 
expression  studies  of  adipogenesis,  so  it  was  important  to  determine  the  effects  on 
differentiation.  It was found here that bFGF  supplementation during expansion did  not 
seem to bias differentiation towards a certain lineage (either adipogenesis or osteogenesis, 
Fig. 3.7), which could potentially cause misleading results in gene expression studies of 
differentiation, and was thus adopted as the hMSC expansion method in subsequent work.
The  classic  method  of inducing adipogenesis  in hMSCs  involves  a modification to  the 
protocol  for  preadipocyte  cell  lines  (using  insulin,  IBMX  and  dexamethasone), 
specifically the  addition  of a putative  PPARy  ligand  (indomethacin).  It  was  found that 
indomethacin does indeed contribute an important role to hMSC adipogenesis, especially 
in combination with dexamethasone as these two substances induced differentiation to a 
similar, but not equal,  extent (by qualitative assessment) to the combination of all  four 
reagents (Fig. 3.8). It was found that the four reagents together induced the most cells to 
differentiate,  as  well  as  producing  many  cells  containing  multiple  lipid  droplets.  The 
morphology of differentiated  cells  varied  widely between conditions,  and  although  the 
combination  of  insulin,  indomethacin  and  dexamethasone  gave  rise  to  adipocytes 
containing the most lipid, relatively few cells actually differentiated. The results suggest 
that  each  of the  four  individual  reagents  plays  an  important  role  in  inducing  hMSC 
adipogenesis,  but  their  combination  produces  a  synergistic  effect.  In  other  work, 
alternative PPARy ligands, such as troglitazone (Neubauer et al 2004), or glucocorticoids 
like hydrocortisone (Gimble et al  1995)  have been employed  in the hMSC  adipogenic 
cocktail. However, early studies of hMSC adipogenesis do not seem to have addressed the 
specific abilities of each of these factors to induce adipogenesis, and may have adopted the 
use of such substances based on empirical studies of preadipocyte induction (1.6.1). Thus,
141the results described here present novel information regarding the effect of the different 
inducers on hMSC adipogenesis.
When  PPARy  was  over-expressed  in  hMSCs  and  LiSa-2  cells,  it  was  found  that 
differentiation occurred without the need for chemical  inducers, albeit to a lower extent 
than  in  chemically  induced  cells  (Fig.  3.9).  PPARy2  induced  the  most  extensive 
differentiation, which is  in line with it’s adipose-specific expression and higher ligand- 
independent  activation  capacity  than  PPARy 1   (Mueller  et  al  2002).  PPARy-induced 
adipogenesis was more efficient in LiSa2s than in hMSCs as a higher proportion of cells 
contained lipid droplets, which could indicate that LiSa2s are more committed to undergo 
adipogenesis than hMSCs. However, less lipid accumulated per cell in the LiSa2 line than 
in  hMSCs,  but  this  may  be  expected  of a  liposarcoma  cell  line  as  liposarcomas  only 
partially resemble adipose tissue (Helman and Meltzer 2003). A comparison of PPARy2 
over-expression  in  hMSCs  in  this  study  and  NIH-3T3  fibroblasts  in  previous  work 
(Tontonoz  et  al  1994b)  shows  that  fibroblasts  require  more  stimuli  (i.e.  PPARy  over­
expression plus  dexamethasone  and  a PPAR ligand)  than hMSCs  to  differentiate.  This 
reflects  the  fact that  fibroblasts  are not  normally capable  of adipogenic  differentiation, 
whereas hMSCs are able to differentiate into this lineage, and so represent a stage (albeit 
an early, uncommitted stage) along the pathway towards adipocytes. A clear observation 
in this experiment was that although all cells were expressing PPARy, only a proportion 
differentiated. Explanations for this could be cell-to-cell differences in the level of PPARy 
expression.  Additionally,  differentiation  in  PPARy2-expressing  cells  occasionally 
occurred in clusters. This could indicate that differentiating cells produce an endogenous 
PPARy ligand that enhances differentiation in neighbouring cells, which could possibly be 
15-deoxy-Al2,14-prostaglandin  J2  (Forman  et  al  1995).  These  effects  of PPARy  over­
expression  on  hMSC  differentiation  have  not previously been  described,  and  therefore 
provide  novel  information  regarding  the  propensity  of  hMSCs  to  differentiate  to 
adipocytes. Furthermore, the results demonstrate that retroviral introduction of exogenous 
genes into hMSCs can be used to study the effect on differentiation.
The time-course of adipogenesis was investigated in terms of cell morphology and lipid 
accumulation,  as  well  as  on  the  mRNA  level,  in  order  to  define  the  timeframe  of
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focus on the early regulatory events. In the majority of bone marrows, rounded cells were 
observed one day after initiation of differentiation and small lipid droplets accumulated by 
day 2 (Fig. 3.10 and 3.11). An important observation was that hMSCs from some bone 
marrows produced lipid droplets by day  1, indicating that the rate of differentiation was 
faster.  Taken  together  with  the  observation  of  variable  expansion  capacity  between 
donors,  this  has  important  implications  for  gene  expression  studies  (see  Chapter 4.2). 
These observations suggest that by day  1-2 of differentiation the transcriptional program 
that leads to expression of genes characterising mature adipocytes, such as those involved 
in lipid synthesis or uptake, had been completed in some cells.  Indeed, it was found by 
RT-PCR that  PPARy  and  C/EBPa  (two  transcriptional  regulators of late  adipogenesis) 
were upregulated as early as the 1  day timepoint, and their targets aP2 and adipsin, which 
are markers of mature adipocytes, were upregulated by day 2 (Fig. 3.12).
Where the initial observation of lipid accumulation during hMSC adipogenesis has been 
reported in other work, it has varied from day 3 to day 5 of differentiation (Nakamura et al 
2003, Hung et al 2004a). Furthermore, upregulation of PPARy was not observed at day 1  
in hMSCs (Nakamura et al 2003, Sekiya et al 2004), but was found to be upregulated at 
day 3 compared to day 0 in another study (Hung et al 2004a). This indicates that hMSC 
adipogenesis  described  in  this  thesis  is  more  rapid  than  in  other reports.  A  definitive 
explanation  for this  is  not  forthcoming;  as  bFGF  increases  hMSC  proliferation  rate  it 
could be hypothesised that it would also increase their ability to differentiate, but this was 
not observed to be the case  in the work described here (Fig.  3.7).  Possible reasons  for 
rapidity of adipogenesis in this work compared with other reports are:  variations  in the 
source and passage number of the hMSCs used - commercially obtained hMSCs such as 
those used by Nakamura et al (2003) are not as well defined in these terms. Additionally, 
the fact that adipogenesis was performed on subconfluent hMSCs may have hindered the 
rate of differentiation in the study by Sekiya and co-workers (Sekiya et al 2004).  Other 
explanations for the differences are that the specific growth media and supplement used in 
this  work  favour  rapid  differentiation,  or  that  the  cells  were  maintained  at  optimal 
conditions (for example, passaged before reaching confluence), which may not have been 
achieved in other work. Nevertheless, the differences in differentiation rate will not affect
143the  validity  of the  work  in  this  thesis:  a  careful  analysis  was  performed  here,  which 
ensured that subsequent microarray experiments would detect previously uncharacterised 
events  and  also  demonstrated  the  fact that comparisons  can  still  be  made  between the 
transcriptional events identified in different studies.
From day 2 until day 7 of differentiation, both the number of cells containing lipid and the 
amount of lipid per cell increased. This might suggest that the process of adipogenesis is 
not  entirely  synchronous.  However,  these  observations  are  consistent  with  other 
microarray  studies  (Nakamura  et  al  2003,  Sekiya  et  al  2004)  and  are  an  inevitable 
consequence of the system used; for example, although cells are left for at least one day 
post-confluence before differentiation is induced, they may still have undergone growth 
arrest to different degrees. In spite of this, gene expression changes were observed using 
RT-PCR (Fig 3.12), which would not be possible if differentiation was asynchronous to a 
large degree. Furthermore, numerous other studies of hMSC differentiation have identified 
clear gene expression patterns during adipogenic (Nakamura et al 2003, Sekiya et al 2004, 
Yloslato  et  al  2006)  as  well  as  osteogenic  (MAPCs  (1.4.2.3),  Qi  et  al  2003)  and 
chondrogenic differentiation (Sekiya et al 2002). Thus, it can be concluded that in vitro 
hMSC differentiation is a robust system for studying transcriptional regulation.
The  observation  that  little  increase  in  the  number  of cells  that  contain  lipid  occurred 
between 7-14 days suggests that no further cells were differentiating during this time, but 
rather that the effect of terminal differentiation, i.e. lipid accumulation, was propagated. 
Thus,  the  7  day timepoint  is  likely  to  represent  an  accurate  endpoint,  in  terms  of the 
transcriptional  differentiation  program.  At  this  point,  near  to  60%  of  cells  had 
accumulated lipid; this is comparable to other studies of hMSC adipogenesis (Nakamura 
et al 2003, Sekiya et al 2004), but is less than 3T3Lls where as many as 90% of cells will 
differentiate (Soukas et al 2001).  This  is however likely to  reflect the more  committed 
nature of the 3T3L1 line.
A  further  observation  from  the  RT-PCR  analysis  was  that  LIFR,  a  marker  of 
preadipocytes and their early differentiation, was upregulated at 5h and then expression 
decreased  again at 2d.  Taken together with upregulation at day  1   of later regulators of
144adipogenesis,  this  shows that the early events,  which are the  focus of this work,  occur 
within the  first  day of differentiation,  and  even  at this  stage preadipocyte markers  are 
upregulated.  As  a  result  of  these  observations,  the  initial  microarray  study  of  gene 
expression was focused on the 9h timepoint of differentiation, in order to discover whether 
further preadipocyte genes, and also markers of the earliest phase of gene expression from 
a microarray study of hMSC adipogenesis (Nakamura et al 2003), were expressed at this 
stage (Fig. 3.13). It was found that all genes analysed in both this study and the Nakamura 
study showed  comparable patterns  of regulation,  in terms  of up  or downregulation,  as 
much as could be concluded from this study as only 3 timepoints were analysed with only 
one array per timepoint. Also, the phases of gene expression were similar; genes that were 
upregulated late (7-14d) in the Nakamura study were also upregulated late (7d) here, and 
genes  upregulated  at  the  earliest  timepoint  (day  1)  were  upregulated  at  9h  here.  An 
explanation for these findings, as already discussed, could be that differentiation occurs 
more  rapidly  in  the  system  used  here  so  the  “day  1”  genes  are  upregulated  earlier. 
However, it is also possible that these genes were also upregulated during the first day of 
differentiation  in  the  Nakamura  study,  but  it  was  not  detected  due  to  the  timepoints 
employed.  Nevertheless,  the  combined  outcome  from  these  experiments  was  the 
description  of the  hMSC  adipogenesis  time-course  in  this  system,  from  which  it  was 
revealed that gene expression studies focusing on the first 9h of differentiation would be 
most  likely  to  detect  previously  undescribed  gene  expression,  which  may  represent 
important regulatory steps in early adipogenesis.
145CHAPTER 4. TRANSCRIPTIONAL PROFILING AND GLOBAL 
ANALYSIS OF EARLY hMSC ADIPOGENESIS.
1464.1  Introduction and aims
The molecular pathways controlling adipogenesis have been studied in great detail using 
murine  preadipocyte  cell  lines  such  as  3T3-L1  (1.6.1).  This  work  has  led  to  the 
identification of factors such as PPARy (Tontonoz et al 1994a,  1994b), which is essential 
in  co-ordinating  the  expression  of mature  adipocyte  genes  (1.6.2).  As  these  cells  are 
committed to the adipocyte lineage, genes such as PPARy could be considered markers of 
the  later  stages  of adipogenesis.  Adipogenic  differentiation  of hMSCs  would  involve 
additional regulatory stages early during their differentiation, which may control processes 
such as lineage commitment (Rosen and Spiegelman 2000). Some research has aimed to 
investigate the molecular control of hMSC adipogenesis, occasionally using microarrays 
(1.7.2 and discussed below). However, previous studies have not investigated earlier than 
one day after induction of hMSC adipogenesis (Nakamura et al 2003, Sekiya et al 2004), 
and thus little is known of the molecular events occurring at this early stage. Identifying 
genes  and  pathways  that  are  required  at  this  point  of differentiation  could  extend  our 
knowledge of the early mechanisms of stem cell differentiation.
Oligonucleotide microarrays are used to investigate gene expression via the hybridisation 
of  fluorescently  labelled  target  molecules,  synthesised  from  RNA  extracted  from  a 
biological  sample,  to  a  microarray  containing  multiple  oligonucleotide  probesets,  each 
representing  different  genes  (Knudsen  2004).  The  fluorescent  signal  from  a  target 
hybridised to a probe is a reflection of the abundance of the specific RNA in the original 
sample,  so  can be used as a measure of gene expression (1.7.1.1).  The development of 
microarray technology combined with the sequencing of the human genome has provided 
an opportunity to investigate gene expression on a genome-wide scale. Affymetrix have 
recently developed the U133 Plus 2.0 GeneChip, which contains around 54,000 probesets 
that represent over 47,000 transcripts, including all known human genes plus hypothetical 
proteins and ESTs (Affymetrix 2003). This array therefore allows comprehensive genome- 
wide  analysis of expression changes,  and  it’s use  in this  study would provide the  first 
insight into the global regulation of the early stages of hMSC adipogenesis.
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identification  of  biological  trends  from  large  datasets  produced  by  microarray  gene 
expression analysis (1.7.1.2).  The outcome is an expression value for each gene in each 
sample assessed,  following which significant gene expression changes between samples 
can  be  calculated.  A  point  to  note  regarding  this  technique  is  that  it  yields  only  a 
comparative analysis of gene expression levels between two or more different conditions. 
Thus, it is possible to tell whether a gene is expressed to a higher or lower level in sample 
A than in sample B. However, it does not demonstrate the absolute expression level of the 
gene in either sample, and it may be the case that some genes are expressed to a high level 
in sample A, but because their expression did not change significantly in sample B they 
are  excluded  from  further  analysis.  Nevertheless,  in  the  context  of this  differentiation 
time-course  study,  analysing  significant  gene  expression  changes  should  identify 
biological trends in the expression data, as has previously been accomplished (Hackl et al 
2005, Yloslato et al 2006).
A major advantage of microarray experimentation is that as the expression of large gene 
sets is determined simultaneously, the role of entire pathways or cellular processes during 
adipogenesis can be assessed. Gene Ontology (GO) is a systematic nomenclature that can 
be  used  to  identify  the  molecular  processes  that  are  represented  by  a  list  of  genes 
(Ashbumer  et  al  2000).  Three  categories  are  used  which  aim  to  describe  how  gene 
products behave in a cellular context; these are molecular function, biological process and 
cellular component. Each GO category contains numerous terms arranged in a hierarchical 
structure  that  describe  different  aspects  of  the  category,  and  gene  products  can  be 
described  by  one  or  more  term  from  each  of  these  categories.  Molecular  function 
describes activities at the molecular level, such as “catalytic activity” or “DNA binding”. 
A biological process term describes a series of events which are accomplished by more 
than one molecular function, an example being “signal transduction”. Finally, the cellular 
component category describes intracellular location, for example “nucleus”.
Through  the  categorisation  of genes  according  to  their  expression  pattern  across  the 
differentiation time-course, combined with tools that annotate these genes using methods 
such as GO, the specific stage during differentiation at which different processes act can
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annotation;  signalling pathways,  gene  families  and metabolic processes  (amongst other 
things) can all be analysed via this method to give an integrated view of a specific process 
(Zeeberg  et  al  2003,  Zhang  et  al  2005,  Mi  et  al  2005,  Ingenuity®  Systems, 
www.ingenuity.com).  It  is  also  possible  to  attach  a  statistical  significance  to  these 
findings, thus allowing robust identification of potential areas for future research.
Although microarrays have previously been used to analyse the transcriptional events of 
3T3L1  and  hMSC  adipogenesis,  the  results  of  these  studies  have  left  gaps  in  the 
knowledge of this process for a number of reasons. Firstly, differentiation has only been 
assessed from the first day of hMSC adipogenesis onwards, so much of the earliest stages 
of regulation are likely to have been missed by these studies. Secondly, the largest arrays 
that were used to study hMSC differentiation analysed  12000 genes (Sekiya et al 2004, 
Yloslato et al 2006), so a great deal more information could be obtained by using the latest 
Affymetrix arrays covering all known human genes. Finally, early microarray studies of 
adipogenesis did not include global annotation analysis, probably due to the small size of 
the  microarrays  used  combined  with  the  fact  that  automated  tools  to  annotate  large 
datasets have only become available in recent years. The number of studies which now 
contain such analyses is increasing (Hackl et al 2005, Tan et al 2006, Yloslato et al 2006), 
but this has not yet been used to it’s full potential to characterise hMSC adipogenesis.
Aims
The major aims of this chapter are to:
•  Obtain  gene  expression  profiles  of the  early  stages  of hMSC  adipogenesis  using 
Affymetrix oligonucleotide microarrays
•  Confirm  the  accuracy  and  reproducibility  of this  data,  and  identify  and  validate 
patterns of gene expression that occur during differentiation
•  Characterise,  on  both  global  and  gene-be-gene  levels,  the  molecular processes  and 
functional categories of genes that may control the early stages of adipogenesis
•  Finally, develop selection criteria based on the known function of genes and use this to 
identify potential novel candidates for the molecular control of adipogenesis.
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The aims of this experimental section were to perform a differentiation time-course and 
generate transcriptional profiles of adipogenesis at the early stages. Secondly, through data 
processing and  statistical  analysis methods,  an initial biological  insight into  adipogenic 
regulation would be gained.
4.2.1 Microarray strategy
In Chapter 3, it was found that lipid accumulation was visible at day 2 of differentiation 
(Fig  3.10),  and  markers  of  late  adipogenesis  were  upregulated  at  day  1   (Fig  3.12). 
Additionally,  an  exploratory microarray study identified  some preadipocyte  markers  as 
upregulated  at  9h  during  differentiation  (Fig  3.13).  It  was  therefore  decided  that 
microarray experiments should focus on the initial 9h of differentiation, in order to capture 
the  earliest  transcriptional  events.  Furthermore,  some  variation  in  differentiation  rates 
between bone marrows had been observed (Fig 3.11). This could mean that, if a specific 
timepoint was assayed in hMSCs from several bone marrows, slightly different stages of 
differentiation  may  be  captured.  Inaccurate  microarray  data  may  result  from  this,  as 
biological variation (the genuine changes in gene expression that regulate adipogenesis) 
could be masked by the patient-to-patient variation.  It was therefore decided to perform 
the  microarray  studies  using  a  single  bone  marrow,  and  subsequently  confirm  the 
observations  using  hMSCs  from  other  bone  marrows  to  ensure  that  gene  expression 
changes were not patient-specific. Therefore, frozen hMSCs (at passage 2) isolated from a 
single bone marrow (a 31 year-old male donor) were thawed, expanded (2.2.1), allowed to 
reach  confluence,  and  then  differentiation  to  adipocytes  was  initiated  (2.2.2.1).  Figure
4.1 A shows the experimental design, which was set up in three independent experiments 
so that replicate arrays could be performed at each chosen timepoint.
Morphological changes during differentiation were  followed by Oil Red O  staining and 
phase  contrast  microscopy  (2.2.3.1).  During  the  first  3h  of  differentiation  no 
morphological changes were observed. At 9h however, some cells were already changing 
from a fibroblastic morphology into a more rounded shape, characteristic  of adipocytes 
(Fig. 4.IB). As in previous experiments, lipid accumulation was observed at day 2 and
1501jwM Dex, 500//M IBMX 
10/yg/ml IN, 200/yM IM (no bFGF) + 1ng/ml bFGF
p2  Expansion  p4
B
Figure  4.1.  Time-course  of hMSC  adipogenesis  for  microarray  analysis.  A,  Schematic  of 
differentiation program and microarray timepoints. Cells were expanded to passage 4 (2.2.1), 
then seeded  at  approximately 4x1 C F cells/cm'  and  grown to  confluence  in media  containing 
lng/ml  bFGF.  Differentiation  was  induced  via  removal  of  bFGF  and  addition  of  the 
differentiation cocktail (2.2.2.1).  RNA was extracted (2.6.1) at the timepoints indicated from 
three separate differentiations using hMSCs from a single bone marrow (31  yr old male). Dex, 
dexamethasone;  IBMX,  isobutylmethylxanthine;  IN,  insulin;  IM,  indomethacin;  B, 
Morphological  characteristics  of differentiating hMSCs.  At  the  timepoints  indicated  hMSCs 
were  fixed,  stained with Oil  Red O  (2.2.3.1)  and  visualised  via  phase contrast microscopy. 
Scale bars represent 100/xm.
151lipid-laden cells were abundant at day 7. The morphological changes visible at 9h suggest 
that  substantial  transcriptional  changes had  already occurred,  and could be captured by 
performing microarrays at,  and prior to, this point.  Total RNA was extracted  (2.6.1)  in 
triplicate (one replicate from each independent experiment) at the timepoints indicated in 
Fig  4.1 A,  namely from confluent cells just prior to  addition of differentiation reagents 
(Oh),  lh,  3h  and  9h  after initiation of differentiation,  and at  the  experimental  endpoint 
(7d).  In  order to  obtain  experimental  replicates,  samples  from  each  independent  time- 
course were  kept  separate during  all  experimental  procedures.  As  well  as  representing 
biological  variation,  experimental  replicates  allow  any  variation  caused  by 
experimentation  to  be  accounted  for,  such  as  the  RNA  extraction  method  or  probe 
synthesis, meaning that the resulting data is more robust. Technical replicates, created by 
pooling samples at a certain stage of experimentation (e.g. pooling RNA after extraction), 
do not account for sources of technical variation that occurred after pooling, and thus give 
a  less  accurate  estimation  of biological  variation  than  experimental  replicates.  After 
quantification,  10fig of total RNA from each timepoint replicate was used to synthesise 
biotin-labelled  cRNA  probes  (2.7.1).  Probes  were  then  fragmented  and  hybridised  to 
Affymetrix U133 Plus 2.0 GeneChip Arrays (2.7.2).
4.2.2  Data processing and statistical analysis reveal biological trends 
Expression  signals  produced  from  array  scanning  were  pre-processed  using  the  robust 
multiarray analysis (RMA) method of Irizarry et al (2003). This technique was chosen as a 
comparison of this method and two other Affymetrix array processing methods, the MBEI 
method of Li and Wong (2001) and MAS5.0 from Affymetrix (2001), found it to perform 
to a higher degree of accuracy (Irizarry et al 2003b). Furthermore, GC-RMA, a modified 
version of RMA (Wu and Irizarry 2004), was not a standard data pre-processing technique 
at the time of this analysis. RMA produces log2-scale expression values for each probeset, 
in the range 4 (low expression) to  16 (high expression) (2.7.3). These expression values 
were used to identify significant gene expression changes between successive timepoints 
(Oh-lh,  lh-3h, 3h-9h, 9h-7d, named “phases” of differentiation). This approach was used 
rather  than  comparing  each  timepoint  to  the  Oh  arrays  as  it  was  deemed  a  more 
biologically  relevant  strategy  for  analysing  time-course  data.  The  Linear  Models  for 
Microarray  Analysis  (LIMMA)  method  was  employed  for  these  calculations,  which
152combines robust estimation of variance with a standard t-test, and so gives a more accurate 
estimate of statistical significance associated with gene expression changes (Smyth 2004, 
2.7.3). The False Discovery Rate method of Benjamini and Hochberg (FDR, Benjamini 
and  Hochberg  1995)  was  used  to  address  false  positives  within  the  resulting  list  of 
significantly changed  genes.  When  multiple  statistical tests  are performed,  some  genes 
may be classified as significant by chance;  these are termed  false positives (2.7.3).  For 
example,  if  1000  genes  are tested  and  a  significance  level  of 0.05  is  chosen,  50  false 
positives would be expected.  FDR reduces the proportion of false positives  in a list  of 
genes classified as significant (according to a particular cut-off) by correcting probability 
p values to higher q values (2.7.3). The significance criteria of q<0.05 was adopted as it 
was decided that a more stringent cut-off, such as q<0.01, may miss small but important 
expression changes (which can often be the case for transcription factors).  Furthermore, 
using probability values is more accurate than using a fold-change cut-offs, as variation 
between  timepoint  replicates  is  taken  into  account  when  statistical  significance  is 
calculated, but is not represented by fold-change values. Genes with significant changes in 
at least one of these phases were selected for further analysis (Appendix Tables 1  and 2).
The global expression profiles for each array were next used in average linkage clustering 
(2.7.3) to investigate the relationship between them. This relationship is represented by a 
dendrogram  in  which  the  distance  between  two  arrays  (measured  by  the  dendrogram 
branch length) is an indication of the similarity between their expression profiles. The Oh 
and lh replicates clustered together on the dendrogram, indicating that gene expression at 
these timepoints was similar (Fig. 4.2A).  One 3h replicate was a slight outlier, but was 
most similar to the other 3h replicates, which in turn were most similar to the Oh and  lh 
arrays. Both the 9h replicates and 7d replicates formed two separate clusters, with the 7d 
arrays  occupying  an  entirely  separate  branch  of the  dendrogram  to  the  other  arrays, 
indicating that between 3h-9h and 9h-7d, many expression changes had occurred that led 
to distinct profiles at these timepoints. The number of significant expression changes that 
occurred in each phase of differentiation supported these findings. Eighty-four probesets 
showed a significant expression change in the first hour of differentiation (Fig. 4.2B). This 
number increased progressively in each phase of differentiation, and culminated in more 
than 14000 significant expression changes occurring in the final phase, an unexpectedly
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Figure 4.2. Expression changes that occur during adipogenesis result in distinct transcriptional 
profiles. A, Similarity of expression profiles between replicate timepoints. Global expression 
profiles  from  each  microarray  were  used  in  average  linkage  clustering  using  Euclidean 
distances  (2.7.3)  to  determine  the  relationship  between  them;  B,  Number  of  significant 
expression changes detected in microarray analysis. Normalised, log2-transformed expression 
values  were  used  to  calculate  significant  (q<0.05)  expression  changes  for  each  probeset 
between successive timepoints, designated as phases of differentiation (2.7.3). Microarray data 
processing and production of the cluster dendrogram was performed in collaboration with Dr. 
S. Henderson.
154high number, which would indeed account for the  specific expression profile of the  7d 
arrays.  These results  suggest that distinct  stages  of differentiation were  captured  at the 
timepoints chosen, and that transcriptional regulation at the early stages of adipogenesis 
involved a large number of genes.
In order to explore the patterns of expression during adipogenesis that were caused by 
these changes, agglomerative hierarchical clustering using Euclidean distances was used 
to group the probesets  showing at least one significant expression change  according to 
their  expression  pattern  across  the  entire  time-course  (2.7.3).  Only  the  5000  most 
significantly changed probesets in the 9h-7d phase were included in this analysis to reduce 
complexity; this phase was not the main focus for identification of novel early regulators, 
and  this  number  was  deemed  sufficient  to  illustrate  the  nature  of later  transcriptional 
events. Based on the significance cut-off chosen for this study (q<0.05), 6319 probesets 
that were transcriptionally regulated during adipogenesis were analysed in this manner. 
This  represents  12%  of the  total  probesets  on  the  microarray,  again  highlighting  the 
complexity of the early transcriptional control of adipogenesis,  as well as the ability of 
microarray profiling to identify such detailed regulation. This number corresponds to 4276 
known  genes,  which  reflects  the  fact  that  the probesets  may  also  represent  ESTs  and 
hypothetical proteins, and also that several probesets may represent a single gene.
The expression patterns of each gene1  are illustrated graphically on a heatmap (Eisen et al 
1998), and a cluster dendrogram is produced to illustrate similarity in expression patterns 
between  genes  (Fig.  4.3A,  Appendix  Figure  1,  Folder  2  and  Table  3).  Within  the 
dendrogram,  certain  nodes  (the  point  at  which branches  meet)  define  a  gene  group  in 
which  all  members  have  a  characteristic  expression  profile.  The  heatmap  was  broken 
down into  17 separate nodes (Fig. 4.3A, coloured bars; B, graphs) that represent distinct 
expression patterns, and cover 99% (6244) of the clustered genes (Fig. 4.3A and B).
^rom this point onwards, the word gene will be used in place of probeset to describe an 
entity  with  a  significant  expression  change  during  adipogenesis.  This  is  for  ease  of 
explanation, but the entities could still be hypothetical proteins and ESTs,  and multiple 
probesets could represent a single gene.
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156Figure 4.3.  Expression patterns of probesets showing significant expression changes during 
adipogenesis. A, Agglomerative hierarchical clustering with Euclidean distances was used to 
group probesets according to their expression pattern over the timecourse (2.7.3).  Only the 
5000 most significantly changed probesets between 9h-7d were included in this analysis as 
such changes were not the major focus of this study. Coloured bars designate nodes in the 
heatmap  that  represent  14  gene  clusters  with  distinct  expression  profiles.  *=  For 
representational purposes these clusters have been reduced to 33% of their normal size relative 
to the other clusters. Gene expression change is measured in standard deviations  from the 
mean expression of each gene, and red colours represent expression above average, whereas 
green colours represent expression below average. Microarray data processing and production 
of the heatmap were performed in collaboration with Dr. S. Henderson; B, Representation of 
the overall expression trend for each cluster. The graphs were created by plotting the average 
number of standard deviations from the mean of each gene, for all genes in a cluster (y-axis), 
and at each timepoint during differentiation (x-axis). Data represent mean number of standards 
deviations,  ±S.D.  The  cluster number and  number  of probesets  contained  in  each  cluster 
(brackets) are indicated. The expression pattern of a representative gene from each cluster was 
confirmed  using  RT-PCR  analysis  (2.6.3.1),  and  is  shown  below  each  graph.  GAPDH; 
internal  control;  -RT:  no  reverse  transcription control  (using  SOCS3  primers).  PCR cycle 
numbers: GAPDH: 25; all other genes 30.
157In  some  cases,  the  expression  patterns  of two  nodes  were  so  similar  that  they  were 
grouped together into “expression clusters”  for further analysis.  Thus,  11  out of the  14 
expression clusters were represented by an individual node of the heatmap, and 3  of the 
clusters (6, 8 and 9) each contained 2 nodes that were grouped together. The expression 
patterns  revealed  that  adipogenic  regulation  occurs  in  either transient  waves  of up-  or 
downregulation  (for example  clusters  1   and  6),  or  as  more  sustained  changes  in  gene 
expression (as in clusters 5 and 9). The number of genes in each cluster varied over two 
orders of magnitude and was likely to be caused by the expression pattern defining the 
cluster,  as  clusters  representing  early changes  consistently contained  fewer  genes  than 
those representing later gene expression changes. However, it seems that sustained gene 
expression changes, rather than transient changes, are the predominant form of regulation 
during adipogenesis, as clusters representing this type of pattern were on the whole the 
largest. The detection of temporal gene expression patterns during adipogenesis illustrates 
the stage at which a gene acts, as well as giving an indication as to how it might interact in 
a genetic network, for example it may function together with other genes that are regulated 
in a similar manner. For this reason, most future data analysis was based on the clusters 
described above.
4.3  Validation of microarray data analysis and differentiation system
4.3.1  Microarray data accurately reflect changes in mRNA levels
Microarray experiments inherently contain numerous data processing steps following any 
experimental work.  It is therefore vital to ensure that resulting data is reproducible and 
accurately represents biological changes that occurred in the initial experiment. Therefore, 
the aim of these experiments and analyses was to verify the efficacy and reliability of both 
the experimental system and analysis methods used.
To assess the reproducibility of the microarray results, box-plots were produced (2.7.3) to 
summarise  the  distribution  of  expression  values  (in  RMA  units)  of  each  timepoint 
replicate  before  normalisation  (Fig.  4.4).  Box-plots  permit  simple  visualisation  and 
efficient comparison of multiple datasets. The box plots revealed that the spread of
158o>
Figure 4.4. Reproducibility of the microarray data. Box-plots were created (2.7.3) to show the 
distribution of expression intensities for each array, after background correction and before 
normalisation.  Median  average  expression  values  (the  data  point  representing  the  50th 
percentile) for each array are represented by the line within the box, and the upper and lower 
edges of the box represent the 75th and 25th percentile, respectively, of the expression value 
data for each array.  Dashed bars indicate the maximum and minimum expression value on 
each array. Box-plots were produced in collaboration with Dr. S. Henderson.
159expression values was similar between every array, as indicated by the similar size of each 
box (the inter-quartile range, representing the middle 50% of the data),  and the fact the 
there was no large skew in any of the datasets (represented by the median line being close 
to the centre of the box). Furthermore, the range of expression values on each array was 
comparable.  Thus,  no  array was  an  outlier compared  to  the  other arrays,  which  could 
affect  later calculations  such  as normalisation;  by way of an  example,  outliers  can be 
caused by factors such as poor washing after staining causing inaccurately high expression 
values over an entire array. Pearson correlation coefficients between all replicate arrays at 
each  timepoint  were  also  calculated  (2.7.3).  The  average  coefficient  at  each  timepoint 
ranged from 0.984-0.993, showing that the data are reproducible.
In order to determine whether the microarray data accurately reflected changes in mRNA 
level, a representative gene from each cluster was next chosen and it’s expression during 
differentiation analysed using RT-PCR (2.6.3.1).  In every case, the expression profile of 
each gene closely matched the expression pattern from the microarray data (Fig 4.3B). For 
example, DLX2 was found in cluster  12, and hence showed upregulation at 3h followed 
by downregulation at 7d; RT-PCR analysis also detected similar changes in mRNA levels. 
This  demonstrates  that  the  data  collection  and  processing  methods  employed  produce 
results that accurately portray the changes in mRNA levels during adipogenesis.
As  the  microarray  study  used  hMSCs  isolated  from  a  single  bone  marrow,  the 
conservation of gene expression changes in hMSCs from other donors was investigated. 
Time-course differentiations were performed using hMSCs from an additional three bone 
marrows and the expression of a selection of genes was analysed at identical timepoints 
(Fig. 4.5). In the majority of cases the expression of each gene followed a similar pattern 
in all four bone marrows, although some variation was observed. For example, the SOCS3 
trend of downregulation at 3h was conserved, but in some bone marrows further changes 
including downregulation at  7d  were  seen  for this  gene.  These results  suggest that the 
same transcriptional events control adipogenesis in different hMSC samples, although the 
timing  and  magnitude  of change  may  vary  to  some  extent.  Additionally,  they  further 
confirm that the  system used and microarray data obtained  in this  investigation can be 
used to gain an accurate insight into hMSC adipogenesis.
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Figure  4.5.  Gene  expression  patterns  identified  accurately  represent  regulation  of  hMSC 
adipogenesis.  MSCs  from  three  bone  marrows  (24(5,  305,  389)  were  differentiated  to 
adipocytes  (2.2.2.1)  and  RNA  was  extracted  (2.6.1)  at identical timepoints  to  those used  in 
microarray studies (315)-  Expression of a selection of genes used to validate the microarray 
data were again analysed using RT-PCR (2.6.3.1).  Heatmap bars represent expression of the 
gene  in  the  microarray  data;  where  multiple  probesets  were  present  for  a  single  gene,  a 
representative  probeset  was  chosen.  -RT:  no  reverse  transcription  control  (using  SOCS3 
primers). PCR cycle numbers: GAPDH: 25; all other genes 30.
1614.3.2  hMSC differentiation recapitulates known adipogenic regulation and adipogenesis 
in vivo
Although hMSC  adipogenesis  is  a  well  established  in  vitro  differentiation  system,  the 
extent  to  which  this  recapitulates  known  adipogenic  events  and  results  in  cells  that 
resemble  adipocytes  in  vivo  must  be  assessed.  When  a  search  for  well  characterised 
regulators and adipogenic markers was performed within the microarray data, numerous 
factors  were  found  to be  differentially expressed  over the  time-course  and  followed  a 
temporal order of expression that resembled the transcriptional cascade known from the 
literature to bring about adipogenesis (1.6.2 and Fig. 4.6). The expression of both C/EBP/3 
and -6 increased early during differentiation, at lh and 3h respectively (clusters 12 and 5). 
This upregulation preceded PPARy and C/EBPa expression at day 7 (cluster 3), agreeing 
with their role as transcriptional activators of these genes (Wu et al 1996). LIFR is known 
to be expressed in preadipocytes and promotes adipogenesis partly through activation of 
C/EBP/3 and -8 (Aubert et al  1999);  LIFR was upregulated transiently at 9h (cluster 4). 
Transcriptional  activators  of  PPARy  such  as  SREBP1  and  STAT5A  and  -5B  were 
upregulated alongside PPARy at day 7 (cluster 3), whereas the PPARy repressor FOXC2 
was downregulated at this timepoint (cluster 6). A final observation was the upregulation 
also  at  7d  of adipocyte  markers  such  as  aP2  and  fatty  acid  synthase  (FASN),  which 
correlates  with  their  regulation  by  PPARy  and  C/EBPa  and  also  the  observation  of a 
mature adipocyte phenotype at this stage. The identification of many known adipogenic 
regulators as  well  as the temporal  order of their expression  in this  study validates this 
system as a reliable model of adipogenic differentiation.
The  transcriptional  resemblance  of 7  day-differentiated  adipocytes  to  adipose  tissue  in 
vivo  was  investigated  by  determining  the  expression  at  this  timepoint  of  genes  and 
pathways known to be important in adipose tissue (Ailhaud 2001, Urs et al 2004, Viguerie 
et al 2005).  Cluster 3  (genes upregulated at day 7) contained many genes known to be 
expressed  in  mature  adipocytes  (Table  4.1).  These  included  secreted  proteins  such  as 
leptin,  which  is  not  expressed  at  high  levels  by  3T3-L1  cells  (Rosen  and  Spiegelman 
2000). This could indicate that hMSC adipogenesis is a more robust differentiation model. 
Other genes identified were transport  and storage molecules such as aP2  and perilipin, 
along with many genes involved in the metabolism of lipid and carbohydrates. An
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Figure 4.6. Expression of known adipogenic regulators and adipocyte markers during hMSC 
adipogenesis  follows  an  ordered  temporal  pattern.  Each  heatmap  bar  (created  by  resizing 
sections of the  heatmap in Figure 4.3,  thus each replicate  array  is represented by a  strip  of 
colour) indicates the expression of the specific gene across the timecourse. 0, Oh;  1, lh; 3, 3h; 
9, 9h;  7,  7d.  Where more than one probeset was present for the same gene, a representative 
probeset was included. Other probesets can be viewed in Appendix Figure  1.  Genes with no 
heatmap bars did not exhibit a significant expression change during adipogenesis.
Table  4.1  (overleaf).  Genes/pathways  characterising  adipocytes  in  vivo  that  were 
expressed/enriched in 7d-differentiated hMSCs. All genes were identified in cluster 3  (genes 
showing permanent upregulation at day 7). The entire gene list from this cluster was used to 
identify  KEGG  pathways  showing  significant  enrichment  (p<0.01,  see  section  2.7.4.1  for 
enrichment calculations).
163Gene Fold change 9h-7d (RMA 
units)
q value
Signalling molecules and receptors
Leptin 0.72 6.868E-04
Leptin receptor 3.42 3.325E-10
Angiotensinogen 1.43 7.056E-06
Adipsin 7.09 2.028E-14
Adiponectin 9.23 6.167E-17
Adiponectin receptor 2 0.83 5.078E-06
|32 adrenergic receptor 0.68 6.589E-04
oQ . adrenergic receptor 2.37 2.872E-07
Metabolism, transport  and storage
Perilipin 6.01 2.112E-14
Adipose differentiation-related protein 1.40 1.172E-07
aP2 6.71 9.172E-17
Fatty acid translocase, receptor for thrombospondin 2.49 2.405E-08
Fatty acid transport protein 1 1.19 8.290E-05
Fatty acid synthase 3.45 1.997E-09
Lipoprotein lipase 7.11 2.301E-13
Fatty acid CoA ligase 1.15 1.214E-04
Fatty acid desaturase 1 0.90 8.161E-06
Stearoyl CoA desaturase 4.28 1.094E-09
Glycerol-3-phosphate dehydrogenase 1  (soluble) 4.49 1.714E-09
Lipase, hormone sensitive 4.19 1.291E-06
Apolipoprotein B 0.65 5.705E-05
Diacylglcyerol acyltransferase 1 2.07 2.147E-05
Glycerophosphate acyltransferase 2.92 2.214E-09
Phospoenolpyruvate carboxykinase 7.46 2.74 IE-15
Phoshodiesterase 3B 3.27 7.894E-08
Acyl-Coenzyme A dehydrogenase, C-4 to C-12 
straight chain
1.52 1.346E-04
KEGG Pathway Number of genes in 
pathway upregulated 9h-7d
Enrichment p 
value
Oxidative phosphorylation 47 2.0E-29
Fatty acid metabolism 23 6.4E-17
Citrate cycle (TCA cycle) 18 9.3E-18
Pyruvate metabolism 18 2.7E-12
Insulin signaling pathway 15 7.9E-03
Glycolysis / Gluconeogenesis 12 1.3E-04
Glycerolipid metabolism 11 1.7E-04
Adipocytokine signaling pathway 11 1.4E-03
ATP synthesis 10 1.5E-05
Biosynthesis of steroids 9 1.7E-07
Fatty acid elongation in mitochondria 7 1.8E-07
164automated  annotation  tool  (see  section 4.4.1)  was  next  used to  search  for members  of 
KEGG metabolic pathways in cluster 3, in order to identify metabolic pathways that were 
significantly enriched in this cluster compared to a reference list (all genes on the U133 
Plus 2.0 array, 2.7.4.1). Many metabolic pathways defining adipocytes were enriched in 
the gene cluster upregulated at day 7, including lipid metabolism, energy generation and 
adipocyte signalling pathways (Table 4.1). These results demonstrate that differentiation 
of hMSCs  with  adipogenesis-inducing  substances  produces  cells  which,  at  day  7  of 
differentiation, have a transcriptional profile that strongly resembles mature adipocytes.
4.4  Identification  of molecular  processes  and  factors  involved  in  early 
adipogenesis
4.4.1  Molecular processes characterising early adipogenesis revealed by Gene Ontology 
annotation
Global  annotation of the  microarray data using  Gene  Ontology (GO)  terminology was 
performed  in  order  to  identify  the  molecular  processes  that  act  at  specific  stages  of 
adipogenesis.  The  efficacy  of  a  range  of  web-based  annotation  tools  was  assessed, 
including Panther (Mi et al 2005) and GOMiner (Zeeberg et al 2003). GO Tree Machine 
and WebGestalt (Zhang et al 2005) were found to be the most suitable for this study, as 
the  possible  data  input formats  included  Affymetrix  probeset  IDs,  and  a  reference  list 
containing annotations of all genes on the U133 Plus 2.0 array was available, which was 
not the case for some other annotation tools. Furthermore, WebGestalt could annotate the 
microarray data in a number of ways,  and uses a statistical test to apply a significance 
value to each annotation, allowing the most interesting biological trends to be identified. 
GO annotations were obtained for genes in each cluster using WebGestalt.  On average 
52%  of input  IDs  had  associated  GO  annotations;  this  is  because  the  clusters  contain 
hypothetical proteins and ESTs as well as known genes;  also not all known genes have 
functional  annotations.  Significantly enriched  GO terms in each cluster,  compared with 
what would be expected from all the genes on the U133  Plus 2.0 array, were identified 
using a hypergeometric test with the significance cut-off of p<0.05  (2.7.4.1), apart from 
the  largest  clusters  (3  and  10)  where  a  higher  cut-off of p<0.01  was  used.  This  was
165because the large size of these two clusters, combined with the fact that they were not the 
focus for studying the earliest stages of adipogenesis, and hence only the most significant 
trends were focused on. An additional criterion that the GO term must also contain at least 
10%  of genes  in  the  cluster  was  added  to  decrease  the  probability  of a  significant 
enrichment  occurring  by  chance.  A  list  of  all  enriched  GO  terms  can  be  found  in 
Appendix Table 4,  and Figure 4.7  summarises the biological process terms that passed 
both significance criteria. The GO “Biological Process” category was the focus for further 
analysis  as  it  was  decided  that  this  would  describe  the  transcriptional  events  of 
adipogenesis in the most informative manner.
Developmental  genes  are  significantly  enriched  in  several  clusters;  a  transient 
upregulation  of a  subset  of these  genes  is  observed  at  3h  (cluster  6),  whereas  many 
developmental genes, more specifically those involved in muscle development in cluster 
7,  are permanently downregulated at various points during differentiation (clusters  7,  9 
and  11). This may indicate a requirement for specific genes to control an early stage of 
differentiation, but an important step during adipogenesis is the downregulation of genes 
that may be involved in the development of other tissues.
Transcription  plays  a  major  role  throughout  adipogenesis;  GO  terms  related  to 
transcription constitute the majority of enriched terms in the clusters representing early 
regulation.  Such genes are more frequently found to be upregulated (clusters 5, 6,  8,  12 
and  13) than downregulated (clusters 9 and  14). This suggests that adipogenesis requires 
the  upregulation  of  many  transcription  factors  at  specific  timepoints  to  regulate 
progression  of differentiation  that  were  not  expressed,  or  expressed  at  low  levels,  in 
undifferentiated hMSCs.
The response to stress process was enriched in cluster 2 (genes permanently upregulated at 
9h).  This  suggests  that  some  stress-inducing  conditions  are  encountered  during  early 
adipogenesis,  likely as a result of the application of the induction cocktail, but no clear 
pro-apoptotic response was detected using microarrays at the early stages of adipogenesis. 
Genes involved in cell death and apoptotic processes are permanently upregulated at 3h 
(cluster 5).  However, half of these  genes  are  also  termed  “negative  regulation  of
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167Figure 4.7. Biological trends revealed by significant enrichment of Gene Ontology biological 
process  terms  in  each  expression  cluster.  GO  annotations  for genes  in  each  cluster were 
obtained using WebGestalt (Zhang et al 2005),  and  significantly enriched GO  terms were 
identified  using  the  hypergeometirc  test  (p<0.05,  apart  from  clusters  3  and  10:  p<0.01, 
2.7.4.1). An additional criterion that enriched categories must also contain  >10% of genes in 
the cluster was used. Numbers within grey boxes indicate the number of genes from a cluster 
with a specific GO term. The number of dots adjacent to each GO term indicates the level in 
the hierarchical GO tree at which it was found.  * Due to software limitations only the 525 
most  significantly  changed  genes  in  these  clusters  could  be  included  for  analysis.  GO 
categories:  BP,  biological  process;  MF,  molecular  function;  CC,  cellular  component.
168apoptosis” (Appendix Table 4); although this GO term was significantly enriched (p<0.05) 
it contained less than 10% of genes in the cluster so was not included in the main figure. 
Furthermore, the morphological data (Fig. 4.2.B) indicates that there is no visible decrease 
in cell number at 9h that could reflect apoptotic cell death.
In  the  initial  hour  of  differentiation,  a  small  number  of  mitosis  and  chromosome 
organisation-related genes are transiently upregulated (cluster 8). Other cell cycle-related 
genes are also upregulated at 7d following downregulated expression (cluster 4); half of 
these are involved in negative regulation of progression through the cell cycle (Appendix 
Table 4). A significant number of cell cycle genes are downregulated at 7d (cluster  10), 
and few of these genes are involved in the negative regulation of cell cycle progression 
(GO term not  significantly enriched).  This  fits with the observation that differentiation 
requires  growth  arrest,  and  indicates  that  this  takes  place  after  the  first  9h  of 
differentiation.
Cell  communication  is  defined  as  a  process  by  which  a  cell  communicates  with  it’s 
surroundings, and includes genes in the signal transduction and cell adhesion categories. 
These terms represent a significant proportion of genes downregulated at 9h (cluster 11), 
and 7d (cluster 10). This suggests certain signalling cascades may need to be repressed in 
order for the correct channelling of adipogenic signals during differentiation. Additionally, 
it indicates that as the transition from stem cell to adipocyte is made, specific subsets of 
genes that may have maintained the interaction of hMSCs with the environment are not 
required.  Instead, adipocytes may require a different selection of genes that mediate this 
role, perhaps reflecting the altered environment in which they reside (adipose tissue), and 
their new endocrine role (1.5.2). Cell and organelle organisation and biogenesis are also 
repressed at 9h or 7d (clusters  10,  11  and  14).  Such genes are involved in the assembly 
and maintenance of cell  organelles  or structures.  This  indicates that early adipogenesis 
does not involve large changes in internal cell structure.
Cluster  3,  representing  genes  upregulated  at  the  endpoint  of  differentiation,  was 
significantly enriched for genes involved in lipid metabolism, a major process expected to 
operate within an adipocyte. Most of these genes are also located within the biosynthesis
169category,  indicating  that  lipid is  being  synthesised  from  smaller molecules,  an  energy- 
requiring process.  Carboxylic  acid metabolism  and  generation of precursor metabolites 
and  energy  genes  are  enriched,  suggesting  that  the  cells  are  indeed  producing  high 
amounts of energy needed for use in these metabolic processes. A large subset of genes 
that  are upregulated  at  7d  are involved  in  localisation  and transport,  which encompass 
uptake and intracellular transport of macromolecules and larger cellular components. This 
fits with the dramatic change in morphology observed during adipogenesis, as well as the 
increased requirement for nutrients to supply the metabolic processes occurring.
4.4.2  Identification of  functional trends using manual database annotation 
Although GO annotation yielded detailed information regarding the processes involved in 
early  adipogenesis,  limitations  to  it’s  functionality  mean  that  important  data  may  be 
missed. For example, not all genes are described by GO terms, and the method by which 
gene  function  is  annotated  can  sometimes  be  vague,  or  is  not  based  entirely  on 
experimental observation but may also involve some speculative comments. Furthermore, 
the  hierarchical  nature  of  the  GO  classification  system  means  that  large,  “parent” 
categories that give a vague view of gene function may be deemed enriched in a specific 
cluster (for example  “metabolism”,  Fig.  4.7)  whereas  smaller daughter  categories  (i.e. 
categories within the parent category where genes are grouped more specifically according 
to their role) that give a better view of adipogenic processes (for example “regulation of 
transcription”,  a  daughter  of “metabolism”)  are  not.  Therefore,  as  well  as  automated 
analyses of global processes, detailed annotation of the function of individual genes was 
undertaken  using  manual  searches  of online  databases  including  EntrezGene,  OMIM, 
PubMed and GeneCards (2.7.4.2). The analysis was focused mainly on clusters showing 
the earliest regulation during differentiation, namely clusters  1,  5-9,  and  12, in order to 
gain  further insight into the events characterising early adipogenesis.  Several biological 
trends were identified that occurred either in a single cluster, or were noted throughout 
early differentiation.
Co-expression of genes in cluster 5 regulated by members of the induction cocktail.
Around 33% of genes in cluster 5 (containing 72 genes, permanently upregulated from 3h) 
for which  a function could be annotated were  found to be  either directly regulated by
170constituents of the induction cocktail used to induce adipogenesis, or to be involved in 
pathways  stimulated  by  these  reagents.  Glucocorticoid-regulated  genes  were  most 
abundant  (Table  4.2).  These  genes  included  C/EBP5  and  GILZ,  which  are  known  to 
regulate  adipogenesis positively and  negatively respectively  (Wu  et al  1996,  Shi  et al
2003).  RASD1  is  also regulated by glucocorticoids but  is not known to play a role  in 
adipogenesis;  it’s exact function is unknown but it may be involved in dexamethasone- 
induced  alterations  in  cell  morphology,  growth  and  extracellular  matrix  interactions 
(Kemppainen et al 2003, Vaidyanathan et al 2004).  It’s  co-expression with adipogenic 
regulators combined with their conserved method of regulation could indicate a role for 
RASD1  in cooperating with such factors to control adipogenesis.
The  upregulation  of  genes  involved  in  insulin/IGF  signalling  and  cAMP-regulated 
processes was also observed in cluster 5. These include FOXOIA, which plays a major 
role  in  mediating  insulin-induced  adipogenesis  (Nakae  et  al  2003).  FOXOIA  is  also 
known to be important for glucocorticoid-stimulated PDK4 expression (Kwon et al 2004); 
PDK4 is also found in cluster 5. Additionally, one probeset for PDE4D (cAMP-specific) 
is located in cluster 5.  PDE4D degrades the second messenger cAMP  (the intracellular 
level of which is increased by IBMX), thus controlling signalling by this molecule, and 
some  isoforms  of this  gene  are  upregulated  by  cAMP  levels  (LeJeune  et  al  2002). 
Although  4  other  probesets  for  this  gene  are  located  in  cluster  12,  they  also  show 
upregulation at 3h. These observations indicate a high level of functional clustering at this 
timepoint; many genes with similar functions are co-expressed. Additionally, it highlights 
the ability of differentiation inducers to stimulate transcriptional regulation at a specific 
timepoint.  These  results  therefore  suggest  that  an  important  step  in  the  control  of 
adipogenesis at 3h may be the coordinated upregulation of several  signalling pathways 
mediated  by  the  differentiation  inducers,  which  act  in  concert  to  transmit  signals 
throughout adipogenesis, as their expression is permanently upregulated.
Regulation  of  developmental  genes  at  a  specific  stage  of  adipogenesis.  Cluster  5 
(permanent upregulation  from 3h)  and cluster 9  (218  genes,  permanent downregulation 
from 3h) both contained a number of genes found to play a role in the development or 
function of mesodermal and non-mesodermal tissues (Table 4.3). Indeed, the GO term
171Cluster 5: Genes relate* to signalling by induction cocktail components
Glucocorticoid-regulated/
processes
Insulin/IGFl- 
regul ated/processes
cAMP-
regulated/processes
RAS, dexamethasone-induced 
1  (RASD1)
Delta sleep inducing peptide, 
immunoreactor (GILZ) 
Glucocorticoid induced 
transcript 1  (GLCCI1) 
Pyruvate dehydrogenase 
kinase, isoenzyme 4 (PDK4) 
FK506 binding protein 5 
(FKBP5)
Metallothionein IK (MT1K) 
Metallothionein IF 
(functional) (MT1F) 
CCAAT/enhancer binding 
protein 8 (C/EBP5)
Inhibitor of DNA binding 4 
(ID4)
Forkhead box 01A 
(FOXOIA)
Forkhead box Ol A 
(FOXOIA)
Inositol(myo)-l(or 4)- 
monophosphatase 2 (IMPA2) 
Suppressor of cytokine 
signalling 2 (SOCS2)
Insulin receptor substrate 2 
(IRS2)
Phosphoinositide-3-kinase, 
regulatory subunit, 
polypeptide 1  (PIK3R1)
Phosphodiesterase 
4D, cAMP-specific 
(PDE4D)
Table 4.2.  Genes in cluster 5 (permanently upregulated at 3h) that are regulated by,  or act 
downstream of, induction cocktail components. These functions were identified using manual 
database searches (2.7.4.2).
172A  Genes implicated in the development/function of other lineages - Cluster 5
Neural Mesenchymal tissue formation
Snail homolog 2 (Drosophila) 
(SNAI2)
Suppressor of cytokine 
signaling 2 (SOCS2)
Basic helix-loop-helix 
transcription factor 6 (HATH6) 
Putative small membrane 
protein (NID67)
Snail homolog 2  Sine oculis homeobox homolog  T-box 2 
(Drosophila) (SNAI2)  2 (Drosophila) (SIX2)  (TBX2) 
Inhibitor of DNA  Inhibitor of DNA binding 4 
binding 1  (ID1)  (ID4)
B  Genes implicated in the development/function of other lineages - Cluster 9
Neural Bone Muscle Cartilage Adipose
Chromosome 5 Osteoblast Potassium A disintegrin-like and Eight twenty one
open reading frame specific factor inwardly- rectifying metalloprotease with protein/myeloid
13 (neuronal 2 (fasciclin I- channel, subfamily thrombospondin type translocation gene
protein 3.1) like) (OSF2) J, member 2 1  motif, 1 on 8q22
(KCNJ2) (ADAMTS1) (ETO/MTG8)
Potassium Vitamin D Mesenchyme A disintegrin-like and Ectodermal-
inwardly-rectifying (1,25- homeo box 2 metalloprotease with neural cortex
channel, subfamily dihydroxyvita (MEOX2) thrombospondin type (with BTB-like
J, member 2 min D3) 1  motif, 5 domain) (ENC1)
(KCNJ2) receptor
(VDR)
(aggrecanase-2)
(ADAMTS5)
Prickle-like 1 Mesenchyme Ankyrin repeat High mobility
(Drosophila) homeo box 2 domain 1  (cardiac group AT-hook 2
(PRICKLE 1) (MEOX2) muscle)
(ANKRD1)
(HMGA2)
Ectodermal-neural Hepatocyte Tripartite motif- Kruppel-like
cortex (with BTB- growth factor containing 32 factor 6 (KLF6)
like domain) (HGF) (TRIM32)
(ENC1)
Ras and Rab Muscleblind-like Kruppel-like
interactor 2 (RIN2) (Drosophila)
(MBNL1)
factor 2 (KLF2)
Acti vity-dependent GATA-binding Early growth
neuroprotector protein 6 (GATA6) response 1
(ADNP) (EGR1/KROX20)
Neuron navigator 1
(NAVI)
Kruppel-like factor
6 (KLF6)
Homeobox B2
(HOXB2)
Table 4.3. Genes implicated in the development/function of other lineages identified by manual 
annotation.  A,  Genes  in  cluster  5  (permanently upregulated  at  3h)  and  B,  genes  in  cluster  9 
(permanently downregulated  at  9h)  with  functions  related  to  the  development  or  function  of 
mesodermal and non-mesodermal lineages. These functions were identified using manual database 
searches (2.7.4.2).
173“development” was found to be enriched in cluster 9.  Cluster 5 was found to contain 2 
genes involved in the regulation of development during GO annotation (Appendix Table 
4)  but  this  did  not  pass  the  stringent  significance  criteria  used.  However,  manual 
characterisation  identified  gene  functions  that  were  not  necessarily  covered  by  GO 
annotation, and in this way 20% of genes with a known function in cluster 5 were defined 
as having a function related to development. These included the transcription factor SIX2, 
the exact function of which is unknown, but SIX gene family members are known to be 
involved in vertebrate development and maintenance of the differentiated state of tissues 
(Laclef et al 2003, Lagutin et al 2003). Although involved in the development of other 
lineages,  such  genes  may  have  an  additional  role  in  controlling  adipogenesis,  but 
functional investigation would be required to confirm this.
Genes controlling the development of a number of tissues constituted  17% of cluster 9, 
and thus were permanently downregulated from 3h. Many of these genes are associated 
with the bone, muscle and cartilage lineages, which MSCs are capable of forming.  For 
example, the transcription factor MEOX2 was downregulated, and has been shown to be a 
regulator  of  vertebrate  limb  myogenesis  (and  skeletal  development  in  concert  with 
MEOX1)  (Mankoo  et  al  1999,  2003).  The  expression  of a  subset  of neuronal  genes 
including ADNP,  which plays  a role  in neurodevelopment  (Pinhasov  et al 2003),  was 
particularly interesting as it may imply that hMSCs are capable of differentiating into this 
lineage  -  a  matter  under  considerable  debate  (Lu  et  al  2004,  Neuhuber  et  al  2004). 
Furthermore, some of the genes in this cluster were known regulators of adipogenesis, and 
included ENC1  which is also involved in the function of neuronal cell types (Zhao et al 
2000).  These  results  suggest  that  hMSCs  express  a  number  of genes  associated  with 
different lineages, and an important step during early adipogenesis could be the permanent 
downregulation  of  such  genes  in  order  to  steer  differentiation  along  the  adipogenic 
pathway.  Furthermore, it is possible for such genes to regulate the development of more 
that one tissue type, suggesting that some may have additional roles specific to the earliest 
stages of adipogenesis.
Occurrence  of  chromatin  modification  throughout  adipogenesis.  Chromatin 
modification genes were found to be regulated throughout adipogenesis, and as such were
174located  in  numerous  expression  clusters.  The  transcriptional  regulation  of SMARCF1 
during adipogenesis has never before been reported; here it was identified in cluster 8, and 
showed transient upregulation at  lh.  It  is thought to be  a  component of the  SWI/SNF 
ATP-dependent  chromatin  remodelling  complex,  and  is  known  to  transactivate 
glucocorticoid receptor-dependent transcription (Inoue et al 2002); this is notable when 
associated  with the upregulation of many glucocorticoid-responsive  genes  at 3h.  Other 
genes associated with chromatin remodelling were located in clusters  1, 6, 8 and 9. Their 
frequency of regulation, both positive and negative, throughout adipogenesis, may indicate 
that the control of this process plays an important role at many stages of differentiation. 
Indeed, transcription regulators are highly enriched in clusters 6, 8 and 9 where chromatin 
remodellers  are  found  (Fig  4.7),  indicating  that  some  chromatin  remodellers  may  be 
expressed  in  order  to  regulate  transcription  at  specific  differentiation  stages,  whereas 
others must be repressed into order for the correct transcriptional program to proceed.
4.4.3  Role of  classical signalling pathways in adipogenesis
The Wnt, TGF/3 and BMP signalling pathways are known to regulate adipogenesis: Wnt 
and TGF/3 signalling inhibit the process whereas BMP signalling promotes differentiation 
(Ignotz and Massague  1985, Ahrens et al  1993, Asahina et al  1996, Locklin et al  1999, 
Ross et al 2000, Choy et al 2000, Bennett et al 2002, Choy and Derynck 2003, Tang et al
2004).  However,  little  detail  is  known  regarding  the  temporal  regulation  of  specific 
pathway  members  throughout  the  process  of  differentiation  in  hMSCs.  This  was 
investigated  by  generating  graphical  pathway  maps  to  represent  significant  expression 
changes occurring in these pathways during each phase of differentiation (Oh-lh,  lh-3h, 
3h-9h, 9h-7d, Figs. 4.8 and 4.9). Pathway maps were generated using Ingenuity Pathway 
Analysis  (Ingenuity®  Systems,  www.ingenuity.com,  2.7.4.1),  and  modifications  were 
made where pathway members not included on the maps were identified during manual 
annotation.
Wnt pathway regulation during adipogenesis. The first transcriptional regulation of the 
canonical  Wnt  pathway  occurs  between  l-3h,  where  pathway  inhibitors  DKK1  and 
DACT1  are  downregulated,  along  with  upregulation  of the  Wnt  receptor  FZD4  and 
PPP2R1B, a regulatory subunit of PP2A which stabilises the /3-catenin complex (Fig. 4.8).
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Figure  4.8.  Temporal  regulation  of  Wnt  signalling  pathway  components  during  hMSC 
adipogenesis.  Log2  fold-change  values  for  significantly changed  genes  from  each  phase  of 
differentiation  were  mapped  onto  pathway  diagrams  using  Ingenuity  Pathway  Analysis
(2.7.4.1).  Figure  adapted  from  Ingenuity  Pathway  Analysis  (Ingenuity®  Systems, 
www.ingenuity.com).
176t ^ i   i H b   t^ p  i- i@ i  1h-3h  [ ^ f |  Wi/vr r ^ i   a c R *   t3 p( - @ Oh-1h
L  BM P Re I Re/ RTK
AK1 M
[a b ;
'QmaAi' ,bmao4.
CmiuU' sOmaCMy
reap: 'csp; ;c8p; :c8p;
Target g en es
Q w rtW |— faM 0 W 7
Type I 
BM PR c Type I BM P R c, ACVRtC,
■   ACVRt  | 
TCFBRI
RTK RTK
fak;
Sm * j1
x8p; £8P.
S m ad l
Target g e n es
(^ ) Upregulation 
Q  Downregulation
Differential 
regulation of 
related genes
Figure 4.9.  Temporal  regulation  of TGF/3 and  BMP  signalling  pathway components  during 
hMSC adipogenesis. Log2 fold-change values for significantly changed genes from each phase 
of differentiation  were  mapped  onto  pathway  diagrams  using  Ingenuity  Pathway  Analysis
(2.7.4.1).  Figure  adapted  from  Ingenuity  Pathway  Analysis  (Ingenuity®  Systems, 
www.ingenuity.com).
177As differentiation progresses the number of pathway members that are transcriptionally 
regulated  increases,  and  from  3-9h  both  up  and  downregulation  is  observed.  FZD4  is 
further upregulated, along with pathway intermediates /3-catenin and GBP and regulators 
including  another  PP2A  subunit.  Genes  involved  in  the  inhibition  of Wnt  signalling, 
including sFRPl, DKK1  and TBL1X are also upregulated. Other members such as DVL1 
(as  well  as  it’s  inhibitor DACT1)  and  the transcription  factors TCF7L1  and TCF4  are 
downregulated,  so an overall trend does not describe the regulation at this point.  In the 
final phase of differentiation studied, from 9h-7d, a trend of downregulation is observed, 
as  genes  at  all  levels  of  Wnt  signalling  are  downregulated  including  the  signalling 
molecules  Wnt5A  and  5B,  target  receptors  FZD  1,6,7,8,  and  LRP6,  signalling 
intermediates such as /3-catenin, GSK3/3 and APC and finally target transcription factors 
TCF7L2 and TCF4. Some upregulation still occurs, for example TCF7L1 and DVL2.
These results demonstrate that Wnt signaling during hMSC adipogenesis is regulated on a 
temporal level, and this involves components at all stages of the signaling pathway. This 
analysis  led to  the  identification of DACT1,  which  is  not  currently known  to  regulate 
adipogenesis.  DACT1  represses the  Wnt pathway through stabilisation of the /3-catenin 
degradation complex (Cheyette et al 2002), and is expressed from 0-lh, then expression 
decreases at 3h and further by 9h (Fig. 4.8). Taken together with the upregulation of /3- 
catenin at 9h, this expression pattern may implicate DACT1  in controlling Wnt pathway 
expression during adipogenesis.
TGF/3  and  BMP  pathway  regulation  during  adipogenesis.  Similar  to  the  Wnt
signalling  pathway,  few  genes  related  to  TGF/3  or  BMP  signalling  show  expression 
changes in the first hour of differentiation (Fig. 4.9). From l-3h, upregulation of the TGF/3 
family  ligand  INHBB,  and  TGIF,  an  intermediate  of  TGF/3  signalling  and  itself  a 
transcriptional target of the pathway is observed. Also at this stage, the TGF/3 signalling 
inhibitor SMURF2 is downregulated, whereas no regulation of BMP signalling members 
is detected.  From 3-9h,  both pathways  show  interesting regulatory trends,  as the major 
SMAD protein in BMP signalling,  SMAD1,  is upregulated, along with a BMP pathway 
target SMAD6. This is in contrast to the TGF/3 branch, where SMAD3 is downregulated 
along with TGIF, various ligands and the pathway targets PAI1  and SMAD7. ACVR1, a
178TGF/3-type  receptor,  and  DCN  which  sequesters  TGF/3  ligands,  are  upregulated. 
Regulation of these pathways then shows significantly different patterns in the final phase 
of differentiation. Every BMP pathway member that changes expression is downregulated, 
apart  from  the  target protein  SMAD6.  This pattern  is  mirrored  in the  TGF/3 pathway, 
where kinases that mediate an alternative route for TGF/3 signalling are downregulated, 
combined with multiple ligands and receptors.
These observations indicate that the TGF/3 and BMP pathways are regulated in contrasting 
directions  during  adipogenesis;  the  general  trend  for  TGF/3 pathway  members  during 
differentiation  is  downregulation,  whereas  some  BMP  signalling  components  are 
transiently upregulated at 9h. This could suggest different requirements for these pathways 
at  specific  stages  of adipogenesis.  Analysis  of the  TGF/3  signalling  pathway  revealed 
regulation of TGIF, which has not been shown previously during adipogenesis (Fig. 4.9). 
TGIF,  as  well  as  being  transcriptionally  induced  by  TGF/31  signalling,  acts  as  a  co­
repressor  of  SMAD2/3-mediated  transcriptional  activation  by  forming  repressive 
complexes containing histone deacetylases (Wotton et al 1999, Chen et al 2003), so may 
be involved in a negative feedback loop to inhibit TGF/3 signalling. The pattern of TGIF 
upregulation at 3h followed by downregulation alongside other TGF/3 components could 
indicate a role for TGIF during adipogenesis.
4.5  Identification of novel candidate regulators of early adipogenesis
Characterisation of novel regulators of early adipogenesis would further knowledge of the 
molecular control of early stem cell differentiation. The identification in this study of 6319 
probesets regulated during adipogenesis provides a unique opportunity to do this. Manual 
functional annotation of clusters representing the earliest regulation (described in section 
4.4.2)  as  well  as  some  analysis  of additional  clusters  was  therefore  used  to  identify 
candidates  for  novel  regulators  of adipogenesis.  A  number  of selection  criteria  were 
designed to identify such genes, which were deemed of interest if they passed at least one 
of these criteria:
179•  Functional  association  with  differentiation  or  tissue  development,  especially  of 
mesenchymal cells/tissues.
•  Functional association with genes (e.g.  C/EBP proteins) or processes (e.g. cell  shape 
change) known to play a part in adipogenesis, but with no known role in the process.
•  Specifically defined as regulators of signalling pathways involved in adipogenesis (e.g. 
Wnt pathway), but with no known role in the process.
•  Regulated  by  the  reagents  used  to  induce  adipogenesis,  or  acting  as  part  of their 
downstream pathways.
•  Transcription  factors/factors involved in the regulation of transcription were  deemed 
particularly interesting as they have the ability to control large subsets of downstream 
genes, so may have a significant role in differentiation.
This analysis identified over  100 interesting candidate genes,  summarised in Table 4.4, 
which were regulated during adipogenesis but had no  known  role  in the process.  This 
number highlights the potential of this study to identify possible novel early adipogenic 
regulators. Below, selected candidates of particular interest are discussed.
HOXB2  and  SNAIL 1   were  both  chosen  mainly  due  to  their  known  roles  in  the 
development of other tissues. SNAIL 1   is a transcriptional repressor of ectodermal genes 
within  the  neural  crest  and  mesoderm  during  development,  in  a  process  known  as 
epithelial-mesenchymal transition (Leptin 1991). Transient upregulation of SNAIL 1   at 3h 
(cluster 6) could indicate a requirement for suppression of non-mesodermal genes during 
adipogenesis that may be mediated by this gene. HOXB2 belongs to the homeobox family 
of transcription factors that are known to be involved in development, and is thought to 
have a specific role in neuronal patterning and differentiation in certain areas of the mouse 
hindbrain (Gavalas et al 2003). HOXB2 is permanently downregulated at 3h (cluster 9); if 
downregulation of genes involved in the differentiation of other tissues (such as HOXB2) 
is crucial for the progression of adipogenesis,  alteration of the expression of this factor 
may affect differentiation of hMSCs to adipocytes.
180Cluster Gene Name
1  Helicase (DNA) B
1  Ret finger protein
2  Transforming growth factor, beta 
receptor III (betaglycan, 300kDa)
5  Casein kinase 1, delta
5  Growth arrest-specific 1
5  Glucocorticoid induced transcript  1
5  Basic helix-loop-helix transcription
factor 6 
5  Inositol(myo)-1  (or 4)-
monophosphatase 2 
5  Putative small membrane protein
NID67
5  Phosphodiesterase 4D, cAMP-specific
(phosphodiesterase E3 dunce homolog, 
Drosophila)
5  Period homolog 1  (Drosophila)
5  Proline-rich nuclear receptor
coactivator 1  
5  Prickle-like 2 (Drosophila)
5  RAS, dexamethasone-induced 1
5  Sine oculis homeobox homolog 2
(Drosophila)
5  Snail homolog 2 (Drosophila)
5  Suppressor of cytokine signaling 2
5  T-box 2
5  Transforming growth factor beta- 
Stimulated protein TSC-22
6  Basic transcription element binding 
protein  1
6  Chromobox homolog 4 (Pc class
homolog, Drosophila)
6  cAMP responsive element binding
protein 3-like 2 
6  cAMP responsive element modulator
6  Cofactor required for Spl
transcriptional activation, subunit 7, 
70kDa
6  Diphtheria toxin receptor (heparin-
binding epidermal growth factor-like 
growth factor)
6  Ephrin-B2
6  F-box and leucine-rich repeat protein
12
6  Forkhead box Q1
6  GTF2I repeat domain containing 1
6  Jumonji homolog (mouse)
6  Kruppel-like factor 4
6  Kruppel-like factor 13
6  Large tumor suppressor, homolog 2
_______(Drosophila)_________________________
Gene
Symbol
Reason
for
selection
Present in 
shRNA 
library Y/N
HELB
RFP
TGFBR3
CSNK1D
GAS1
GLCCI1
HATH6
IMPA2
NID67
PDE4D
PERI
PNRC1
PRICKLE2
RASD1
SIX2
SNAI2
SOCS2
TBX2
TSC22
BTEB1
CBX4
CREB3L2
CREM J
CRSP7
DTR r  -  ^!
EPHB2
FBXL12 H
FOXQ1 i
GTF2IRD1
JMJ
KLF4
KLF13
LATS2 H
N
Y
Y
Y
Y 
N
Y
N
Y
Y 
N
N
Y
Y
Y
Y
Y
Y
Y
Y 
N
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
181Cluster Gene Name Gene
Symbol
Reason
for
selection
Present in 
shRNA 
library Y/N
6
6
Lipoma HMGIC fusion partner-like 2 
Insulin receptor tyrosine kinase 
substrate
LHFPL2
LOC55971/
IRTKS
Y
Y
6 Mesoderm development candidate 1 MESDC1 Y
6 Mix interactor MONDOA Y
6
6
6
6
Nuclear receptor subfamily 4, group A, 
member 1
Nuclear receptor subfamily 4, group A, 
member 2
Nuclear receptor subfamily 4, group A, 
member 3
PR domain containing 4
NR4A1
NR4A2
NR4A3
PRDM4 ■
Y
Y
Y
Y
6 LIM domain protein RIL Y
6
6
Snail homolog 1   (Drosophila) 
Sprouty homolog 4 (Drosophila)
SNAI1
SPRY4 ■1TM Y
N
6
6
6
6
6
6
6
6
Slingshot 1
Transcription factor 8 (represses 
interleukin 2 expression) 
Transducin-like enhancer of split 3 
(E(spl) homolog, Drosophila) 
Tumor necrosis factor receptor 
superfamily, member IB 
Transducer of ERBB2, 1  
Zinc finger protein 36, C3H type, 
homolog (mouse)
Zinc finger protein, multitype 2 
Zinc finger protein 331
SSH1
TCF8
TLE3
TNFRSF1B
TOB1
ZFP36
ZFPM2
ZNF331
T
a
Y
Y
Y
Y
Y 
N
I
7 SI00 calcium binding protein A10 
(annexin II ligand, calpactin I, light 
polypeptide (pi 1))
S100A10 Y
8
8
8
Cysteine-rich motor neuron  1  
El A binding protein p400 
Helicase, lymphoid-specific
CRIM1
EP400
HELLS
■i N
N
N
8
8
Myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, Drosophila) 
Nuclear factor of activated T-cells 5, 
tonicity-responsive
MLL
NFAT5
Y
Y
8
8
8
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily f, member 1  
Sprouty homolog 2 (Drosophila)
Zinc finger protein 288
SMARCF1
SPRY2
ZNF288 m
Y
Y 
N
9 Rho GTPase activating protein  18 ARHGAP18 N
9 K1AA0537 gene product aka ARK5 
AMP-activated protein kinase family 
member 5
ARK 5 Y
9 Bromodomain containing 8 BRD8 Y
9 Cbp/p300-interacting transactivator, 
with GIu/Asp-rich carboxy-terminal 
domain, 2
CITED2 Y
182Cluster Gene Name
Core promoter element binding 
protein/ Kruppel-like factor 6 
Dapper homolog 1, antagonist of beta- 
catenin (xenopus)
9  Deleted in liver cancer 1
9  Dual specificity phosphatase 14
9  E2F transcription factor 7
9  Eukaryotic translation initiation factor
2C, 4
9  GRB2-associated binding protein 1
9  GATA binding protein 6
9  HMG-box transcription factor 1
9  Hepatocyte growth factor (hepapoietin
A; scatter factor)
9  Homeo box B2
9  Immediate early response 3
9  Inhibitor of growth family, member 3
9  Jub, ajuba homolog (Xenopus laevis)
9  V-jun sarcoma virus 17 oncogene
homolog (avian)
9  Kruppel-like factor 7 (ubiquitous)
9  Mesenchyme homeo box 2 (growth
arrest-specific homeo box)
9  Nuclear receptor coactivator 6
9  Protein kinase (cAMP-dependent,
catalytic) inhibitor alpha 
Protein phosphatase 2C, magnesium- 
dependent, catalytic subunit 
Protein phosphatase 1, regulatory 
(inhibitor) subunit 12A 
9  Prickle-like 1  (Drosophila)
9  Protein kinase C-like 2
9  Pumilio homolog 2 (Drosophila)
9  RAD54B homolog
9  Regulator of G-protein signalling 4
9  E3 ubiquitin ligase SMURF2
9  Suppressor of cytokine signalling 5
9  Son of sevenless homolog 1
(Drosophila)
9  Nuclear antigen Sp 100
9  Transcriptional regulator interacting
with the PHS-bromodomain 2
Vitamin D (1,25- dihydroxyvitamin 
D3) receptor 
9  Zinc finger protein  143 (clone pHZ-1)
9  Zinc finger protein 238
10  Development and differentiation 
enhancing factor 1
10  FAT tumor suppressor homolog 1
(Drosophila)________________________
Gene
Symbol
Reason
for
selection
COPEB/
KLF6
DACT1
DLC1
DUSP14
E2F7
EIF2C4
GAB1
GATA6
HBP1
HGF
HOXB2
IER3
ING3
JUB
JUN
KLF7
MEOX2
NCOA6
PKIA
PPM2C
PPP1R12A
PRICKLE1
PRKCL2
PUM2
RAD54B
RGS4
SMURF2
SOCS5
SOS1
SP100
TRIP-Br2
aka
SERTAD2
VDR
ZNF143
ZNF238
DDEF1
FAT
Present in 
shRNA 
library Y/N
Y
Y 
N 
N
Y
Y 
N
Y
Y
Y
Y 
N
Y
Y
Y
Y
Y
N
N
Y 
N
Y
Y
Y
Y
Y
Y
Y
Y
Y 
N
183Cluster Gene Name Gene
Symbol
Reason
for
selection
Present in 
shRNA 
library Y/N
10 Serum/glucocorticoid regulated kinase SGK Y
10 TGFB-induced factor (TALE family 
homeobox)
TGIF Y
12 Dual specificity phosphatase 1 DUSP1 Y
12 Dual specificity phosphatase 5 DUSP5 Y
12 Potassium voltage-gated channel, Isk- 
related family, member 4
KCNE4 N
13 Homeo box A7 HOXA7 Y
13 BMP and activin membrane-bound 
inhibitor homolog (Xenopus laevis)
BAMBI N
|  KEY Reason for selecting gene of interest (GOI)
Function associated with differentiation/development (of mesenchymal 
tissues)
Association with adipogenic factors/processes but no known role in the 
process
■
Novel regulators of signalling pathways involved in adipogenesis
Regulated by the reagents used to induce adipogenesis, or part of their 
downstream pathways
Transcription factor/involved in regulation of transcription
Table  4.4.  Novel  candidates  for  adipogenic  regulators  identified  by  functional  annotation. 
Functional  information  for  genes  showing  early  regulation  was  obtained  using  manual 
database searches and interesting candidate genes were selected using stringent criteria related 
to  relevant  functional  information  (Key).  These  functions  were  identified  using  manual 
database searches (2.7.4.2).
184The identification of TCF8 and FAT as genes of interest was based primarily on their roles 
in processes related to adipogenesis, or a relationship to adipose tissue. TCF8 resides at a 
major susceptibility locus for obesity on chromosome  10 (Hager et al 1998, Hinney et al 
2000).  It  is  a transcription  factor that  has  been  shown  to  augment  BMP2  and  TGF/31  
signalling (Postigo 2003), and plays a role in skeletal development (Takagi et al  1998), 
indicating that it also has a role in pathways known to control mesodermal differentiation. 
TCF8 was upregulated early in another microarray study of hMSC adipogenesis (Sekiya et 
al 2004). Here, it showed early upregulation from l-3h followed by downregulation at 7d 
in one probeset (cluster 6); 3 other probesets for this gene showed only downregulation at 
7d (cluster 10). The probeset showing upregulation at l-3h had the identification “_s_at”, 
meaning that it shared some probes  in common with another gene.  However,  the other 
gene (SNFl-like  kinase)  was represented by 2  further probesets  on the  U133  Plus  2.0 
array (as stated on NetAffx, www.affymetrix.com/analysis/index.affx), but these probesets 
did  not  show  altered  expression  during  adipogenesis.  It  could  not  be  definitively 
concluded therefore that cross-hybridisation by SNFl-like kinase transcripts had caused 
the observed expression change, so TCF8 was included for further analysis. The patterns 
of expression change might suggest that TCF8 could play an early role in adipogenesis, 
but is not required at the later stages, or must be downregulated in order for the final stage 
of differentiation to proceed.  It would be interesting to  investigate  further whether this 
gene plays a role in adipogenesis.
The  FAT  gene  encodes  a  transmembrane  receptor  which  is  part  of  the  cadherin 
superfamily (and was so named according to Drosophila FAT mutants being oversized 
due to increased cell proliferation). The Drosophila orthologue of this gene controls cell 
proliferation during development, and it is thought that FAT may also be important in cell 
communication (Dunne et al 1995). This gene showed downregulation at 7d (cluster 10). 
This regulation combined with the putative function of FAT may suggest that this gene 
has  an  early  role  in  controlling  cell  proliferation  and  communication  during  early 
adipogenesis, or that it must be repressed during later differentiation.
DACT1  and  TGIF,  described  in  section  4.4.3,  were  identified  due  to  their  role  as 
regulators  of  the  Wnt  and  TGF/3  signalling  pathways,  respectively.  TOB1  was  also
185identified in this study. TOB1 interacts with the BMP-SMADs 1, 5 and 8 and inhibits their 
transcription factor activity (Yoshida et al 2000). TOB1 was upregulated at 3h, and then at 
9h became downregulated (cluster 6) -  this was the time at which expression of SMAD1  
was  seen,  again  implicating  this  gene  as  being  involved  in  the  regulation  of  BMP 
signalling during adipogenesis.
SGK was  included as  a candidate  gene  for a number of reasons.  It  is  transcriptionally 
regulated  by  serum  and  glucocorticoids  (Itani  et  al  2002),  and  has  cAMP-dependent 
kinase  activity,  providing  evidence  of  a  relationship  between  this  gene  and  the 
differentiation inducers used. It has also been shown to be activated by TGF/3 signalling 
and  high  glucose  levels,  and  is  implicated  in  diabetic  nephropathy  (Saad  et al 2005). 
During adipogenesis, SGK was upregulated at l-3h followed by strong downregulation at 
7d (cluster 10). This may indicate an early role for SGK, possibly mediated by one/several 
of the differentiation inducers,  followed by repression of the gene in mature adipocytes 
which may be required for normal cellular function.
Finally,  several  genes  that  were  identified  as  candidate  adipogenic  regulators  during 
manual  annotation  have  recently been  confirmed  in  other work  as  regulators  of either 
3T3L1  or hMSC adipogenesis, although the mechanisms by which this occurs were not 
known  in  every case  (Table  4.5  and  Fig.  4.6).  DTR  was  identified  in  this  study  as  a 
potential candidate as its levels were shown to correlate with fat accumulation in humans 
(Matsumoto  et  al  2002)  and  a  mitogenic  role  in  fibroblasts  and  smooth  muscles  was 
described  (Higashiyama  et al  1991).  In July 2005  DTR was  shown to  stimulate  MSC 
proliferation whilst preventing differentiation (Krampera et al 2005). The upregulation of 
DTR  at  3h  in  this  study  could  possibly  fit  with  an  early  proliferative  role,  and  its 
downregulation from 9h-7d would be expected in order for differentiation to proceed. The 
potential  to  identify novel  adipogenic  regulators  among  this  candidate  list  is  therefore 
exemplified by this gene.
186Gene Function Expression
group
Reference
KLF6 Promotes adipogenesis through repression of 
DLK1
9 Li et al 2005
KLF15 Promotes adipogenesis through induction of 
PPARy expression in cooperation with C/EBPa
3 Mori  et al 2005a
KROX20 Promotes adipogenesis partly through C/EBP/3 4 Chen  et al 2005
O/E-l Promotes adipogenesis; mechanism unknown 3 Akerblad  et al 
2002
ETO/MTG8 Inhibits early adipogenesis through C/EBP/3 9 Rochford  et al 
2004
TAZ Molecular switch promoting osteogenesis whilst 
inhibiting adipogenesis in MSCs
14 Hong  et al 2005
GILZ Sequence-specific transcriptional repressor of 
PPARy
5 Shi  et al 2003
KLF2 Inhibits preadipocyte differentiation to adipocytes, 
partly through DLK1 restoration
9 Baneijee et al 2003, 
Wu  et al 2005
DTR Promotes MSC proliferation but inhibits 
differentiation
6 Krampera  et al 
2005
Table  4.5.  Genes  recently  implicated  in  adipogenesis  that  were  identified  in  expression 
clusters.
1874.6 Discussion
The  experiments  described  in  this  chapter  have  demonstrated  that  early  adipogenesis 
involves  complex  transcriptional  regulation  that  occurs  in  defined  temporal  patterns. 
Identification  and  analysis  of gene  clusters  with  specific  expression  patterns  revealed 
novel  information  regarding  molecular  processes  that  are  important  during  early 
adipogenesis. From the large dataset produced, it was possible to identify numerous novel 
candidate regulators of adipogenesis.
These  results  have  shown  that  adipogenesis  involves  transcriptional  regulation  that  is 
initiated as early as lh after the induction of differentiation and that 6319 probesets show 
significant expression changes over the time-course (given the significance cut-off criteria 
employed in this study).  This indicates the rapidity by which the  addition of hormonal 
inducers of differentiation was transduced into transcriptional changes, and demonstrates 
the  overall  complexity  of  adipogenic  regulation.  This  level  of  detail  and  the  early 
transcriptional  response  have  not  previously  been  described  during  adipogenesis.  The 
largest arrays previously used on hMSC or murine 3T3L1  adipogenesis covered  12,000 
(Sekiya et al 2004, Yloslato et al 2006) or 16,000 genes (Hackl et al 2005) respectively, 
whereas the microarrays used in this study covered all known human genes. The number 
of genes with significant expression changes during adipogenesis varied in other work but 
was at most 1016 (Burton et al 2004). This is likely to be a reflection of the different array 
sizes and selection criteria used to  identify significant genes.  I do not consider that the 
selection criteria used here, that identified over 6300 significant genes, were not stringent 
enough, as stricter criteria would be likely to miss small but important expression changes.
The  increasing number of significant changes detected  in  each phase  of differentiation 
may be a reflection of the increasing length of time between timepoints studied (Fig 4.1 
and Fig 4.2B). However, when the expression profiles of replicate arrays were compared 
(Fig 4.2A), the  7d and 9h arrays, and also  3h though to  a lesser extent,  were found to 
display  expression  profiles  unique  to  the  particular timepoint,  indicating  that  different 
stages of the transcriptional regulation of adipogenesis were captured at each timepoint.
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temporally ordered changes in gene expression which occur in distinct patterns. Fourteen 
separate  gene  clusters,  each with  a different  regulatory pattern,  were  identified  in this 
analysis. Smaller microarray studies of adipogenesis that employed hierarchical clustering 
detected 5-9 gene clusters (Ross et al 2002, Burton et al 2004, Nakamura et al 2003), and 
it would be expected that with a larger gene set, as in this study, more detailed regulation, 
and  therefore  a  higher  number  of clusters,  would  be  detected.  Several  studies  used 
additional  clustering  methods  such  as  k-means  clustering  and  self-organising  maps  to 
further analyse these regulatory patterns (Burton et al 2004, Hackl et al 2005) but it was 
decided here that hierarchical  clustering  had identified  a  reasonable  number of clearly 
separable clusters  containing genes with  similar regulatory patterns,  so  further analysis 
was unnecessary. All genes tested by RT-PCR analysis showed mRNA level changes that 
recapitulated  the  expression  patterns  detected  by  microarray  analysis,  so  it  can  be 
concluded that the microarray analysis accurately reflected biological changes (Fig 4.3). It 
was  also  shown that  every regulatory pattern  assessed was  conserved  in differentiated 
hMSCs  from  several  other donors  (Fig.  4.5),  which  is  an  analysis  that  is  infrequently 
performed  in  other  hMSC  work,  but  which  demonstrates  the  important  fact  that  the 
observations are not an artefact of the particular bone marrow used.
Evidence  supporting  this  differentiation  system  as  an  accurate  model  of adipogenesis 
came from the identification of many crucial adipogenic regulators in the heatmap (Fig. 
4.6).  A  small  number  of  known  regulators,  for  example  GATA2  and  -3,  were  not 
significantly changed during adipogenesis. A possible explanation for this is that they may 
not  have  passed  significance  level  applied  in  this  investigation  (q<0.05).  Indeed, 
transcription factors such as these need only small expression changes to have significant 
effects.  Post-transcriptional  changes  such  as phosphorylation,  rather that transcriptional 
control, could be the major regulator of genes such as CREB, providing a possible reason 
for  it’s  absence  from  the  genes  showing  significant  transcriptional  change  during 
differentiation.  Furthermore,  as  explained  earlier (section  4.1),  it  is  possible  that  these 
genes were expressed to a high level during adipogenesis, but if their expression did not 
change then the comparative nature of microarray studies means that they would not have 
been  included  in  the  analysis.  Other  studies  of hMSC  or  3T3L1  adipogenesis  tend  to
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gene expression changes (for example, Sekiya et al 2004, Burton et al 2004), indicating 
that this is a common issue amongst experiments of this nature,  although an additional 
causative factor in other studies is that the microarrays used may not have represented all 
known adipogenic regulators.
The expression at 7d of numerous genes known to play a role in adipocytes in  vivo,  as 
well as the enrichment at this endpoint of relevant metabolic pathways, indicates that at 7d 
cells resemble adipocytes in vivo both transcriptionally and morphologically (Table 4.1 
and  Fig.  4.IB).  The  7d  adipocytes  were  morphologically  similar  to  brown  adipocytes 
(multiple  fat  droplets  rather  than  a  single  large  droplet,  1.5.1),  but  studies  of brown 
adipocyte morphology have mainly been performed in rodents. Furthermore, other studies 
of hMSC differentiation reveal multi-vesicle adipocytes (Pittenger et al 1999, Sekiya et al 
2004), so this morphology could reflect either an inter-species difference in morphology, 
or that the induction cocktail use does not fully recreate the in vivo signals that initiate 
adipogenesis.  However,  as  upregulation  of the  BAT-specific  marker  UCP1  was  not 
observed,  the  transcriptional  program  occurring  is  not  likely  to  be  favouring 
differentiation towards brown adipocytes.
Genes that are regulated in a similar manner throughout adipogenesis, and hence fall into 
the same expression cluster, may have related roles. It was therefore possible to use the 
gene  clusters  to  identify  global  events  and  processes  that  act  at  specific  stages  of 
differentiation. As the microarray used in this study covered all known human genes, this 
analysis  has  provided  a  level  of  detail  and  accuracy  regarding  global  processes  of 
adipogenesis  that  is  greater than  previous  studies,  which used  smaller  arrays  and  less 
comprehensive analysis (Sekiya et al 2004, Yloslato et al 2006). The information gained 
is  limited  only by the  annotation  method  used.  However,  both  automated  and  manual 
annotation were used to infer gene function, so a high level of detail was obtained.
Gene  clusters  representing  expression  changes  at  the  earliest  timepoints  investigated 
contained high proportions of transcription factors and developmental genes (Fig. 4.7 and 
Table 4.3). Another early trend was the upregulation at 3h of genes involved in response
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downregulation  of cell  communication  and  the  cell  cycle,  as  well  as  upregulation  of 
certain metabolic processes (Fig. 4.7). These findings suggest that the earliest events of 
adipogenesis  are  centred  on  the  transduction  of  environmental  stimuli  into  cellular 
responses  which involve the action of many transcription  factors.  Some developmental 
genes and transcription factors are repressed whereas others, which were not expressed (or 
expressed at lower levels) in hMSCs, are upregulated. Such events are likely to direct cells 
along the adipogenic lineage and control the downstream events identified. These findings 
highlight the importance of the early stages of adipogenesis and also the potential  from 
this study to understand more regarding the control of stem cell differentiation.
The results described here provide novel information in a number of ways. Similar to the 
findings described here,  other studies using GO annotation also  identified a decrease in 
cell cycle genes and an increase in lipid metabolism and bioenergetics genes during hMSC 
adipogenesis (Yloslato et al 2006). However, this study augments such work as the list of 
genes  involved  in  these  processes  is  more  complete,  and  many  more  trends  that  may 
describe the earlier events of differentiation have also been identified.  Adipogenesis in 
hMSCs has previously been shown to involve downregulation of genes specific to other 
lineages  (Hung  et  al  2004a).  Furthermore,  a  recent  study  showed  that  a  subset  of 
developmental genes, including members of the HOX (HOX A5, C8 and C9)  and TBX 
(TBX15) families, were differentially expressed in different fat depots of mice or humans 
(subcutaneous and visceral, 1.5.2), and the expression of two of these genes (HOXA5 and 
TBX 15)  correlated  with  the  extent  of obesity  in  humans  (Gesta  et  al  2006).  It  was 
concluded  that  such  genes  may play  a  role  in  body  fat  distribution  and  obesity.  The 
discovery  here  of  HOXA7,  HOXB2  and  TBX2  as  differentially  expressed  during 
adipogenesis adds further detail to the array of developmental genes that may be involved, 
and the previous findings (Gesta et al 2006) add weight to a possible role for these genes 
in  controlling  adipogenesis.  It  was  shown  through  manual  annotation  that  certain 
processes, such as chromatin remodelling, occur throughout differentiation. It has recently 
been  shown  that  downregulation  of  histone  deacetylases,  a  subset  of  chromatin 
remodellers, during early 3T3L1 adipogenesis is required for their differentiation, and that 
histone acetylation at the promoters of adipocyte-specific genes it tightly associated with
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chromatin remodellers in this study, and their specific times of regulation, may serve to 
enhance understanding as to how they may control differentiation at the early stages.
Analysis  of the  expression  of Wnt,  TGF/3  and  BMP  signalling  pathways  components 
provided  an overview  of transcriptional  regulation  of pathway members  during hMSC 
adipogenesis (Figs. 4.8 and 4.9). As the major signalling events of these pathways occur at 
the  post-transcriptional  level  (e.g.  phosphorylation),  gene  expression  changes  may  not 
directly affect signalling,  so the  functional  consequences of the transcriptional changes 
cannot be concluded without further investigation. However, these analyses provide novel 
information in a number of ways; they indicate not only the exact pathway components 
that are regulated, but the specific stage of differentiation at which regulation occurs.
Although  recent  studies  have  identified  some  members  of the  Wnt  pathway  that  are 
expressed  in  preadipocytes  (Bennett  et  al  2002)  and  hMSCs  (Etheridge  et  al  2004), 
expression  of  Wnt  signalling  pathway  components  has  not  been  followed  in  detail 
throughout hMSC differentiation. The results described in this thesis define the temporal 
expression patterns of specific pathway members that are regulated during differentiation, 
and show that many of the same components are regulated that were identified previously 
(e.g. FZD1, TCF4, sFRP4, DKK1), but identifies regulation of further genes (e.g. DACT1, 
GBP,  PP2A  subunits).  Additionally,  this  work  provides  a  basis  for  future  functional 
studies aimed at elucidating the stage at which Wnt signalling plays a role during hMSC 
adipogenesis. Activation of Wnt signalling at any point during the first 3 days of 3T3L1 
differentiation was found to inhibit adipogenesis (Bennett et al 2002), and although it is 
known that Wnt signalling can inhibit hMSC adipogenesis, the exact timepoint at which 
this may occur is not known. The observation here that many Wnt pathway members are 
downregulated after 9h in this study might indicate that, similar to preadipocytes, hMSCs 
at  the  later  stages  of differentiation  would  be  refractory  to  Wnt  activators,  so  studies 
should focus on earlier timepoints to investigate the effects of Wnt signalling. Finally, the 
temporal view of transcriptional regulation of Wnt signalling could also be integrated with 
other  regulation  identified  at  similar  timepoints,  allowing  inferences  as  to  crosstalk 
between pathways during differentiation to be made.
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The continued downregulation of many TGF/3 pathway components identified (Fig 4.9) 
would  fit with  it’s  role  as  an inhibitor of differentiation,  and  the  observation that this 
begins as soon as the 3h-9h phase might indicate that downregulation of this pathway is 
required  early in  order  for differentiation to progress.  SMAD3  mediates  the  inhibitory 
action of TGF/3 in preadipocytes through inhibiting C/EBP protein transactivation function 
(Choy and Derynck 2003). Indeed, downregulation of SMAD3 rather than SMAD2 was 
observed  in  this  work,  and  this  occurred  at  the  same  timepoint  that  C/EBP/3  and  -8 
expression increased.  Therefore,  many of the observations made here  fit with previous 
work, but provide additional information as to the exact pathway members regulated and 
the timepoints at which this regulation occurs.
BMP-2,-4 and -7 can activate adipogenesis in bone marrow stromal cells (Ahrens et al 
1993,  Asahina et al  1996,  Tang  et al 2004).  A  significant upregulation  of SMAD1,  a 
transducer of BMP signalling was observed, as well as targets of this pathway, between 3h 
and 9h. SMAD1  and 5, as well as BMP-type receptors, were then downregulated during 
the latest phase of differentiation studied. Such temporal patterns have not previously been 
reported. It is tempting to speculate that any activatory role of BMP signalling would be 
more likely to be occurring during this early 3-9h phase when signalling components are 
upregulated,  and  later on,  when  BMP  signalling  is  no  longer required,  the pathway  is 
downregulated on the transcriptional level. Functional confirmation of these suggestions 
would  add  further knowledge  regarding  the  methods by which  these  pathways  control 
hMSC adipogenesis.
The major aim of this thesis was to identify novel factors involved in regulating the early 
stages of hMSC adipogenesis. Candidate genes were selected using functional information 
obtained from manual annotation of genes showing early regulation. The selection criteria 
employed optimised the likelihood of these genes having a role in adipogenesis; indeed, 
since candidate genes were identified, other research groups have described the role of a 
small number of these genes in adipogenesis (Table 4.5  KLF6 and DTR, Li et al 2005, 
Krampera  et al 2005).  This  further  supports  the  potential  of other  candidate  genes  in
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L1 adipogenesis, for example KLF2 (Baneijee et al 2003, Wu et al 2005) and ETO/MTG8 
(Rochford et al 2004) also showed early regulation during hMSC adipogenesis (cluster 9, 
downregulation from 3h, Table 4.5). This correspondence between the 3T3L1  and hMSC 
differentiation programs is likely to be due to the fact that similar induction cocktails are 
used to initiate adipogenesis in both systems,  so  some genes may respond in a similar 
manner. However, many more genes are co-regulated with these factors in this study, and 
thus are interesting candidates for novel adipogenic regulators. Moreover, as the hMSC 
system has been employed here it may be that these additional genes are not expressed in 
3T3Lls.  Importantly, the majority of candidate adipogenic regulators identified here are 
unique to this study.
Some candidate genes, including SNAI2, GAS1  and TCF8, were  identified in previous 
studies of hMSC adipogenesis.  GAS1  and SNAI2 were found by Nakamura et al to be 
upregulated from day 1  to day 9 during differentiation, and GAS1 was upregulated at day 
3  in the study of Hung and co-workers (Nakamura et al 2003, Hung et al 2004a). Here, 
these genes were also shown to be upregulated,  but it was found that this upregulation 
occurred as early as 3h (Cluster 5,  Table 4.4),  highlighting the  importance of studying 
these early timepoints. TCF8 was upregulated at day 1   followed by downregulation in the 
work of Sekiya et al (2004);  it was  shown here  to  be down regulated  at  7d,  and  one 
probeset showed upregulation at  l-3h (cluster 6); this regulation has not previously been 
reported and would be interesting to investigate further. A recent study of genes regulated 
during multilineage hMSC differentiation and their subsequent “de-differentiation” back 
to  “hMSCs”  after  removal  of the  differentiation  cocktails  identified  several  genes  in 
common with this thesis (Song et al 2006). Interestingly, one of these was DACT1, which 
showed decreased expression during adipogenic  and osteogenic  differentiation and was 
upregulated  during  “dedifferentiation”,  and  hence  was  defined  as  a  gene  involved  in 
maintaining the stem cell properties of hMSCs, but this function was not tested. DACT1 
was  also  downregulated  during  differentiation  in  the  work  described  here,  so  this 
correlation  further demonstrates  the potential  of this  work to  identify novel  genes  that 
control the ability of hMSCs to undergo adipogenesis.
194CHAPTER 5. INVESTIGATION OF THE ROLE OF NOVEL 
CANDIDATE GENES IN hMSC ADIPOGENESIS THROUGH 
RNAi SCREENING TECHNIQUES.
1955.1  Introduction and aims
RNA interference is an endogenous cellular mechanism that can be exploited to silence 
the expression of a target gene at the mRNA  level through the introduction of double­
stranded RNA molecules targeting that gene (Fire et al 1998, section 1.7.3.1). Initial work 
in C. elegans used long dsRNAs to induce gene silencing, but such molecules trigger an 
interferon response in mammalian cells (Williams and Haque  1997, section  1.7.3.2). The 
technique was adapted for use in mammalian cells via the use of short, 21 -23nt dsRNA 
oligonucleotides,  named  siRNAs,  which mimic  intermediates of the  endogenous  RNAi 
pathway, and thus mediate gene silencing (Fig.  1.5, Elbashir et al 2001).  siRNAs bring 
about only a transient effect on gene expression. Hence, methods for stable expression of 
siRNA  in  mammalian  cells  were  developed  involving  vectors  from  which  19-29nt 
shRNAs  could  be  stably  expressed  (Brummelkamp  et  al  2002,  Paddison  et  al  2002, 
1.7.3.2).
The  use  of RNAi  to  identify  genes  involved  in  stem  cell  differentiation  has  several 
advantages, as there is a clear loss-of-function phenotype, and stably-expressed shRNAs 
can be used to ensure a constant level of gene knock-down throughout the relatively long 
time-course of differentiation. Indeed, several categories of viral vector have been used to 
stably deliver shRNA into a variety of cell types, including stem cells. Lentiviral vectors 
have been used to facilitate shRNA expression in ESCs (Rubinson et al 2003, Clements et 
al 2006), HSCs (Scherr et al 2003) and hMSCs (Cho et al 2006, Clements et al 2006), and 
have the advantage that they can infect non-dividing as well as dividing cells. Although 
adenoviral vectors are also used  for delivering shRNA into many cell  types, they have 
been less  successful  at delivering  shRNA into  stem cells,  perhaps because the primary 
receptor for adenoviruses is expressed poorly on such cells (Zou and Yoder 2005). A wide 
range of retroviral vectors are available for the delivery of shRNA into cells,  and their 
relatively small size allows for ease of manipulation (Brummelkamp et al 2002, Paddison 
et al 2002).
In the developing era of functional genomics,  RNAi is becoming a widely used tool to 
investigate  the  function  of multiple  genes  simultaneously.  Although  other  functional
196genomics  techniques  such  as  microarrays  identify  transcriptional  changes  that  may 
indicate a role for a gene in a specific process,  the use of techniques  such as RNAi  is 
required in order to functionally confirm such a hypothesis. This has the potential to yield 
much  detail  regarding  a particular  process  such  as  stem  cell  differentiation.  A  major 
advance  in  this  field  was  the  production  of  RNAi  libraries,  in  which  hundreds  or 
thousands of siRNAs or shRNAs are designed to target individual genes (1.7.3.3). Large- 
scale RNAi libraries targeting a broad spectrum of genes (Bems et al 2004, Paddison et al 
2004) as well as smaller libraries focusing on specific processes or functions (Aza-Blanc 
et al 2003)  have been  developed,  and  are  thus  versatile  in  allowing broad  studies,  or 
targeted screens focusing on a selection of genes, to be performed. Moreover, novel genes 
involved in numerous processes including fat storage in C.  elegans (Ashrafi et al 2003), 
apoptosis  (Aza-Blanc  et al 2003)  and  the p53  pathway  (Bems  et al 2004)  have  been 
identified, highlighting the efficacy of these RNAi libraries.
RNAi  libraries can be used in several formats,  including selection-based  screening and 
systematic  screening.  Selection-based  screens  involve transduction  of a cell  population 
with a shRNA pool targeting multiple genes. A selection is then applied according to the 
function  or  process  under  investigation,  such  that  shRNA-mediated  silencing  permits 
preferential selection of cells with a new phenotype. This technique has most often been 
used  when  the  shRNA  of  interest  confers  a  growth  advantage  under  selection,  but 
fluorescent reporters can also be used (Echeverri  and Perrimon 2006).  Identification of 
shRNAs conferring this new phenotype can be accomplished through the use of molecular 
barcodes (1.7.3.3, Westbrook et al 2005, Cullen et al 2005). However, this approach is 
limited in the range of functions that can be studied,  and it has been reported than the 
simultaneous silencing of multiple genes, as could be the case in a pooled screen, results 
in weakened silencing of each gene (Echeverri and Perrimon 2006).  Systematic screens 
entail high-throughput transduction of cells with individual siRNA/shRNAs, followed by 
assay  for a particular function,  which may  involve  a  fluorescent reporter system.  This 
method is more experimentally intensive than a selection-based screen (depending on the 
number of genes being studied), but is a more direct approach as any shRNAs producing a 
phenotype are immediately known (Brummelkamp et al 2003, Cullen and Arndt 2005).
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NKi  library)  targeting  7914  human  genes  (Bems  et  al  2004).  Three  shRNAs  were 
designed per gene, and when a pool of the 3 shRNAs was employed, an average inhibition 
of 70% was achieved for 70% of all genes (Bems et al 2004). The NKi RNAi library is 
designed  such  that  a  19nt  sequence  targeting  a  specific  gene  is  separated  from  it’s 
antisense version by a specific hairpin loop sequence. This cassette is under the control of 
the  HI  promoter,  and  resides  in  a  retroviral  vector  with  puromycin  resistance.  The 
shRNAs  in  this  library  were  designed  using  strict  criteria  to  maximise  knock-down 
efficiency and minimise off-target effect (Bems et al 2004). Design criteria included that 
shRNAs must share minimal sequence identity with other genes in order to reduce off- 
target  effects,  and  they must  target  every transcript  variant  of a  specific  gene.  The  3 
shRNAs targeting each gene are cloned separately into this vector, and are subsequently 
pooled to form a mixed plasmid population (Fig 5.1 A). This library has proved successful 
in a number of screens (Bems et al 2004, Kolfshoten et al 2005).
Aims
The main aim of these experiments was to implement a high-throughput shRNA screen of 
candidate genes and assess the effect of shRNAs on target gene expression and hMSC 
adipogenesis. Specific aims required to achieve this are:
•  to  isolate shRNAs of interest from the NKi  library and develop strategies to deliver 
shRNA to stem cells using retroviral vectors
•  to  perform  loss-of-fimction  screens,  in  different  formats,  and  assess  the  effects  of 
shRNA expression on target gene expression and adipogenesis
•  finally,  to  develop  a  lentiviral  strategy  to  transduce  hMSCs  with  custom-designed 
shRNAs for a smaller number of the most interesting candidates and assess the effect 
on gene expression and differentiation.
1985.2  Development and optimisation of a technique for retroviral delivery 
of shRNAs isolated from an RNAi library
Microarray  profiling  of  early  hMSC  adipogenesis  identified  108  candidate  novel 
regulators (Table 4.4). In order to assess the role of such a large number of candidates, the 
use of the NKi retroviral RNAi library was adopted. The aim of this experimental section 
was to develop methods to use shRNAs from this library in a functional screen.
shRNAs targeting 77%  (83) of the candidate adipogenic  regulators were present in the 
NKi library (Table 4.4). It was necessary to select 21 of these candidates for investigation, 
due to technical difficulties with the shRNA library discussed below. Table 5.1  therefore 
lists the most interesting 21  candidate genes with shRNAs present in the library, chosen 
according to their annotated functions. PPARy was also targeted in this library, and hence 
could possibly be used as a positive control (if the shRNA was functional), as knock-down 
of this  major adipogenic  regulator has  been  shown to  prevent  adipogenesis  in  3T3Lls 
(Hosono et al 2005).
5.2.1  shRNA isolation method I
The library is  stored  as bacterial  glycerol  stocks with a single well of a 384-well plate 
containing bacteria transformed with all 3  shRNAs for a specific gene (Fig.  5.1 A). The 
initial method for isolating the shRNAs for each candidate gene (or gene of interest, GOI) 
was therefore to inoculate bacterial cultures directly from the library stocks and isolate a 
mixed population of plasmids containing shRNAs for each of the 83 GOIs (method I, Fig 
5.2A). Plasmids containing shRNA inserts can be identified by a simple diagnostic digest 
using EcoKl and Xhol restriction enzymes (2.4.2.1,  Fig.  5.IB), yielding a 6kb  fragment 
representing the vector backbone, plus a ~320bp fragment containing the shRNA  insert 
and  HI  promoter  (plasmids  with  no  shRNA  insert  would  show  a  ~260bp  fragment). 
Examination  of  restriction  digestion  products  revealed  multiple  band  sizes  in  many 
samples (Fig, 5.2B, lane iii). These bands were visible for 34 out of 83 (42%) genes, and 
ranged in size from ~500bp to over 6kb (Fig.  5.2B and C).  It is highly likely that these 
bands represent multiple recombination products;  it was discovered that a high level of 
recombination occurs between the viral LTRs of this vector during replication in bacterial
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Dapper homolog 1, antagonist of beta- 
catenin (xenopus)
DACT1 9 Wnt signalling inhibitor during development
FAT tumor suppressor homolog 1  
(Drosophila)
FAT 10 Cell proliferation and communication during 
development
Homeo box A7 HOXA7 13 Thought to regulate gene expression and 
differentiation during development
Homeo box B2 HOXB2 9 Role in devlopment, neuronal patterning and 
differentia  tion
Insulin receptor tyrosine kinase substrate IRTKS 6 Possible association with insluin signalling
Jumonji homolog (mouse) JMJ 6 Required for nerual tube formation and heart 
development in mice, anti-proliferative role
Lipoma HMGIC fusion partner-like 2 LHFPL2 6 Possible association with Kpxma
Mesenchyme homeo box 2 (growth arrest- 
specific homeo box)
MEOX2 9 Mesoderm induction, KO mouse has 
muscular/skeletal abnormalities
Mesoderm development candidate 1 MESDC1 6 Possible association with mesoderm development
Serum/glucocorticoid regulated kinase SGK 10 Regulated by glucocorticoids, TGF/3 signalling and 
glucose levels
Sine ocuKs homeobox homolog 2 
(Drosophila)
SIX2 5 Associated with ligament and tendon 
differentiation, maintainance of differentiated state
Snail homolog 1  (Drosophila) SNAI1 6 Represses ectodermal genes within the embryonic 
mesoderm
Snail homolog 2 (Drosophila) SNAI2 5 Epithelial-mesenchymal transition; expressed in 
emerging mesodermal cells
Sprouty homolog 2 (Drosophila) SPRY2 8 Negative regulator of bFGF signalling
Slingshot 1 SSH1 6 Activated downstream of PI3K, role in insulin- 
induced membrane protrusion and actin dynamics
T-box 2 TBX2 5 Limb pattern formation and transcritpitonal 
regulation of genes resuired for mesoderm
Transcription factor 8 (represses 
interleukin 2 expression)
TCF8 6 Resides at a major susceptibility locus for obesity, 
regulates SMAD proteins
Transforming growth factor, beta receptor 
III (betaglycan, 300kDa)
TGFBR3 2 TGFBR3-sp>ecific antisera inhibit mesenchyme 
formation
TGFB-induced factor (TALE family 
homeobox)
TGIF 10 Forms transcriptional repressor complex with 
SMAD2/4
Transducer of ERBB2,1 TOB1 6 Regulates BMP-SMAD activity
Zinc fmger protein, multitype 2 ZFPM2 6 Controls expression of GATA proteins, 
specifically GATA4 during cardiac development
Peroxisome proliferator-activated 
receptor, gamma
PPARy 3 Major positive adipx>genic regulator - pxrasible 
px)sitive control
Table 5.1. Most interesting 21 out of the 83 candidate adipogenic regulators (plus PPARy) for 
which shRNAs were designed in the NKi shRNA library, and reasons for their selection as 
defined by interesting functional attributes.
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Figure 5.1.  Schematic showing NKi RNAi library design and retroviral vector.  A,  Design of 
NKi library. Three shRNAs were designed per gene and cloned individually into pRetroSuper- 
Puro.  Plasmids  containing  individual  shRNAs  were  mixed  and  stored  as  bacterial  glycerol 
stocks,  with one well  per gene.  The  library represents  7914  human genes.  B.  pRetroSuper- 
Puro.  Retroviral  vector,  based  on  pMSCV  retroviruses  with  the  addition  of  the  shRNA 
expression  cassette.  shRNA  expression  is  driven  by  the  HI  promoter,  and  ampicillin  and 
puromycin  resistance  ORFs  allow  for  drug  selection  in  bacterial  and  mammalian  cells, 
respectively. pRS Fwd and pRS Rev primers can be used to amplify the region containing the 
shRNA and HI promoter.
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Number of GOIs with this 
outcome (/83)
Insert present  no 16(19%)
recombination
Recombination (insert 34 (42%)
present/absent)
Low plasmid yield 26 (31%)
No bacterial growth from 7 (8%)
library
Figure  5.2.  Outcome  of  shRNA  library  screening  method  I.  A,  Bacterial  cultures  were 
inoculated directly from bacterial  glycerol  stocks of the library and  the three shRNA vector 
constructs (plasmids) for each gene were isolated as a mixed plasmid population (2.4.2.6); B, 
Representative agarose gel separation of EcoRl/Xhol restriction digestions of mixed plasmid 
populations for different GOIs (2.4.2.1). This technique was used to identify GOIs for which 
the  shRNA  insert  was  present  (320bp  band).  Multiple  bands  were  observed  for  several 
constructs  as  a  result  of recombination  inherent  in  the  library.  L,  lkb  Plus  DNA  ladder 
(Invitrogen); (i) Vector backbone and insert bands of correct size; (ii) No/low plasmid yield: 
possible  contamination  of  library  with  ampicillin-resistant  bacteria;  (iii)  Some/multiple 
recombination products; C, Summary of the outcome of method I.
202cultures, thus resulting in the elimination of shRNA inserts (personal communication from 
NKi  library distributors).  Some recombined plasmids  contained  the  shRNA  insert  (for 
example, Fig. 5.2B, lane iii), whereas the majority did not, suggesting that as suspected, 
recombination  was  occurring  and  resulting  in  loss  of the  shRNA  insert.  A  further 26 
(31 %) genes gave a low plasmid yield even after two separate plasmid isolations, which 
was reflected by faint bands or no bands after digestion, indicating that there may have 
been some contamination in the library with ampicillin-resistant bacteria, or that a portion 
of the vector containing only the ampicillin ORF was present (Fig. 5.2B, lane ii). Bacterial 
cultures for 7 (8%) of genes could not be grown. Finally,  16 (19%) GOIs contained no 
recombination and a reasonable to high level of shRNA insert (Fig. 5.2B, lane i). It was 
clear from these observations that for the majority of genes, direct shRNA isolation would 
yield too little un-recombined shRNA vectors for use in the screening strategy.
5.2.2  shRNA isolation method II
A  PCR  screening method was therefore  developed  in an attempt to  identify individual 
bacterial colonies that contained plasmids encoding shRNAs (i.e. plasmids in which the 
shRNA had not been excluded by recombination) (Fig.5.3A). As stated above, it was not 
possible to use this more detailed strategy to identify shRNAs for all 83 GOIs represented 
in the RNAi library, so further experiments were limited to the top 21  candidates (Table
5.1), plus PPARy. These candidates were chosen due to their interesting functions, rather 
than because shRNA insert bands were identified in method I, so it was possible that some 
of these shRNAs contained recombination. To perform PCR screens, bacterial clones were 
isolated  for  each  gene  via  streaking  of  library  stocks  on  LB-agar  plates  containing 
100/xg/ml ampicillin. Ten bacterial colonies per gene were then suspended in dh^O and 
were  used  as  template  DNA  for  PCR  with  the  pRS  primers  (Fig.  5.IB)  for  the 
identification  of  positive  bacterial  clones,  i.e.  clones  containing  shRNA-encoding 
plasmids  (Fig.  5.3B  i,  2.6.3.1).  Positive clones were  identified by a ~640bp  band after 
PCR  amplification  and  separation  of  PCR  fragments  on  agarose  gels  (2.6.3.3).  The 
presence  of shRNA  inserts  in  plasmids  purified  from  bacterial  colonies  identified  as 
positive in the PCR screen was confirmed by EcoRVXhol restriction digestion of these 
plasmids (Fig. 5.3B ii). Plasmids containing shRNAs were then sequenced with the pRS 
Seq primer (Table 2.3, 2.4.2.7) to identify the 3 different shRNAs for each gene. Using the
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Outcome of PCR screen 
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No. GOIs with this outcome (122 
top GOIs)
Sufficient positive clones 6
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Figure  5.3.  Outcome of shRNA library screening method D.  A,  Library bacterial  stocks  for 
each top 22 GOI (inclusive of PPARy) were streaked onto LB-agar + ampicillin (100^g/ml) 
plates to isolate bacterial clones. Bacteria were used directly as a PCR template with the pRS 
primers  to  identify  positive  clones  for  each  gene,  indicated  by  a  640bp  PCR  fragment 
(2.6.3.1); B, (i), An acceptable number of positive clones were identified for some genes; (ii) 
these were amplified via overnight culture in LB + ampicillin (100/zg/ml), then plasmids were 
isolated (2.4.2.6)  and confirmed as positive with EcoRUXhol  restriction digestion.  Plasmids 
were sequenced to recover each of the 3  shRNAs for that gene; (iii), Some genes yielded no 
positive  clones  in  the  PCR  screen.  The  constructs  for  these  genes  were  then  sub-cloned 
according to method III. L, lkb Plus DNA ladder; C, Outcome of method II.
204PCR screening method,  sufficient (5-10) positive clones were identified for 6 of the 22 
genes (Fig. 5.3C). For two genes,  1-4 positives were isolated, but this was deemed to be 
insufficient  to  recover  all  3  shRNAs  for that  gene.  Furthermore,  14  genes  yielded  no 
positive clones after PCR screening (Fig. 5.3B iii), again suggesting that during bacterial 
amplification  of  the  library  for  distribution,  shRNA-positive  clones  were  lost  by 
recombination, or alternatively that contamination with ampicillin-resistant bacteria was 
present. Thus, this method resulted in the isolation of shRNA inserts for 6 genes. These 
genes were, on the whole, those shown to have visible insert bands in method I. It was 
therefore likely that the shRNA inserts for other genes were present at such low levels that 
a further method was required to recover them.
5.2.3  shRNA isolation method III
Method  III  involved utilising a  PCR cloning strategy.  Bacterial  library stocks  for each 
gene  for which  no,  or few,  shRNAs  were  isolated  in  method  II,  were  used  as  a  PCR 
template (either directly from the frozen library stocks, or after overnight culture, 2.4.4.1) 
to amplify the region containing the shRNA  expression cassette (containing the shRNA 
insert and HI  promoter, 2.4.4.1, Fig. 5.IB). EcoRl/Xhol restriction digestion of the PCR 
fragment was used to  excise the  shRNA  expression cassette  and  these  fragments were 
subsequently ligated back into an empty retroviral vector containing the same restriction 
sites.  Following  sub-cloning,  method  II  was  repeated  to  screen  for  bacterial  clones 
containing  plasmids  in  which  the  shRNA  had  ligated,  in  order  to  recover  individual 
shRNAs (Fig. 5.4A). Initially, a version of pRetroSuper-Puro which contained no shRNA 
insert (Fig.  5.4D lanes  1   and 2) was used that had been isolated from the RNAi library. 
The  likely  absence  of an  endogenous  shRNA  in  this  vector precluded  inadvertent  re- 
ligation of endogenous shRNA rather than target shRNA.
As a result of isolation methods II and III, shRNAs were recovered for  19 out of the 22 
GOIs; for the remaining 3 genes, it was not possible to amplify the bacterial stocks (Table
5.2).  When  the  shRNA-positive plasmids  were  sequenced  (using  the pRS  Seq  primer, 
2.4.2.7) and BLAST searches were performed it was revealed that for 7 of the  19 genes, 
shRNAs targeting other non-candidate genes had been isolated; on occasion shRNAs for 2 
non-candidate genes were identified, making it unlikely that the wrong well had been
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shRNAs
B
Outcome of sub-cloning (method III) No. GOIs with this outcome (/16 
with few/no +ves from method II)
Could not amplify insert 3
Contaminating shRNAs isolated 5
shRNA for GOI isolated but mutated 1
shRNA for GOI isolated 7
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No. shRNAs isolated per gene
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Figure 5.4. Outcome of shRNA library screening method III. A, Library bacterial stocks were 
used directly as a PCR template to amplify mixed shRNA inserts. These were sub-cloned back 
into pRetroSuper-Puro (2.4.4.1) and individual shRNAs isolated as in method II; B, Outcome 
of shRNA  isolation  using  methods  II  and  III.  shRNAs  for  GOIs  were  isolated  via  PCR 
screening (method II), sub-cloning (method III), or both; C, Number of shRNAs recovered for 
each GOI;  D, The pRetroSuper-Puro vector backbone used for sub-cloning had recombined. 
Two preps of empty vector (lanes  1   and 2) plus representative shRNA plasmids  isolated by 
PCR screening (method II, lanes 3 and 7), or sub-cloning (method III, lanes 4-6) were digested 
with£coRI and^TioI restriction enzymes (2.4.2.1). L, lkb Plus DNA ladder.
206Gene Outcome of library method: Number of
name I
(Direct
isolation)
II
(PCR screening)
m
(Sub-cloning)
shRNAs 
cloned into 
pSilR-Hl
DACT1 NG No bacterial growth Could not amplify -
FAT R,NI No positives Cloned 2
HOXA7 LY Sufficient positives - 2
HOXB2 R, NI No positives Cloned 2
IRTKS R,NI No bacterial growth Could not amplify -
JMJ R, NI No positives Contamination -
LHFPL2 NR, I Sufficient positives - 3
MEOX2 NR, I Sufficient positives - 1
MESDC1 NG No bacterial growth Contamination -
SGK R,I Sufficient positives 
(contamination)
” “
SEX2 R, NI No positives Cloned 2
SNAI1 NG No bacterial growth Could not amplify -
SNAI2 R, NI No positives Cloned 1
SPRY2 NG No positives Contamination -
SSH1 NR, I No positives Cloned - mutation -
TBX2 NR, I Sufficient positives - 1
TCF8 R, NI No positives Cloned 3
TGFBR3 LY Few positives Contamination -
TGIF R, NI No positives Cloned 2
TOB1 NR, NI Sufficient positives 
(contamination)
" -
ZFPM2 R,NI Few positives Contamination -
PPARg - - Cloned 1
Table 5.2. Summary of the outcome of shRNA isolation strategies for the 22 GOIs from the 
shRNA  library.  NG,  No  growth;  R,  recombination;  NR,  no  recombination;  I  insert  band 
visible;  NI,  no  insert  band  visible;  LY  low  plasmid  yield.  Each  shRNA  was  cloned  into 
pSilencer HI-5.0 Retro.
207picked in the library glycerol stocks (Table 5.2). These contaminating genes were found to 
reside in wells adjacent to the GOI in the original library stocks, and it was likely shRNA 
levels for GOIs were so low in these cases that they may have been present at the same 
levels  as  contaminating  genes,  making  isolation  of  contaminating  shRNAs  likely. 
Furthermore, although a single shRNA for one GOI was isolated, it was found to contain a 
mutation rendering it non-functional (Table 5.2).  Thus,  as a combined result of shRNA 
recovery methods II and III, shRNAs for 11  out of the 22 GOIs (including PPARy) were 
isolated  (Fig.  5.4B,  5.3C, Table  5.2).  The number of shRNAs  isolated per gene varied 
from  1-3, with most genes represented by 2 shRNAs (Fig. 5.4C). It is likely that certain 
shRNAs  for  a  specific  gene  were  overrepresented  in  the  library  compared  with  other 
shRNAs for that gene, due to bacterial growth reducing the complexity of the shRNA pool 
(Downward 2004).  This would occur when bacteria  selectively amplify certain  shRNA 
inserts over others, possibly due a specific shRNA having a deleterious effect on bacterial 
growth or being more difficult to amplify,  eventually resulting in the loss of a specific 
shRNA from the bacterial pool. This could account for the isolation of all 3 shRNAs for 
only 2  genes.  Indeed,  although  sequencing was performed on  5-10 positive  clones per 
gene, in 4 cases these all represented a single shRNA sequence.
During this process, it was unfortunately found that the pRetroSuper-Puro backbone used 
for sub-cloning had recombined; restriction digestions of bacterial clones identified from 
PCR screens (method II) showed a normal 6kb backbone plus insert band (Fig. 5.4D, lanes 
3 and 7), whereas the vector stock plus shRNA plasmids isolated via sub-cloning (method 
III) revealed a backbone lacking around 2kb (Fig 3.4D, lanes  1, 2, 4-6).  In preliminary 
experiments it was indeed found that hMSCs transduced with shRNAs recovered using the 
PCR screening method (method II) could survive puromycin selection, whereas shRNAs 
that had been sub-cloned into the (recombined) pRetroSuper-Puro backbone did not confer 
puromycin resistance to hMSCs so were non-functional (data not shown). However, this 
work had resulted in the isolation of multiple constructs containing specific shRNAs that 
could be easily sub-cloned into further vectors.
pSuperRetro-GFP-Neo  (pSR-GFP/Neo,  OligoEngine)  was  chosen  for  sub-cloning  as  it 
contained  a  selection  cassette  resulting  in  a  NeoR -GFP  fusion  protein  (Fig.5.5A),  so
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Figure  5.5.  pSR-GFP/Neo  does  not  recombine,  and  may  not  produce  competent  virus.  A, 
Schematic  of pSuperRetro-Neo-GFP;  B,  EcoRUXhol  restriction  digest  (2.4.2.1)  of  empty 
pSR-GFP/Neo  isolated  after  bacterial  amplification  yielded  lkb  stuffer  band  and  ~7.3kb 
backbone of expected size, with no recombination products. L,  lkb Plus DNA ladder; C, pSR- 
GFP/Neo  does  not  produce  functional  virus.  The  293gp  viral  packaging  cell  line  was  co­
transfected with 2\i% control vector pMSCVPuro-WRPE-GFP (i) or empty pSR-GFP/Neo (ii) 
plus  2/tg  VSVG  helper plasmid  (2.5.1).  Viral  supernatants  were harvested  48h  after  media 
change, and used at a  1:2 dilution (supplemented with 4/xg/ml polybrene) to transduce hMSCs 
(2.5.5). This was repeated to increase transduction rates. Two days after the 2nd transduction, 
cells expressing GFP were visible in control vector-transduced cells (iii), but pSR-GFP/Neo 
transduction produced no visible GFP +ve cells (iv). Neomycin (500jig/ml) selection of pSR- 
GFP/Neo-transduced hMSCs was carried  out  for 5d (2.5.5).  pSR-GFP/Neo-transduced cells 
did  not  survive  selection  (v).  Scale  bars  represent  200/tm.  ND,  not  determined.
pSR-GFP/Neo 
8371 bp  stuffer
H1 Promoter
.3' dLTR
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209neomycin  selection  as  well  as  GFP  expression  could  be  used  to  identify  shRNA- 
expressing cells. Importantly, it also contained iscoRI and Xhol restriction sites allowing 
straightforward  sub-cloning  from  the  library  vector.  The  pSR-GFP/Neo  backbone  was 
stable  as  no  evidence  of recombination was  observed  after bacterial  amplification  and 
subsequent purification of the vector;  bands of the correct  size (representing the  intact 
backbone  and excised stuffer fragment) were obtained after EcoRVXhol digestion (Fig. 
5.5B).  As  confirmation of it’s  ability to produce virus  and  confer GFP  expression and 
neomycin resistance in hMSCs was a time-consuming process, sub-cloning of the shRNA 
inserts  from  pRetroSuper-Puro  to  pSR-GFP/Neo  was  performed  simultaneously  with 
vector validation (2.4.4.2). Unexpectedly, validation of the virus production capability of 
the  vector showed  that  although  GFP  expression  was observed  in 293gps  (a  retroviral 
packaging cell line) transfected (2.5.1) with empty pSR-GFP/Neo (Fig.5.5C, ii), no GFP 
expression was observed in hMSCs transduced (2.5.3) with viral supernatant from these 
cells (Fig.  5.5C,  iv).  A high proportion of both 293gps transfected with a control  GFP 
construct  (pMSCV-Puro-eGFP-WPRE,  Fig.  2.1),  and  hMSCs  transduced  with  this 
construct,  expressed GFP (Fig.  5.5B,  i  and  iii),  demonstrating that the transfection and 
transduction  methodologies  had  been  successful.  Neomycin  selection  (2.5.5)  of pSR- 
GFP/Neo-transduced  cells  resulted  in  100%  cell  death,  strongly  suggesting  that  pSR- 
GFP/Neo was not capable of producing functional virus (Fig. 5.5C, v). Other laboratories 
had  indeed  reported  similar  observations  to  the  company  producing  this  vector 
(OligoEngine, personal communication). Therefore, pSR-GFP/Neo could not be used for 
the shRNA screening experiment.
Due to the above problem a third vector was selected. pSilencer HI-5.0 Retro (pSilR-Hl) 
is analogous to the RNAi library vector, as it contains a puromycin resistance cassette, and 
the  presence  of EcoRI  and Xhol  sites  again  allowed  for  use  of a  simple  sub-cloning 
protocol (Fig. 5.6A). No evidence of recombination was observed within this vector upon 
bacterial  amplification  (Fig.  5.6B,  lane  i).  Before  sub-cloning  shRNA  inserts  into  this 
vector, its functionality was confirmed. MSCs were transduced with virus produced from 
pSilR-Hl  or  the  pMSCV-Puro-eGFP-WPRE  control  vector  and  puromycin  selection
(2.5.5)  killed the majority of untransduced cells (Fig. 5.6B, i). A stable population could 
be expanded  from  the  surviving pSilR-Hl-transduced cells (Fig. 5.6B, ii), indicating that
210pSilR-H1 -shRNA constructs
Amp
5' LTR
pSilencer 5.1-H1  Retro
CoE1 6253bp
\ Origin pSilR-H1-shRNA 
constructs
shRNA in se r tk /Xh° l I2156) 
H1 Promoter*^/" Hindlll (2177) 
Pol II Prorrwtej^vA  BamHI (2239) 
Puro  ^ .K ^ E c o R I (2338)
B
■   i  ii
-6 k b
-320bp
-  6kb
-320bp
Figure  5.6.  pSilR-Hl  does  not  recombine  and  produces  functional  virus.  A,  Schematic  of 
pSilR-Hl;  B,  pSilR-Hl  produces  functional  virus.  hMSCs  were  transduced  with  viral 
supernatant produced from 293gps co-transfected with 2^tg pMSCVPuro-WRPE-GFP control 
vector (i) or 2/tg pSilR-Hl  (ii) plus 2/zg VSVG helper plasmid (2.5.1 and 2.5.3). Transduction 
was  performed  in  duplicate,  and  2d  after  the  2nd  transduction,  selection  with  puromycin 
(750ng/ml) was initiated (2.5.5).  Selection killed the majority of non-transduced cells after 4
•  I
days, as assessed by GFP expression in control  vector-transduced cells (i), and resulted in a 
surviving population of pSilR-Hl-transduced cells (ii). Scale bars represent 200/zm; C, pSilR- 
H1 does not recombine. EcoRUXhol restriction digest (2.4.2.1) of empty vector after bacterial 
amplification (lane i; lane ii = uncut vector). All other lanes: EcoRl/Xhol restriction digest of 
pSilR-Hl  containing all GOI shRNAs. Correct backbone and insert bands are present. L,  lkb 
Plus DNA ladder.
211this  vector  produced  functional  virus  and  puromycin  selection  could  be  employed  to 
recover  stably  transduced  populations.  Sub-cloning  was  completed  (2.4.4.2)  and  no 
recombination was observed in any of the 20 shRNA-containing plasmids (Fig. 5.6C). The 
shRNA inserts were sequenced as before to ensure that no mutations had occurred during 
sub-cloning.  Table  5.2  summarises  the  final  number of shRNAs  that  were  cloned  into 
pSilR-Hl, and the methods that were used to recover them (see also Table 2.4 for shRNA 
sequences). Thus,  shRNAs for candidate regulators of adipogenesis were isolated and a 
method for their delivery and stable expression in hMSCs was developed.
5.3  shRNA retroviral screens and the effect on candidate gene expression 
and hMSC adipogenesis
5.3.1  shRNA screen using pooled shRNAs for each candidate gene
The simultaneous use of several different siRNAs targeting a single gene has been shown 
to increase the level of knock-down of expression of that gene (Zou and Yoder 2005). 
This could be because not all siRNA sequences are guaranteed to produce a knock-down 
(1.7.3.2),  and  it  could  be  hypothesised  that  different  siRNAs  may  act  in  synergy  to 
produce a higher knock-down than if used separately. As more than one shRNA had been 
isolated for 7 out of the  11  GOIs (Fig. 5.4C), this technique was initially adopted for the 
loss-of-function screen in order to maximise any knock-down effects.
The viral packaging cell line 293gp was transfected with either pooled shRNAs (1:1 ratios 
of each shRNA) for those genes with more than one shRNA, or with single shRNAs, plus 
VSVG helper plasmid (2.5.1). The PPARy shRNA was included in these experiments so 
that, if this shRNA was functional (which was not guaranteed), it could act as a positive 
control to demonstrate the functional consequences of silencing an adipogenic regulator 
on the ability of hMSC to differentiate to adipocytes. Additionally, a scrambled hairpin 
(Scr)  with  no  significant  sequence  homology to  any human  gene  (Ambion  2005)  was 
included  as  a  control  to  assess  non-specific  effects  of hairpin  introduction.  The  viral 
supernatant produced was filtered, diluted  1:2 with fresh media and applied to passage 5 
hMSCs at 30-50% confluence with 4/xg/ml polybrene (2.5.3). This process was repeated to
212increase the percentage of transduced cells; retroviruses can only transduce dividing cells 
as they do not contain a nuclear localisation signal that allows them to pass through the 
nuclear membrane,  so they can only access the genome when the nuclear membrane is 
absent during cell division. A GFP-expressing control virus (pMSCV-Puro-eGFP-WPRE) 
was also transduced into hMSCs as a control to monitor the success of each experimental 
stage,  as  it  was  assumed  that  transfection,  transduction  and  drug  selection  efficiencies 
would be comparable between this control vector and all other vectors. After selection of 
transduced cells with puromycin for 3-4d (2.5.5),  FACS  analysis of hMSCs transduced 
with  the  GFP-expressing  control  virus  (2.3.2)  revealed  a  shift  in  the  mean  population 
fluorescence  after drug  selection (Fig.  5.7A),  which  indicated that puromycin  selection 
had killed the majority of untransduced cells. Furthermore, although a proportion of cells 
expressed a high level of GFP, most transduced cells were expressing GFP at a low level. 
Cells were grown to confluence and then induced to differentiate into adipocytes using the 
classic induction regimen (2.2.2.1). RNA was also extracted at confluence (2.6.1) for use 
in RT-PCRs to assess knock-down effect,  as  it had been confirmed that all  GOIs were 
expressed to some extent in undifferentiated hMSCs (Fig. 5.8A).
Differentiation was continued for 14 days then cells were fixed and stained with Oil Red 
O (2.2.3.1) to assess the extent of adipocyte formation (Fig.  5.7B  and C).  The average 
number of adipocytes per field of view ranged  from 27-42  for cells transduced with a 
shRNA-containing vector (Fig. 5.7B). Non-transduced hMSCs yielded an average of 106 
adipocytes  per  field  of  view,  significantly  more  than  cells  containing  the  scrambled 
hairpin  (p<0.001,  using  a  two-sample  Student’s  t-test),  suggesting  a possible  effect  of 
hairpin  introduction  or  viral  transduction  on  differentiation.  However,  there  were  no 
statistically significant differences in the extent of differentiation between the scrambled 
hairpin and any of the shRNAs targeting candidate genes (p>0.05). It was next determined 
whether any of the shRNAs had reduced the expression of their target genes at the mRNA 
level. cDNA was synthesised (2.6.2)  from the RNA collected from confluent cells,  and 
RT-PCR  analysis  using  gene-specific  primers  (2.6.3.2,  and  Table  2.3  for  primer 
sequences) revealed that for each GOI-shRNA, expression was similar to that in hMSCs 
transduced  with  the  scrambled  hairpin,  but  this  was  less  that  it’s  expression  in 
untransduced  hMSCs  (Fig. 5.8B).  Expression  of GAPDH,  a  housekeeping  gene  that
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Figure 5.7. Continued overleaf.
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215Fig 5.7. Effect on adipogenesis of transduction with shRNA (pools) targeting candidate genes. 
hMSCs  underwent  2  rounds  of  transduction  (2.5.3)  with  viral  particles  produced  from 
transfection of 293gps with pooled shRNAs for each GOI (where more than one shRNA had 
been isolated), plus scrambled shRNA and PPARy control (2.5.1).  Cells were treated with 
puromycin (750ng/ml for 4 days) to select for stably transduced cells (2.5.5), then grown to 
confluence and induced to differentiate (2.2.2.1);  A,  FACS  analysis  of hMSCs  transduced 
with virus produced from pMSCVPuro-GFP-WRPE (2.3.2). Shown is the number of GFP+ 
events in un-transduced hMSCs, hMSCs transduced with the GFP virus prior to puromycin 
selection, and hMSCs transduced with the GFP virus, after puromycin selection. Upper graphs 
represent the distribution of events (green dots) on the FL1  (green) versus FL2 (red) filters, 
and the gate (R4) used to separate GFP- from GFP+ events. Lower histograms (purple-filled) 
represent  the  number  of GFP+  events  at  different  fluorescent  intensities.  The  bar  chart 
represents  the  mean  population  fluorescence  in  each  condition;  B  and  C,  At  day  14  of 
differentiation,  cells  were  fixed  and  stained  with  Oil  Red  O  (2.2.3.1).  Experiments  were 
performed in duplicate; B, Quantification of the effect on differentiation of shRNA expression 
in each condition. Data represent number of adipocytes per field of view and are mean ± SD. 
Four  fields  of view  were  counted  per  condition.  *,  p<0.001  using  a  two-sample  t-test 
(assuming equal variance). T-tests were performed by comparing the mean of the Scrambled 
control sample to all other means; C, representative image showing extent of differentiation 
for each shRNA pool, or individual shRNA. Scale bars represent 200/mi.
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Fig 5.8. Effect of (pooled) shRNA screen on candidate gene expression in hMSCs. RNA was 
extracted  from confluent hMSCs  stably expressing shRNA(s)  for each GOI (2.6.1).  cDNA 
was synthesised (2.6.2) and used as a PCR template with gene-specific primers to investigate 
gene  expression  levels  (2.6.3.2);  A,  the  timepoint  at  which  gene  expression  knock-downs 
should be investigated was determined by confirming that confluent hMSCs (Oh) expressed 
each GOI to some degree. Additional timepoints during differentiation (lh or 3h, as indicated) 
were  investigated  for  some  genes.  SIX2  and  PPARy  expression  in  confluent  hMSCs  had 
already  been  confirmed  (Fig.  4.3);  B,  the  expression  of  each  GOI  was  compared  in  3 
conditions: hMSCs expressing shRNA targeting the GOI (shRNA), scrambled hairpin (Scr) or 
untransduced hMSCs (MSC);  C,  The expression of each GOI  in PPARy-shRNA cells was 
assessed  as  an  additional  control  to  examine  whether the  reduced GOI  expression  in  Scr- 
shRNA cells was due to a transcriptional response specifically to the Scr 19nt sequence; D, 
GAPDH internal control and no reverse transcription controls (using adipsin primers) for each 
condition. PCR cycle numbers: GAPDH: 25; all other genes: 28.
217served as an internal control to ensure equal amounts of cDNA had been used, was equal 
in each condition (Fig. 5.8D).  PPARy expression however was lower in PPARy-shRNA 
transduced cells that in Scr-shRNA transduced cells (Fig. 5.8B).
It  was  possible  that  the  reduction  in  GOI  expression  in  hMSCs  transduced  with  Scr- 
shRNA  was  due  to  sequence-specific,  off-target  effects  of  the  scrambled  shRNA 
sequence, meaning that even partial similarities (possibly as few as 11 bases) in sequence 
between the scrambled shRNA and the GOI mRNA could result in silencing of the GOI 
by the Scr-shRNA. This is a phenomenon that has previously been documented (Jackson 
et al 2003).  Alternatively,  the  introduction  of any  shRNA  sequence  into  hMSCs  may 
induce a general reduction  in gene  expression (that is not dependent on  sequence).  To 
address  this  issue,  the  expression  of  each  GOI  was  additionally  assessed  in  cells 
transduced  with  PPARy-shRNA.  It  was  observed  that,  in  many  cases,  target  gene 
expression was similar in hMSCs transduced with PPARy-shRNA, the shRNA targeting 
that  gene,  and  Scr-shRNA  (Fig.  5.8C).  Expression  in  untransduced  hMSCs  was  again 
often higher than in any of these three cell types. Therefore, the scrambled hairpin was not 
inducing  sequence-specific  off-target  effects,  as  the  same  reduction  in  target  gene 
expression  was  seen  in  cells  containing  the  PPARy-shRNA  (i.e.  a  different  shRNA 
sequence).  Instead,  it  is possible  that  a more  general  response to  viral  transduction  or 
hairpin introduction was occurring in all transduced cells.
5.3.2 shRNA screen using individual shRNAs for each candidate gene 
Although it has been reported that pooled shRNAs targeted against a specific gene may 
result  in  a more  efficient  expression  knock-down,  this  effect  was  not  observed  in  the 
previous  experiments.  It  was  therefore  possible  that  the  presence  of  non-functional 
shRNAs  in  the pools  may  have  dampened  the  knock-down  effect  of other,  functional 
shRNAs that were also present.  Hence,  a further screen was  implemented to  assess the 
effect of individual shRNAs for those genes where shRNAs had previously been pooled.
The  experimental  set-up  was  performed  as before.  An  additional  empty  vector control 
(pMSCV-Puro, Fig. 2.1) was included to assess the effect of the transduction process on 
hMSC  differentiation.  Double  transduction  of  passage  6  hMSCs  followed  by  drug
218selection yielded a high level of stably transduced cells, as assessed by FACS analysis of 
cell  transduced  simultaneously with  the pMSCV-Puro-eGFP-WPRE  control  virus  (Fig. 
5.9A). MSCs were then grown to confluence and induced to differentiate. After 13 days of 
differentiation,  adipogenesis  was  quantified.  It  was  found  that  the  average  number  of 
adipocytes per field of view ranged from 40-73 in hMSCs expressing GOI-shRNAs (Fig. 
5.9B). However, TBX2-X showed a significantly lower average number of adipocytes per 
field  of view  (mean  average:  30,  p<0.01  compared  to  scrambled  control,  or  p<0.05 
compared to empty vector control); these adipocytes also contained less lipid droplets than 
in other conditions (Fig. 5.9C). LHFPL2-X, LHFPL2-Y and TGIF-X shRNA expression 
resulted  in  significantly  less  adipocyte  formation  than  in  Scr-shRNA-transduced  cells 
(p<0.05); however, this result was not statistically significant if the empty vector control 
was  used  for comparison (p>0.05).  Scr-shRNA  cells  showed  75,  empty  vector 60  and 
untransduced  hMSCs  76  adipocytes  per  field  of view,  on  average  (Fig.  5.9B  and  C); 
although these differences were not statistically significant this indicates that there is some 
experimental variation between control samples, which means that statistical significance 
should be interpreted with caution. As the reduction in adipocyte formation with TBX2-X 
was significant when compared to both controls, this result is considered reliable.  In the 
majority of cases, the extent of differentiation did not differ significantly between control 
samples and cells transduced with GOI-shRNAs.
RT-PCR analysis was again used to investigate whether any reduction in gene expression 
had occurred (Fig.  5.10). The expression of each GOI was assessed in cells transduced 
with  each  shRNA  targeting  that  GOI,  plus  Scr-shRNA,  empty  vector-transduced  and 
untransduced cells. No large differences in expression of any GOI were seen between any 
of  these  conditions,  including  TBX2-X  or  LHFPL2-X  which  had  shown  lower 
differentiation.  In these experiments, higher gene expression levels were not detected in 
untransduced hMSCs. These observations suggest that, as in the pooled shRNA screen, no 
knock-down of gene expression was observed with any of the shRNAs targeting GOIs, 
which could explain the observation of no reduction in adipogenesis  in the majority of 
cases.
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221Fig 5.9. Effect on adipogenesis of individual shRNAs targeting candidate genes. hMSCs were 
transduced  with  viral  particles  (2.5.3)  produced  from  transfection  of  293gps  with  each 
shRNA, plus PPARy, scrambled shRNA and an equivalent empty vector control (2.5.1) Cells 
were  treated  with  puromycin  (750ng/ml  for 4  days)  to  select  for  stably  transduced  cells
(2.5.5), then grown to confluence and induced to differentiate (2.2.2.1); A, FACS analysis of 
hMSCs transduced with virus produced from pMSCVPuro-WRPE-GFP (2.3.2). Shown is the 
number of GFP+ events in un-transduced hMSCs, hMSCs transduced with the GFP virus prior 
to puromycin selection, and hMSCs transduced with the GFP virus, after puromycin selection. 
Upper graphs represent the distribution of events (green dots) on the FL1  (green) versus FL2 
(red) filters, and the gate (R4) used to separate GFP- from GFP+ events. Lower histograms 
(purple-filled) represent the number of GFP+ events at different fluorescent intensities. The 
bar  chart  represents  the  percentage  of GFP+  cells  in  each  condition,  corrected  for  the 
untransduced control; B and C, at day 13 of differentiation, cells were fixed and stained with 
Oil Red O (2.2.3.1). Experiments were performed in duplicate; B, Quantification of the effect 
on differentiation of shRNA expression. Data represent number of adipocytes per field of view 
and are mean ±  SD.  Three  fields  of view were counted per condition.  *,  p<0.05  and  **, 
p<0.01, using a two-sample t-test (assuming equal variance) when the mean value for each 
condition was  compared with the Scrambled control;  o,  p>0.05  (not significant) when the 
mean value for each condition was compared with the empty vector control; C, representative 
image  showing  extent  of differentiation  for  each  shRNA.  Scale  bars  represent  250/im.
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Fig 5.10. Effect of individual shRNA expression on candidate gene mRNA levels. RNA was 
extracted (2.6.1) from confluent hMSCs stably expressing shRNA for each GOI. cDNA was 
synthesised  (2.6.2)  and  used as  a PCR  template  with gene-specific primers  (2.6.3.2).  The 
expression  of each  GOI  was  compared  in  4  conditions:  hMSCs  expressing  each  shRNA 
targeting the GOI (X, Y, or Z), scrambled hairpin (Scr), empty pMSCV-Puro vector (EV) or 
untransduced hMSCs (MSC). GAPDH and no reverse transcription controls (using adipsin 
primers) for each condition. PCR cycle numbers: GAPDH: 25; TBX2, MEOX2, SIX2: 35; all 
other genes: 30.
2235.4  Development and  optimisation  of a technique for lentiviral  delivery 
of custom-designed shRNAs
Due to the problems associated with the previous strategy, a second shRNA strategy was 
designed  to  maximise  the  chance  of  observing  a  knock-down  of  gene  expression. 
Lentiviruses are capable of transducing non-dividing as well as dividing cells due to the 
presence of a nuclear localisation signal that facilitates their transport through the nuclear 
membrane  of  non-dividing  cells.  The  use  of  lentiviruses  would  therefore  increase 
transduction  rates.  Furthermore,  this  strategy,  where  possible,  used  shRNA  sequences 
obtained from published research, which were therefore more likely to silence target gene 
expression. The aim of this experimental section was therefore to develop and optimise 
the use of lentiviral vectors and custom-designed shRNAs for investigating candidate gene 
function during adipogenesis.
5.4.1  shRNA design and lentiviral cloning strategy
This  strategy was  implemented  for the  top  GOIs,  namely  DACT1,  SNAI1,  SIX2,  and 
TCF8.  It was not possible to recover shRNAs  for DACT1  and  SNAI1  from the RNAi 
library  (Table  5.2),  so  these  genes  would  be  investigated  for the  first  time  using  this 
strategy. SIX2 and TCF8 shRNAs had produced no expression knock-down in either the 
pooled or individual shRNA screens (sections 5.3.1 and 5.3.2), so this strategy provided a 
further opportunity to  investigate  their function.  DACT1  (Yau  et al 2005)  and  SNAI1 
(Kajita et al 2004)  shRNA  sequences were obtained  from published work  so  only one 
shRNA construct was required  for each of these genes.  Literature searches revealed no 
published 19nt shRNAs for SIX2 or TCF8. Although shRNA design software is becoming 
more advanced, it still does not guarantee that a single shRNA will silence a target gene. 
Therefore,  to  maximise  the  chance  of obtaining  a  knock-down,  software  produced  by 
OligoEngine (available  at www.oligoengine.com) was used to design two  19nt shRNA 
sequences for both SIX2 and TCF8 (named SIX2/TCF8-a and -b, Table 2.4).
DNA oligonucleotides  were designed  (and purchased  from  OligoEngine),  such that the 
sense  and  antisense  19nt  sequence  for  each  shRNA  were  separated  by  a  hairpin  loop 
sequence  (Fig 5.11). BgRl  and  Hindlll  restriction  site sequences were included at the 5*
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Figure  5.11.  Design of lentiviral  shRNA strategy.  shRNA  sequences  for the top GOIs were 
either obtained  from published work or designed using OligoEngine RNAi design software. 
The shRNA oligonucleotides were designed such that BglII (which produces compatible ends 
with BamWl  digests)  and  Hindlll  sites  could  be  used  to  clone  the  shRNA  oligonucleotide 
downstream of the HI  promoter in pSilR-Hl  (step  1).  Additionally, an extra EcoKl site was 
added to the oligonucleotide downstream of the shRNA so that EcoRI restriction digestion of I
the resulting pSilR-Hl-shRNA plasmid would excise a fragment containing the HI  promoter 
and the shRNA (step 2). This fragment could then be ligated into the EcoRI site of CSGW.
225and  3'  oligonucleotide  ends,  respectively  (2.4.5.1).  The  pairs  of  complementary 
oligonucleotides were annealed (2.4.5.2), and due to the restrictions sites at the 5' and 3f 
ends the resulting dsDNA fragment could be cloned directly into pSilR-Hl downstream of 
the HI  promoter (Step  1, Fig. 5.11, 2.4.5.3).  Importantly, an additional EcoRI sequence 
was  incorporated  into  each  oligonucleotide  downstream  of the  shRNA.  Thus,  iscoRI 
digestion of pSilR-Hl  containing the annealed oligonucleotide resulted in excision of the 
HI promoter and shRNA insert (due to the presence of another EcoRI site upstream of the 
HI  promoter,  Fig.  5.6),  which was  subsequently ligated  into  the EcoRI  site of CSGW
(2.4.5.4).  CSGW is  a  lentiviral  vector containing the eGFP  gene  as  a selection marker 
(Clements et al 2006,  see  Fig.  5.11  for vector map,  Fig 2.2  for explanation of CSGW 
function). The published DACT1  shRNA sequence used contained an EcoRI site (Table 
2.4), so this oligonucleotide was not cloned into CSGW, and the adipogenic screen for this 
gene was performed using the pSilR-Hl construct as described in section 5.3.
5.4.2  Optimisation of lentiviral infection technique
Competent viral particles are produced from CSGW by co-transfection of the 293T cell 
line with this vector and three other packaging plasmids,  pLPl, pLP2  and  pLP/VSVG 
(Fig.  2.2).  These  vectors  cumulatively  contribute  all  the  proteins  required  to  produce 
competent viral particles, but their presence on 3 separate plasmids reduces the probability 
of recombination  producing  an  active,  replication-competent  virus.  Furthermore,  293T 
cells allow production of large amounts of viral particles. Accordingly, viral supernatant 
for each construct shRNA-CSGW was produced (2.5.2). Additionally, virus was produced 
from  empty  CSGW,  plus  CSGW  containing  a  shRNA  targeting  the  v-cyclin  gene  of 
KSHV, under the control of the U6 promoter,  for use as a control for off-target hairpin 
effects. Viral supernatant was filtered, aliquoted and stored at -80°C.
Initially, the minimum amount of virus that could transduce the maximum number of cells 
was determined. A high (-80% or more) transduction rate renders further selection steps 
unnecessary, and transduced cells can be identified through GFP expression. Furthermore, 
it is preferable to use the minimum viral  titre necessary to  avoid cytotoxic  effects.  To 
optimise cell transduction, the CSGW constructs were first titrated. Thus, 5xl04 hMSCs 
per condition were transduced in suspension with serial dilutions of virus produced from
226each CSGW construct (2.5.4),  and after 48h the proportion of GFP+ cells was analysed 
using FACS (Fig 5.12).  Initially, a control hairpin targeting the KSHV LANA gene was 
employed, but was found be of insufficient quality for use, so the later adoption of the v- 
cyc-shRNA precluded it’s addition in these analyses.  Representative data for the empty 
CSGW  construct  are  shown,  and  indicate  that  the  lowest  dilution  assessed  (1:2),  was 
required to  give  the  maximum  transduction  rate;  higher dilutions  resulted  in  less  cells 
expressing GFP (Fig. 5.12). Thus, a saturation stage, where excess virus was being used, 
had not been reached in this dilution series.
When  the  transduction  rate  at  this  dilution  was  compared,  it  was  found  that  CSGW 
transduction resulted  in more than  80%  of cells  expressing GFP,  whereas the  shRNA- 
CSGW constructs yielded a 25-57% transduction rate (Fig. 5.13A). This suggests that the 
presence of a hairpin may decrease the efficiency of virus production or transduction of 
target cells. The viral copy number per cell was next determined using Q-PCR. Genomic 
DNA was extracted (2.5.6)  from hMSCs transduced as described with a  1:2 dilution of 
viral supernatant from each of the constructs. Primers detecting the viral packaging signal 
(vj/) in CSGW, plus GAPDH to assess the number of cells present in the sample, were used 
to calculate the average number of copies of virus present in each cell (2.5.6). It was found 
that empty CSGW transduction led to  an average of 12.2  copies per cell,  whereas  this 
number ranged  from 2.8-6.1  for shRNA-CSGW constructs (Fig.  5.13B).  The pattern of 
viral copy number per cell was comparable to the pattern of number of GFP+ cells for each 
construct (Fig 5.13A and B). It could be expected that a higher average viral copy number 
per  cell  would  correspond  to  a  higher  number  of  GFP+  cells,  thus  indicating  the 
correspondence  between  these  observations  for  each  construct.  This  finding  again 
highlighted the fact that the presence of shRNA hairpins either yields a lower viral titre 
after 293T transfection, or that viral particles containing shRNA hairpins are less able to 
transduce target cells. Furthermore, it was noted that GFP expression appeared stronger in 
empty CSGW-transduced cells than in those transduced with shRNA-CSGW (Fig. 5.13C). 
A number of possibilities could explain this observation, including that the presence of a 
shRNA may have affected the level of gene expression from the lentivirus, or may have 
had a wider effect on gene expression. Due to the significant differences in transduction 
rates  between  empty  and  hairpin-containing  CSGW,  it  was  decided  to  use  neat viral
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Figure 5.12. Titration of the hMSC transduction rate for each lentiviral construct. 293T cells 
were transfected with lentiviral construct for each gene plus packaging plasmids (2.5.2). After 
60h the viral  supernatant was  harvested,  filtered  and  added  to hMSCs at different dilutions
(2.5.4); A, FACS analysis (2.3.2) of GFP expression after hMSC transduction with decreasing 
dilutions of CSGW (empty lentiviral vector, shown as a representative titration). The pattern 
of transduction rate at different dilutions  is representative of all  other constructs,  but  actual 
numbers vary (see Fig. 5.13A).
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Figure  5.13.  Quantification  of  optimal  hMSC  transduction  rate  for  each  construct  and 
resulting viral  copy number per cell;  A,  hMSC  transduction  rate  for each construct.  FACS 
analysis  (2.3.2)  for GFP  expression  was  performed  48h  after  hMSC  transduction  with  1:2 
dilutions  of viral  supernatant  produced  from  293T  transfection  with  each  viral  construct. 
CSGW:  empty  lentiviral  vector;  B,  Viral  copy  number per cell  for each  shRNA.  Genomic 
DNA was  extracted  from hMSCs  transduced with each  lentiviral  construct  and  quantitative 
PCR with primers targeting the viral packaging signal (vj/) was used to quantify the number of 
integrated virus per cell (2.5.6).  Data represent number of viral copies per cell and are mean 
±S.D.  This  was performed  in collaboration  with  R.  Vart;  C,  FACS  histogram plots  of GFP 
fluorescence  after  hMSC  transduction  with  1:2  dilutions  of viral  supernatant.  Purple  filled 
histograms indicate GFP  fluorescence produced by the lentiviral construct indicated, and the 
green line indicates GFP fluorescence in hMSCs transduced with empty CSGW.
230supernatant for shRNA-CSGW transduction,  whereas the  1:2  dilution of empty CSGW 
viral supernatant would be maintained, in an attempt to normalise the transduction rate for 
each construct during the lentiviral screen.
5.5  Investigation  of the  role  of  candidate  genes  in  adipogenesis  using 
lentiviral shRNA delivery
Having  produced  lentiviral  constructs  containing  shRNAs  targeting  top  adipogenic 
candidates  and  optimised  the  conditions  for  lentiviral  transduction  of  hMSCs,  an 
adipogenic screen was next performed to assess whether these shRNAs were capable of 
reducing target gene expression, and whether this had an effect on adipogenesis.
According to the optimisation  described  above,  5xl04 passage  6  hMSCs per condition 
were  transduced  in  suspension  with  undiluted  viral  supernatant  for  shRNA-CSGW 
constructs,  and  a  1:2  dilution  of  empty  CSGW  viral  supernatant  was  used.  Viral 
supernatant  from  the  v-cyc-shRNA  construct  was used  neat;  although  the  transduction 
efficiency or viral copy number had not been determined for this construct, it was deemed 
probable that the presence of a hairpin would cause the same reduction in transduction 
efficiency that was observed for the other hairpin constructs. After 60h, GFP expression in 
transduced hMSCs was  determined.  Cells were  also  expanded  for 3  passages  to  assess 
whether GFP expression was maintained over this time. Figure 5.14A shows that for most 
constructs, near  100% of cells were transduced under these conditions,  and the level of 
GFP expression was maintained after expansion. These results suggest that the use of neat 
viral  supernatant  had  had  the  desired  effect  of increasing  transduction  efficiency  for 
shRNA-CSGW constructs. Furthermore, there was no need for further selection of stably 
transduced cells, as GFP expression showed that the majority of cells would be expressing 
the  shRNA.  With  the  shRNA  construct  SIX2-b,  a  slight  reduction  in  GFP+  cells  was 
observed after expansion, from 97.1  to 88.5%, possibly indicating a growth disadvantage 
conferred by this shRNA (if it also had an effect on target gene expression). However, this 
rate of transduction was deemed sufficiently high for use in the differentiation screen.
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Figure 5.14. Transduction rate and extent of differentiation during lentiviral shRNA screen of 
top GOIs; A, hMSCs were transduced with neat viral supernatant (apart from empty vector -  
1:2  dilution)  in  order  to  maximise  transduction  rates  (2.5.4).  Cells  were  analysed  for GFP 
expression  using  FACS  analysis  (2.3.2)  48h  after  transduction  (blue  bars),  and  after  3 
passages  (purple bars),  in order to  assess whether a  growth  disadvantage  was  conferred  on 
transduced  cells.  CSGW:  empty  lentiviral  vector;  v-cyc:  CSGW  containing  shRNA  hairpin 
targeting v-cyclin gene of KSHV; MSC: untransduced hMSCs. ND, not determined; B, extent 
of differentiation  in  cells  transduced  with  each  construct.  Transduced  cells  were  grown  to 
confluence then induced to differentiate to adipocytes (2.2.2.1).  At day  14 of differentiation, 
cells were fixed and stained with Oil Red O (2.2.3.1), and the number of adipocytes per field 
of view was counted for 4 fields of view per condition. Data represent number of adipocytes 
per field of view and are mean ± SD. Experiments were performed in duplicate. Two-sample 
t-tests (assuming equal variance) identified no significant differences (p>0.05) when the mean 
of each condition was compared to the v-cyc shRNA control; C, representative field of view 
for each condition. Scale bars represent 200/tm.
233Transduced  hMSCs  were  therefore passaged  once  at  a ratio  of 1:3  and  then  grown  to 
confluence in triplicate wells for each condition. RNA was extracted from one well for use 
in  RT-PCR,  and  the  remaining  confluent  cells  were  induced  to  differentiate  using  the 
adipogenic  induction  cocktail.  Differentiation was  carried out  for  14  days,  after which 
time the cells were fixed and stained with Oil Red O, and differentiation was quantified 
(Fig 5.14B). The average number of adipocytes per field of view ranged from 40-62; the 
highest number was observed in untransduced hMSCs (average: 62), but this was similar 
to the number observed  in cells  expressing the  SIX2-a  shRNA  (average:  58).  The two 
shRNAs  targeting  TCF8  showed  the  lowest  extent  of differentiation,  but  this  was  not 
significantly  different  from  the  rate  of  differentiation  observed  in  v-cyc-shRNA 
transduced  cells  (p>0.05,  two-sample  Student’s  t-test),  which was  considered the  most 
appropriate control  in this experiment as the viral copy number per cell is  likely to be 
similar in all cells containing shRNAs. No visible differences in adipocyte shape or size 
were  observed  between  any  of the  conditions  (Fig  5.14C).  These  results  suggest  that 
shRNA expression did not affect the process of adipogenesis.
As  with  previous  retroviral  screens,  it  was  crucial  to  next  determine  whether  any 
expression knock-downs had been produced by shRNA  introduction.  Therefore,  cDNA 
was synthesised from RNA extracted from transduced hMSCs, and was used as a PCR 
template using gene-specific primers. The expression of each gene was determined in cells 
transduced  with  each  shRNA  targeting  that  GOI,  plus  v-cyc-shRNA,  empty  vector- 
transduced  and  untransduced  cells  (Fig.  5.15).  As  with  the  pooled  shRNA  retroviral 
screen,  expression of each  GOI  seemed  slightly higher in untransduced hMSCs,  and  a 
drop  in  expression  was  seen  after  transduction  even  with  empty  virus.  However,  no 
significant difference was  seen in the  extent of adipogenesis between these  conditions, 
meaning that the process of differentiation was unaffected by the process of transduction. 
Interestingly, a consistent observation was the lower expression of SIX2 and TCF8 in cells 
transduced with SIX2 b-shRNA and TCF8 a-shRNA, respectively (Fig. 5.15). This could 
indicate that the SIX2-b and TCF8-a shRNAs had induced some extent of transcriptional 
silencing of their respective target genes. However, there was no significant increase or 
decrease in adipogenesis with these shRNAs.
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Figure 5.15. Effect of lentiviral-mediated shRNA expression on candidate gene mRNA levels. 
RNA was extracted (2.6.1) from confluent hMSCs expressing shRNA(s) for each GOI. cDNA 
was synthesised (2.6.2) and used as a PCR template with gene-specific primers (2.6.3.2). The 
expression  of each  GOI  was  compared  in  4  conditions:  hMSCs  expressing  each  shRNA 
targeting  the  GOI  (shRNA),  shRNA  hairpin  targeting  KSHV  viral  cyclin  (v-cyc),  empty 
CSGW  vector  (CSGW)  or  untransduced  hMSCs  (MSC).  GAPDH:  internal  cDNA  loading 
control and -RT, no reverse transcription control (using adipsin primers). PCR cycle numbers: 
GAPDH: 25, all other genes: 28.
235As described earlier, the DACT1 shRNA could not be cloned into the lentiviral vector, so 
only step one of cloning was carried out and DACT1-shRNA was cloned into pSilR-Hl. 
Transfection of 293gps followed by viral transduction of hMSCs was carried out as with 
the retroviral screens. The scrambled-shRNA, empty pSilR-Hl and untransduced controls 
were again included. Figure 5.16A shows that after four days of puromycin selection, the 
majority of cells transduced with the pMSCV-Puro-GFP-WPRE control vector expressed 
GFP,  indicating that  selection was  efficient.  This vector was  again used  as  an  internal 
control as it was assumed that the control virus represented the other constructs in terms of 
the  efficiency  of  each  experimental  step.  After  drug-selected  cells  were  grown  to 
confluency, differentiation was induced and continued for 15d, then cells were Oil Red O- 
stained  and  differentiation was  quantified.  Average numbers  of adipocytes per field  of 
view ranged from 27-34 in the four conditions and there were no statistically significant 
differences  between  these  observations  (p>0.05,  Fig.  5.16B).  No  major morphological 
differences  were  seen  in  adipocytes  from  each  condition  (Fig.  5.16C).  When  the 
expression  of DACT1  was  examined,  no  reduction could  be  seen  in  DACT1  shRNA- 
transduced  cells  compared  with  controls  (Fig.  5.16D).  These  results  suggest  that  this 
shRNA did not lead to reduced DACT1 expression during adipogenesis, and consequently 
differentiation was unaffected.
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237Figure 5.16.  Outcome of shRNA screen for DACT1.  The published sequence for shRNA- 
DACT1  contained  an  EcoRI  site  within  the  shRNA,  so  this  oligonucleotide  could  only 
undergo step 1  of the lentiviral screening strategy (Fig. 5.11) and was cloned only into pSilR- 
Hl. hMSCs were transduced with viral particles (2.5.3) produced from transfection of 293gps 
with  DACT1-shRNA, plus  scrambled  shRNA  (Scr)  and  an  equivalent  empty vector (EV) 
control (2.5.1) Cells were treated with puromycin (750ng/ml for 4 days) to select for stably 
transduced cells (2.5.5), then grown to confluence and induced to differentiate (2.2.2.1); A, 
The majority of cells  simultaneously transduced with pMSCV-Puro-WPRE-GFP  expressed 
GFP  after  selection.  Scale  bar  represents  200/im;  B,  extent  of  differentiation  in  cells 
transduced with each construct. At day 15 of differentiation, cells were fixed and stained with 
Oil Red O (2.2.3.1), and the number of adipocytes per field of view was counted for 4 fields of 
view per condition. Data represent number of adipocytes per field of view and are mean ± SD. 
Experiments  were  performed  in  duplicate  Two-sample  t-tests  (assuming  equal  variance) 
identified no significant differences (p>0.05) when the mean of each condition was compared 
to  the  Scrambled  control;  C,  representative  field  of view  for  each  condition.  Scale  bars 
represent  200/mi;  D,  effect  of DACT1-shRNA  on  DACT1  levels  in  hMSCs.  RNA  was 
extracted (2.6.1) from confluent hMSCs transduced with either DACT1-shRNA, Scr, EV or 
untransduced  hMSCs  (MSC),  and  DACT1-specific  primers  were  used  to  investigate 
expression in each condition (2.6.3.2). -RT: no reverse transcription control (adipsin primers). 
PCR cycle numbers: GAPDH: 25, DACT1: 28.
2385.6  Discussion
The  results  presented  in  this  chapter  describe  the  development,  optimisation  and 
performance  of two  targeted  shRNA  screening  techniques  aimed  at  investigating  the 
function  of  candidate  genes  in  hMSC  adipogenesis.  Although  shRNAs  targeting  a 
selection  of  candidate  genes  were  isolated  and  efficiently  delivered  to  hMSCs  via 
retroviral or lentiviral vectors, no significant silencing effect was observed for the majority 
of target  genes,  and  therefore  no  effect  on  adipogenesis  was  apparent.  However,  two 
lentivirally  delivered  shRNAs  may  have  induced  a  knock-down  of their  target  genes, 
indicating that this methodology is functional, but that further work would be needed to 
determine whether these genes play a role during adipogenesis.
The initial approach undertaken was to use the NKi RNAi library to perform a shRNA 
screen targeting 83 novel candidate regulators, and investigate their role in adipogenesis. 
However,  attempts  at  recovering  shRNAs  for  these  genes  revealed  a  high  level  of 
recombination inherent in the library (Fig 5.2), and resulted in recovery of shRNAs for 
only 10 GOIs (Table 5.2). Recombination has been documented as a major problem by the 
developers of this library, and also affects other vector-based RNAi libraries (Downward 
2004).  This  suggests  that  large-scale  screens  with  this  library  are  only possible  when 
recombination is absent, as in the master copy held by the library developers (Bems et al 
2004, Kolfshoten et al 2005, and personal communication from NKi library distributors). 
The  issue  of recombination  is  being  addressed  in  modified  versions  of vector-based 
libraries  via  the  use  of  recombination-deficient  bacterial  strains,  or  the  inclusion  of 
selectable markers close to the shRNA insert (Echeverri and Perrimon 2006). However, in 
this study, strategies were developed that allowed use of the RNAi library on a smaller 
scale, through sub-cloning of shRNA inserts into an alternative, non-recombining vector. 
In  addition,  a lentiviral-based  shRNA  screen was  also  employed which resulted  in the 
inclusion of 2 further GOIs, plus an additional analysis of 2 GOIs that were included in the 
retroviral  library  screen,  resulting  in  a  thorough  analysis  of  12  GOIs.  Although  this 
number is  the  maximum that could be  achieved  in this  study,  it may have  limited the 
chance of identifying a candidate gene that plays an essential role in the early stages of 
hMSC  adipogenesis.  Further  work  could  be  designed  to  use  newer,  non-recombining
239vectors in a more high-throughput format to study a larger number of genes; possibly all 
genes identified through the microarray studies of Chapter 4.
A trend resulting from each shRNA screen was that adipogenesis was not  significantly 
reduced (or a reliable significant decrease could not be detected as there was a level of 
variation  in  control  samples)  after  transduction  with  any  shRNA  construct  (or  pool), 
compared  to  the  appropriate  controls  (either  control  hairpin  or  empty  vector,  where 
present, Figs 5.7, 5.9, 5.14, 5.16). RT-PCR analysis revealed that the majority of candidate 
genes did not appear to have been silenced by their shRNAs, providing an explanation for 
the lack of effect on adipogenesis (Fig 5.8, 5.10, 5.15, 5.16). Possible reasons for this lack 
of silencing  are  discussed  below.  An  exception  to  this  was  TBX2  X-shRNA  in  the 
retroviral individual screen, where adipogenesis was significantly decreased compared to 
both the scrambled shRNA and empty vector controls (Fig.  5.9). Although this shRNA 
gave the lowest rate of adipogenesis in the pooled screen, it was not significantly less than 
the other shRNAs. Furthermore, no decrease in TBX2 expression was detected using RT- 
PCR  in  either  screen,  suggesting  that  this  result  may  have  been  due  to  experimental 
variation. It is possible that a knock-down had occurred which was not identified by the 
RT-PCR methodology. The use of more sensitive quantitative RT-PCR could address this 
issue, but was beyond the time-frame of this study.
RT-PCR analysis of gene expression in the lentiviral screen indicated a possible decrease 
in SIX2 and TCF8 expression with the shRNA SIX2-b and TCF8-b (Fig 5.15). This effect 
was consistently observed. These genes were included in both the retroviral library screen 
and lentiviral screen, which suggests that the custom-designed shRNA sequences for these 
genes were more effective at silencing gene expression than those isolated from the RNAi 
library. Alternatively, lentiviral transduction may have resulted in more efficient shRNA 
expression within cells than with retroviral transduction. Lentiviruses have been reported 
to induce gene knock-down in hMSCs (Cho et al 2006, Clements et al 2006). There is less 
literature describing the use of retrovirally-delivered shRNA in hMSCs, although several 
studies have used  a retroviral  vector to deliver shRNA  into  murine MSCs (Hong et al 
2005,  Okuyama et al 2006).  Lentiviral  vectors  have  several  advantages  over retroviral 
vectors,  including  that  they  can  be  easily  and  accurately  titred  (see  below),  and  can
240transduce non-dividing as well as dividing cells. Thus, it could be suggested that lentiviral 
vectors, where possible, should be the focus of future work involving shRNA in hMSCs.
Overall, the observations suggest that these shRNAs were functional and the method of 
delivery  into  hMSCs  allowed  them  to  exert  a  silencing  effect  on  gene  expression. 
However,  as adipogenesis was unaffected,  it is probable that  either the knock-down of 
TCF8 and SIX2 was too small to produce an effect on differentiation, or that it was large 
enough  but  these  genes  play  a  redundant  role,  or  have  no  role,  in  adipogenesis.  The 
percentage of transduced cells was found to decrease slightly over three passages in SIX2- 
b-transduced hMSCs (Fig.  5.14A). This could possibly indicate,  if the knock-down did 
cause significant inhibition of SIX2 function, that SIX2 may play a role in hMSC biology 
rather than specifically in differentiation. Western blots would be required to assess SIX2 
and TCF8 protein levels, but were not performed in this thesis due to time constraints.
The  most  probable  explanation  for the  fact  that  few  shRNAs  produced  an  observable 
decrease  in  target  gene  expression  is  that  they  were  non-functional.  As  previously 
mentioned,  si(sh)RNA  design  strategies  are  not  yet  100%  efficient,  so  there  is  no 
guarantee that every shRNA will be able to silence gene expression. Furthermore, it was 
stated that only  70%  of NKi  library targets were  silenced  in  initial  work  (Bems  et al 
2004), and this was when pools of 3 shRNAs were used; for many genes targeted in this 
thesis only  1   or 2 shRNAs could be isolated, reducing the chances of finding at least  1  
functional  shRNA.  Both the SNAI1  and DACT1  shRNAs were expressed  from the U6 
promoter in published work (Kajita et al 2004, Yau et al 2005), whereas the HI promoter 
was used here, providing a possible explanation for the absence of knock-down by these 
functionally-confirmed shRNAs. It is also possible that hMSCs are somewhat resistant to 
the effects of RNAi:  cell type-specific differences  in efficiency of shRNA  and siRNA- 
mediated  gene  silencing  have  been  reported,  which  were  hypothesised  to  be  due  to 
differences  in  expression  of  intermediates  of the  RNAi  pathway  in  certain  cells,  or 
differences in an interferon response elicited by the viral shRNA constructs in each cell 
type (Bantounas et al 2004). Importantly, several additional observations indicate that in 
some cases,  other factors during experimentation may have affected the extent of gene 
knock-downs, and/or the ability to detect them.
241During the pooled retroviral screen, it was noted that target gene expression was lower in 
cells  transduced  with  both  scrambled  shRNA  as  well  as  GOI-shRNA,  compared  with 
untransduced hMSCs (Fig. 5.8A). This was accompanied by a significant decrease in the 
extent of adipogenesis in these cells, compared with untransduced hMSCs. This effect was 
also seen, but to a lesser (non-significant) extent, in the lentiviral screen (Fig. 5.15). Gene 
expression  seemed  higher  in  untransduced  hMSCs  than  in  cells  containing  hairpin 
constructs; even cells containing empty vector only showed GOI expression more similar 
to  v-cyc-shRNA  control  cells than to  untransduced hMSCs.  However,  in  the  lentiviral 
screen this decrease in gene expression after hairpin (or possibly vector) introduction was 
less, and was not accompanied by a decrease in adipogenesis. Moreover, such effects were 
not observed in the individual library screen or the DACT1  experiment,  suggesting that 
the cause of these observations is variable in its extent and occurrence.
It has been reported that some siRNA sequences can induce the silencing of genes other 
than  their  target  gene  due  to  regions  of partial  homology,  possibly  as  small  as  11 
nucleotides (Jackson et al 2003). It was therefore possible that silencing of the GOIs had 
been induced in cells transduced with the non-human shRNA controls (scrambled and v- 
cyc). However, this was not likely to be the case as GOI expression was also reduced in 
PPARy-shRNA-transduced  cells  (Fig.  5.8C),  indicating  that  the  effect  was  more 
widespread  and  not  sequence-specific.  Furthermore,  GOI  expression  was  also  slightly 
reduced in empty CSGW-transduced cells. Therefore, the observations of decreased gene 
expression  and  occasionally  decreased  adipogenesis  are  likely  to  have  been  due  to 
sequence-independent effects of either shRNA introduction, viral introduction, or both.
Double-stranded  RNA,  in  the  form  of shRNA  or siRNA,  has  been  shown  to  produce 
sequence-independent  (termed  non-specific)  stimulation  and  suppression  of non-target 
genes (Persengiev et al 2004, Kariko et al 2004). It could be hypothesised therefore that 
the expression of shRNAs (control or GOI-shRNA) induced non-specific silencing of a 
subset of genes,  including the GOIs.  However,  it seems unlikely that the effect of this 
phenomenon would be broad enough to affect every GOI, or to affect enough genes to 
impair adipogenesis (as in the pooled retroviral screen).
242A further, and more probable, explanation for the observations is the induction of an anti­
viral interferon response. Interferon responses can be triggered by dsRNA in the form of 
both shRNA and siRNA (Bridge et al 2003, Sledz et al 2003), and have also been shown 
to occur after the introduction of some vectors into cultured cells (Akusjarvi et al  1987, 
Bridge et al 2003). This response results in upregulation of interferon-stimulated genes, 
mRNA  degradation  and  a general  reduction  in protein  synthesis  (Williams  and  Haque 
1997).  Thus,  it  is  possible  that  either  shRNA  or  vector  introduction  triggered  such  a 
response,  which  led  to  the reductions  in  gene  expression  and  adipogenesis  specific  to 
some of the screens. This would possibly make observing shRNA-induced knock-downs 
more difficult, as control as well as GOI-targeted cells may already have some extent of 
decrease  in  gene  expression  and/or  differentiation  capability.  Confirmation  that  these 
observations  were  specifically  due  to  an  interferon-mediated  response  would  require 
analysis  of  the  expression  of  interferon-related  genes  such  as  2’5’-oligoadenylate 
synthetase in these experiments. This analysis is beyond the scope of this thesis, but an 
interferon  response  is  currently considered  hypothetically as  the  most  viable  option  to 
explain the cumulative findings.
It is not possible in the pooled shRNA screen to determine whether such an effect may 
have been caused by the shRNA or the virus itself; the Scr-shRNA was initially deemed a 
sufficient control so an empty vector was not included. However, the slight reduction in 
gene expression after empty CSGW transduction would indicate that the virus itself is, at 
least in part,  responsible  for such an effect.  Furthermore,  in the pooled  shRNA  screen, 
puromycin-selected control cells (which therefore all contained the pMSCV-Puro-WPRE- 
GFP  control  vector)  mostly  expressed  GFP  at  a  low  level  (Fig.  5.7A),  which  could 
indicate that during this experiment, a response had been triggered that resulted in lower 
GFP expression. However, in subsequent experiments this effect was not seen and GFP 
expression was high,  and in previous work in Chapter 3  retroviruses had been used to 
transduce  hMSCs  with the  PPARy gene  with no  effects  on hMSC biology (other than 
those caused by PPARy, Fig. 3.9).
243A possible reason for this observed variability in response to virus/shRNA expression was 
that the viral titre or viral copy number per cell may have varied between experiments. 
Retroviruses were not titred as stocks of the viral supernatant must be frozen whilst titring 
via Q-PCR.  As retroviral particles are relatively unstable when frozen, the viral titre is 
reduced significantly by this process,  so Q-PCR results would not represent the titre of 
frozen  stocks.  Furthermore,  the  maximum  virus  concentration possible  is  always  used 
during experimentation to avoid low cell densities after drug selection. MSCs, and stem 
cells  in  general,  can  be  difficult  to  transduce  (Godfrey  2006),  and  low  cell  densities 
produced by low transduction rates lead to cell senescence and an inability to expand cells 
after drug selection. It is therefore possible that viral titre was higher in the pooled shRNA 
screen than in the individual shRNA screen, resulting in variation in the response to viral 
transduction or hairpin introduction. Alternatively (or additionally), if fewer hMSCs were 
dividing,  or were  dividing more slowly during the  transduction process  for the pooled 
screen,  then  those  cells  that  were  dividing  may  have  become  highly  transduced  (as 
retroviruses can only transduce dividing cells). This may have resulted in a population of 
highly transduced cells specifically in this experiment that then induced a response.
The overall effect of a general decrease in gene expression or differentiation capability in 
all  cells  (i.e.  including  control  cells  thus  the  effect  is  not  caused  by  the  target  gene 
shRNA) could be that any expression knock-down or phenotype produced by functional 
shRNAs  would  be  masked.  This  could  have  occurred  in  the  pooled  shRNA  screen. 
However,  the individual  shRNA  screen was  in  many ways  a replication of the pooled 
screen, and provided more information as each shRNA was assayed individually. As no 
non-specific  effects  were  observed,  the  experimental  readout  is  likely  to  be  accurate. 
Furthermore, effects in the lentiviral screen were minimal,  and gene knock-downs were 
detected. Thus, a comprehensive study of the effect of shRNAs targeting 12 GOIs on gene 
expression  and  hMSC  adipogenesis  has  been  performed,  although  knock-down  of 
expression was observed for only 2 genes.
There have been several papers documenting the use of siRNA oligonucleotides to study 
gene function in hMSC differentiation (Luo et al 2004, Xu et al 2006) and in other stem 
cell populations (Oliveira and Goodell 2003, Matin et al 2004). It is possible therefore that
244siRNAs are more effective at silencing gene expression in stem cells, although they are 
also capable of inducing non-specific cellular responses (Sledz et al 2003).  However,  I 
consider that their use to study processes such as hMSC differentiation may not be ideal as 
they have only a transient effect on gene expression, and as differentiation was continued 
in  this  study  for  14  days,  continued  reapplication  of siRNA  would  be  necessary  and 
knock-down effect may vary. In summary, this study has utilised a novel approach to the 
study  of early  hMSC  differentiation,  as  vector-mediated  shRNA  was  employed  and 
multiple  genes  were  investigated  simultaneously;  previous  work  has  often  focused  on 
individual  genes.  Potential problems  of such  an  approach  have  also  been  documented, 
specifically involving variable non-specific  effects of virus or hairpin  introduction into 
hMSCs, which have highlighted possible areas for future optimisation.
245CHAPTER 6. THE EFFECT OF TRANSFORMING 
MUTATIONS ON hMSC DIFFERENTIATION IN  VITRO.
2466.1  Introduction and aims
The  existence  of  cancer  stem  cells  (1.8.1)  was  first  demonstrated  in  acute  myeloid 
leukaemia (Bonnet and Dick 1997). Further cancer stem cell populations have since been 
prospectively isolated  from  solid  tumours  of the breast  and brain  (Al-Hajj  et al 2003, 
Singh et al 2003, Singh et al 2004). Cancer stem cells have the ability to reconstitute the 
full and specific range of cell types in their cancer of origin after transplantation into an 
animal model, and also to give rise to further cancer stem cells that have this same ability 
after serial transplantation (Bonnet and Dick 1997, Al-Hajj et al 2003, Singh et al 2004). 
Thus,  cancer  stem  cells  have  the  potential  for  self-renewal  as  well  as  (aberrant) 
differentiation. The striking resemblance of cancer stem cells to normal stem cells has led 
to the suggestion that cancer may arise from the aberrant functioning of normal stem cell 
attributes (1.7.2, Reya and Clevers 2005). In support of this, numerous genetic alterations 
that lead to tumour progression also control normal stem cell function (1.8.2, Pardal et al 
2003, Reya and Clevers 2005, Polyak et al 2006). Based on such observations, it has been 
suggested  that tumourigenic  mutations that  give  rise to these  abnormal  properties  may 
arise in adult stem cells,  and evidence in support of this hypothesis has been provided 
(1.8.2, Bonnet and Dick 1997, Marx 2003, Pardal et al 2003). Thus, studying the effects of 
tumourigenic events on aspects of stem cell function such as differentiation may provide 
further understanding of the mechanisms of cancer progression.
The progression of normal  human cells  into cancer cells  is termed transformation,  and 
results from the stepwise accumulation of genetic alterations that lead to loss of tumour 
suppressor  gene  function  and  abnormal  activation  of  proto-oncogenes  (Hahn  and 
Wienberg 2002, Vogelstein and Kinzler 2004). A large body of research has described the 
cellular pathways perturbed during the progression of many cancers (1.8.3, reviewed in 
Hahahan  and  Weinberg  2000).  As  a result  of such  studies,  in  vitro  models  of cellular 
transformation have been developed (Hahn et al  1999,  Rangarajan et al 2004). In  vitro 
transformation involves the introduction of a defined set of genetic elements, termed here 
transforming  “hits”,  into  recipient  cells.  These  include  hTERT,  oncogenic  H-Ras  (H-
Y12
Ras  ), viral oncogenes such as HPV16 E6 and E7 which inhibit the functions of p53 and 
pRb respectively, and SV40 ST antigen which inhibits c-Myc inactivation. The presence
247(or mutation) of such genes is observed in numerous cancer sub-types: by way of example, 
p53 mutations are seen in more than 50% of all human cancers (Harris  1996), and more 
than  90%  of human  tumours  exhibit  telomerase  activity  (Shay  and  Bacchetti  1997). 
Therefore,  such  systems  are  likely  to  be  accurate  models  of the  molecular  pathways 
involved  in  human  cancer,  and provide  the  opportunity to  study molecular aspects  of 
cancer progression in vitro.
Sarcomas are a group of soft tissue tumours that often resemble their tissue of origin, for 
example bone, adipose and cartilage (1.8.4, Helman and Meltzer 2003).  As hMSCs are 
capable of differentiating into such tissue types (Pittenger et al  1999), it is a possibility 
that the accumulation of tumourigenic mutations in hMSCs may be the cause of sarcoma 
formation,  associated  with  aberrant  hMSC  differentiation  (Helman  and  Meltzer  2003). 
Thus, studies aimed at investigating whether in vitro transformation of these cells results 
in changes in their differentiation capability may provide answers to this question.
Several groups have demonstrated that long term culture of both murine and human MSCs 
can lead to  spontaneous transformation and tumour formation in immunodeficient mice 
(1.8.4, Serakinci et al 2004, Bums et al 2005, Rubio et al 2005, Miura et al 2006). One 
study found that the resulting tumours (fibrosarcomas) contained a sub-population of cells 
that  could  form  cell  clusters  in  culture  and  further  tumours  after  re-transplantation, 
strikingly similar to cancer stem cells, although this study was not performed at the single­
cell  level  (Miura  et  al  2006).  The  genetic  alterations  resulting  in  this  spontaneous 
transformation were found to involve elevated telomerase activity, c-Myc over-expression, 
and loss of some  cell cycle regulators  including the  INK4A/ARF locus;  these  findings 
were consistent between different studies (Serakinci et al 2004, Rubio et al 2005, Miura et 
al 2006). Serakinci and co-workers also described a mutation causing activation of K-Ras 
(Serakinci  et al 2004).  This  suggests  that  the  use  of step-wise  transformation  models 
outlined above would be a relatively accurate representation of the processes of hMSC 
transformation. These studies however did not give a full assessment of the differentiation 
capabilities of the transformed MSCs, although one group found that transformed murine 
MSCs exhibited some bone formation within tumours (Miura et al 2006).
248There have been several studies that have investigated the effect of stepwise introduction 
of transforming genes on MSC immortalisation, transformation and differentiation (1.8.4). 
In  two  studies,  the  introduction  of hTERT  was  found  to  immortalise  hMSCs  without 
reducing their differentiation potential even at high passages (Simonsen et al 2002, Shi et 
al 2002); in fact, osteogenesis was enhanced in one case (Shi et al 2002). The effect of 2 
(E6 and E7, Hung et al 2004b) or 3  (hTERT,  E6 and E7,  Okamoto et al 2002) hits on 
hMSCs  have  been  investigated:  it  was  found  that  osteogenic,  chondrogenic  and 
adipogenic differentiation were unaffected. However, these cells were only immortalised 
and not transformed. It may be that further hits that lead to hMSC transformation could be 
associated with changes in differentiation potential, but this theory is as yet unexplored.
Aims
The  main  aim  of this  chapter  is  to  determine  the  effect  of transformation  on  hMSC 
differentiation.  Human MSCs containing increasing numbers of transforming genes to a 
maximum of 5 hits will be employed. To achieve this aim:
•  The morphology and growth properties of these cell lines will be investigated in order 
to optimise conditions for differentiation experiments
•  The  ability of each  cell  line to undergo both  adipogenesis  and osteogenesis  will be 
determined using several techniques.
2496.2  Characterisation  of hMSCs  after  the  introduction  of transforming 
hits
In vitro cell transformation involves the ectopic expression of a limited selection of genes 
which induce the deregulation of major cellular pathways and the ultimate production of 
cancer-like cells (Hahn et al 1999, Rangarajan et al 2004). The introduction of such genes 
into  hMSCs  would,  in  all  probability,  have  significant  effects  on  properties  such  as 
proliferation and morphology. The aim of these experiments was therefore to examine the 
effects of the addition of transforming hits on several cellular properties, in order to define 
experimental conditions for differentiation studies.
Transformation of hMSCs was accomplished using retroviral vectors separately encoding 
five genes: hTERT, HPV16 E6 and E7, SV40 ST and H-RasV 12. Through disruption of the 
function  of cellular  genes,  the  expression  of these  exogenous  genes,  or  transforming 
“hits”, results in cellular immortalisation, inhibition of apoptosis, deregulated cell cycle 
and increased growth, motility and proliferation (Fig 1.7 and Fig. 6.1).  Each transforming 
hit was introduced successively into hMSCs in a defined order through retroviral infection 
and drug selection. The expression of each transforming hit, or their downstream targets, 
was confirmed via Western blotting and microarray analysis of gene expression; this work 
was undertaken by J.  Funes (Funes et al 2006,  submitted). The resulting cell lines (the 
word “line” will subsequently be used for ease of explanation, but it should be noted that 
these populations are not true cell lines as they are not clonally derived) contained several 
combinations and increasing numbers of transforming hits, ranging from 0-5 (Fig. 6.1). In 
work also performed by J. Funes and others, it was found that the expression of hTERT (1 
hit) was sufficient to immortalise hMSCs in this system. Additionally, 5 hit cells showed 
robust transformed characteristics, giving rise to colonies in soft agarose and tumours in 
immunodeficient mice.  Other cell  lines showed partial characteristics of transformation: 
all E7-containing cell lines formed colonies in soft agar with 4 hit (hTERT, E6, E7, ST) 
cells showing colonies soonest (Funes et al 2006,  submitted). The 4(E7) cells (hTERT, 
E7, ST, H-Ras) gave rise to large colonies in soft agar and tumours in 2 out of 6 mice, 
indicating that they expressed the expected array of transforming hits, although this has 
not yet been confirmed via Western blotting (Funes et al, unpublished observations).
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Figure 6.1  Schematic view of stepwise in vitro transformation system and cell “lines” created 
for study.  Successive introduction of viral or human proteins, known as transforming “hits”, 
results  in  the  inhibition  of  tumour  suppressor  gene  function  or  constitutive  activation  of 
oncogenes,  leading  to  activation  of  pathways  required  for  cellular  transformation  and 
ultimately the production of a cancer cell. hTERT introduction leads to telomere stabilisation 
and  immortalisation.  pRb  and  p53  are  inactivated  by  viral  oncoproteins  E7  and  E6 
respectively,  leading  to  bypass  of apoptosis  and  cell  cycle  pathways.  SV40  ST  inactivates 
PP2A,  leading to stabilisation of Myc and  increased proliferation and angiogenic properties. 
Oncogenic RAS (VI2 H-Ras) transmits constitutive signals through several pathways, leading 
to  increased  growth,  motility,  and  angiogenesis.  Defined  cell  populations  containing 
increasing  numbers  or  different  combinations  of  “hits”  were  created  for  functional 
investigation, ev: empty vector. These cell “lines” were produced by Dr. J. Funes.
251In order to investigate the morphology of these cell lines, cells were seeded at 2.5 xlO4 
cells/cm2 (near confluence for parental hMSCs),  and allowed to reach confluence (l-2d 
after  seeding).  Parental  hMSCs  maintained  their  elongated  morphology,  and  this  was 
similar in 1   (hTERT) and 2(E6) (hTERT-E6) hit cells; the elongated shape seemed more 
pronounced  in  2(E7)  (hTERT-E7)  cells  (Fig.  6.2A).  The  3  hit  (hTERT-E6-E7)  cells 
contained  a  mixture  of cellular morphologies,  with  some  cells  retaining  a  spindle-like 
shape whereas others  appeared shortened.  As the number of hits  increased  to 4,  4(E6) 
(hTERT-E6-ST-HRas)  or  5  (hTERT-E6-E7-ST-HRas),  hMSCs  appeared  substantially 
smaller and more rounded; this effect was most pronounced in 5 hit cells (Fig. 6.2A). The 
4(E7)  line  retained  some  elongated  cells  but  cells  again  appeared  smaller.  These 
observations  suggest  that  increasing  the  number  of  transforming  hits  from  3  to  5 
progressively induces morphological  changes  away from the classic  fibroblastic  hMSC 
morphology.
Cell  counts  were next performed  at  confluence  and after incubation of confluent  cells 
without passaging for 7 days (2.2.6), in order to assess proliferation rates and the extent of 
contact  inhibition in each cell  line.  Parental  hMSCs  and  1   and  2(E6)  hit cells  showed 
similar cell numbers at confluence, ranging from 1.9-2.8 xlO4 cells/cm2 (Fig. 6.2B), which 
could  in part be  due  to  their  similar morphology  and  size.  The  4(E6)  population  also 
showed similar density at confluence (2.9 xlO4 cells/cm2). Cell numbers for the parental 
hMSC,  1   hit  and 4(E6)  cell  lines  did not  increase  significantly after 7d  (p>0.05,  two- 
sample Student’s t-test), indicating that these cells were sensitive to contact inhibition, and 
consequently  growth  arrest  was  induced  after  confluence.  Interestingly,  2(E7)  cells 
yielded  4.6x104  cells/cm2  at  confluence,  double  the  number  of  their  hTERT-E6 
counterparts and also more than 3 hit cells, indicating that the presence of E7 (thus loss of 
Rb) may induce a higher proliferation rate and/or smaller cell size (Fig. 6.2B, and Funes et 
al 2006, submitted). In both 2(E7) and 3 hit hMSCs, cell numbers increased significantly 
from  confluence  to  7d  (p<0.05  and  p<0.01,  respectively),  indicating  a  lower 
responsiveness  to  contact  inhibition.  More  than  twice  as  many  4  hit  cells  (4.7  xlO4
2  t  4  2
cells/cm ) and more than three times as many 5 hit cells (6.0 xlO  cells/cm ) were present 
at confluence compared with parental hMSCs (1.9 xlO4 cells/cm2), which may be due to 
their smaller size allowing a higher number of cells to be accommodated in a monolayer,
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Figure 6.2. Continued overleaf.
253Figure 6.2. Morphology and growth properties of hMSCs after introduction of transforming 
hits. hMSCs were successively transduced with virus carrying each transforming gene then 
drug-selected,  producing  cell  populations  with  different  numbers  and  combinations  of 
transforming hits (J. Funes et al 2006, submitted). A, Cells were grown to confluence and 
their morphology analysed via phase contrast microscopy.  Scale bars represent  150/mi;  B, 
cells of each type were seeded in 6-well plate format and counted at confluence and 7d after 
confluence (7d). Counts were performed in duplicate for each condition (2.2.6). Data represent 
number of cells/cm2  and are mean ± standard deviation. *, p<0.05 and **, p<0.01 using a two- 
sample  Student’s  t-test  (assuming  equal  variance).  0,  at  this  stage,  some  4(E7)  cells  had 
detached  from  the  plate  but  remaining  cells  were  still  proliferating,  and  the  5  hit  cell 
monolayer were beginning to detach.
254but could also indicate a higher proliferation rate to achieve this cell number in this time. 
Furthermore, significant increases in cell number of 4 (p<0.05) and 5  (p<0.01) hit cells 
was observed at 7d, suggesting that cell-to-cell contact did not inhibit proliferation after 
confluence  (Fig.  6.2B).  Additionally,  4(E7)  cells  were  observed  to  proliferate  rapidly 
during this time, and by 6-7d the cell monolayer had detached from the plastic surface. 
Remaining adherent 4(E7) cells continued to proliferate, but detached cells may have been 
lost  during  harvesting  for  cell  counts,  resulting  in  unrepresentatively  low  counts. 
However,  the  difference  between  the  number  of cells  present  at  Od  and  7d  was  still 
statistically significant (p<0.05), even after loss of the cell monolayer. At this time 5 hit 
cells were also beginning to detach (see also Fig. 6.3, arrowheads). These results suggest 
that  2(E7),  3,  4,  5  and  4(E7)  cell  lines  may have  an  increased  proliferation  rate  and 
decreased responsiveness to contact inhibition; this would correlate with the transformed 
state of 5 and possibly 4(E7) cells. In contrast to this, 1  hit and 4(E6) cells, and also 2(E6) 
cells  (but  only in  terms  in  terms  of their morphology,  as  their  cell  number  increased 
significantly  between  0  and  7d  (p<0.05))  remain  more  similar  to  parental  hMSCs, 
indicating that the number or combination of transforming hits had not produced a large 
effect on their morphology or loss of contact inhibition.
During cell culture, it was also noted that the colour of the growth media, which contained 
phenol red, became progressively more yellow as the number of hits increased (Fig 6.3). 
This  indicates  a higher media  acidity in cells with more  transforming  hits,  which  was 
likely  to  be  due  to  increased  metabolic  products  (e.g.  lactate)  caused  by  higher  cell 
numbers, rather than from increased metabolic activity of each cell, as it was shown that 
glucose  uptake  and  lactate  production  (markers  of  the  rate  of  glycolysis)  are  not 
significantly higher in transformed  hMSCs  that  in parental  hMSCs  (Funes  et al 2006, 
submitted). Interestingly, this effect was less pronounced in cells incubated in osteogenic 
media, and even less so in adipogenic media, suggesting that components of these media 
cause a reduced rate of metabolism or proliferation.
As a cumulative result of the observations of a higher ability to continue proliferating after 
confluence and high media acidity produced by 4 and 5 hit cells, it was decided that for 
differentiation experiments, media would be changed every other day instead of every 3
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Figure 6.3. Media pH for each cell line at day 9 after seeding, indicated by phenol red colour. 
Media colour was  visualised  in normal  growth conditions or after adipogenic or osteogenic 
induction.  Yellow  colours  indicate  an  acidic  pH,  whereas  red  indicates  a  higher  pH. 
Arrowheads indicate detached cell monolayers at day 9. X: Cells surplus to this study.
256days  as  in  all  previous  experiments.  This  was  performed  in  an  attempt  to  prevent 
metabolic by-products from accumulating in the media and becoming toxic, or mutagenic, 
to  the  cells.  Furthermore,  differentiation  would  be  continued  for  as  short  a  time  as 
necessary in an attempt to avoid cell detachment during the process.
6.3  The effect of transforming hits on hMSC adipogenesis
Having  established  some  of the properties  of hMSCs  containing  different  numbers  of 
transforming hits, experiments were set up with the aim of investigating the ability of each 
cell line to differentiate into adipocytes.
Each cell type containing different transforming hits was seeded at 2.5 xlO4 cells/cm2 in 
12-well plate  format  and then left for 24h to achieve  full  confluence.  Parental  hMSCs 
were at passage 8 whereas the passage number of other cell lines ranged from 21-29 (Fig. 
6.4);  this reflected the fact that  several rounds of viral transduction and drug  selection 
were required to produce cells containing higher numbers of hits, inevitably resulting in 
higher passage numbers for cells with more hits. Furthermore, the faster proliferation rate 
of 3-5 hit cells entails a need for more frequent passaging. The experimental format was as 
follows:  a  duplicate  set  of  confluent  cells  (i.e.  cells  containing  the  full  range  of 
transforming  hits)  was  induced  to  undergo  differentiation  using  adipogenic  media
(2.2.2.1),  whereas  two  further  sets  of cells  were  incubated  in  normal  growth  media 
(without bFGF) for the duration of the experiment. Media was changed every other day. 
RNA was extracted from one set of control cells immediately after confluence, and was 
extracted  from one  set of adipocytes when differentiation was terminated  (2.6.1).  This 
format was  repeated  in  separate  experiments,  and the  results  of a  single  representative 
experiment  are  shown  here.  During  adipogenic  differentiation  no  cell  detachment  was 
observed,  whereas  4(E7),  5  and  2(E7)  hit  cells  detached  during  this  time  in  control 
medium.  This  indicates  that  the  adipogenic  cocktail  has  potent  growth  inhibitory 
properties, a process required for adipogenesis (Rosen and Spiegelman 2000).
257Figure 6.4. Effect of successive transforming hits on hMSC adipogenesis. Post-confluent cells 
of each type were induced to differentiate into adipocytes using the classic induction cocktail 
(2.2.2.1).  Differentiation  was  continued  for  10  days,  with  media  changes  every  other  day; 
parallel cells were supplemented every other day with normal growth medium. At the end of 
differentiation cells were fixed and stained with Oil Red O and visualised via phase contrast 
microscopy (2.2.3.1). Passage numbers: MSCs, p8;  1  hit, p21; 2(E6), p21; 2(E7), p25; 3, p24, 
4, p27; 5, p29, 4(E6), p22; 4(E7), p29; A, a representative field of view indicating the extent 
of  differentiation  in  each  cell  line.  Scale  bars  represent  150/xm;  B  (overleaf),  High 
magnification  images  of  differentiated  cells.  Scale  bars  represent  150/mi;  C  (overleaf), 
Control  cells  incubated  in  hMSC  growth  media  (without  bFGF)  showed  no  detectable 
differentiation. Scale bars represent 150/mi. *, cell monolayers had detached in the duration of 
the experiment, but remaining adherent cells continued proliferating.
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259At day 10, differentiation was terminated and cells that were not used for RNA extraction 
were stained with Oil Red O in order to visualise lipid accumulation (2.2.3.1,  Fig. 6.4). 
Accurate quantification of adipogenesis was not possible due to the morphology of the 4 
and 5 hit cell lines causing inaccurate quantification of the proportion of cells containing 
lipid. Furthermore, the number of lipid droplets per cell, as well as the number of cells that 
differentiated, was a major factor for assessment, so a qualitative assessment was deemed 
necessary, and was able to account for both of these factors.  Whereas no differentiation 
was observed in any of the control cell populations incubated in growth media only (Fig. 
6.4C), parental hMSCs induced to differentiate accumulated multiple lipid droplets in the 
majority of cells (Fig. 6.4A and B). Similar lipid-laden adipocytes were seen in 1  hit cells, 
though they were fewer in number than with parental hMSCs. The number of adipocytes 
decreased  further in the 2  and 3  hit cell  lines,  as  did the extent of lipid  accumulation, 
although multiple lipid droplets were still present in differentiated cells. Occasional lipid- 
filled adipocytes were also visible in the 4(E6) cell line, although they were not common. 
These  results  indicate  that  cells  containing  1-3  transforming  hits  are  still  capable  of 
forming  mature  adipocytes  containing  multiple  lipid  droplets,  but  the  extent  of this 
differentiation is slightly decreased compared with parental cells. Additionally, 4(E6) cells 
are still capable of differentiating into adipocytes containing multiple lipid droplets, and 
the extent of differentiation is similar to that of the 2 or 3 hit cells, indicating that E7 (Rb) 
may have a more potent inhibitory affect than E6 (p53) on adipogenic ability. In the 4 hit 
cell  line,  cells  containing  several  lipid  droplets  were  visible,  but  the  lipid  often  only 
partially filled the cells and no  fully laden adipocytes were observed. A more dramatic 
effect was seen in the 5 hit and 4(E7) population, where the majority of cells contained 
only a few lipid droplets, indicating that their ability to accumulate lipid was significantly 
impaired.
To further investigate the effect of hMSC transformation on adipogenesis, RT-PCR was 
employed  to  analyse the  expression of aP2,  PPARy and  C/EBPa  (adipogenic  markers, 
section  1.6.2)  in  control  and  differentiated  cells  containing  different  hits  (2.6.3.1,  Fig 
6.5A). Low but detectable expression of all three genes was seen in most undifferentiated 
cell  lines,  and  PPARy  mRNA  expression  showed  a  slight  increase  in  undifferentiated 
control cells with 2 or more hits, excluding 4(E7) cells. Expression of these genes was
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Figure  6.5.  Effect  of successive  transforming  hits  on  mRNA  levels  of adipogenic  markers. 
RNA was collected from day  10 differentiated cells, and control cells one day after reaching 
confluence  (2.6.1).  cDNA  was  synthesised  (2.6.2)  and  gene-specific  primers  were  used  for 
PCR  to  determine  adipogenic  marker  expression  in  each  cell  type  after  differentiation
(2.6.3.1).  A,  expression  of adipogenic  genes  in  all  cell  lines  under  investigation.  /3-actin, 
internal  control;  -RT:  no  reverse  transcription  control  (osteocalcin  primers);  B,  focused 
analysis  of gene  expression  in 4,  4(E7),  and  5  hit  lines  compared  with parental  cells.  PCR 
cycle numbers used: /3-actin: 25, all other genes: 28.
261higher in all cell lines at day 10 of adipogenesis, but was reduced in the 4(E7) and 5 hit 
cells compared to other cells. C/EBPa expression was also reduced in 4 hit cells, and aP2 
and PPARy expression appeared lessened in the 2(E6) hit line, indicating that loss of p53 
may contribute to the negative effect on adipogenic gene expression. In these analyses /C 3 - 
actin (a cytoskeletal protein present in most cell types) rather than GAPDH was used as an 
internal control, as it had been found that transformation affected metabolic pathways such 
as glycolysis, in which GAPDH is involved (Funes et al 2006, submitted). The level of /3- 
actin expression was comparable in all cell lines.
As  the  4,  4(E7)  and  5  hits  cells  showed  impaired  differentiation  in  terms  of  lipid 
accumulation,  an  analysis  of  expression  of  adipogenic  markers  in  these  cells  in 
comparison with parental (0) cells was next performed (Fig. 6.5B). Again, low expression 
of PPARy, aP2 and C/EBPa was observed in differentiated 4(E7) and 5 hit cells compared 
to normal hMSC, albeit a small decrease for PPARy in the 5 hit cells. C/EBPa expression 
was also reduced in 4 hit cells, but the expression of PPARy or aP2 was not decreased in 4 
hit cells.
Taken  together,  these  results  suggest  that  the  introduction  of  four  transforming  hits, 
including  hTERT,  E7,  ST  and  H-Ras,  or  the  additional  introduction  of E6,  does  not 
abolish  hMSC  adipogenesis,  but  impairs  the  process,  as  evidenced  by  decreased  lipid 
accumulation and adipogenic marker gene expression.
An important factor to be taken into account in these experiments was the passage number 
of the cells used. As previously stated, whereas hMSCs were used at around passage 8, all 
cells  containing  transforming  hits  had  undergone  further  rounds  of  passaging. 
Untransformed  hMSCs  lose  their  ability  to  differentiate  at  higher  passage  numbers, 
although  the  exact  passage  number  at  which  this  occurs  is  variable  between  reports 
(Conget and Minguell  1999, Tsutsumi et al 2001, Fig. 3.5).  It is therefore possible that 
passage number,  as well  as  the introduction of genes required  for transformation,  may 
affect differentiation. To address this issue, it was necessary to perform differentiations of 
parental and transformed cells of similar passages, and compare this with differentiation as 
higher passages, to determine whether the process is affected. The only cell line available
262at a low passage was hMSC-hTERT (not containing empty vector). As stated, it was not 
possible to  expand hMSCs to a high passage,  so  differentiation of hMSCs  and hMSC- 
hTERT was carried out at passage 6 and compared to 1  hit cells differentiated at higher 
passages  (pi9,  p21  and  p22,  Fig.  6.6).  Low  passage  hMSCs  and  hMSC-hTERT 
differentiated to a similar extent at passage 6, and this was comparable to differentiation of 
1   hit  cells  at  higher  passages  (p>0.05,  two  sample  Student’s  t-test),  although  here 
differentiation and possibly also the rate of apoptosis was more variable between samples 
indicating that passage  number may have  a  slight  effect.  Indeed,  1   hit  cells  shown  in 
Figure 6.4 appeared to have a reduced rate of differentiation compared to parental hMSCs, 
and  less  apoptosis  appeared  to  have  occurred,  indicating  that  the  spontaneous 
accumulation of further mutations could not be ruled out in some experiments.
6.4  The effect of transforming hits on hMSC osteogenesis
hMSCs are multipotent,  and hence are capable of differentiating into  several cell types 
(Pittenger  et  al  1999,  Fig.  3.3).  Therefore,  the  effect  of  hMSC  transformation  on 
osteogenesis was also investigated in addition to their differentiation to adipocytes.
Experiments were  set up in an identical manner to adipogenesis  as follows:  six sets of 
cells  containing  each  combination  of  transforming  hits  were  seeded  and  grown  to 
confluence. Passage number was identical to adipogenesis experiments (Fig. 6.7). One day 
post-confluence,  osteogenesis  was  induced  in  three  set  of  cells  (2.2.2.2)  whereas 
remaining cells (3  sets) were incubated in normal growth media (without bFGF).  RNA 
was  extracted  from  one  set  of  control  cells  immediately  after  confluence,  and  was 
extracted  from one set of hMSCs differentiated to osteoblasts when differentiation was 
terminated. The remaining sets of cells (2 per condition) were used to assess osteogenesis 
via  histochemical  staining.  This  format  was  repeated  in  separate  experiments,  and  the 
results of a representative experiment are shown. Media was changed every other day, and 
initially  osteogenesis  was  continued  for  14d.  The  normal  duration  of  osteogenic 
differentiation is 2 Id (Pittenger et al 1999), but  it  was  found  that by this stage the 2(E7)
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Figure 6.6. Comparison of differentiation rates of parental hMSCs and hMSC-hTERT cells at 
low and high passage numbers. hMSCs, with or without hTERT, were induced to differentiate 
to adipocytes at passage 6, as were  1   hit cells at higher passages (2.2.2.1);  A, At day  10 of 
differentiation  cells  were  fixed  and  stained  with  Oil  Red  O  (2.2.3.1).  Scale  bars  represent 
200/im;  B,  Differentiation was quantified by counting the number of adipocytes per field of 
view for 3 fields of view per condition. Data represent number of adipocytes per field of view 
and are mean ± SD.
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Figure 6.7. Effect of successive transforming hits on hMSC osteogenesis. Post-confluent cells 
containing  each  combination  of  transforming  hits  were  induced  to  differentiate  into 
osteoblasts using a classic  induction cocktail  (2.2.2.2). Differentiation was continued  for  14 
days, with media changes every other day;  parallel cells were supplemented every other day 
with normal growth medium.  At the end of differentiation cells were fixed and stained with 
alizarin  red  (2.2.3.3)  to  visualise  calcium  deposition,  or  assayed  for  alkaline  phosphatase 
activity (2.2.3.2). Passage numbers: hMSCs, p8;  1   hit, p21; 2(E6), p22; 2(E7), p25; 3, p24, 4, 
p27;  5, p29, 4(E6), p22; 4(E7), p29;  Black arrowheads indicate cell  lines where monolayers 
were lost during experimentation. X indicates surplus wells not required for this study.
265and  3-5  hit  cell  lines  induced  to  differentiate  had  detached  as  monolayers  (data  not 
shown), likely due to higher growth rates and lack of growth arrest in such cells.
By day 14 of differentiation, it was found that all 4(E7) and some 5 hit cells that had been 
induced to differentiate to osteoblasts had detached from the plastic surface, as had some 
3-5  hit undifferentiated cells, as assessed by floating cell monolayers (excluding 4(E6), 
Fig. 6.7). Again, this is probably due to the lack of contact inhibition in these cell lines 
leading  to  their  eventual  overgrowth  and  loss  of  plastic  adherence.  Furthermore,  it 
suggests that osteogenic media does not induce strong anti-proliferative signals that are 
sufficient to overcome this effect, unlike adipogenic media. It was therefore not possible 
to assess the extent of osteogenesis in 4(E7) cells at 14d, and the loss of some 5 hit cells 
allowed only a partial investigation.
An  alkaline  phosphatase  activity  assay  (2.2.3.2)  and  alizarin  red  staining  of calcium 
deposition  (2.2.3.3)  were  used  to  assess  osteogenesis  where  possible.  Undifferentiated 
cells stained for alkaline phosphatase activity showed a background level of staining that 
became more intense as the number of hits increased (Fig. 6.7). This may have been due to 
some spontaneous differentiation to osteoblasts in these cells, but it should be noted that 
these  staining techniques  are  not  controlled  for  cell  number,  and  it  is  not  possible  to 
accurately  quantify  these  osteogenic  stains  at  a  single-cell  level.  Therefore,  increased 
staining intensity may be due to increased cell number, which occurs as the number of hits 
increases (Fig. 6.2B), making comparisons between cell lines in each condition inaccurate. 
However, alkaline phosphatase activity was higher for each cell line when differentiation 
was induced than in undifferentiated cells, indicating that a greater level of osteogenesis 
had occurred in these cells. It was not possible to assess calcium deposition using alizarin 
red  staining  in  3-5  hit  control  cells  (Fig.  6.7)  in  the  experiment  illustrated,  but  in 
equivalent experiments where 3-4 hit control cells could be stained with alizarin red at day 
14,  an  increase  in  staining  intensity  was  seen  with  increasing  hits,  similar  to  the 
observations with alkaline phosphatase activity (data not shown). Where possible, it was 
observed that alizarin red staining was more intense in differentiated cell lines compared 
to their non-differentiated  counterparts,  apart  from parental  cells  and  1   hit cells where 
there was minimal difference (Fig. 6.7).
266RT-PCR  analysis  of osteogenic  markers  was  next  performed  to  assess  the  extent  of 
osteogenesis  on  the  mRNA  level.  As  the  amount  of RNA  used  in  each  reaction  is 
normalised, this allows comparison between different cell lines. The genes studied were: 
the main osteogenic transcription factor CBFA1  (Ducy et al 1997); PLZF, a transcription 
factor that is expressed upstream of CBFA1  during osteogenesis (Ikeda et al 2005, Fig. 
6.8A)  and  COL1A1,  alkaline  phosphatase  (tissue  non-specific,  also  known  as  the 
bone/liver/kidney  isoform)  and  osteocalcin,  which  are  expressed  at  high  levels  in 
differentiated osteoblasts (Ducy et al 2000). It was not possible to assess gene expression 
in day  14  4(E7)  differentiated  cells  due to  their consistent  detachment,  but  RNA  was 
collected from 5 hit differentiated cells.
Expression of the internal control, /3-actin, was similar in all cell lines. CBFA1 expression 
was observed in most undifferentiated cell lines excluding parental hMSCs and 4(E7) cells 
(Fig. 6.8B). Expression of this gene increased after differentiation in parental cells, but no 
significant  increase  in  CBFA1  expression  was  seen  in  other  cell  lines.  Similarly, 
osteocalcin  expression  was  observed  in  some  undifferentiated  cells,  specifically  in the 
2(E6) and 3 hit cell lines, and slight increases in mRNA levels were observed in parental 
and  2(E7)  hMSCs  but  not  cells  containing  4  (all  combinations)  or  5  hits.  COL1A1 
expression was  detected  in  all  undifferentiated  cells  and  did  not  increase  greatly  after 
differentiation  in  any  cell  line.  Both  alkaline  phosphatase  and  PLZF  showed  higher 
expression in each differentiated cell line compared to undifferentiated controls, with the 
exception of alkaline phosphatase expression in 5 hit cells which appeared similar in both 
conditions.  In summary,  a single pattern does not describe the  expression  of all  of the 
genes  analysed,  either after differentiation  or between  cell  lines.  Increases  in  CBFA1, 
PLZF and ALP expression occurred during differentiation of parental hMSCs; osteocalcin 
and  COL1A1  showed  a  slight  increase  in  gene  expression.  Furthermore,  alkaline 
phosphatase activity was higher in differentiated than undifferentiated hMSCs, although 
calcium deposition was not detectably stronger.  The  observations of increased  alkaline 
phosphatase staining and expression of several osteogenic markers in parental hMSCs is 
similar to previous reports  of hMSC  osteogenesis (Pittenger et al  1999,  Gronthos et al 
2003a), which supports this  system as a reliable model of differentiation;  the lack of a 
large increase in calcium deposition seen here during differentiation compared to definite
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Figure 6.8. Effect of successive transforming hits on mRNA levels of osteogenic markers. A, 
Schematic  of osteogenesis  highlighting  the  genes  analysed  in  this  study  and  their  time  of 
expression during differentiation;  B,  RNA  was  collected (2.6.1)  from  day  14  differentiated 
cells and control cells one day after reaching confluence.  cDNA was synthesised (2.6.2) and 
gene-specific  primers  for CBFA1,  osteocalcin, COL1A1, ALP  (alkaline  phosphatase,  tissue 
non-specific) and PLZF were used in PCR to determine osteogenic marker expression in each 
cell  line  after  differentiation  (2.6.3.1).  -RT:  no  reverse  transcription  control  (osteocalcin 
primers).  PCR  cycle  numbers  used:  /3-actin,  COL1A1:  25;  ALP,  PLZF:  28;  osteocalcin, 
CBFA1: 30.
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268increases in the literature may be explained by the fact that differentiation is classically 
carried out for 21 days, whereas here it was terminated at day 14.
As adipogenesis was impaired in cells containing 4 or 5 hits, it was of interest to attempt 
to specifically analyse osteogenesis in these cells. As this was not possible in previous 
experiments where osteogenesis was assessed at day  14, a further study was undertaken 
focusing on 4 and 5 hit cells, and osteogenesis was carried out for only 6 days in order to 
prevent loss of any cell lines through overgrowth after continued culture. The 4(E7) cells 
were not included in this analysis as they were continually lost by the 6 day timepoint. To 
this end, osteogenesis was induced in three sets of confluent cells as before, whereas three 
further  sets  of  cell  lines  were  incubated  in  normal  growth  media,  and  at  day  6 
differentiated and control cells were stained for osteogenic activity (Fig 6.9A). All cells 
survived  as  adherent  monolayers.  Both  alkaline  phosphatase  and  alizarin  red  revealed 
strong staining in control (undifferentiated) cells containing 4 or 5 hits;  again this may 
have been due to an increase in cell number between lines causing differences in overall 
staining intensity. Nevertheless, the extent of osteogenesis can theoretically be assessed 
through comparison of induced and control cells of a specific line. However, no difference 
in staining intensity was seen in any condition between control and differentiated cells, 
apart from in the parental hMSCs where alkaline phosphatase activity seemed greater in 
differentiated  cells  (Fig  6.9A).  This  was possibly due  to  the time  at which  cells  were 
stained;  as osteogenesis  is  normally carried  out  for 21  days,  it is  likely that  at  6  days 
osteogenesis is still in it’s early stages and would not have progressed enough to produce 
differences in induced cells compared to control cells. Thus, due to the growth properties 
of transformed cells, it was not possible to conclusively assess osteogenesis in this system 
through staining techniques.
As before, RNA was extracted from one set each of control and day 6 differentiated cells 
(Fig. 6.9B), and a representative selection of three osteogenic markers were analysed for 
their expression using RT-PCR.  In this set of experiments, expression of all three genes 
was detected in undifferentiated parental hMSCs, as well as cells containing 4 or 5 hits, 
indicating  that  these  genes  are  normally  expressed  to  some  extent  in  undifferentiated 
hMSCs. However, expression of CBFA1, osteocalcin and COL1A1 was comparable in
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Figure 6.9.  Focused analysis of the effect of four or five transforming hits  on osteogenesis. 
Differentiation was carried out for 6 days in an attempt to minimise cell over-proliferation and 
loss of adherence, after which time control and differentiated cells were stained and RNA was 
extracted.  A, alkaline phosphatase activity assay (2.2.3.2) and  alizarin red  stain for calcium 
deposition (2.2.3.3) on undifferentiated cells (-) and cells induced to differentiate (+) (2.2.2.2); 
B, RT-PCR analysis (2.6.3.1) of expression of a selection of osteogenic marker genes and -  
RT  control  (osteocalcin  primers).  PCR  cycle  numbers  used:  /3-actin:  25;  COL1A1:  20; 
osteocalcin, CBFA1: 32.
270both control and differentiated cells, indicating that osteogenesis had not progressed far 
enough  for  any  changes  to  be  observed.  In  both  differentiated  and  undifferentiated 
conditions,  CBFA1,  osteocalcin  and  COL1A1  were  expressed  at  comparable  levels  in 
parental  hMSCs  and  4  hit  cells.  However,  whereas  CBFA1  and  osteocalcin  were 
expressed to the highest level in 5 hit cells, COL1A1 was expressed at lower levels in the 
5  hit  line compared to 4  hit or parental  hMSCs.  Thus,  no  single pattern described  the 
expression of these genes in each cell line.
One consistent observation during experimentation was an increase in staining with both 
alkaline phosphatase activity and alizarin red as the extent of transformation increased. In 
order to assess whether this was due to increasing cell number or an inherent increase in 
levels of osteogenic properties in individual cells, subconfluent cells of each type that had 
not  been  induced  to  differentiate  were  assayed  for  alkaline  phosphatase  activity  and 
visualised at the single-cell level (Fig. 6.10A). Quantification of the percentage of cells 
staining positive for alkaline phosphatase activity (ALP+) in each cell line revealed that 
every cell line, apart from the  1   hit (which showed significantly less ALP+ cells), 2(E7) 
and 4(E7) cells showed a significantly higher percentage of ALP+ cells than the parental 
hMSC cell line (Fig. 6.1 OB). The largest increases were seen in the 2(E6), 3, 4 and 5 hit 
cells.  This  correlates  with  the  higher  expression  levels  of  certain  osteogenic  genes 
observed in the undifferentiated 2(E6) and 3 hit cell lines (Fig. 6.8.B), and also with the 
staining  that  was  seen  in  all  four  of  these  undifferentiated  cell  lines  in  previous 
experiments  (Fig.  6.7,  Fig.  6.9A).  This may indicate that these cell  lines possess more 
osteogenic properties than other cell lines, but it should be noted that alkaline phosphatase 
is not a marker that is fully specific to osteogenesis.
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Figure  6.10.  Background  level  of  alkaline  phosphatase  activity  in  undifferentiated, 
subconfluent  cells  of each  type.  Cells  undergoing  normal  passaging  were  kept  at  similar 
densities  then  stained  for  alkaline  phosphatase  activity  (2.2.3.2).  A,  representative  field  of 
view for each cell line after staining. Scale bars represent 200/zm; B, quantification of alkaline 
phosphatase activity in subconfluent cells of each cell line. Three fields of view were counted 
per cell line. Data represent % alkaline phosphatase positive cells per cell line and are mean ± 
standard deviation.  *, p<0.05;  **, p<0.01  and  ***p<0.0001  using a two-sample Student’s t- 
test (assuming equal variance), when values were compared to the parental hMSC cell  line.
2726.5 Discussion
The  results  described  in  this  chapter have  demonstrated  that  introducing  transforming 
mutations  progressively  alters  the  growth  properties  and  morphology  of  hMSCs. 
Importantly, it was also discovered that when 5 hits, or even a specific combination of 4 
hits,  are  introduced,  adipogenesis  is  impeded  at both  the  cellular and  molecular level, 
providing novel information regarding the properties of transformed hMSCs.
Analysis of the proliferation capability,  extent of contact inhibition and morphology of 
hMSCs  containing  increasing  numbers  of transforming  hits  was  initially performed  to 
characterise the cells for further differentiation experiments. It was shown in related work 
that,  in  this  system,  the  addition  of  hTERT  to  hMSCs  was  sufficient  for  their 
immortalisation, but 5 hits were required to induce transformation characterised by growth 
in soft agar and tumour formation in mice.  Furthermore, 4 hit and 4(E7)  cells  attained 
some transformed properties. (Funes et al 2006, submitted and unpublished observations). 
Indeed, it was shown here that 5 hit, 4 hit and to the highest extent 4(E7) cells, showed an 
ability to  overcome  contact  inhibition  and continue  to  expand  after confluence,  which 
could be correlated with their transformed phenotype (Fig. 6.2B). Additionally, their small 
and  rounded  morphology  was  significantly  changed  from  that  of  parental  hMSCs 
(although 4(E7) cells retained some spindle shape, Fig. 6.2A). In support of these findings, 
MSCs from mice or humans also became smaller in size after spontaneous transformation 
(Rubio et al 2005, Miura et al 2006).
The 2(E7)  and  3  hit cells had  attained  an intermediate phenotype,  where cell  shape  is 
slightly  changed  from  parental  cell  morphology  but  has  not  fully  acquired  the  small, 
rounded  shape  of  4  or  5  hit  cells.  Furthermore,  some  proliferation  occurred  after 
confluence indicating that, to some extent, the cells were capable of overcoming contact 
inhibition.  This  would  fit  with  the  findings  in  this  system  that  these  cells  are  not 
transformed, as transformation entails loss of contact inhibition, and with previous studies 
that indicate that hMSCs containing up  to  3  hits do not display transformed properties 
(Okamoto et al 2002,  Hung et al 2004b). The fact that 2(E7) cells seem to be smaller, 
and/or can proliferate  more  after confluence  than  2(E6)  cells  indicates  that  loss  of Rb
273plays  a  significant  role  in  transformation;  indeed,  another  study  showed  that  hMSCs 
transduced with combinations of up to 3 hits including E7 had lower population doubling 
times than those lacking E7 (Mori et al 2005b).
Finally, it was found that cells containing 1  or 2(E6) hits, and surprisingly the 4(E6) cells, 
behave similarly to parental cells in that they are sensitive to contact inhibition (Fig 6.2). 
Further,  1   and  2(E6)  hits  cells  retain  morphologies  similar  to  normal  hMSCs.  The 
observation  that  cells  containing  4  hits  but  lacking  E7  are  not  as  aggressive  as  cells 
containing  only  hTERT  and  E7  again  indicates  that  the  loss  of Rb  may play  a  large 
contribution to the aggressive phenotype observed when E7 is present, and that loss of p53 
is  not  sufficient  to  induce  this  phenotype.  Similar  to  these  findings,  other  studies  of 
hMSCs  immortalised  with  telomerase  have  not  reported  morphological  changes  or 
changes in proliferation rate after introduction of hTERT (Shi et al 2002), but the effects 
of the combinations of transforming hits exemplified by the 4(E6) cells used here, or even 
the 2(E6) cells, on growth and morphology of hMSCs or other cell types, have not been 
reported.
In  summary,  as  well  as  providing  an  experimental  basis  and  set-up  for  subsequent 
differentiation experiments, these observations of hMSC characteristics would allow an 
understanding of the relationship between differentiation capability and the progression 
towards, or attainment of, transformation in each cell line.
The effect of transformation on hMSC osteogenesis
Each of the  cell  lines containing 0-5  transforming hits  was  assessed  for its’  ability to 
undergo differentiation to both osteoblasts and adipocytes; a well-documented ability of 
untransformed  hMSCs  (Pittenger  et  al  1999).  For  osteogenesis,  differentiation  was 
initially  assessed  at  14d.  Alkaline  phosphatase  activity  and  calcium  deposition  assays 
suggested that cells containing 0-3 hits, and also 4(E6) cells, were capable of some level 
of  osteogenesis  after  induction,  compared  with  their  un-induced  controls  (Fig.  6.7), 
although calcium deposition was not extensive in parental  and  1   hit differentiated cells. 
RT-PCR studies were not conclusive; a trend observed for ALP and PLZF was an increase 
in gene expression after osteogenic induction in some cell lines, which is in line with the
274results of histochemical  staining, but not all genes analysed showed this pattern so this 
conclusion is not fully supported (Fig. 6.8). However, previous work has reported similar 
findings; the introduction of hTERT maintained (Simonsen et al 2002) or increased (Shi et 
al 2002) hMSC osteogenic capacity, and Okamoto et al showed that hMSCs containing 
hTERT, E6 and E7 are still capable of undergoing osteogenesis, associated with increases 
in ALP and  COL1A1  (Okamoto et al 2002).  However,  in that  study osteogenesis  was 
terminated at 21 days, so the endpoint of 14 days used here may have been too early to see 
some gene expression changes, or large increases in osteogenic staining intensity.
At day 14 it was not possible to comprehensively assess osteogenesis in 4, 4(E7) or 5 hit 
cells. Their aggressive proliferation led to the instability and subsequent detachment of the 
monolayer of all 4(E7) cells and some 4 and 5 hit cells between around days 7 and  14 of 
differentiation. In an attempt to combat this problem, osteogenesis was terminated after 6 
days, at which time all cell lines were still attached as monolayers. However, when each 
differentiated cell line was stained and compared with it’s undifferentiated counterpart, no 
significant differences in staining intensity, and therefore the extent of osteogenesis, were 
seen (Fig. 6.9A). Similar to this, RT-PCRs showed no particular pattern of expression of 
osteogenic marker genes between cell lines, and no visible differences in expression after 
differentiation (Fig.  6.9B).  Thus,  using this  system it was not possible  to  conclusively 
assess osteogenesis in these cell lines. As previous studies have not assessed osteogenesis 
in 4 or 5 hit lines or after spontaneous differentiation, such problems have not previously 
been described. Due to the linked nature of transformation and differentiation pathways, it 
would  be  difficult  to  overcome  this  problem  in  vitro.  Possible  solutions  include 
differentiation on a single-cell level in conditions that do not allow further cell growth, as 
in the system used by McBeath et al (2004), which assessed differentiation of hMSCs on 
fibronectin  “islands”  that  allowed  attachment  of  only  a  single  cell,  or  after  hMSC 
treatment with mitomycin-C, which arrests cell proliferation (McBeath et al 2004).
An observation common to 6 and 14 day experiments was a background level of alkaline 
phosphatase activity and calcium deposition in undifferentiated cells that was proportional 
to the number of hits. This may have been due either to increased osteogenic capacity of 
these cell lines, or a higher background level of staining due to the inevitable increase in
275cell  number.  When  this  was  assessed  on  the  single  cell  level  using  the  alkaline 
phosphatase assay, it was found that in the 2(E6), 3, 4, 4(E6) and 5 hit cell lines, a higher 
proportion of cells  were positive  for alkaline phosphatase  activity than  in the parental 
hMSCs (Fig. 6.10). This correlated with previous observations (Fig. 6.7, 6.8B, 6.9A), and 
may indicate that these  cells have accumulated  osteogenic properties as  a result of the 
transforming  hits.  However,  alkaline  phosphatase  activity  is  induced  under  conditions 
other than osteogenesis (the alkaline phosphatase isoform expressed in bone can also be 
expressed  in  other  tissues  such  as  liver  and  kidney),  so  in  itself is  not  a  definitive 
osteogenic  marker.  As  a  further indication  of enhanced  osteogenic properties  in  some 
undifferentiated cell lines, background expression level of CBFA1, osteocalcin and ALP 
was seen in some of these undifferentiated cell lines,  specifically 2(E6)  and 3  hit lines, 
which was higher than in parental hMSCs.  It has been reported that the introduction of 
hTERT causes upregulation of CBFA1 and osteocalcin expression (Gronthos et al 2003b), 
so  this  may,  at  least  in  part,  explain  these  observations,  as  gene  expression  is  also 
increased in the  1   hit cell line (Fig. 6.8B).  Surprisingly however, the  1   hit line showed 
significantly less  alkaline phosphatase  activity than parental  hMSCs,  at  the  single  cell 
level.  Heterozygous  loss  of  Rb  results  in  a  500-fold  increase  in  the  incidence  of 
osteosarcoma  (1.8.2,  Thomas  et al  2006).  It  could  therefore  be  hypothesised  that  the 
introduction of E7, and therefore loss of Rb, could affect background levels of osteogenic 
markers  in undifferentiated  hMSCs;  however,  the  2(E7)  and  4(E7)  cells  did  not  have 
significantly  higher  alkaline  phosphatase  activity,  or  background  osteogenic  gene 
expression levels, than parental hMSCs. It is therefore possible that this effect is context- 
dependent;  i.e.  it  is  affected by the other transforming  mutations that  are  also  present. 
Patients with Li-Fraumeni syndrome (characterised by inherited heterozygous loss of p53) 
are also more susceptible to osteosarcoma, as well as other tumour types, than the general 
population (Malkin et al 1990). This suggests that this gene is intrinsically linked to the 
osteogenic differentiation pathway,  and hence the  introduction of E6,  and therefore the 
loss  of p53  and  Rb  function,  may  alter  the  propensity  for  hMSCs  to  differentiate  to 
osteoblasts.  All  of the  cells  lines  in  which  E6  was present  showed  increased  alkaline 
phosphatase activity in sub-confluent undifferentiated cells (Fig. 6.10), indicating that this 
transforming mutation may play a major role in altering alkaline phosphatase activity in 
hMSCs. However, it must again be stated that in itself, this observation is not sufficient to
276draw  conclusions  regarding  osteogenesis,  and  a  more  comprehensive  analysis  of 
differentiation,  at  the  single-cell  level  if possible,  would  be  needed.  Of note,  tumours 
formed  by  5  hit  cells  in  immunodeficient  mice  did  not  exhibit  characteristics  of 
osteosarcomas, but rather resembled spindle cell tumours (Funes et al 2006, submitted), 
which does not support the conclusion that 5 hit cells have a higher propensity to undergo 
osteogenesis.
In  summary,  although  several  attempts  were  made  to  assess  osteogenesis  after hMSC 
transformation  and  both  staining  and  RT-PCR  techniques  were  employed,  it  was  not 
possible to conclusively assess osteogenesis in 4 (excluding 4(E6)) or 5 hit cell lines in 
this  system.  The  growth  properties  of  transformed  hMSCs  precluded  the  study  of 
osteogenesis  at  it’s  classic  21  day  endpoint  or  even  a  full  analysis  at  14  days,  and 
insufficient  differentiation  at  the  early  6  day  timepoint  rendered  the  experiments 
inconclusive. However, these studies suggest that cells containing with  1-3 transforming 
hits, and also the 4(E6) cell lines, were capable or some extent of osteogenesis, similar to 
previous  findings  (Okamoto  et  al  2002,  Simonsen  et  al  2002,  Shi  et  al  2002). 
Furthermore,  the  introduction  of some  transforming  genes  may  enhance  spontaneous 
hMSC osteogenic capacity.
The effect of transformation on hMSC adipogenesis
The  adipogenic  differentiation  system  was  found  to  have  a  major  advantage  in  that 
adipogenic induction resulted in significant growth arrest, even in the more transformed 
cell lines (Fig. 6.3). This may have been due the adipogenic induction cocktail causing 
increased  expression of PPARy and  C/EBPa,  which  are  known  to  bring  about  growth 
arrest  during  adipogenesis  through  induction  of  several  CDK  inhibitors  (1.6.2.1). 
Additionally, adipogenic differentiation needs a shorter time period than osteogenesis to 
be  accomplished.  Thus,  adipogenesis  could  be  assessed  in  all  cell  lines  and  a 
comprehensive analysis of the effect of transformation was possible.
It was found that adipogenesis was not significantly impaired in all cell  lines with less 
than 3 hits, and also in the 4(E6) line, as lipid-laden cells were visible (Fig. 6.4), although 
not  as  numerous  as  with  differentiated  parental  hMSCs.  It  is  likely  that  this  was  not
277caused,  in the  most part,  by differences  in passage number between cell  lines,  as  low 
passage  hMSCs  expressing  hTERT  were  as  capable  of adipogenesis  as  untransduced 
hMSCs,  and  there  was  no  significant  difference  when  compared  with  high  passage 
hMSCs,  although  differentiation  was  more  variable  (Fig.  6.6).  In  line  with  these 
observations, hMSCs expressing hTERT were still capable of forming adipocytes after 40 
or 60 population doublings (Shi et al 2002). Additionally, adipogenic gene expression was 
similar in these cell lines to parental cells (Fig. 6.5A). At the mRNA level, 2(E6) hit cells 
showed  a  slightly lower  ability to  differentiate,  as  expression  of PPARy  and  aP2  was 
reduced compared to other cell lines. There was a further decrease in lipid accumulation as 
the number of hits increased to 3, but no drop in the expression of adipogenic markers, 
which  would  suggest  that  mature  adipocytes  are  still  being  formed.  These  results  are 
similar to other observations where equivalent 3 hit cells, or cells containing just E6 and 
E7, were capable of forming mature adipocytes (Okamoto et al 2002, Hung et al 2004b). 
However, in the results reported here, adipogenesis appears less robust in 2 and 3 hit lines 
than previously reported. This could be due to differences in induction conditions, or due 
differences in the extent of transformation between the studies; the study by Okamoto et al 
required 3 hits (hTERT, E6 and E7) to immortalise hMSCs (Okamoto et al 2002), whereas 
here only hTERT was required, suggesting that the 3 hit cells used in this thesis may more 
closely resemble  transformed  cells  than  those  used previously,  possibly  due  to  higher 
expression of the transforming genes in the cells described here, or the unknown source or 
passage number of the hMSCs used in the Okamoto study.
When 4 (including 4(E7))  or 5  transforming hits  were  introduced  into  hMSCs,  a more 
dramatic effect was observed. Individual cells contained few, small lipid droplets in 5 hit 
and 4(E7) cells; slightly more lipid accumulation was observed in 4 hit cells (Fig. 6.4). It 
could be hypothesised that a decrease in lipid accumulation may be a result of a higher 
metabolic rate rather than decreased differentiation; however this decrease was associated 
by a drop in expression of adipogenic genes, most prominently in the 4(E7) cells, and to a 
lesser  extent  in  4  hit  cells  (Fig.  6.5B).  It  can  therefore  be  concluded  that  although 
adipogenesis still occurs in these cell lines, it is impaired. This effect is most pronounced 
in  the  4(E7)  and  5  hit  cell  lines,  thus  hMSC  transformation  can  be  associated  with 
impaired  adipogenesis.  This  observation  has  not  previously  been  reported.  It  remains
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Myc and constitutive Ras activity) are the cause of this loss of differentiation, rather than 
it being a direct effect of transformation. To address this possibility, these hits would have 
to be introduced individually into hMSCs to investigate whether adipogenesis is similarly 
affected. However, introduction of c-Myc or oncogenic Ras individually into primary cells 
can  result  in  apoptosis  or  senescence  (Rangarajan  et  al  2004).  It  could  therefore  be 
concluded that, in this system, the additional introduction of hTERT and loss of p53 and 
Rb activity play an important role in the observations. Inducing hMSC transformation via 
different means (as discussed below) and determining the effect on differentiation would 
also be of use in resolving this issue.
As previously described (1.8.2), the molecular pathways involved in transformation and 
stem cell functions such as differentiation are highly inter-linked. This is indeed the case 
in adipogenesis,  and could  go  some  way to  explaining the molecular basis behind the 
impairment  of  differentiation  in  cells  that  display  transformed  characteristics.  The 
presence of E7, and thus the loss of Rb function, seems to be required for this effect, as 
4(E6) cells behave in a similar manner to cells containing less transforming hits. Although 
Rb  is known to  inhibit  late-stage  adipogenesis  involving  PPARy (Fajas  et al 2002),  it 
enhances early adipogenesis  through the  C/EBP  proteins  (Chen et al  1996,  Cole  et al 
2004,  1.6.2.1);  thus,  loss  of Rb  function  may  block,  or  impede,  the  early  stages  of 
differentiation. Overexpression of Ras has been shown to increase adipogenesis in 3T3L1 
cells, which could be expected as it is a downstream effector of insulin signalling (Porras 
et al 1994). This pro-adipogenic signal from Ras can be transmitted through Raf-1 kinase; 
however, Ras signalling can also inhibit adipogenesis if signals are transmitted through the 
MAPK  pathway  (Font  de  Mora  et  al  1997).  This  occurs,  at  least  in  part,  through 
phosphorylation and inactivation of PPARy mediated by ERK1 and ERK2 (Hu et al 1996, 
Font de Mora et al 1997). Furthermore, c-Myc is known to be an inhibitor of the terminal 
stages of 3T3-L1  differentiation (Heath et al 2000). Interestingly, a study in Rb-deficient 
MEFs  demonstrated that  Rb  is  capable  of down-modulating ERK1/2  activity,  possibly 
through suppression of Ras  (Hansen et al 2002).  It was hypothesised that the block in 
differentiation  observed  in  these  Rb-deficient  cells  could  be  caused  by  increased  Ras 
activity leading to MAPK-mediated c-Myc stabilisation. It is notable that, in this system,
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adipogenesis. However, the results of the Hansen study could provide a theory regarding 
how the loss of Rb, activation of Ras, and stabilisation of c-Myc (as in the 5 hit line), or 
combinations thereof (4 or 4(E7) lines), could act in concert (or in synergy) to cause a 
defect to adipogenesis.
This work provides evidence that in vitro transformation of hMSCs can be associated with 
impaired  adipogenic  differentiation.  This  finding  is  in  agreement  with  the  fact  that 
tumours,  and more  specifically sarcomas,  are constituted mainly by cells  that partially 
resemble mature cell types, and that cancer stem cells are capable of forming all cell types 
in their tumour of origin, so it would not be expected that differentiation would be entirely 
abolished. Human myxoid liposarcomas, a malignant sarcoma of adipose tissue containing 
cells partially resembling  adipocytes,  are  defined by  a chromosomal  translocation  that 
fuses the basic helix-loop-helix domain of the CHOP 10 gene (an inhibitor of adipogenesis 
under normal circumstances,  1.6.2.3  and Fig. 4.6) with the RNA binding domain of the 
FUS  gene,  or  rarely  the  EWS  gene  (Perez-Mancera  and  Sanchez-Garcia  2005).  This 
results  in  deregulated  protein-binding  activities  of  CHOP 10,  which  may  block 
adipogenesis  by  interfering  with  C/EBP/3  function  (Adelmant  et  al  1998).  The 
mechanisms underlying the transforming ability of this fusion protein are not clear, but 
require the FUS/EWS RNA binding domain (Zinszner et al 1994). In relation to the theory 
that cancer stem cells may arise via mutations in a normal stem cell population, it has been 
suggested that the CHOPIO-FUS translocation may occur in hMSCs, causing a lineage- 
specific block in differentiation at a stage along the adipogenic pathway (Perez-Mancera 
and Sanchez-Garcia 2005). However, this remains a theory, and it is also possible that the 
translocation  may  occur  in  adipogenic  precursors.  It  would  therefore  be  of interest  to 
investigate the effect on hMSC transformation and differentiation of other transforming 
hits; specifically the introduction of the FUS-CHOP10 fusion gene into hMSCs in vitro. 
Such work may lead to further understanding of the mechanisms by which transformation 
affects adipogenesis.
280CHAPTER 7. GENERAL DISCUSSION.
2817.1  Conclusions and discussion
The research described in this thesis has resulted in the following main novel observations:
•  hMSC adipogenesis can be stimulated via the overexpression of PPARy alone, without 
the need for addition of differentiation inducers.
•  Distinct  temporal  patterns  of transcriptional  regulation  define  the  earliest  stages  of 
hMSC adipogenesis. This involves over 4200 genes, many of which were described as 
being regulated during hMSC adipogenesis for the first time in this thesis.
•  Specific  biological  processes  such  as  the  up-  and  downregulation  of  subsets  of 
developmental  genes  and  temporal  regulation  of  Wnt,  TGF/3  and  BMP  pathway 
components are involved in early hMSC adipogenesis
•  A  novel  functional  genomics  strategy  combining  gene  expression  profiling, 
comprehensive global annotation and functional screens was developed and applied to 
investigate early hMSC adipogenesis
•  Finally, transformation of hMSCs results in impaired adipogenesis.
Elucidation  of the  molecular  mechanisms  underlying  stem  cell  differentiation  would 
extend our knowledge  of the processes  of early development,  and may also  provide  a 
means  to  exploit  this  unique  attribute  of  stem  cells  in  regenerative  medicine.  The 
properties of MSCs render this population and ideal system with which to achieve such 
aims.  Their  potential  to  regenerate  damaged  tissues  has  already  been  highlighted  by 
animal studies and even some clinical trials (Toma et al 2002, Horwitz et al 1999, 2002, 
1.4.6). Furthermore, they are a well-defined cell population, and their isolation from adult 
human bone marrow, or other tissue sources, means that a large numbers of hMSCs can be 
obtained  easily  and  without  confounding  ethical  issues.  Crucially,  hMSCs  are  easily 
manipulated in culture and can robustly differentiate into  several cell  lineages  in  vitro, 
including adipocytes. Despite this, little is known regarding the earliest molecular events 
of hMSC  differentiation  to  adipocytes,  as  much  research  into  adipogenesis  has  used 
committed  precursor  cell  lines.  The  earliest  stages  of stem  cell  differentiation  involve 
processes such as lineage commitment,  and it is possible that the molecular events that 
regulate these processes may be similar between different stem cell populations, or within 
the various lineages of one stem cell type. Thus, whereas molecular regulation at the later
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understanding  of  the  early  molecular  events  of  adipogenesis  may  have  broader 
applications in other stem cell types. It was therefore aim of this thesis to investigate the 
hypothesis that hMSC adipogenesis involves important molecular events that occur at an 
early stage of differentiation.  The major strategy to  achieve this aim was the use  of a 
combination of functional genomics techniques, the results of which revealed much detail 
regarding the molecular processes at the early stages of hMSC adipogenesis.
In  Chapter  3  optimal  hMSC  isolation,  growth  and  differentiation  to  adipocytes  was 
established as the first step towards this goal. The properties of the hMSCs used, in terms 
of their surface marker profile, growth kinetics and ability to undergo differentiation, were 
found to be similar to previous reports (Pittenger et al  1999, Tsutsumi et al 2001), and 
hence it was concluded that accurate comparisons could be made between this work and 
the work of other researchers.  Subsequently, it was shown that gene expression changes 
could be detected in this system within the first 9h of hMSC adipogenesis that were likely 
to represent crucial early molecular events. Furthermore, it was concluded that this stage 
of differentiation had not previously been characterised by other work. This research thus 
provided a basis for later studies that were aimed at detecting and defining these events. 
Although  it  was  found  in  Chapter  4  that  several  known  regulators  of preadipocyte 
differentiation,  such as C/EBP/3 and KLF2,  were also transcriptionally regulated during 
early hMSC differentiation, this was concluded to be possibly due to the similar methods 
used to induce differentiation of preadipocyte cell lines and hMSCs. Additional genes that 
showed similar expression patterns to  these known regulators  had not previously been 
shown to be regulated during adipogenesis, and therefore presented a unique opportunity 
to identify novel regulators of early hMSC adipogenesis.
The microarray expression profiles obtained during differentiation (Chapter 4) revealed 
that the first 9h of hMSC adipogenesis involved expression changes in 6319 probesets, 
equivalent to over 4200 known genes (given the data processing methods and significance 
cut-off employed). Although other microarray time-course studies have investigated this 
process, arrays covering only a subset of human genes were used (Nakamura et al 2003, 
Sekiya et al 2004).  This  thesis  was the  first study to  use  genome-wide microarrays to
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regulation at the  early stages  of hMSC  adipogenesis  is  more complex than previously 
known. In a similar fashion to the regulation of preadipocyte differentiation, some genes 
described in this thesis had been identified in other studies of hMSC  adipogenesis, but 
many more genes were not known to be regulated during this process.
This  thesis  employed  hierarchical  clustering  of genes  showing  significant  expression 
changes, combined with a number of global annotation methods, with the aim of obtaining 
an overview of the pathways and biological processes that function at specific stages of 
early hMSC adipogenesis. The work described here represents a step beyond the analytical 
methods  used  in  other  microarray  studies  of  stem  cell  function.  Frequently,  gene 
expression changes during stem cell differentiation have been represented in simple lists 
indicating up-regulated or down-regulated genes (for example, Hung et al 2004a, Sekiya 
et al 2002, 2004), but this does not give an indication as to the interacting gene networks 
that may play vital roles.  It  is becoming more common as the technology advances to 
employ global annotation methodologies to perform microarray data analyses, which can 
be  used  to  interpret  the  function  of the  regulated  genes  and  thus  identify  biological 
processes, signalling pathways or gene families (as a non-exhaustive list) that may play a 
role in the process under investigation.  This has been the case in 3T3-L1  adipogenesis 
(Hackl et al 2005), a recent study of hMSC differentiation to adipocytes and chondrocytes 
(Yloslato  et al  2006),  and  also,  for  example,  in  work  concerning  mESC  pluripotency 
(Palmqvist et al 2005). However, if small microarrays are used (as in all these studies), an 
incomplete view of regulatory pathways and processes with be obtained as all components 
will not have been analysed. Additionally, some annotation methods can neglect important 
information; GO is not yet fully comprehensive and hence some known human genes do 
not possess GO annotations, and pathway maps for visualising microarray data may not 
contain all members of a certain signalling pathway. This problem can be addressed by 
employing several annotation techniques,  as demonstrated by the  studies by Hackl  and 
Palmqvist, but in the field of hMSC adipogenesis this has yet to be achieved. This thesis 
made use of several different annotation methods, as well as genome-wide arrays, and thus 
presents the most comprehensive view of the pathways and processes involved in hMSC 
adipogenesis.  By  way  of  example,  although  previous  work  had  indicated  that
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2004a), the use of Gene Ontology as well  as manual  annotation of specific  expression 
clusters  demonstrated  further  detail  regarding  the  full  range  of developmental  genes 
involved. Furthermore, the involvement of the Wnt, TGF/3 and BMP signalling pathways 
during adipogenesis in hMSC or C3H10T1/2  cells (a multipotent murine cell line with 
differentiation capabilities similar to MSCs, 1.6.1) has previously been described (Locklin 
et al 1999, De Boer et al 2004, Etheridge et al 2004, Tang et al 2004), but through the use 
of global pathway analysis techniques, the exact pathway components involved as well as 
their specific timing of expression was revealed by work in this thesis.
The  automated  and  manual  annotation  techniques  identified  a  substantial  number  of 
candidate  regulators  of  the  early  stages  of  hMSC  adipogenesis.  A  shRNA  library 
screening strategy was chosen to investigate the roles of these candidates (Chapter 5), the 
reasons for this decision being twofold.
Firstly,  it was shown in Chapter 3  that retroviral transduction of hMSCs with a vector 
expressing PPARy  isoforms  permitted  evaluation  of the  effect of exogenous  genes  on 
differentiation.  Interestingly,  this  is  the  first  report  of the  ability  of PPARy  to  induce 
spontaneous  adipogenesis  in  hMSC  without  the  need  for  induction  reagents.  Taken 
together with other studies reporting the retroviral over-expression of genes in MSCs of 
human or murine origin (Shi et al 2002, McBeath et al 2004), or RNAi-mediated gene 
silencing in these cells (Hong et al 2005, Xu et al 2006), this work confirmed that the use 
of such tools would allow thorough investigation of candidate gene function during hMSC 
differentiation.
Secondly, shRNA library screens are documented as an effective high-throughput method 
of identifying factors from a large initial gene set (i.e. all genes covered by the library, or a 
chosen  subset  of  genes)  that  are  involved  in  a  specific  process  (Bems  et  al  2004, 
Downward 2004).  It appears from the literature that high-throughput methods are rarely 
used to follow on from microarray experiments, and instead only one or few genes are the 
focus of further research (Ross et al 2002, Ikeda et al 2005). This is perhaps because other 
microarray studies, on the whole, yield smaller lists of significantly changed genes than
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the  context  of this  thesis,  and  perhaps  as  an  example  for  future  functional  genomics 
research,  shRNA  screening  was  considered  a  particularly  relevant  technique  for  the 
downstream functional analysis of data produced by microarray expression profiling. The 
combination of these two approaches would maximise the output of results; performing a 
shRNA screen alone has the potential to identify novel  factors involved in early hMSC 
adipogenesis, but no information regarding their mechanism of action would be obtained. 
In  combination  with  microarray  gene  expression  analysis,  information  regarding  co­
regulated genes, common pathways members or genes with a similar function would be 
provided, allowing for more efficient characterisation of the role of specific genes during 
adipogenesis.  Thus,  this  thesis  has  described  the  use  of a  novel  strategy  designed  to 
maximise the output  of results  from microarray studies that has not been  employed  in 
previous work. Future work (discussed in 7.2) would aim to use modified techniques of 
shRNA screening to realise the frill potential of this strategy.
A  further  undertaking  of  this  thesis  was  to  investigate  the  effect  of  the  stepwise 
introduction of genes involved in neoplastic transformation on hMSC differentiation. It is 
a strong possibility that cancer-initiating stem cells may arise from transforming mutations 
in normal stem cell populations. In this thesis it was therefore hypothesised that modelling 
this situation in vitro, for which hMSCs were again an ideal system, and investigating the 
effect of transformation on a fundamental property of stem cells, i.e. differentiation, may 
increase our knowledge  of the processes  involved  in cancer progression.  In the results 
described in Chapter 6,  it was found that when hMSCs were transformed adipogenesis 
could  still  occur,  but  in  an  impaired  fashion.  When  fewer  transforming  genes  were 
introduced  into  hMSCs  that  were  not  sufficient  in  number  or  type  to  induce 
transformation, such a pronounced effect on differentiation was not observed. It could be 
hypothesised that this result would be  expected,  as the process of transformation often 
involves  perturbation  of pathways  linked  to  stem  cell  self-renewal  or  differentiation. 
Several studies have assessed the ability of hMSCs to become spontaneously transformed, 
but  did not address  their differentiation  ability  after transformation  (Rubio  et al 2005, 
Serakinci  et  al  2004).  In  addition,  although  the  step-wise  model  of introduction  of 
transforming hits has been applied to hMSCs, no study has achieved full transformation of
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of the effect of the in vitro differentiation capability of transformed hMSCs. Step-wise in 
vitro transformation has not been described in other adult stem cell populations,  so the 
work described here may be a useful basis for further studies.
7.2  Future directions
The work described in this thesis presents a number of interesting possibilities for future 
research which, given more time and enhanced technologies, could elucidate further the 
molecular regulation of early hMSC adipogenesis.
The largest potential for adding to the results described in this thesis would come from 
developing the shRNA screening strategy to allow a more thorough analysis of the wealth 
of  information  provided  by  the  microarray  studies.  A  major  technical  difficulty 
encountered during the shRNA screens described in this thesis was recombination of the 
retroviral  vector  leading  to  the  loss  of shRNA  inserts.  Therefore,  future  work  could 
involve using advanced  shRNA  libraries that utilise vectors with selectable markers  to 
exclude recombined plasmids, or a shRNA library that was amplified in a recombination- 
deficient  bacterial  strain  (Echeverri  and  Perrimon  2006).  This  would  lead  to  a  great 
increase  in  the  efficiency  of the  strategy,  as  experimental  procedures  would  be  more 
straightforward and a higher number of genes could be analysed simultaneously. Indeed, 
the first shRNA isolation method described in Chapter 5 (5.2.1) could be employed, and 
its  relative  simplicity  highlights  the  potential  rapidity  of  shRNA  isolation,  if 
recombination  does  not  introduce  a  complicating  factor.  The  availability  of  high- 
throughput laboratory equipment could allow the screen to be performed in 96-well plate 
format,  as  the  loss-of-function  readout  in  hMSC  differentiation  is  clearly visible,  and 
enough cells would likely be present in each well for sufficient quantification of a knock­
down effect.  Finally, to complement such work (but on a smaller scale) the availability of 
inducible shRNA libraries (Ngo et al 2006) could allow gene knock-downs to be induced 
at specific stages of differentiation, thus allowing a more in-depth analysis of whether a 
gene is required only at the early stages of hMSC adipogenesis.
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small reductions in the expression of TCF8 and SIX2, but no corresponding reduction in 
adipogenesis was observed. Given more time, it would be interesting to investigate further 
these observations, such as whether these shRNAs lead to a noticeable reduction in protein 
levels,  or  whether  modified  shRNAs  (i.e.  using  the  same  19nt  shRNA  sequence  but 
different hairpin loop sequences or the U6 promoter) could achieve a more robust knock­
down of expression of these genes. It was also found in Chapter 5 that lentiviral vectors 
may be more efficient than retroviral vectors at achieving gene-knockdowns in hMSCs, as 
the shRNAs that produced these observed gene expression knock-downs were delivered 
into hMSCs using a lentiviral vector. Lentivirus-based shRNA libraries do not yet exist, so 
it would be difficult to perform  large-scale  screens using these  vectors,  but to  study a 
small number of genes using lentivirally-mediated shRNA would be possible. Further to 
this, a recurring observation was that vectors, or hairpin-containing vectors, induced what 
was  possibly  an  interferon  response,  leading  to  a  reduction  in  differentiation  or  gene 
expression. However, the occurrence of an interferon response is currently speculation and 
it would therefore be useful,  in terms of optimising the use of vector-based  shRNA in 
hMSCs, to investigate whether the expression of interferon-related genes is induced after 
hMSC transduction.
An exciting possibility is now arising from advances in global gene expression analysis 
technology as well as the knowledge of the entire human genome sequence (Lander et al 
2001, Venter et al 2001). This is the identification of transcription factor binding sites in 
the upstream promoter elements of large gene groups selected from microarray studies, 
with  the  aim  of  elucidating  transcriptional  networks  controlling  the  process  under 
investigation (Karanam  et al 2004).  Recently,  this  technique was used  to  follow up  a 
microarray study of hMSC adipogenesis (Yloslato et al 2006). Several novel downstream 
targets  of PPARy  and  C/EBPa  were  described  via  analysis  of the  upstream promoter 
elements  of genes that  were  co-regulated  with  known  PPARy  or  C/EBPa  targets,  and 
subsequent  identification  of  PPARy  and/or  C/EBPa  binding  sites  in  these  promoter 
regions. This strategy could be applied directly to the microarray study described in this 
thesis. Transcription factors with known binding sites that were up-regulated at an early
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expression  cluster as  this  factor,  or showing  expression changes  (whether it be up-  or 
downregulation) at the same timepoint, or with known targets of the transcription factor, 
could  be  analysed  for  the  presence  of  the  specific  binding  site.  Thus,  putative 
transcriptional networks could be compiled that define the earliest transcriptional events of 
hMSC adipogenesis, which could subsequently be functionally tested using the strategy 
described  above.  Several  limitations  to  this  method  exist,  such  as  the  incomplete 
knowledge  of the  DNA  binding  sequences  for all  transcription  factors,  as  well  as  the 
possibility that a binding site may lie outside of the region being analysed. However, this 
form  of analysis  would  provide  a  further  opportunity  to  extract  biologically  relevant 
information for the microarray data.
Some  interesting  avenues  for  further  investigation  arose  from  the  studies  of hMSC 
transformation and the  effect on differentiation.  As  discussed  in Chapter 6,  it was not 
possible  with  the  system  used  to  accurately  assess  the  ability  of hMSCs  to  undergo 
osteogenesis. Methods that allow osteogenesis to be assessed on a single-cell level such as 
seeding cells on  fibronectin “islands”,  and  inhibiting their ability to proliferate  (which 
would not be likely to affect differentiation as growth arrest rather than proliferation is a 
required  step  for  differentiation)  could  be  developed.  In  combination  with  studies  of 
adipogenesis, this would allow investigation of whether hMSC transformation causes  a 
bias  to  differentiation  into  a  particular  lineage.  Finally,  it  could  also  be  of  clinical 
relevance  to  investigate  the  effect  on  hMSC  differentiation  of  other  methods  of 
transformation. An intriguing candidate for this would be the FUS-CHOPIO fusion protein 
that is commonly observed in liposarcomas, tumours of mesenchymal origin. This has not 
yet  been  expressed  in  hMSCs,  but  such  research  has  the  potential  to  discover  the 
mechanisms by which some mesenchymal tumours originate. It is thought that the FUS- 
CHOPIO  translocation  results  in  a  block  in  differentiation  at  a  point  prior  to  PPARy 
expression (Adelmant et al  1998).  If novel regulators of early adipogenesis were to be 
identified as a result of the work described in this thesis, their expression could be studied 
during differentiation of hMSCs expressing the FUS-CHOPIO translocation in order to 
understand the mechanisms or the precise stage at which this translocation may prevent 
normal hMSC adipogenesis.
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324APPENDIX
The following legends describe Tables, Folders and Figures that can be found on the CD- 
ROM attached into the inside back cover of this thesis.
Appendix  Folder  1.  .cel  files  for  each  timepoint  replicate,  containing  the  raw 
(unprocessed) signal data produced from Aflymetrix microarray scanning.
Appendix Folder 2. Alternative viewing option (see Appendix Figure  1) of hierarchical 
clustering of significantly changed genes, represented as cluster dendrogram and heatmap. 
The complete heatmap and cluster dendrogram, searchable by gene name, can be viewed 
by  downloading  and  installing  the  Treeview  Software  (Eisen  et  al  1998)  from 
http://rana.lbl.gov/EisenSoftware.htm  (free  for  non-commercial,  academic  and  not-for- 
profit users). To view the heatmap, open the “hc.cdf’ file in Appendix Folder 2 using the 
Treeview software.
Appendix Figure 1. Hierarchical clustering of significantly changed genes, represented as 
cluster dendrogram and heatmap. The heatmap has been segmented due to it’s large size, 
and is displayed as the  17 nodes of the cluster dendrogram that form the  14 expression 
clusters  used  for  analysis  in  this  thesis.  For  each  node,  it’s  position  in  the  cluster 
dendrogram is indicated by a purple colour.
Appendix Table 1. Full list of genes identified as having at least one significant expression 
change  between  two  consecutive  timepoints  in  the  microarray  time-course  study. 
Significant expression changes were identified by comparing the expression of each gene 
between consecutive timepoints (i.e. Oh-lh, lh-3h, 3h-9h, 9h-7d). The significance cut-off 
used was q<0.05,  and q values were calculated  as described  in section  2.7.3.  Only the 
5000  most  significant  changes  in  the  9h-7d  phase  are  included  in  this  list  as  further 
changes were not included in the hierarchical clustering  analysis. Negative  fold-change 
values indicate down-regulated gene expression between two consecutive timepoints (due 
to  the  log2  scale  of RMA  expression  units).  NA  indicates  probesets  with  no  gene 
annotation (these may represent ESTs, for example).
325Appendix  Table  2.  Expression  values  for  significantly  changed  gene  on  each  array 
replicate. Expression values are represented in RMA units (log2). NA indicates probesets 
with no gene annotation.
Appendix Table 3. Gene lists for each expression cluster. These gene lists were used to 
retrieve Gene Ontology annotations and perform GO category enrichment calculations.
Appendix Table 4. Gene Ontology Biological Process, Molecular Function and Cellular 
Component categories that were significantly enriched in each expression cluster (p<0.01 
for clusters 3  and  10, p<0.05,  for all other clusters,  and containing at least  10% of the 
genes in that cluster). GO category annotations were retrieved and significant enrichment 
calculated as described in section 2.7.4.1. Numbers preceding GO terms relate to the level 
in  the  GO  hierarchical  tree  at  which  the  GO  term  was  found.  Numbers  proceeding 
expression  clusters  are  the  total  number  of genes  in  the  node/number  of genes  with 
annotated  functions.  Rows  in red  indicate  GO terms passing both significance criteria. 
Observed: number of genes observed in  an expression cluster with a specific GO term; 
Expected: number of genes annotated with that GO term expected to be observed, given 
the size of the cluster and the number of genes with the specific GO term in the reference 
list (all genes on the U133  Plus 2.0 GeneChip). Enrichment ratio: observed/expected; p- 
value, calculated using hypeigeometric test.
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